<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomedicines</journal-id><journal-id journal-id-type="iso-abbrev">Biomedicines</journal-id><journal-id journal-id-type="publisher-id">biomedicines</journal-id><journal-title-group><journal-title>Biomedicines</journal-title></journal-title-group><issn pub-type="epub">2227-9059</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7996784</article-id><article-id pub-id-type="pmid">33652704</article-id><article-id pub-id-type="doi">10.3390/biomedicines9030234</article-id><article-id pub-id-type="publisher-id">biomedicines-09-00234</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><italic>Cannabis sativa</italic>: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Oultram</surname><given-names>Jackson M. J.</given-names></name><xref ref-type="aff" rid="af1-biomedicines-09-00234">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7353-3850</contrib-id><name><surname>Pegler</surname><given-names>Joseph L.</given-names></name><xref ref-type="aff" rid="af1-biomedicines-09-00234">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2126-8538</contrib-id><name><surname>Bowser</surname><given-names>Timothy A.</given-names></name><xref ref-type="aff" rid="af2-biomedicines-09-00234">2</xref></contrib><contrib contrib-type="author"><name><surname>Ney</surname><given-names>Luke J.</given-names></name><xref ref-type="aff" rid="af3-biomedicines-09-00234">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6327-3618</contrib-id><name><surname>Eamens</surname><given-names>Andrew L.</given-names></name><xref ref-type="aff" rid="af1-biomedicines-09-00234">1</xref></contrib><contrib contrib-type="author"><name><surname>Grof</surname><given-names>Christopher P. L.</given-names></name><xref ref-type="aff" rid="af1-biomedicines-09-00234">1</xref><xref ref-type="aff" rid="af2-biomedicines-09-00234">2</xref><xref rid="c1-biomedicines-09-00234" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Dra&#x00161;ar</surname><given-names>Pavel B.</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Capasso</surname><given-names>Raffaele</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-biomedicines-09-00234"><label>1</label>Centre for Plant Science, University of Newcastle, University Drive, Callaghan, NSW 2308, Australia; <email>Jackson.Oultram@uon.edu.au</email> (J.M.J.O.); <email>Joseph.Pegler@uon.edu.au</email> (J.L.P.); <email>Andy.Eamens@newcastle.edu.au</email> (A.L.E.)</aff><aff id="af2-biomedicines-09-00234"><label>2</label>CannaPacific Pty Ltd., 109 Ocean Street, Dudley, NSW 2290, Australia; <email>tim@cannapacific.com.au</email></aff><aff id="af3-biomedicines-09-00234"><label>3</label>School of Psychological Sciences, University of Tasmania, Hobart, TAS 7005, Australia; <email>luke.ney@utas.edu.au</email></aff><author-notes><corresp id="c1-biomedicines-09-00234"><label>*</label>Correspondence: <email>Chris.Grof@newcastle.edu.au</email>; Tel.: +612-4921-5858</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>2</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2021</year></pub-date><volume>9</volume><issue>3</issue><elocation-id>234</elocation-id><history><date date-type="received"><day>01</day><month>2</month><year>2021</year></date><date date-type="accepted"><day>23</day><month>2</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="pmc" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><italic>Cannabis sativa</italic> (<italic>Cannabis</italic>) is one of the world&#x02019;s most well-known, yet maligned plant species. However, significant recent research is starting to unveil the potential of <italic>Cannabis</italic> to produce secondary compounds that may offer a suite of medical benefits, elevating this unique plant species from its illicit narcotic status into a genuine biopharmaceutical. This review summarises the lengthy history of <italic>Cannabis</italic> and details the molecular pathways that underpin the production of key secondary metabolites that may confer medical efficacy. We also provide an up-to-date summary of the molecular targets and potential of the relatively unknown minor compounds offered by the <italic>Cannabis</italic> plant. Furthermore, we detail the recent advances in plant science, as well as synthetic biology, and the pharmacology surrounding <italic>Cannabis.</italic> Given the relative infancy of <italic>Cannabis</italic> research, we go on to highlight the parallels to previous research conducted in another medically relevant and versatile plant, <italic>Papaver somniferum</italic> (opium poppy), as an indicator of the possible future direction of <italic>Cannabis</italic> plant biology. Overall, this review highlights the future directions of cannabis research outside of the medical biology aspects of its well-characterised constituents and explores additional avenues for the potential improvement of the medical potential of the <italic>Cannabis</italic> plant.</p></abstract><kwd-group><kwd><italic>Cannabis sativa</italic> (<italic>Cannabis</italic>)</kwd><kwd>cannabinoids</kwd><kwd>tetrahydrocannabinol (THC)</kwd><kwd>cannabidiol (CBD)</kwd><kwd>cannabinoid receptors (CB<sub>1</sub> and CB<sub>2</sub>)</kwd><kwd><italic>Papaver somniferum</italic> (opium poppy)</kwd><kwd>secondary metabolites</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-biomedicines-09-00234"><title>1. Introduction</title><p><italic>Cannabis sativa</italic> (<italic>Cannabis</italic>) is arguably one of the world&#x02019;s most versatile crops. While the genetic origin and evolution of <italic>Cannabis</italic> is a long-standing and heavily debated topic [<xref rid="B1-biomedicines-09-00234" ref-type="bibr">1</xref>,<xref rid="B2-biomedicines-09-00234" ref-type="bibr">2</xref>,<xref rid="B3-biomedicines-09-00234" ref-type="bibr">3</xref>,<xref rid="B4-biomedicines-09-00234" ref-type="bibr">4</xref>], in broad terms, today, <italic>Cannabis</italic> can be separated into two distinct categories, specifically &#x02018;hemp&#x02019; and &#x02018;marijuana&#x02019;. Much like other agricultural crop commodities, <italic>Cannabis</italic> has been domesticated and bred for thousands of years to produce phenotypic and/or chemotypic traits of value to humans [<xref rid="B2-biomedicines-09-00234" ref-type="bibr">2</xref>,<xref rid="B3-biomedicines-09-00234" ref-type="bibr">3</xref>,<xref rid="B4-biomedicines-09-00234" ref-type="bibr">4</xref>,<xref rid="B5-biomedicines-09-00234" ref-type="bibr">5</xref>]. The chemotypic distinction between hemp and marijuana predominantly stems from the abundance of the principal psychoactive cannabinoid, &#x00394;<sup>9</sup>-tetrahydrocannabinol (THC), present in the plant as the acidic form, &#x00394;<sup>9</sup>-tetrahydrocannabinolic acid (THCA) [<xref rid="B6-biomedicines-09-00234" ref-type="bibr">6</xref>]. To be considered hemp, <italic>Cannabis</italic> must possess a low percentage of THC relative to the total dry weight of flowers, with this low THC percentage varying from country to country. In order to be legally cultivated as hemp, the cultivated plants must possess less than 0.3% THC (<italic>w/w</italic>) in Canada [<xref rid="B4-biomedicines-09-00234" ref-type="bibr">4</xref>,<xref rid="B7-biomedicines-09-00234" ref-type="bibr">7</xref>] and China [<xref rid="B8-biomedicines-09-00234" ref-type="bibr">8</xref>], whereas since 2001, the European Union determined that the THC content (<italic>w/w</italic>) of hemp must be below 0.2% [<xref rid="B6-biomedicines-09-00234" ref-type="bibr">6</xref>].</p><p>Hemp has traditionally been bred as a source for textile products due to the strong, elongated bast fibres present in the phloem of the stem. More recently, the elevated cellulosic content of hemp cell walls has garnered interest in the plant as a source for the development of sustainable biofuel production [<xref rid="B6-biomedicines-09-00234" ref-type="bibr">6</xref>]. Hempseed, and hempseed oil, have historically been utilised as a food source, with more contemporary research revealing their unique dietary value. In particular, the essential polyunsaturated fatty acids (PUFAs), linoleic acid (LA) and linolenic acid (LNA), comprise 50&#x02013;70% and 15&#x02013;25% of the total fatty acid content of hempseed, respectively; a 3:1 ratio promoted as nutritionally optimal [<xref rid="B9-biomedicines-09-00234" ref-type="bibr">9</xref>,<xref rid="B10-biomedicines-09-00234" ref-type="bibr">10</xref>,<xref rid="B11-biomedicines-09-00234" ref-type="bibr">11</xref>,<xref rid="B12-biomedicines-09-00234" ref-type="bibr">12</xref>,<xref rid="B13-biomedicines-09-00234" ref-type="bibr">13</xref>]. PUFAs found in hempseed oil are incorporated into phospholipid bilayers and are integral to membrane fluidity and the maintenance of its permeability [<xref rid="B14-biomedicines-09-00234" ref-type="bibr">14</xref>]. Moreover, the two proteins, edestin and albumin found in hempseed, contain rich amino acid profiles comparable to that of high-quality soybean and egg white [<xref rid="B15-biomedicines-09-00234" ref-type="bibr">15</xref>]. Given the functions and importance of both fatty and amino acids, hempseed and hempseed oil may have some potential, albeit minor, for reducing the incidence of certain diseases, while in parallel conferring a range of health benefits [<xref rid="B15-biomedicines-09-00234" ref-type="bibr">15</xref>,<xref rid="B16-biomedicines-09-00234" ref-type="bibr">16</xref>,<xref rid="B17-biomedicines-09-00234" ref-type="bibr">17</xref>]. Alternatively, marijuana has traditionally been bred for its recreational intoxication properties derived from the THCA-containing resin produced on the protruding secretory hair-like structures known as trichomes which are predominantly located on female reproductive parts of the <italic>Cannabis</italic> plant [<xref rid="B18-biomedicines-09-00234" ref-type="bibr">18</xref>,<xref rid="B19-biomedicines-09-00234" ref-type="bibr">19</xref>]. The sticky resin produced from these specialised epidermal glands is a rich mix of cannabinoid and non-cannabinoid constituents, numbering at least 104 and 441, respectively [<xref rid="B20-biomedicines-09-00234" ref-type="bibr">20</xref>,<xref rid="B21-biomedicines-09-00234" ref-type="bibr">21</xref>]. Most recently, two novel cannabinoids, namely &#x00394;<sup>9</sup>-tetrahydrocannabiphorol (&#x00394;<sup>9</sup>-THCP) and cannabidiphorol (CBDP), near identical in structure to THC and cannabidiol (CBD), respectively, were identified [<xref rid="B22-biomedicines-09-00234" ref-type="bibr">22</xref>]. Notably, &#x00394;<sup>9</sup>-THCP was demonstrated to possess higher cannabimimetic activity than THC, and its recent discovery is therefore postulated as a potential candidate cannabinoid responsible for variation in pharmacological properties observed in uncharacterised <italic>Cannabis</italic> varieties. This also identifies the likelihood of secondary metabolites present in <italic>Cannabis</italic> resin that remain to be discovered.</p><p>In addition to possessing a range of phenotypic and chemotypic traits of interest to the textile, medicinal, food and energy industries as an agricultural crop, <italic>Cannabis</italic> is extremely versatile and hardy, hence the application of the colloquial term for this species, &#x02018;weed&#x02019;. The phenotypic flexibility of <italic>Cannabis</italic> provides it with the capacity to adapt and survive a range of abiotic and biotic insults, such as drought [<xref rid="B23-biomedicines-09-00234" ref-type="bibr">23</xref>], heavy metal stress [<xref rid="B24-biomedicines-09-00234" ref-type="bibr">24</xref>], high temperature [<xref rid="B25-biomedicines-09-00234" ref-type="bibr">25</xref>], poor soil nutrient content [<xref rid="B3-biomedicines-09-00234" ref-type="bibr">3</xref>], high plant density [<xref rid="B26-biomedicines-09-00234" ref-type="bibr">26</xref>], and stem damage from the larva of <italic>Ostrinia nubilalis</italic>, the European corn borer [<xref rid="B27-biomedicines-09-00234" ref-type="bibr">27</xref>]. Tolerance to a range of abiotic stress conditions is exemplified by the tap root of <italic>Cannabis</italic> which is able to adapt to highly variable edaphic conditions, either penetrating deep (greater than 2 metres) into dry soil, or developing an extensive lateral root network in response to its growth in soil that has a high moisture content [<xref rid="B26-biomedicines-09-00234" ref-type="bibr">26</xref>]. Further, the widespread legalisation of medicinal application and recreational use of <italic>Cannabis</italic> is driving the growth of diverse research programs encompassing the broad scope, from plant breeding to clinical trials. In the United States of America (USA), for example, to date, 33 states have approved the medicinal use of <italic>Cannabis</italic>, while 14 states and territories have legalised the recreational use of marijuana by adults. At the federal level in the USA, however, <italic>Cannabis</italic> remains a &#x02018;<italic>Schedule I Substance</italic>&#x02019;. In direct contrast to the heavy legislation of <italic>Cannabis</italic> in the USA, its direct neighbour, Canada, legalised the use of <italic>Cannabis</italic> across the country in 2018 under the &#x02018;<italic>Cannabis Act</italic>&#x02019; [<xref rid="B28-biomedicines-09-00234" ref-type="bibr">28</xref>]. As the legislative approval of <italic>Cannabis</italic> use increases worldwide, there will be an increasing need for interdisciplinary research to characterise secondary metabolites of interest and to increase the production of <italic>Cannabis</italic> to meet the demand for medicinal and recreational products.</p><p>Currently, there exists an extant literature on the medical potential for the best characterised cannabinoids, THC and CBD [<xref rid="B29-biomedicines-09-00234" ref-type="bibr">29</xref>,<xref rid="B30-biomedicines-09-00234" ref-type="bibr">30</xref>,<xref rid="B31-biomedicines-09-00234" ref-type="bibr">31</xref>,<xref rid="B32-biomedicines-09-00234" ref-type="bibr">32</xref>,<xref rid="B33-biomedicines-09-00234" ref-type="bibr">33</xref>,<xref rid="B34-biomedicines-09-00234" ref-type="bibr">34</xref>]. Significantly less attention in medical research has been paid to the potential for the minor phytocannabinoids to treat illnesses, and there is still the need for methods to produce these cannabinoids cost-effectively for commercial production. In particular, the medical <italic>Cannabis</italic> industry faces significant challenges in multiple aspects of product development. For instance, THC is associated with multiple side effects, and furthermore, pharmaceutical-standard THC and CBD are expensive to produce. Due to these hurdles, many companies around the world which have attempted to capitalise on the increasing legality of <italic>Cannabis</italic> have been unsuccessful [<xref rid="B35-biomedicines-09-00234" ref-type="bibr">35</xref>]. Therefore, here we review the current literature describing emerging research concerning the medical potential of the minor cannabinoids, as well as to outline the agricultural and production considerations that will be necessary to meet the needs of the growing medical market. Readers interested primarily in the effects of CBD and THC should consult any of the substantial reviews on these topics that are published elsewhere and referred to here in <xref ref-type="sec" rid="sec2dot2-biomedicines-09-00234">Section 2.2</xref>. It should also be noted that there are some recent review articles on the molecular targets of the minor cannabinoids [<xref rid="B36-biomedicines-09-00234" ref-type="bibr">36</xref>,<xref rid="B37-biomedicines-09-00234" ref-type="bibr">37</xref>], but to the best of our knowledge, no published review of the current literature has combined this research with the potential for improving <italic>Cannabis</italic> yield and extraction efficacy to make these possibilities economically and logistically pragmatic. This review therefore presents a novel, interdisciplinary perspective on the practical possibilities for improving the <italic>Cannabis</italic> species for its utilisation in the cannabinoid industry in the near future.</p></sec><sec id="sec2-biomedicines-09-00234"><title>2. The Endocannabinoid System and Its Associated Molecular Targets</title><sec id="sec2dot1-biomedicines-09-00234"><title>2.1. An Overview of the Endocannabinoid System</title><p>The discovery of the endogenous cannabinoid system followed the initial isolation [<xref rid="B38-biomedicines-09-00234" ref-type="bibr">38</xref>] and synthesis [<xref rid="B39-biomedicines-09-00234" ref-type="bibr">39</xref>] of the primary psychoactive compound in <italic>Cannabis</italic>, THC. Following on from this in the late 1980s, and into the early 1990s, two cannabinoid receptors, CB<sub>1</sub> and CB<sub>2</sub>, were identified [<xref rid="B40-biomedicines-09-00234" ref-type="bibr">40</xref>,<xref rid="B41-biomedicines-09-00234" ref-type="bibr">41</xref>]. Surprisingly, it was discovered that CB<sub>1</sub> was highly abundant in the central nervous system (CNS), and in the CNS, CB<sub>1</sub> is one of the most profuse G protein-coupled receptors [<xref rid="B42-biomedicines-09-00234" ref-type="bibr">42</xref>]. The identification of these two CB receptors subsequently led to the discovery of an endogenous receptor ligand termed arachidonylethanolamide (anandamide), a receptor ligand accurately predicted to exist based on the presence of the CB receptors themselves [<xref rid="B43-biomedicines-09-00234" ref-type="bibr">43</xref>]. A second receptor ligand, 2-arachidonoylglycerol (2-AG) was later identified [<xref rid="B44-biomedicines-09-00234" ref-type="bibr">44</xref>,<xref rid="B45-biomedicines-09-00234" ref-type="bibr">45</xref>]. Anandamide and 2-AG are both synthesised from arachidonic acid. Synthesis of anandamide is complex, and therefore remains to be elucidated, though it is thought to occur largely via the cleavage of arachidonic acid by a phospholipase D from its membrane precursor, N-arachidonoyl phosphatidylethanolamine [<xref rid="B46-biomedicines-09-00234" ref-type="bibr">46</xref>]. The synthesis of 2-AG occurs following the conversion of diacylglycerol by the metabolic enzyme, diacylglycerol lipase (DAGL). Hydrolysis of anandamide occurs via the enzyme activity of fatty acid amide hydrolase (FAAH), whereas 2-AG is hydrolysed by both FAAH and monoacylglycerol lipase (MAGL) [<xref rid="B47-biomedicines-09-00234" ref-type="bibr">47</xref>]. Inhibition of these enzymes increases anandamide and 2-AG concentrations and has therapeutic potential [<xref rid="B48-biomedicines-09-00234" ref-type="bibr">48</xref>,<xref rid="B49-biomedicines-09-00234" ref-type="bibr">49</xref>,<xref rid="B50-biomedicines-09-00234" ref-type="bibr">50</xref>]. Similarly, it is possible that modulation of precursory compounds of anandamide and 2-AG may have therapeutic potential [<xref rid="B51-biomedicines-09-00234" ref-type="bibr">51</xref>].</p><p>Previous investigations into CB receptor distribution within the fetal, neonatal and adult human brain revealed that the CB receptors were primarily localised to areas responsible for; (1) higher cognitive function; (2) movement, and; (3) control of sensory and motor functions of the autonomic nervous system [<xref rid="B52-biomedicines-09-00234" ref-type="bibr">52</xref>]. Protein crystallisation has revealed the structure of CB<sub>1</sub> [<xref rid="B53-biomedicines-09-00234" ref-type="bibr">53</xref>] and CB<sub>2</sub> [<xref rid="B54-biomedicines-09-00234" ref-type="bibr">54</xref>] to assist in the characterisation of the molecular binding of ligands, such as THC, and potentially other key cannabinoids, both naturally or synthetically produced. Using radiolabelled synthetic cannabinoids, it was shown that the highest density of cannabinoid binding, and thus CB receptor localisation, appeared in the basal ganglia, hippocampus and cerebellum [<xref rid="B42-biomedicines-09-00234" ref-type="bibr">42</xref>]. Cannabinoids were shown to function on hippocampal presynaptic receptors, via regulating the release of &#x003b3;-aminobutyric acid (GABA) to modulate higher cognitive functions, while also increasing the activity of p38 mitogen-activated protein kinases [<xref rid="B55-biomedicines-09-00234" ref-type="bibr">55</xref>,<xref rid="B56-biomedicines-09-00234" ref-type="bibr">56</xref>]. Similarly, GABA modulation in the basal ganglia, specifically the presynaptic striatal projection neuron axons and their termini, was found to be stimulated to differing degrees by either endocannabinoids or synthetic cannabinoids [<xref rid="B57-biomedicines-09-00234" ref-type="bibr">57</xref>,<xref rid="B58-biomedicines-09-00234" ref-type="bibr">58</xref>]. The binding of the CB<sub>1</sub> receptor by both endogenous and exogenous cannabinoids also modulates excitatory synaptic transmission in Purkinje cells located in the cerebellum [<xref rid="B59-biomedicines-09-00234" ref-type="bibr">59</xref>,<xref rid="B60-biomedicines-09-00234" ref-type="bibr">60</xref>,<xref rid="B61-biomedicines-09-00234" ref-type="bibr">61</xref>,<xref rid="B62-biomedicines-09-00234" ref-type="bibr">62</xref>]. Crucially, endocannabinoid signalling was recognised as the mediatory secondary messenger responsible for long-term potentiation, and depression [<xref rid="B49-biomedicines-09-00234" ref-type="bibr">49</xref>,<xref rid="B63-biomedicines-09-00234" ref-type="bibr">63</xref>], which are both fundamental to the control of synaptic transmission. CB<sub>1</sub> receptors and endocannabinoid signalling also interacts with other systems in the brain, such as the dopaminergic [<xref rid="B64-biomedicines-09-00234" ref-type="bibr">64</xref>], and glucocorticoid [<xref rid="B65-biomedicines-09-00234" ref-type="bibr">65</xref>] pathways, to modulate stress response and associative learning processes.</p><p>While early understanding of receptor distribution suggested exclusive &#x02018;central&#x02019; aggregation in specific regions of the brain, it is now understood that there is a more extensive presence of CB<sub>1</sub> type receptors in peripheral tissues. Two CB<sub>1</sub> receptor isoforms have since been identified, both of which display distinct expression patterns in pancreatic &#x003b2;-cells and liver hepatocytes [<xref rid="B66-biomedicines-09-00234" ref-type="bibr">66</xref>]. Antagonism of peripheral CB receptors located in skeletal muscles was shown to trigger glucose uptake, while simultaneously initiating lipid mobilisation in white adipose tissue [<xref rid="B67-biomedicines-09-00234" ref-type="bibr">67</xref>]. Though the protein expression pattern of CB<sub>1</sub> does show some overlap with CB<sub>2</sub> in peripheral tissues, and conversely some CB<sub>2</sub> receptors are cerebrally positioned [<xref rid="B68-biomedicines-09-00234" ref-type="bibr">68</xref>,<xref rid="B69-biomedicines-09-00234" ref-type="bibr">69</xref>,<xref rid="B70-biomedicines-09-00234" ref-type="bibr">70</xref>,<xref rid="B71-biomedicines-09-00234" ref-type="bibr">71</xref>,<xref rid="B72-biomedicines-09-00234" ref-type="bibr">72</xref>], peripheral receptors are predominantly CB<sub>2</sub> type receptors. Analysis of <italic>CB<sub>2</sub></italic> transcript levels has previously revealed its expression in the tonsils, spleen, and peripheral blood mononuclear cells, where further cell isolation showed detectable <italic>CB<sub>2</sub></italic> transcript levels in polymorphonuclear neutrophils (PMN), T4 cells, T8 cells, natural killer (NK) cells, macrophages, and B cells. However, at the protein level, the CB<sub>2</sub> receptor appears to be restricted to B cells [<xref rid="B73-biomedicines-09-00234" ref-type="bibr">73</xref>]. Similarly, CB<sub>2</sub> receptor binding has been observed in other immune system regions, namely the lymph node cortex, as well as in the Peyer&#x02019;s patches, which are areas of B lymphocyte aggregation [<xref rid="B74-biomedicines-09-00234" ref-type="bibr">74</xref>]. The expression and/or localisation of functional CB<sub>2</sub> protein has also been reported for mast cells, modulating their initial activation, or downregulating their activity post their initial activation, an activity change which can in turn provoke an anti-inflammatory response [<xref rid="B75-biomedicines-09-00234" ref-type="bibr">75</xref>]. Anandamide and 2-AG, as well as their metabolic enzymes, are detectable in blood [<xref rid="B76-biomedicines-09-00234" ref-type="bibr">76</xref>,<xref rid="B77-biomedicines-09-00234" ref-type="bibr">77</xref>], hair [<xref rid="B78-biomedicines-09-00234" ref-type="bibr">78</xref>,<xref rid="B79-biomedicines-09-00234" ref-type="bibr">79</xref>,<xref rid="B80-biomedicines-09-00234" ref-type="bibr">80</xref>], saliva [<xref rid="B81-biomedicines-09-00234" ref-type="bibr">81</xref>,<xref rid="B82-biomedicines-09-00234" ref-type="bibr">82</xref>,<xref rid="B83-biomedicines-09-00234" ref-type="bibr">83</xref>], breast milk [<xref rid="B84-biomedicines-09-00234" ref-type="bibr">84</xref>,<xref rid="B85-biomedicines-09-00234" ref-type="bibr">85</xref>], and reproductive fluids [<xref rid="B84-biomedicines-09-00234" ref-type="bibr">84</xref>,<xref rid="B86-biomedicines-09-00234" ref-type="bibr">86</xref>]. Compounded with the peripheral anti-inflammatory response, CB<sub>2</sub> receptor agonists can mediate peripheral antinociception without the psychotropic CNS effects associated with phytocannabinoid CB<sub>1</sub> receptor binding [<xref rid="B87-biomedicines-09-00234" ref-type="bibr">87</xref>,<xref rid="B88-biomedicines-09-00234" ref-type="bibr">88</xref>]. This characteristic of exerting medically beneficial effects, while simultaneously avoiding any psychotropic responses, is likely to form a key focus of future cannabinoid research.</p></sec><sec id="sec2dot2-biomedicines-09-00234"><title>2.2. The Expanded Cannabinoid System and Its Less Characterised Receptors</title><p>It has been clearly demonstrated that the collective effects of cannabinoid administration cannot be explained solely by the presence of CB receptors. Conversely, it has been increasingly recognised that cannabinoids have the potential to affect other molecular targets and receptor types, particularly given their role as presynaptic secondary messengers on various neuron species [<xref rid="B89-biomedicines-09-00234" ref-type="bibr">89</xref>,<xref rid="B90-biomedicines-09-00234" ref-type="bibr">90</xref>] (<xref rid="biomedicines-09-00234-t001" ref-type="table">Table 1</xref>). One such receptor is the G protein-coupled receptor (GPCR), GPR55, with the <italic>GPR55</italic> transcript identified in the adrenals, jejunum, and ileum in mammalian systems [<xref rid="B91-biomedicines-09-00234" ref-type="bibr">91</xref>]. Studies on canine, rat and mouse gastrointestinal systems collectively suggest that GPR55 may be involved in smooth muscle contractions and colonic motility, especially when activated by CBD, pointing to a potential target for treatment of some gastrointestinal disorders [<xref rid="B92-biomedicines-09-00234" ref-type="bibr">92</xref>,<xref rid="B93-biomedicines-09-00234" ref-type="bibr">93</xref>,<xref rid="B94-biomedicines-09-00234" ref-type="bibr">94</xref>,<xref rid="B95-biomedicines-09-00234" ref-type="bibr">95</xref>]. Human embryonic kidney 293 (HEK293) cells expressing the GPR55 protein have been assessed for their response when treated with the lysolipid, L-&#x003b1;-lysophosphatidylinositol (LPI), as well as following their treatment with endogenous, synthetic or phytocannabinoids. LPI was found to induce phosphorylation of the protein, extracellular signal-related kinase (ERK) in GPR55-expressing cells, while also initiating a transient Ca<sup>2+</sup> signal involved in downstream messaging and intracellular processing [<xref rid="B96-biomedicines-09-00234" ref-type="bibr">96</xref>]. The degree of elevation in the concentration of Ca<sup>2+</sup> increases in HEK293 cells when mediated by GPR55-phospholipase C coupling varied depending on whether THC, anandamide, methanandamide or the CB<sub>2</sub> agonist, JWH015 was administered [<xref rid="B97-biomedicines-09-00234" ref-type="bibr">97</xref>]. However, there was no Ca<sup>2+</sup> response initiated by CBD, the CBD regioisomer abnormal CBD, the endogenous cannabinoids, 2-arachidonoylglycerol and <italic>O</italic>-arachidonoyl ethanolamine, or the synthetic cannabinoids, WIN55,212-2 and CP55,940 [<xref rid="B97-biomedicines-09-00234" ref-type="bibr">97</xref>]. Beyond Ca<sup>2+</sup> transients, cannabinoid ligand interaction with the GPR55 receptor promotes ERK phosphorylation, as well as the varied activation of cyclic adenosine monophosphate (cAMP) response element binding protein (CREB), nuclear factor-<sub>&#x003ba;</sub>B (NF-<sub>&#x003ba;</sub>B) and nuclear factor of activated T-cell (NFAT) transcription factors, the latter two of which are involved in inflammation of endothelial cells and irritable bowel syndrome (IBS) [<xref rid="B98-biomedicines-09-00234" ref-type="bibr">98</xref>,<xref rid="B99-biomedicines-09-00234" ref-type="bibr">99</xref>,<xref rid="B100-biomedicines-09-00234" ref-type="bibr">100</xref>,<xref rid="B101-biomedicines-09-00234" ref-type="bibr">101</xref>]. The <italic>GPR55</italic> transcript can also be found in the basal ganglia, hippocampus, forebrain, cerebellum, cortex and large dorsal root ganglion (DRG) [<xref rid="B97-biomedicines-09-00234" ref-type="bibr">97</xref>,<xref rid="B102-biomedicines-09-00234" ref-type="bibr">102</xref>,<xref rid="B103-biomedicines-09-00234" ref-type="bibr">103</xref>,<xref rid="B104-biomedicines-09-00234" ref-type="bibr">104</xref>]. The expression of <italic>GPR55</italic> in these tissues significantly broadens the potential for its therapeutic application. For instance, activation of the GPR55 receptor by THC enhances neuronal excitability and reduces the M-type potassium current, which when combined with the expression pattern of <italic>GPR55</italic> in the large DRG, indicates a nociceptive role [<xref rid="B97-biomedicines-09-00234" ref-type="bibr">97</xref>]. Inflammatory pain was modulated by abnormal CBD through GPR55 antagonism in acute arthritis models in rats [<xref rid="B105-biomedicines-09-00234" ref-type="bibr">105</xref>]. Evidence of pro-nociception was observed in rats when the abundance of GPR55-dependent Ca<sup>2+</sup> increased in periaqueductal grey neurons and which preceded a pain threshold reduction [<xref rid="B106-biomedicines-09-00234" ref-type="bibr">106</xref>]. However, another study [<xref rid="B107-biomedicines-09-00234" ref-type="bibr">107</xref>] reported that GPR55 knockout mice show no difference to wild-type mice in neuropathic pain models.</p><p>Another seven-transmembrane G protein-coupled receptor, termed GPR18, was first identified in canine gastric mucosa and a human colonic cancer cell line, with a high abundance of the <italic>GPR18</italic> transcript detected in human testis and spleen tissue [<xref rid="B108-biomedicines-09-00234" ref-type="bibr">108</xref>]. The candidate ligand was later suggested to be <italic>N</italic>-arachidonoyl glycine (NAGly), an anandamide metabolite, which was first detected when GPR18-expressing cell lines, including the L929, K562 and Chinese hamster ovary (CHO) cell lines produced, high levels of intracellular Ca<sup>2+</sup> and inhibited the production of cAMP following NAGly exposure [<xref rid="B109-biomedicines-09-00234" ref-type="bibr">109</xref>]. In addition, quantitative real-time PCR analysis revealed high levels of <italic>GPR18</italic> expression in peripheral lymphocytes, further supporting the suggestion of a role in immune system function [<xref rid="B109-biomedicines-09-00234" ref-type="bibr">109</xref>].</p><p>The transient receptor potential vanilloid (TRPV) channels are a subfamily of transmembrane ligand-gated ion channels that mediate signal transduction processes initiated by a broad range of noxious stimuli in animals, with the TRPVs, TRPV1 through to TRPV4, activated to varying degrees via cannabinoid application. TRPV expression in several human tissues and the documented role of TRPVs in human disease is a current avenue of interest. The capsaicin and temperature (~42 &#x000b0;C) responsive TRPV1, displays an ambiguous expression profile. However, the weight of evidence suggests that its expression domain is rather broad in animal systems. Specifically, the TRPV1 protein was observed to be localised to the dorsal root and trigeminal ganglions [<xref rid="B110-biomedicines-09-00234" ref-type="bibr">110</xref>], thermoregulatory tissue smooth muscle cells [<xref rid="B111-biomedicines-09-00234" ref-type="bibr">111</xref>], urothelial cells [<xref rid="B112-biomedicines-09-00234" ref-type="bibr">112</xref>], corneal fibroblasts [<xref rid="B113-biomedicines-09-00234" ref-type="bibr">113</xref>], and a broad distribution profile in the brain, including the hippocampus, cortex and olfactory bulb [<xref rid="B114-biomedicines-09-00234" ref-type="bibr">114</xref>]. Sharing 50% sequence identity to TRPV1, TRPV2 has been demonstrated to respond to high-intensity thermal stimuli (~52 &#x000b0;C). However, unlike TRPV1, TRPV2 is insensitive to capsaicin [<xref rid="B115-biomedicines-09-00234" ref-type="bibr">115</xref>]. Given its sensory involvement, TRPV2 localisation in the ganglia is unsurprising. However, TRPV2 is also localised to the brain, lung, spleen, intestine, mast cells and lymphocytes [<xref rid="B115-biomedicines-09-00234" ref-type="bibr">115</xref>,<xref rid="B116-biomedicines-09-00234" ref-type="bibr">116</xref>,<xref rid="B117-biomedicines-09-00234" ref-type="bibr">117</xref>,<xref rid="B118-biomedicines-09-00234" ref-type="bibr">118</xref>], which, when considered together, infers additional TRPV2 function beyond heat sensing, and by extension, activation by non-thermal receptor modulators. The initiation of signal cascades via TRPV2 are potentially involved in diseases and physiological responses including cancer [<xref rid="B119-biomedicines-09-00234" ref-type="bibr">119</xref>], the innate and adaptive immune responses [<xref rid="B116-biomedicines-09-00234" ref-type="bibr">116</xref>,<xref rid="B117-biomedicines-09-00234" ref-type="bibr">117</xref>,<xref rid="B120-biomedicines-09-00234" ref-type="bibr">120</xref>,<xref rid="B121-biomedicines-09-00234" ref-type="bibr">121</xref>], cardiomyopathy [<xref rid="B122-biomedicines-09-00234" ref-type="bibr">122</xref>,<xref rid="B123-biomedicines-09-00234" ref-type="bibr">123</xref>], muscular dystrophy [<xref rid="B124-biomedicines-09-00234" ref-type="bibr">124</xref>,<xref rid="B125-biomedicines-09-00234" ref-type="bibr">125</xref>], and insulin secretion response [<xref rid="B126-biomedicines-09-00234" ref-type="bibr">126</xref>,<xref rid="B127-biomedicines-09-00234" ref-type="bibr">127</xref>,<xref rid="B128-biomedicines-09-00234" ref-type="bibr">128</xref>].</p><p>The cannabinoid-responsive TRPVs, TRPV3 and TRPV4, are also temperature sensitive proteins. The responsive temperature range (27&#x02013;40 &#x000b0;C) for these two receptors is below that of TRPV1 and TRPV2, but they do closely overlap with one another [<xref rid="B129-biomedicines-09-00234" ref-type="bibr">129</xref>,<xref rid="B130-biomedicines-09-00234" ref-type="bibr">130</xref>,<xref rid="B131-biomedicines-09-00234" ref-type="bibr">131</xref>,<xref rid="B132-biomedicines-09-00234" ref-type="bibr">132</xref>]. Their thermosensory involvement localises these two TRPVs to keratinocytes, where they sense warmth on the skin and transmit a signal to nearby neurons [<xref rid="B133-biomedicines-09-00234" ref-type="bibr">133</xref>,<xref rid="B134-biomedicines-09-00234" ref-type="bibr">134</xref>,<xref rid="B135-biomedicines-09-00234" ref-type="bibr">135</xref>,<xref rid="B136-biomedicines-09-00234" ref-type="bibr">136</xref>,<xref rid="B137-biomedicines-09-00234" ref-type="bibr">137</xref>,<xref rid="B138-biomedicines-09-00234" ref-type="bibr">138</xref>]. In the tongue and nasal epithelium, TRPV3 is activated by the &#x02018;pungent&#x02019; carvacrol as well as by thymol and camphor [<xref rid="B133-biomedicines-09-00234" ref-type="bibr">133</xref>,<xref rid="B139-biomedicines-09-00234" ref-type="bibr">139</xref>], whereas the mevalonate (MVA) pathway product and cannabinoid/terpenoid precursor, isopentenyl diphosphate (IPP), has been shown to inhibit TRPV3 activity [<xref rid="B140-biomedicines-09-00234" ref-type="bibr">140</xref>]. TRPV4, in association with aquaporin 5 (AQP5), is additionally involved in osmosensing and regulatory volume decrease in cells following swelling in hypotonic environments [<xref rid="B141-biomedicines-09-00234" ref-type="bibr">141</xref>,<xref rid="B142-biomedicines-09-00234" ref-type="bibr">142</xref>,<xref rid="B143-biomedicines-09-00234" ref-type="bibr">143</xref>,<xref rid="B144-biomedicines-09-00234" ref-type="bibr">144</xref>]. Located in the brain [<xref rid="B145-biomedicines-09-00234" ref-type="bibr">145</xref>,<xref rid="B146-biomedicines-09-00234" ref-type="bibr">146</xref>], kidneys [<xref rid="B147-biomedicines-09-00234" ref-type="bibr">147</xref>], CNS [<xref rid="B148-biomedicines-09-00234" ref-type="bibr">148</xref>], and endocardium [<xref rid="B149-biomedicines-09-00234" ref-type="bibr">149</xref>], TRPV4 activity is also modulated by phorbol esters and arachidonic acid expanding its activation beyond physical stimuli [<xref rid="B150-biomedicines-09-00234" ref-type="bibr">150</xref>,<xref rid="B151-biomedicines-09-00234" ref-type="bibr">151</xref>].</p><p>In addition to the vanilloid subtype of the transient receptor potential channels are the melastatin and ankyrin subtypes. Of the melastatin type, transient receptor potential melastatin 8 (TRPM8) is a cold/menthol-responsive channel located in the DRG and trigeminal ganglia [<xref rid="B152-biomedicines-09-00234" ref-type="bibr">152</xref>,<xref rid="B153-biomedicines-09-00234" ref-type="bibr">153</xref>]. Of the ankyrin subtype, transient receptor potential ankyrin 1 (TRPA1) acts similarly to TRPM8 in response to cold stimuli covering a similar temperature range (~8&#x02013;28 &#x000b0;C). However, it is suggested that TRPA1 contributes to sensation of lower temperatures, and is also similarly localised in sensory neurons [<xref rid="B154-biomedicines-09-00234" ref-type="bibr">154</xref>,<xref rid="B155-biomedicines-09-00234" ref-type="bibr">155</xref>,<xref rid="B156-biomedicines-09-00234" ref-type="bibr">156</xref>,<xref rid="B157-biomedicines-09-00234" ref-type="bibr">157</xref>]. TRPA1 is additionally activated by formalin and allyl isothiocyanates such as mustard oil [<xref rid="B158-biomedicines-09-00234" ref-type="bibr">158</xref>,<xref rid="B159-biomedicines-09-00234" ref-type="bibr">159</xref>], and has further been implicated in eliciting inflammatory pain [<xref rid="B160-biomedicines-09-00234" ref-type="bibr">160</xref>,<xref rid="B161-biomedicines-09-00234" ref-type="bibr">161</xref>,<xref rid="B162-biomedicines-09-00234" ref-type="bibr">162</xref>,<xref rid="B163-biomedicines-09-00234" ref-type="bibr">163</xref>].</p><p>Multiple other targets show notable interactions with the endocannabinoid system; however, a comprehensive description of all interactions is beyond the scope of this review. Briefly, other notable molecular interactions include glycine receptors with anandamide, and in addition, CBD and THC have also been shown to activate glycine receptors [<xref rid="B164-biomedicines-09-00234" ref-type="bibr">164</xref>,<xref rid="B165-biomedicines-09-00234" ref-type="bibr">165</xref>]. Further, THC appears to exhibit dose-dependent effects on glycine receptor activation [<xref rid="B166-biomedicines-09-00234" ref-type="bibr">166</xref>]. The activation of peroxisome proliferator-activated receptors (PPAR), in particular the &#x003b1; and &#x003b3; subtypes, is responsible for many of the metabolic, analgesic, neuroprotective, and other health-related benefits of cannabinoids [<xref rid="B167-biomedicines-09-00234" ref-type="bibr">167</xref>]. Cannabinoids have also been shown to interact with serotonergic sites, particularly with the 5-HT<sub>1A</sub> [<xref rid="B168-biomedicines-09-00234" ref-type="bibr">168</xref>] and 5-HT<sub>2A</sub> [<xref rid="B169-biomedicines-09-00234" ref-type="bibr">169</xref>,<xref rid="B170-biomedicines-09-00234" ref-type="bibr">170</xref>] receptors, and these interactions are strongly associated with disorders such as anxiety and post-traumatic stress [<xref rid="B171-biomedicines-09-00234" ref-type="bibr">171</xref>,<xref rid="B172-biomedicines-09-00234" ref-type="bibr">172</xref>]. Consequently, the spectrum of potential therapeutic applications is very broad for cannabinoids and would require a specifically dedicated and lengthy review in its own right. Currently lacking are robust, double-blind in vivo and clinical studies of the constituents of the broader cannabinoid profile that target specific diseases, and/or can be used to treat the symptoms of these diseases, possibly via targeting the interactions between cannabinoids and these other putative or lesser-known receptors.</p><table-wrap id="biomedicines-09-00234-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">biomedicines-09-00234-t001_Table 1</object-id><label>Table 1</label><caption><p>Receptor modulation by cannabinoids and studies outlining their potential involvement in disease treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Receptor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cannabinoid</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disease/Interaction</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="14" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>CB<sub>1</sub></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anandamide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Appetite</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B173-biomedicines-09-00234" ref-type="bibr">173</xref>,<xref rid="B174-biomedicines-09-00234" ref-type="bibr">174</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Met-F-AEA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thyroid cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro human</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B175-biomedicines-09-00234" ref-type="bibr">175</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">THCB <sub>(PA)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B176-biomedicines-09-00234" ref-type="bibr">176</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">THC <sub>(PA)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epilepsy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B177-biomedicines-09-00234" ref-type="bibr">177</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sleep</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Various studies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B178-biomedicines-09-00234" ref-type="bibr">178</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">THCP <sub>(Ag)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain, anxiety, hypothermia, catalepsy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B22-biomedicines-09-00234" ref-type="bibr">22</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">THCV <sub>(^)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain, anxiety, hypothermia, catalepsy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B179-biomedicines-09-00234" ref-type="bibr">179</xref>,<xref rid="B180-biomedicines-09-00234" ref-type="bibr">180</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parkinson&#x02019;s disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B181-biomedicines-09-00234" ref-type="bibr">181</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Obesity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B182-biomedicines-09-00234" ref-type="bibr">182</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epilepsy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro murine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B183-biomedicines-09-00234" ref-type="bibr">183</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">THC, WIN55,212-2,<break/>CP55, 940</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Emesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Animal models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B184-biomedicines-09-00234" ref-type="bibr">184</xref>,<xref rid="B185-biomedicines-09-00234" ref-type="bibr">185</xref>,<xref rid="B186-biomedicines-09-00234" ref-type="bibr">186</xref>,<xref rid="B187-biomedicines-09-00234" ref-type="bibr">187</xref>,<xref rid="B188-biomedicines-09-00234" ref-type="bibr">188</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">WIN55,212-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parkinson&#x02019;s disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine model</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B189-biomedicines-09-00234" ref-type="bibr">189</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prostate cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro human</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B190-biomedicines-09-00234" ref-type="bibr">190</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WIN55,212-2, JWH-133</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast, lung cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro human</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B191-biomedicines-09-00234" ref-type="bibr">191</xref>,<xref rid="B192-biomedicines-09-00234" ref-type="bibr">192</xref>]</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>CB<sub>2</sub></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBC <sub>(Ag)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inflammation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B193-biomedicines-09-00234" ref-type="bibr">193</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBG <sub>(PA)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inflammatory bowel disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B194-biomedicines-09-00234" ref-type="bibr">194</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HU-308, AM630</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parkinson&#x02019;s disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B195-biomedicines-09-00234" ref-type="bibr">195</xref>,<xref rid="B196-biomedicines-09-00234" ref-type="bibr">196</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">THCP <sub>(Ag)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain, anxiety, hypothermia, catalepsy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B22-biomedicines-09-00234" ref-type="bibr">22</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">THCV <sub>(^)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inflammation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B180-biomedicines-09-00234" ref-type="bibr">180</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>CB<sub>2</sub></bold>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">THCV <sub>(^)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parkinson&#x02019;s disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B181-biomedicines-09-00234" ref-type="bibr">181</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain, anxiety, hypothermia, catalepsy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B179-biomedicines-09-00234" ref-type="bibr">179</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WIN55,212-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prostate cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro human</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B190-biomedicines-09-00234" ref-type="bibr">190</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WIN55,212-2, JWH-133</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast, lung cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro human</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B191-biomedicines-09-00234" ref-type="bibr">191</xref>,<xref rid="B192-biomedicines-09-00234" ref-type="bibr">192</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>GPR55</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abnormal CBD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parkinson&#x02019;s disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B103-biomedicines-09-00234" ref-type="bibr">103</xref>]</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>GPR55</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abnormal CBD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain/arthritis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B105-biomedicines-09-00234" ref-type="bibr">105</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBD <sub>(An)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gastrointestinal disorders</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Canine, murine models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B93-biomedicines-09-00234" ref-type="bibr">93</xref>,<xref rid="B94-biomedicines-09-00234" ref-type="bibr">94</xref>,<xref rid="B95-biomedicines-09-00234" ref-type="bibr">95</xref>,<xref rid="B96-biomedicines-09-00234" ref-type="bibr">96</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CBDV <sub>(An)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rett syndrome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B197-biomedicines-09-00234" ref-type="bibr">197</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LPI inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B198-biomedicines-09-00234" ref-type="bibr">198</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">THC, anandamide, JWH015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro HEK239</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B97-biomedicines-09-00234" ref-type="bibr">97</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>TRPV1</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBDV <sub>(Ag)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-seizure</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro HEK239</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B199-biomedicines-09-00234" ref-type="bibr">199</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBG <sub>(Ag)</sub>, CBGV, CBD <sub>(Ag)</sub>, CBDV <sub>(Ag)</sub>, THCV <sub>(Ag)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Receptor desensitisation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro HEK239</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B200-biomedicines-09-00234" ref-type="bibr">200</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>TRPV2</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBD <sub>(Ag)</sub>, CBGV, CBG <sub>(Ag)</sub>, THCV <sub>(Ag)</sub>, CBDV <sub>(Ag)</sub>, CBN <sub>(Ag)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Receptor desensitisation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro HEK239</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B200-biomedicines-09-00234" ref-type="bibr">200</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>TRPV3</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBGV, CBGA <sub>(Ag)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Receptor desensitisation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro HEK239</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B201-biomedicines-09-00234" ref-type="bibr">201</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>TRPV4</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBGV, CBGA, CBN, CBG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Receptor desensitisation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro HEK239</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B201-biomedicines-09-00234" ref-type="bibr">201</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>TRPM8</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBG <sub>(An)</sub>, CBC <sub>(An)</sub>, CBD <sub>(An)</sub>, CBDV <sub>(An)</sub>, THC <sub>(An)</sub>, THCA <sub>(An)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorectal cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro model</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B200-biomedicines-09-00234" ref-type="bibr">200</xref>,<xref rid="B202-biomedicines-09-00234" ref-type="bibr">202</xref>,<xref rid="B203-biomedicines-09-00234" ref-type="bibr">203</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>TRPA1</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBC <sub>(Ag)</sub>, CBN <sub>(Ag)</sub>, THC <sub>(Ag)</sub>, THCV <sub>(Ag)</sub>, THCA <sub>(Ag)</sub>, CBDA, CBG <sub>(Ag)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Receptor desensitisation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro HEK239</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B200-biomedicines-09-00234" ref-type="bibr">200</xref>,<xref rid="B202-biomedicines-09-00234" ref-type="bibr">202</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CBDV <sub>(Ag)</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ulcerative colitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro human</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B204-biomedicines-09-00234" ref-type="bibr">204</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Muscular dystrophy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro studies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B205-biomedicines-09-00234" ref-type="bibr">205</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>PA = Partial Agonist, Ag = Agonist, ^ = Dose Dependent, An = Antagonist.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2dot3-biomedicines-09-00234"><title>2.3. Examples of the Potential Medicinal Use of Cannabinoids</title><p>While research into the cannabinoids and their role in human disease is still in its infancy, the field abounds in promising preliminary studies. Cannabinoids, both of the endo- and phytocannabinoid categories, have been demonstrated to provide protection against further neurodegeneration in lesioned neurons post-treatment with toxic doses of 6-hydroxydopamine, as well as the neuron degeneration linked to Parkinson&#x02019;s disease [<xref rid="B189-biomedicines-09-00234" ref-type="bibr">189</xref>,<xref rid="B206-biomedicines-09-00234" ref-type="bibr">206</xref>]. Moreover, symptoms of dyskinesia associated with Parkinson&#x02019;s disease and other movement disorders, originating from deficiencies in the cannabinoid receptor-rich basal ganglia in marmosets, and reserpine-treated rats, have been reduced by CB<sub>1</sub> receptor stimulation-mediated suppression of involuntary motor behaviour [<xref rid="B189-biomedicines-09-00234" ref-type="bibr">189</xref>,<xref rid="B207-biomedicines-09-00234" ref-type="bibr">207</xref>,<xref rid="B208-biomedicines-09-00234" ref-type="bibr">208</xref>,<xref rid="B209-biomedicines-09-00234" ref-type="bibr">209</xref>,<xref rid="B210-biomedicines-09-00234" ref-type="bibr">210</xref>]. Central nervous system activation of the CB<sub>2</sub> receptor has exhibited promising results in combating the inflammation and oxidative stress of Parkinson&#x02019;s disease which is associated with dopaminergic neuron loss in the substantia nigra pars compacta in nonhuman models [<xref rid="B195-biomedicines-09-00234" ref-type="bibr">195</xref>,<xref rid="B196-biomedicines-09-00234" ref-type="bibr">196</xref>].</p><p>Studies into the treatment of a variety of cancers through cannabinoid use have also proved valuable. For example, CB<sub>1</sub> and CB<sub>2</sub> activation by either endogenous or synthetic receptor ligands has inhibited prostate [<xref rid="B190-biomedicines-09-00234" ref-type="bibr">190</xref>] and pancreatic [<xref rid="B211-biomedicines-09-00234" ref-type="bibr">211</xref>] adenocarcinoma growth, as well as breast [<xref rid="B191-biomedicines-09-00234" ref-type="bibr">191</xref>] and thyroid [<xref rid="B175-biomedicines-09-00234" ref-type="bibr">175</xref>] tumour growth. Modulation of non-CB receptors by the minor cannabinoids is also under investigation for their role in the initiation of oncogenic signalling cascades that may induce the arrest of the cell cycle, or inhibit the growth of tumours [<xref rid="B212-biomedicines-09-00234" ref-type="bibr">212</xref>]. Endocannabinoid-mediated breast cancer cell proliferation has been inhibited by a reduction in prolactin action at the receptor level [<xref rid="B213-biomedicines-09-00234" ref-type="bibr">213</xref>], and CB<sub>1</sub> and CB<sub>2</sub> receptor activation has induced apoptosis of cancerous cells in the breast [<xref rid="B191-biomedicines-09-00234" ref-type="bibr">191</xref>] and colon [<xref rid="B214-biomedicines-09-00234" ref-type="bibr">214</xref>]. In non-small-cell lung cancer cell lines, treatment with agonists targeting CB<sub>1</sub> and CB<sub>2</sub>, or specifically CB<sub>2</sub>, were demonstrated to induce apoptosis, and to attenuate chemotaxis, metastatic growth and development, metastatic proliferation, and angiogenesis [<xref rid="B192-biomedicines-09-00234" ref-type="bibr">192</xref>]. Similarly, cannabinoid activity against vascularization was also observed in human grade glioma cells in mice, with CB<sub>2</sub> activation reducing tumour angiogenesis by inhibiting vascular endothelial cell migration and the suppression of pro-angiogenic factors in tumour cells [<xref rid="B215-biomedicines-09-00234" ref-type="bibr">215</xref>].</p><p>First alluded to over 40 years ago, the use of <italic>Cannabis</italic> as a treatment for epilepsy has garnered traction in recent years and several comprehensive reviews have recently described the efficacy of cannabinoids in the treatment and/or management of epilepsy [<xref rid="B216-biomedicines-09-00234" ref-type="bibr">216</xref>,<xref rid="B217-biomedicines-09-00234" ref-type="bibr">217</xref>,<xref rid="B218-biomedicines-09-00234" ref-type="bibr">218</xref>]. Further evidence of the involvement of the endocannabinoid systems in seizure mitigation is suggested with inactivation of the endocannabinoid degrading, FAAH, with FAAH shown to reduce both kainic acid associated seizure activity, and synaptic decline and damage to cytoskeletal elements in the hippocampus of rat models [<xref rid="B219-biomedicines-09-00234" ref-type="bibr">219</xref>,<xref rid="B220-biomedicines-09-00234" ref-type="bibr">220</xref>]. A double-blind, placebo-controlled study of 218 patients in which CBD was administered at a dose of 10 and 20 mg per kg reduced the frequency of drop seizures in both children and adults with Lennox-Gastaut syndrome, when compared to conventional epilepsy treatment [<xref rid="B221-biomedicines-09-00234" ref-type="bibr">221</xref>]. A similar double-blind, placebo-controlled study of 120 children with the epilepsy disorder, Dravet syndrome, saw a significant reduction in the frequency of convulsive seizures when treated with CBD, as compared with those administered the placebo [<xref rid="B222-biomedicines-09-00234" ref-type="bibr">222</xref>]. In a retrospective, open-labelled study, Press et al. [<xref rid="B223-biomedicines-09-00234" ref-type="bibr">223</xref>] reported improvements in seizure control and frequency reduction in paediatric patients using oral <italic>Cannabis</italic> extracts, as well as additional improvements in some off-target metrics, including alertness and motor skill usage also observed. Use of a THC extract has attenuated seizure duration and termination via the activation of CB<sub>1</sub>. However, inhibition of CB<sub>1</sub> receptor activity has also been demonstrated to increase the frequency and duration of seizures in non-human models, findings which firmly identify a role for CB<sub>1</sub> in seizure responses [<xref rid="B177-biomedicines-09-00234" ref-type="bibr">177</xref>]. Indeed, transgenic CB<sub>1</sub> overexpressing mice were reported to have reduced kainic acid-induced seizure severity and mortality with reduced hippocampal neuron damage [<xref rid="B224-biomedicines-09-00234" ref-type="bibr">224</xref>]. While these examples suggest promise in the efficacy of cannabinoids, or the modulation of cannabinoid receptor activity against epilepsy, there currently remains deficiencies in access to data emerging from large, controlled clinical studies.</p><p>The treatment of Parkinson&#x02019;s disease, cancer and epilepsy are persistently pursued and remain &#x02018;high-value&#x02019; targets for researchers. However, the importance of treating other less deleterious ailments, or the treatment of the negative side effects that originate from the aggressive treatment strategies of major diseases such as cancer, chemotherapy for example, is not without utility. A suite of clinical trials have supported the ability of <italic>Cannabis</italic>-derived metabolite constituents to (1) act as effective antiemetics [<xref rid="B184-biomedicines-09-00234" ref-type="bibr">184</xref>,<xref rid="B185-biomedicines-09-00234" ref-type="bibr">185</xref>,<xref rid="B186-biomedicines-09-00234" ref-type="bibr">186</xref>,<xref rid="B187-biomedicines-09-00234" ref-type="bibr">187</xref>,<xref rid="B188-biomedicines-09-00234" ref-type="bibr">188</xref>], (2) ease the spasticity symptoms associated with Motor Neuron Disease and Multiple Sclerosis [<xref rid="B225-biomedicines-09-00234" ref-type="bibr">225</xref>], (3) stimulate appetite [<xref rid="B173-biomedicines-09-00234" ref-type="bibr">173</xref>,<xref rid="B174-biomedicines-09-00234" ref-type="bibr">174</xref>,<xref rid="B226-biomedicines-09-00234" ref-type="bibr">226</xref>,<xref rid="B227-biomedicines-09-00234" ref-type="bibr">227</xref>,<xref rid="B228-biomedicines-09-00234" ref-type="bibr">228</xref>,<xref rid="B229-biomedicines-09-00234" ref-type="bibr">229</xref>], (4) help regulate sleep patterns [<xref rid="B178-biomedicines-09-00234" ref-type="bibr">178</xref>,<xref rid="B230-biomedicines-09-00234" ref-type="bibr">230</xref>,<xref rid="B231-biomedicines-09-00234" ref-type="bibr">231</xref>,<xref rid="B232-biomedicines-09-00234" ref-type="bibr">232</xref>], (5) initiate analgesia [<xref rid="B233-biomedicines-09-00234" ref-type="bibr">233</xref>,<xref rid="B234-biomedicines-09-00234" ref-type="bibr">234</xref>,<xref rid="B235-biomedicines-09-00234" ref-type="bibr">235</xref>,<xref rid="B236-biomedicines-09-00234" ref-type="bibr">236</xref>], (6) act as an anxiolytic to alleviate the psychotic symptoms of schizophrenia [<xref rid="B237-biomedicines-09-00234" ref-type="bibr">237</xref>,<xref rid="B238-biomedicines-09-00234" ref-type="bibr">238</xref>,<xref rid="B239-biomedicines-09-00234" ref-type="bibr">239</xref>,<xref rid="B240-biomedicines-09-00234" ref-type="bibr">240</xref>,<xref rid="B241-biomedicines-09-00234" ref-type="bibr">241</xref>], (7) treat anxiety and post-traumatic stress disorders [<xref rid="B31-biomedicines-09-00234" ref-type="bibr">31</xref>,<xref rid="B171-biomedicines-09-00234" ref-type="bibr">171</xref>,<xref rid="B242-biomedicines-09-00234" ref-type="bibr">242</xref>], (8) be utilised as palliative care agents [<xref rid="B243-biomedicines-09-00234" ref-type="bibr">243</xref>,<xref rid="B244-biomedicines-09-00234" ref-type="bibr">244</xref>], (9) aid in the acute inflammatory response and its protracted recovery [<xref rid="B245-biomedicines-09-00234" ref-type="bibr">245</xref>], and (10) mitigate the effects of opioid addiction [<xref rid="B246-biomedicines-09-00234" ref-type="bibr">246</xref>,<xref rid="B247-biomedicines-09-00234" ref-type="bibr">247</xref>].</p><p>A full review of the current understanding of cannabis in the medical sphere is beyond the scope of this review and has been published elsewhere [<xref rid="B90-biomedicines-09-00234" ref-type="bibr">90</xref>,<xref rid="B248-biomedicines-09-00234" ref-type="bibr">248</xref>]. Despite much of the current research remaining in the preliminary stages, requiring a greater amount of more stringent, double-blind studies, the medicinal promise of <italic>Cannabis</italic> is readily evident. Meta-analyses relating to the legitimacy of medical <italic>Cannabis</italic>, specifically the use of CBD and THC in control randomised trials, have been conducted. Studies surrounding the use of CBD indicate that the drug is well tolerated with minimal serious adverse side effects and drug&#x02013;drug interactions [<xref rid="B249-biomedicines-09-00234" ref-type="bibr">249</xref>]. CBD is described as effective in the treatment of refractory seizures, but scientifically stringent data are lacking to claim effectiveness for other indications, with concerns remaining about the quality control in drug preparation and long-term safety [<xref rid="B250-biomedicines-09-00234" ref-type="bibr">250</xref>]. It has been noted that inconsistencies across current studies relating to dosage and administration methods limit the conclusions that can be drawn to direct medical intervention using CBD [<xref rid="B251-biomedicines-09-00234" ref-type="bibr">251</xref>]. Currently, cannabinoid therapies for sleep quality and mental health-related disorders also suggest that while preliminary evidence may indicate positive outcomes, the collation of eligible studies provides insufficient evidence to suggest efficacy or promote usage until additional, and more stringent studies have been conducted [<xref rid="B252-biomedicines-09-00234" ref-type="bibr">252</xref>,<xref rid="B253-biomedicines-09-00234" ref-type="bibr">253</xref>]. Although more stringent studies on the effectiveness of cannabinoids to control pain and spasticity exist, additional comprehensive studies demonstrating improvements in the treatment of chemotherapy associated nausea, sleep disorders, weight gain, and Tourette&#x02019;s syndrome, and which also note the risk of short-term adverse events of cannabinoid treatment, are still required [<xref rid="B32-biomedicines-09-00234" ref-type="bibr">32</xref>].</p></sec></sec><sec id="sec3-biomedicines-09-00234"><title>3. The Cannabinoid and Terpene Pathways of <italic>Cannabis</italic></title><p>It is clear that modulation of the endocannabinoid system can be achieved outside of THC, CBD, and their CB receptors. Despite this, the majority of research conducted to date has sought to understand how these two cannabinoids interact with the various constituents of the expanded endocannabinoid system. However, significant knowledge exists concerning what further compounds can be extracted from <italic>Cannabis</italic> as well as an emerging understanding of how such compounds can be efficiently extracted from the <italic>Cannabis</italic> plant. To date, the most studied phytochemicals in <italic>Cannabis</italic> are the cannabinoids and terpenes. Together, these two classes of phytochemical comprise approximately 41% of the total number of known secondary metabolites identified in <italic>Cannabis</italic> [<xref rid="B21-biomedicines-09-00234" ref-type="bibr">21</xref>,<xref rid="B22-biomedicines-09-00234" ref-type="bibr">22</xref>]. Cannabinoid and terpenoid biosynthesis occurs in hair-like capitate stalked glandular trichomes [<xref rid="B254-biomedicines-09-00234" ref-type="bibr">254</xref>,<xref rid="B255-biomedicines-09-00234" ref-type="bibr">255</xref>], which cover the female floral organs, and exhibit a particularly high density on the bracts (a specialised leaf of the floral organs; <xref ref-type="fig" rid="biomedicines-09-00234-f001">Figure 1</xref>).</p><p>In trichome development, a protodermal cell is enlarged vertically out from the epidermis and subsequently undergoes anticlinal division, prior to a series of periclinal division events to create a secretory and auxiliary tier of cells atop the epidermal basal cells [<xref rid="B256-biomedicines-09-00234" ref-type="bibr">256</xref>,<xref rid="B257-biomedicines-09-00234" ref-type="bibr">257</xref>,<xref rid="B258-biomedicines-09-00234" ref-type="bibr">258</xref>,<xref rid="B259-biomedicines-09-00234" ref-type="bibr">259</xref>]. Additional division events develop the secretory tier of disc cells that form a cavity on the external surface of the trichome from a portion of the outer wall. This cavity then enlarges as the secretory vesicles that harbour a diverse payload of secondary metabolites are extruded into the expanding waxy cavity. Post their cellular release, the secreted vesicles disintegrate upon contact with the thickened outer cuticle wall to release their contents [<xref rid="B256-biomedicines-09-00234" ref-type="bibr">256</xref>,<xref rid="B257-biomedicines-09-00234" ref-type="bibr">257</xref>,<xref rid="B258-biomedicines-09-00234" ref-type="bibr">258</xref>,<xref rid="B259-biomedicines-09-00234" ref-type="bibr">259</xref>].</p><p>The complete biosynthetic pathway of how the prenylated polyketides, particularly minor cannabinoids, are derived from precursor molecules still requires further elucidation, particularly in view of the recent discovery of the two novel cannabinoids, THCP and CBDP [<xref rid="B22-biomedicines-09-00234" ref-type="bibr">22</xref>]. Cannabigerolic acid (CBGA), the key intermediate substrate required for the synthesis of the three primary cannabinoids&#x02014;cannabichromenic acid (CBCA), THCA and CBDA&#x02014;arises from molecular products of the polyketide and methylerythritol 4-phosphate (MEP) pathways. A schematic representation of the MEP pathway is provided in <xref ref-type="fig" rid="biomedicines-09-00234-f002">Figure 2</xref>A. More specifically, the MEP pathway begins in the plastid via the condensation of the substrates, pyruvate and triose phosphate, a reaction that is catalysed by 1-deoxy-D-xylulose-5-synthase (DXS), and which produces 1-deoxy-D-xylulose-5-phosphate (DXP) [<xref rid="B260-biomedicines-09-00234" ref-type="bibr">260</xref>,<xref rid="B261-biomedicines-09-00234" ref-type="bibr">261</xref>,<xref rid="B262-biomedicines-09-00234" ref-type="bibr">262</xref>]. Via the action of 1-deoxy-D-xylulose-5-reductase (DXR) in the presence of the co-factor NADPH, DXP is next reduced to MEP [<xref rid="B263-biomedicines-09-00234" ref-type="bibr">263</xref>] and subsequently, MEP is converted to CDP-ME by the action of the enzyme, 4-diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME) synthase. The kinase, DCP-ME kinase then phosphorylates CDP-ME to produce 4-diphospho-cytidyl-2-C-methyl-D-erythritol-2-phosphate (CDP-ME2P) [<xref rid="B264-biomedicines-09-00234" ref-type="bibr">264</xref>,<xref rid="B265-biomedicines-09-00234" ref-type="bibr">265</xref>]. CDP-ME2P is subsequently converted to 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (ME-2,4cPP) via the activity of the enzyme, ME-2,4cPP synthase, prior to another synthase, 4-hydroxy-3-methylbut-2-enyl diphosphate synthase (HDS), converting ME-2,4cPP to 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate (HDMPP). In the final step of the MEP pathway, HDMPP is used as a substrate by 4-hydroxy-3-methylbut-2-enyl diphosphate reductase (HDR) to produce IPP and dimethylallyl diphosphate (DMAPP) [<xref rid="B264-biomedicines-09-00234" ref-type="bibr">264</xref>,<xref rid="B265-biomedicines-09-00234" ref-type="bibr">265</xref>,<xref rid="B266-biomedicines-09-00234" ref-type="bibr">266</xref>].</p><p>The HDR enzyme is essential for the in planta production of IPP and DMAPP, with over 98% of these two molecules produced by the MEP pathway. IPP and DMAPP both form essential precursor substrates for the biosynthesis of cannabinoids and terpenoids [<xref rid="B261-biomedicines-09-00234" ref-type="bibr">261</xref>]. In the cytosol, IPP is also produced by the MVA pathway (<xref ref-type="fig" rid="biomedicines-09-00234-f002">Figure 2</xref>B). At the start of the MVA pathway, acetyl-CoA is converted to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) by the enzyme, HMG-CoA synthase. Next, HMG-CoA is converted to MVA in the highly rate-limiting step of the MVA pathway, a step that is regulated via the activity of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) [<xref rid="B267-biomedicines-09-00234" ref-type="bibr">267</xref>,<xref rid="B268-biomedicines-09-00234" ref-type="bibr">268</xref>,<xref rid="B269-biomedicines-09-00234" ref-type="bibr">269</xref>]. MVA is then converted to MVA phosphate by MVA kinase (MVK), and subsequently, MVA phosphate is converted to its diphosphate form via the activity of phospho-MVA kinase (PMK). MVA diphosphate is subsequently converted to IPP via its decarboxylation by mevalonate 5-diphosphate decarboxylase (MVD) [<xref rid="B270-biomedicines-09-00234" ref-type="bibr">270</xref>,<xref rid="B271-biomedicines-09-00234" ref-type="bibr">271</xref>,<xref rid="B272-biomedicines-09-00234" ref-type="bibr">272</xref>]. Via the use of yellow fluorescent protein (YFP) fusion constructs, the activity of PMK and MVD has been observed in the peroxisome in <italic>Catharanthus roseus</italic> (Madagascar periwinkle) and <italic>Arabidopsis thaliana</italic> (<italic>Arabidopsis</italic>) to strongly indicate peroxisomal localisation of these two enzymes in planta, and not in the cytosol [<xref rid="B270-biomedicines-09-00234" ref-type="bibr">270</xref>,<xref rid="B271-biomedicines-09-00234" ref-type="bibr">271</xref>,<xref rid="B273-biomedicines-09-00234" ref-type="bibr">273</xref>]. IPP isomerase catalyses the conversion between IPP and DMAPP, a conversion reaction that provides the building blocks for terpene biosynthesis [<xref rid="B274-biomedicines-09-00234" ref-type="bibr">274</xref>,<xref rid="B275-biomedicines-09-00234" ref-type="bibr">275</xref>,<xref rid="B276-biomedicines-09-00234" ref-type="bibr">276</xref>]. Geranyl diphosphate synthase (GPPS) catalyses the production of the ten-carbon (C<sub>10</sub>) molecule, geranyl diphosphate (GPP), via the condensation of one molecule each of DMAPP and IPP [<xref rid="B277-biomedicines-09-00234" ref-type="bibr">277</xref>,<xref rid="B278-biomedicines-09-00234" ref-type="bibr">278</xref>]. Similarly, formation of the C<sub>15</sub> molecule, farnesyl diphosphate (FPP), and the C<sub>20</sub> molecule, geranylgeranyl-diphosphate (GGPP), is catalysed by their specific synthases, farnesyl diphosphate synthase (FPPS) and geranylgeranyl diphosphate synthase (GGPPS), respectively, which condense either 2 or 3 molecules of IPP together with a single molecule of DMAPP [<xref rid="B279-biomedicines-09-00234" ref-type="bibr">279</xref>,<xref rid="B280-biomedicines-09-00234" ref-type="bibr">280</xref>,<xref rid="B281-biomedicines-09-00234" ref-type="bibr">281</xref>]. Together, GPP, FPP and GGPP form the precursors necessary for monoterpene or CBGA biosynthesis (GPP precursor), or the numerous sesqui-, di-, tri-, or tetra-terpene products (FPP or GGPP precursors) found in <italic>Cannabis</italic> [<xref rid="B282-biomedicines-09-00234" ref-type="bibr">282</xref>,<xref rid="B283-biomedicines-09-00234" ref-type="bibr">283</xref>].</p><p>The polyketide pathway is initiated when acetyl-CoA is carboxylated to malonyl-CoA, which in turn serves as the precursor for the fatty acid chains used to produce hexanoate (<xref ref-type="fig" rid="biomedicines-09-00234-f003">Figure 3</xref>) [<xref rid="B254-biomedicines-09-00234" ref-type="bibr">254</xref>,<xref rid="B255-biomedicines-09-00234" ref-type="bibr">255</xref>,<xref rid="B261-biomedicines-09-00234" ref-type="bibr">261</xref>]. The acyl-activating enzyme (AAE), which in <italic>Cannabis</italic> is encoded by two putative genes, termed <italic>CsAAE1</italic> and <italic>CsAAE3</italic>, with the encoded proteins localised to the cytoplasm and peroxisome, respectively, where they function to catalyse the synthesis of hexanoyl-CoA from hexanoate [<xref rid="B255-biomedicines-09-00234" ref-type="bibr">255</xref>]. Condensation of hexanoyl-CoA, together with three malonyl-CoA molecules, is subsequently catalysed by the polyketide synthases, tetraketide synthase (TKS), or olivetol synthase [<xref rid="B284-biomedicines-09-00234" ref-type="bibr">284</xref>,<xref rid="B285-biomedicines-09-00234" ref-type="bibr">285</xref>]. The product of these two synthases, and post a final round of aldol cyclisation by the olivetolic acid cyclase (OAC) enzyme, is olivetolic acid (OA) [<xref rid="B284-biomedicines-09-00234" ref-type="bibr">284</xref>]. Via the utilisation of GPP from the MVA pathway, OA is then prenylated by geranylpyrophosphate:olivetolate geranyltransferase (GOT), to produce CBGA [<xref rid="B286-biomedicines-09-00234" ref-type="bibr">286</xref>,<xref rid="B287-biomedicines-09-00234" ref-type="bibr">287</xref>,<xref rid="B288-biomedicines-09-00234" ref-type="bibr">288</xref>]. The <italic>cis</italic> isomer of GPP, neryl diphosphate (NPP), can be used as a substrate by GOT in place of GPP, to produce cannabinolic acid (CBNA) [<xref rid="B289-biomedicines-09-00234" ref-type="bibr">289</xref>]. CBGA then serves as the primary cannabinoid precursor for the synthesis of cannabichromenic acid (CBCA), THCA and CBDA, with the production of each of these three acids catalysed by a specific oxidocyclisation enzyme, namely the CBCA, THCA and CBDA synthases [<xref rid="B289-biomedicines-09-00234" ref-type="bibr">289</xref>,<xref rid="B290-biomedicines-09-00234" ref-type="bibr">290</xref>,<xref rid="B291-biomedicines-09-00234" ref-type="bibr">291</xref>,<xref rid="B292-biomedicines-09-00234" ref-type="bibr">292</xref>,<xref rid="B293-biomedicines-09-00234" ref-type="bibr">293</xref>]. The use of divarinic acid as a substitute for OA by GOT, putatively produces the propyl cannabinoid homolog, cannabigerovarinic acid (CBGVA) [<xref rid="B286-biomedicines-09-00234" ref-type="bibr">286</xref>,<xref rid="B294-biomedicines-09-00234" ref-type="bibr">294</xref>]. The aforementioned cannabinoid-specific synthases that yield CBCA, CBDA, and THCA can all recruit CBGVA to produce cannabidivarinic acid (CBDVA), cannabichromevarinic acid (CBCVA) and &#x00394;<sup>9</sup>-tetrahydrocannabivarinic acid (THCVA), respectively [<xref rid="B294-biomedicines-09-00234" ref-type="bibr">294</xref>,<xref rid="B295-biomedicines-09-00234" ref-type="bibr">295</xref>,<xref rid="B296-biomedicines-09-00234" ref-type="bibr">296</xref>]. The resulting cannabinoids are maintained in their acidic forms until they are thermally decarboxylated to convert them into their neutral forms [<xref rid="B297-biomedicines-09-00234" ref-type="bibr">297</xref>,<xref rid="B298-biomedicines-09-00234" ref-type="bibr">298</xref>,<xref rid="B299-biomedicines-09-00234" ref-type="bibr">299</xref>,<xref rid="B300-biomedicines-09-00234" ref-type="bibr">300</xref>].</p><p>Research to date has primarily focused on the biosynthetic pathways and putative medical benefits of the two major cannabinoids, THC and CBD. Therefore, the medical and biological potential of the minor cannabinoids that also contribute to the total cannabinoid profile of the <italic>Cannabis</italic> plant have been largely overlooked. The small proportion that these minor cannabinoids contribute to the total cannabinoid profile of the <italic>Cannabis</italic> plant presents a significant obstacle for in-depth analysis of their effects when consumed. A comprehensive, and ever-increasing list of naturally occurring minor phytocannabinoids has been compiled based upon their derivation from THC, CBD, CBG (cannabigerol) and CBC, which represent the diversity that stems from variations to the three fundamental components of cannabinoids, including the (1) resorcinyl core; (2) isoprenyl residue, and; (3) resorcinyl side chain [<xref rid="B20-biomedicines-09-00234" ref-type="bibr">20</xref>,<xref rid="B301-biomedicines-09-00234" ref-type="bibr">301</xref>]. Eighty-two individual cannabinoids from 10 cannabinoid types, specifically the (1) CBG; (2) CBC; (3) CBD; (4) &#x00394;<sup>9</sup>-THC; (5) &#x00394;<sup>8</sup>-THC; (6) cannabicyclol (CBL); (7) cannabielsoin (CBE); (8) cannabinol (CBN); (9) cannabinodol (CBND), and; (10) cannabitriol (CBT) types, in addition to the miscellaneous types, and their transformation products, as well as terpenoids, hydrocarbons, sugars and fatty acids are among the constituents that comprise the chemical cornucopia of glandular trichomes. Further, several minor oxygenated cannabinoids, cannabinoid metabolites, and cannabinoid esters present in <italic>Cannabis</italic> have yet to be isolated and/or experimentally validated but have been identified using a variety of spectroscopic techniques [<xref rid="B302-biomedicines-09-00234" ref-type="bibr">302</xref>,<xref rid="B303-biomedicines-09-00234" ref-type="bibr">303</xref>,<xref rid="B304-biomedicines-09-00234" ref-type="bibr">304</xref>]. In addition, a number of interesting structural formations have been observed in some of the minor cannabinoids. For example, cannabioxepane (CBX) has a tetracyclic skeleton with a seven-membered ring, a structure not previously reported for a characterised cannabinoid, while cannabisol is a &#x00394;<sup>9</sup>-THC dimer with a methylene bridge. However, it must be noted that the binding affinity for specific CB receptors for these minor cannabinoids remains unknown, with some potentially not recognised, and therefore not bound by any known CB receptor [<xref rid="B305-biomedicines-09-00234" ref-type="bibr">305</xref>,<xref rid="B306-biomedicines-09-00234" ref-type="bibr">306</xref>]. The CBD derivative, cannabimovone, and the farnesyl prenylogue of CBG, sesquicannabigerol, were also spectroscopically characterised, with CB receptor binding assays predicting receptor&#x02013;cannabinoid affinity, highlighting the structural and potential psychoactive diversity among the minor phytocannabinoids [<xref rid="B307-biomedicines-09-00234" ref-type="bibr">307</xref>,<xref rid="B308-biomedicines-09-00234" ref-type="bibr">308</xref>]. In addition to the identification of their parent cannabinoid precursors, plausible biochemistry behind the synthesis of these compounds is offered. However, the actual enzymatic production of many of these minor cannabinoids remains to be determined. Furthermore, the non-enzymatic formation of some of the minor cannabinoids is certainly likely, but it remains of interest to understand whether there is a greater portion of enzyme-catalysed reactions in the production of the minor cannabinoids, or indeed whether there are alternative pathways, or even additional pathway entry points in the biosynthesis of cannabinoids, both minor and primary.</p></sec><sec id="sec4-biomedicines-09-00234"><title>4. Minor Cannabinoids and Their Biological Interactions</title><p>There is mounting evidence that the minor cannabinoids described above share combinations of many of the same molecular targets as THC and CBD, and therefore may potentially have unique medical applications that cannot be achieved by THC or CBD alone. The THC propyl homologue, THCV, is a CB<sub>1</sub> and CB<sub>2</sub> competitive antagonist against CP55,940 and WIN55,21&#x02013;2, acting with similar potency to that of THC [<xref rid="B309-biomedicines-09-00234" ref-type="bibr">309</xref>,<xref rid="B310-biomedicines-09-00234" ref-type="bibr">310</xref>]. THCV also antagonised anandamide and methanandamide in mice vas deferens, attenuating stimulated contractile responses [<xref rid="B309-biomedicines-09-00234" ref-type="bibr">309</xref>]. More recently, THCV was shown to similarly displace CP55,940 from CB<sub>1</sub> and CB<sub>2</sub> in CHO cells, and contrary to previous assumptions, was shown to be a weak partial CB<sub>1</sub> agonist at high doses [<xref rid="B179-biomedicines-09-00234" ref-type="bibr">179</xref>]. Moreover, Zagzoog et al. [<xref rid="B310-biomedicines-09-00234" ref-type="bibr">310</xref>] showed THCV to produce anxiolytic, hypothermic, anti-nociceptive, hypolocomotive, and cataleptic effects in vivo in mice. CB<sub>2</sub> agonism by THCV was demonstrated to reduce inflammation and attenuate hyperalgesia in mice following injection of carrageenan and formalin, respectively [<xref rid="B180-biomedicines-09-00234" ref-type="bibr">180</xref>]. Neuroprotective properties were observed in 6-hydroxydopamine lesioned rats, where THCV administration preceded maintenance of tyrosine hydroxylase-positive neurons in this Parkinsonian model [<xref rid="B311-biomedicines-09-00234" ref-type="bibr">311</xref>]. Similarly, THCV delayed onset of abnormal involuntary movements associated with Parkinson&#x02019;s disease in mice, and reduced their severity after administration following symptom onset [<xref rid="B181-biomedicines-09-00234" ref-type="bibr">181</xref>]. The in vitro demonstrated inhibition of GABA release by WIN55,21-2 at Purkinje cell synapses was reversed by THCV, which also prevented the action of WIN55,212&#x02013;2 when used in pre-incubation [<xref rid="B312-biomedicines-09-00234" ref-type="bibr">312</xref>,<xref rid="B313-biomedicines-09-00234" ref-type="bibr">313</xref>]. In vitro studies of insulin-resistant human hepatocytes showed THCV restoration of insulin signaling mediated by CB<sub>1</sub>, while also improving glucose tolerance and increased sensitivity to insulin in mice obesity models [<xref rid="B182-biomedicines-09-00234" ref-type="bibr">182</xref>]. Antiepileptic properties were also established in vitro, specifically when THCV reduced both the frequency and amplitude of epileptiform activity in rat piriform cortex slices [<xref rid="B183-biomedicines-09-00234" ref-type="bibr">183</xref>]. The majority of published studies have focused on the CB<sub>1</sub> and CB<sub>2</sub> receptors, but the in vitro activity of THCV has been observed for the TRPV1 to TRPV4 group of receptors, as well as for the TRPA1 receptor [<xref rid="B200-biomedicines-09-00234" ref-type="bibr">200</xref>,<xref rid="B201-biomedicines-09-00234" ref-type="bibr">201</xref>,<xref rid="B202-biomedicines-09-00234" ref-type="bibr">202</xref>]. THCV can enhance 5-HT<sub>1A</sub> receptor activation to produce antipsychotic-like effects in rats [<xref rid="B314-biomedicines-09-00234" ref-type="bibr">314</xref>], but does not affect other endocannabinoid system constituents such as PPAR&#x003b3; [<xref rid="B315-biomedicines-09-00234" ref-type="bibr">315</xref>], FAAH [<xref rid="B200-biomedicines-09-00234" ref-type="bibr">200</xref>], or MAGL [<xref rid="B200-biomedicines-09-00234" ref-type="bibr">200</xref>]. One clinical trial in humans where THCV was administered once daily for five days followed by intravenous administration of THC suggested that THCV inhibited an increase in heart rate, protected against verbal recall impairment, and reduced the subjective psychoactive intensity induced by THC [<xref rid="B316-biomedicines-09-00234" ref-type="bibr">316</xref>]. Further, THCV affects brain regions associated with reward and aversive stimuli, as well as areas associated with cognitive control [<xref rid="B317-biomedicines-09-00234" ref-type="bibr">317</xref>,<xref rid="B318-biomedicines-09-00234" ref-type="bibr">318</xref>]</p><p>Recently, a four-carbon side chain variant, &#x00394;<sup>9</sup>-tetrahydrocannabutol (THCB), was isolated and which showed CB<sub>1</sub> and CB<sub>2</sub> binding affinities similar to those of THC, with in vivo mice studies suggesting potential analgesic and anti-inflammatory properties [<xref rid="B176-biomedicines-09-00234" ref-type="bibr">176</xref>]. Similarly, the recently identified seven-carbon side chain variant, THCP, was shown to be able to bind to both CB<sub>1</sub> and CB<sub>2</sub> with 33 and 5 times greater affinity than THC, respectively, as well as to initiate catalepsy, hypothermia, analgesia, and reduce locomotion; all indications of potent full CB<sub>1</sub> agonism [<xref rid="B22-biomedicines-09-00234" ref-type="bibr">22</xref>]. THCA has been shown in rodent culture supernatants to reduce the abundance of inflammatory and oxidant markers [<xref rid="B319-biomedicines-09-00234" ref-type="bibr">319</xref>,<xref rid="B320-biomedicines-09-00234" ref-type="bibr">320</xref>], though no other research to our knowledge of this nature has been published. In addition, &#x00394;<sup>8</sup>-THC has been shown to possess higher antiemetic effects than THC [<xref rid="B188-biomedicines-09-00234" ref-type="bibr">188</xref>], and has been successfully trialed for repressing emesis in children [<xref rid="B184-biomedicines-09-00234" ref-type="bibr">184</xref>]. Furthermore, in humans, &#x00394;<sup>8</sup>-THC appears required to be administered at higher doses than THC to display a similar degree of psychoactive properties [<xref rid="B321-biomedicines-09-00234" ref-type="bibr">321</xref>]. THCA is a 5-HT<sub>1A</sub> agonist [<xref rid="B322-biomedicines-09-00234" ref-type="bibr">322</xref>], a PPAR&#x003b3; agonist [<xref rid="B323-biomedicines-09-00234" ref-type="bibr">323</xref>], and displays the same properties against TRP channels as does THC [<xref rid="B200-biomedicines-09-00234" ref-type="bibr">200</xref>]. However, little pharmacological, pharmacokinetic, or recent safety data are available for any of these compounds.</p><p>Improvements in seizure frequency has been reported in an epileptic patient coinciding with increased CBDV serum levels, after which in vitro studies confirmed that CBDV, at least, possesses the ability to influence GABA receptors; a finding that indicates a potential avenue for anticonvulsant properties [<xref rid="B324-biomedicines-09-00234" ref-type="bibr">324</xref>]. Further, in vitro analyses revealed CBDV to have anticonvulsant effects in four seizure models, namely the (1) maximal electroshock-, (2) audiogenic-, (3) penytylenetetrazole-(PTZ), and (4) pilocarpine-induced seizure models [<xref rid="B325-biomedicines-09-00234" ref-type="bibr">325</xref>,<xref rid="B326-biomedicines-09-00234" ref-type="bibr">326</xref>]. Using rat brain tissue samples, PTZ-induced seizures coincided with an increase in <italic>Early growth response 1</italic> (<italic>Egr1</italic>), <italic>Activity-regulated cytoskeleton-associated protein</italic> (<italic>Arc</italic>), <italic>Chemokine</italic> (<italic>C-C motif</italic>) <italic>ligand 4</italic> (<italic>Ccl4</italic>), <italic>Brain-derived neurotrophic factor</italic> (<italic>Bdnf</italic>), and <italic>FBJ osteosarcoma oncogene</italic> (<italic>Fos</italic>) gene expression [<xref rid="B327-biomedicines-09-00234" ref-type="bibr">327</xref>]. Interestingly, the administration of CBDV was shown to reduce the expression of all of these genes [<xref rid="B327-biomedicines-09-00234" ref-type="bibr">327</xref>]. Additional seizure studies identified TRPV1 as the potential receptor modulating anti-seizure effects via the use of <italic>trpv1</italic> knockout mice which showed a reduced response to CBDV [<xref rid="B328-biomedicines-09-00234" ref-type="bibr">328</xref>]. Desensitisation of TRPV1, in addition to TRPV2, by both CBDV and CBD has been observed [<xref rid="B199-biomedicines-09-00234" ref-type="bibr">199</xref>], while Ca<sup>2+</sup> transients were induced in TRVP2-expressing HEK293 cells more potently by CBD than by CBDV. However, THC was a more potent inducer of Ca<sup>2+</sup> transients than either CBDV or CBD [<xref rid="B200-biomedicines-09-00234" ref-type="bibr">200</xref>]. Another study did alternately suggest that CBD was the more potent agonist of TRPV2 than THC, but this study did not include the assessment of CBDV [<xref rid="B329-biomedicines-09-00234" ref-type="bibr">329</xref>]. Cannabinoid administration improved symptoms in mice models of Rett syndrome, including motor control and sociability [<xref rid="B197-biomedicines-09-00234" ref-type="bibr">197</xref>], and through TRPA1, CBDV mediates anti-inflammatory effects in intestinal tissue of humans with ulcerative colitis [<xref rid="B204-biomedicines-09-00234" ref-type="bibr">204</xref>]. Similar to CBD, CBDV inhibits FAAH and anandamide reuptake [<xref rid="B200-biomedicines-09-00234" ref-type="bibr">200</xref>]. However, unlike CBD, CBDV does not show affinity for the CB<sub>1</sub> or CB<sub>2</sub> receptors [<xref rid="B180-biomedicines-09-00234" ref-type="bibr">180</xref>]. CBDV may confer some benefit in patients with Autism Spectrum Disorder [<xref rid="B330-biomedicines-09-00234" ref-type="bibr">330</xref>] and Duchenne muscular dystrophy [<xref rid="B205-biomedicines-09-00234" ref-type="bibr">205</xref>]. CBDV did, however, fail to alleviate the neuropathic pain associated with human immunodeficiency virus (HIV) [<xref rid="B331-biomedicines-09-00234" ref-type="bibr">331</xref>], and in another study, the administration of CBDV induced DNA damage in human cell lines at concentrations similar to those observed in <italic>Cannabis</italic> consumers [<xref rid="B332-biomedicines-09-00234" ref-type="bibr">332</xref>], indicating carcinogenicity potential for CBDV. However, CBDV has been safely trialed in humans at a single 600 mg oral dose [<xref rid="B330-biomedicines-09-00234" ref-type="bibr">330</xref>], and it remains to be determined whether CBDV will be efficacious for other illnesses in clinical trial.</p><p>CBG has shown partial agonism of CB<sub>1</sub> and CB<sub>2</sub>, &#x003b1;<sub>2</sub>-adrenceptor agonism and 5-HT<sub>1A</sub> antagonism, while exerting some minor anti-nociceptive and anxiolytic properties in vivo [<xref rid="B179-biomedicines-09-00234" ref-type="bibr">179</xref>,<xref rid="B333-biomedicines-09-00234" ref-type="bibr">333</xref>]. Mice models of inflammatory bowel disease (IBD) showed positive outcomes with CBG treatment including reductions in the level of reactive oxygen species in intestinal cells, as well as reduced nitric oxide concentration in macrophages through CB<sub>2</sub> modulation [<xref rid="B194-biomedicines-09-00234" ref-type="bibr">194</xref>]. Further in vivo animal studies provided evidence for neuroprotectivity against symptoms of Huntington&#x02019;s disease in 3-nitropropionate treated mice, with improvement in motor function, reduction in proinflammatory marker upregulation and increased antioxidant defenses, with R6/2 mice showing a reduction in the expression profiles of several genes linked to the disease following CBG treatment [<xref rid="B334-biomedicines-09-00234" ref-type="bibr">334</xref>]. Similarly, in vitro analysis of NSC-34 neuronal cells showed that CBG pre-treatment reduced both inflammation and the expression of pro-inflammatory cytokines, and inhibited cell death resulting from the cell culture medium of lipopolysaccharide (LPS) stimulated RAW 264.7 macrophages [<xref rid="B335-biomedicines-09-00234" ref-type="bibr">335</xref>]. CBG shows a similar profile at TRP channels compared to CBD, with agonist properties at TRPV1 through to TRPV4, and at TRPA1, but antagonism at TRPM8 [<xref rid="B200-biomedicines-09-00234" ref-type="bibr">200</xref>]. It is also an anandamide reuptake inhibitor [<xref rid="B336-biomedicines-09-00234" ref-type="bibr">336</xref>], and an LPI inhibitor at GRP55 [<xref rid="B97-biomedicines-09-00234" ref-type="bibr">97</xref>]. As for the propyl analogue of CBG, CBGV, very little information surrounding its clinical application exists, except to show that CBGV has activity at GPR55, TRPV3 and TRPV4 [<xref rid="B198-biomedicines-09-00234" ref-type="bibr">198</xref>,<xref rid="B201-biomedicines-09-00234" ref-type="bibr">201</xref>].</p><p>CBC use in a clinical setting, or in human trials, appears to be untested currently, and additionally, cannabichromevarin (CBCV) currently has even fewer studies dedicated to it. However, CBC has seen some use in animal models and in vitro studies. CBC has been shown to inhibit FAAH, MAGL, and anandamide reuptake [<xref rid="B200-biomedicines-09-00234" ref-type="bibr">200</xref>,<xref rid="B337-biomedicines-09-00234" ref-type="bibr">337</xref>], but has been demonstrated to have no effect at TRPV1 or TRPV2. Further, CBC is a very weak CB<sub>1</sub> agonist [<xref rid="B338-biomedicines-09-00234" ref-type="bibr">338</xref>,<xref rid="B339-biomedicines-09-00234" ref-type="bibr">339</xref>,<xref rid="B340-biomedicines-09-00234" ref-type="bibr">340</xref>], and only exhibits modest agonist properties at CB<sub>2</sub>. An early study suggested that CBC, CBCV, and a CBC variant which lacks a carbon side chain, possessed anti-inflammatory properties in rat edema models and varying anti-bacterial and anti-fungal properties [<xref rid="B341-biomedicines-09-00234" ref-type="bibr">341</xref>]. More recently, CBC was seen to produce anti-inflammatory effects in LPS paw edema models in mice in CB<sub>1</sub>- and CB<sub>2</sub>-independent pathways and also produce hypothermia, catalepsy, and locomotor suppression [<xref rid="B342-biomedicines-09-00234" ref-type="bibr">342</xref>]. The authors went on to suggest that the effects of CBC were altered in the presence of THC, with an additive effect against inflammation [<xref rid="B342-biomedicines-09-00234" ref-type="bibr">342</xref>] and similarly, tail-flick tests revealed that subtle analgesic properties of CBC were potentiated by its combination with THC [<xref rid="B343-biomedicines-09-00234" ref-type="bibr">343</xref>]. Selective CB<sub>2</sub>, but not CB<sub>1</sub> agonism, was exhibited by CBC on mouse pituitary tumour cells, and the persistent administration of CBC caused desensitisation of CB<sub>2</sub> receptors [<xref rid="B344-biomedicines-09-00234" ref-type="bibr">344</xref>]. Intestinal studies suggest that CBC confers some benefit against inflammation. However, this was potentially independent of CB<sub>1</sub>, CB<sub>2</sub>, or TRPA1, the expression of which were all downregulated in the presence of CBC in one study, but shown to be unchanged in another study [<xref rid="B193-biomedicines-09-00234" ref-type="bibr">193</xref>,<xref rid="B345-biomedicines-09-00234" ref-type="bibr">345</xref>]. Colorectal cancer cell viability was attenuated through TRPM8 antagonism by CBG, as well as by the administration of CBD, CBDV, and CBC, albeit to lesser degrees [<xref rid="B203-biomedicines-09-00234" ref-type="bibr">203</xref>]. Other studies have indicated that CBC is not a potent antagonist of TRPM8, and instead suggest that CBD, CBG, THC, and THCA are more effective antagonists of TRPM8 [<xref rid="B200-biomedicines-09-00234" ref-type="bibr">200</xref>,<xref rid="B202-biomedicines-09-00234" ref-type="bibr">202</xref>]. Additionally, CBC, CBN, THC, THCV, THCA, CBDA, and CBG all induced intracellular Ca<sup>2+</sup> increases in HEK293 and rat DRG neurons through TRPA1 [<xref rid="B200-biomedicines-09-00234" ref-type="bibr">200</xref>,<xref rid="B202-biomedicines-09-00234" ref-type="bibr">202</xref>]. CBC has also shown promise in increasing neural stem cell viability in animal models (in vitro), mediated through ERK phosphorylation [<xref rid="B346-biomedicines-09-00234" ref-type="bibr">346</xref>]. However, it is concerning that large amounts of CBC are required to produce pharmacological effects [<xref rid="B90-biomedicines-09-00234" ref-type="bibr">90</xref>], which implies that CBC may be difficult to implement in a human health context.</p><p>The binding affinity of CBN, and of its primary derivatives, to the two main cannabinoid receptors was established in 2000, and showed rather unsurprisingly that alterations at carbon atom positions 1, 3, and 9, resulted in significantly different affinities at both receptors [<xref rid="B347-biomedicines-09-00234" ref-type="bibr">347</xref>]. An earlier study indicated CBN to have cataleptic, hypothermic, and locomotive effects, as did 11-hydroxy-CBN; a hepatic microsome CYP2C- and CYP3A4-catalysed metabolite [<xref rid="B348-biomedicines-09-00234" ref-type="bibr">348</xref>,<xref rid="B349-biomedicines-09-00234" ref-type="bibr">349</xref>]. Additionally, CBN directly inhibited the activity of the human cytochrome P450 family 1 (CYP1) enzymes, CYP1A2 and CYP1B1 [<xref rid="B350-biomedicines-09-00234" ref-type="bibr">350</xref>]. Assays of cultured neuronal cells expressing an inducible disease conferring huntingtin (Htt) protein, suggest that CBN has protective effects against cell death in vivo, with low toxicity even at the high concentrations required for protectivity [<xref rid="B351-biomedicines-09-00234" ref-type="bibr">351</xref>]. Interestingly, cannabinoid receptor loss has been indicated as a pathophysiology of Huntington&#x02019;s disease [<xref rid="B352-biomedicines-09-00234" ref-type="bibr">352</xref>,<xref rid="B353-biomedicines-09-00234" ref-type="bibr">353</xref>], which may suggest that the purported protective action of cannabinoids is independent of cannabinoid receptor binding. Subcutaneously delivered CBN delayed the onset of amyotrophic lateral sclerosis (ALS) symptoms in murine models but failed to affect survival, so was postulated to mask the early spasticity associations without affecting disease progression [<xref rid="B354-biomedicines-09-00234" ref-type="bibr">354</xref>]. A synergistic effect of CBN with CBD at reducing mechanical sensitisation in rat masseter muscles was observed in one study, however high concentrations of CBD ameliorated the efficacy of CBN [<xref rid="B355-biomedicines-09-00234" ref-type="bibr">355</xref>]. CBN has been reported to have no effect at FAAH, MAGL, or TRPV1, but acts as an agonist at TRPA1 and TRPV2 [<xref rid="B200-biomedicines-09-00234" ref-type="bibr">200</xref>].</p><p>Via the use of in silico analyses, the even lesser-known cannabinoids, cannabiripsol (CBR) and CBT, are predicted to have cytochrome P450 inhibitor activity [<xref rid="B356-biomedicines-09-00234" ref-type="bibr">356</xref>]. In another in silico study, CBL, CBT, and CBE were assessed, and ranked in this order, to have acetylcholinesterase-inhibiting function. However, their inhibitory effects were less than those of THC, CBN, and CBDV [<xref rid="B357-biomedicines-09-00234" ref-type="bibr">357</xref>]. Exactly how well in silico studies translate to clinical relevance, or even to in vitro and/or in vivo studies, restricts what conclusions can be accurately drawn. Minor phytocannabinoids do represent an understudied portion of the <italic>Cannabis</italic> plant. Very few studies exist that have utilised an in vivo approach to ascertain the viability of minor cannabinoids to potentially produce any significant medical benefits, and fewer still cover any human clinical trials. There has been indication that some cannabinoids exhibit synergistic action, and as a result there may be value in investigating the interactions among cannabinoids or constituents of the <italic>Cannabis</italic> plant.</p></sec><sec id="sec5-biomedicines-09-00234"><title>5. Directions in <italic>Cannabis</italic> Development for Secondary Metabolite Production</title><p>The establishment of superior varieties of <italic>Cannabis</italic> has been the target for plant breeders since the domestication of this species. To produce new medically relevant <italic>Cannabis</italic> varieties with elevated concentrations of specific minor cannabinoids, or to develop techniques to manipulate the cannabinoid biosynthetic pathway in other organisms, a deeper understanding of the genetics of the <italic>Cannabis</italic> plant is first required. Here we outline the progress in relation to (1) the sequencing of the <italic>Cannabis</italic> genome, and (2) the potential to molecularly manipulate the <italic>Cannabis</italic> plant itself for the altered production of specific cannabinoids. In this regard, we highlight the established success in <italic>Papaver somniferum</italic> (opium poppy), as a parallel example for maximising yield and the concentration of key secondary metabolites of medical and commercial relevance.</p><sec id="sec5dot1-biomedicines-09-00234"><title>5.1. Next-Generation Sequencing of the Cannabis Plant and Its Potential for Genetic Manipulation</title><p>Over the last 25 years, various experimental approaches have been employed to unveil the wealth of information contained in the <italic>Cannabis</italic> genome. Using early DNA sequencing and karyotyping techniques, the X and Y sex chromosome characteristics of <italic>Cannabis</italic> were uncovered, as were the diploid (2n = 20) genome sizes for male and female plants [<xref rid="B358-biomedicines-09-00234" ref-type="bibr">358</xref>,<xref rid="B359-biomedicines-09-00234" ref-type="bibr">359</xref>]. The female <italic>Cannabis</italic> plant was revealed to have a genome size of 818 megabase (Mb), while the male <italic>Cannabis</italic> plant was determined to have a larger genome size of 843 Mb; specifically due to the larger size of the Y chromosome, compared to the X chromosome of female plants [<xref rid="B358-biomedicines-09-00234" ref-type="bibr">358</xref>]. Microsatellite markers have been employed as a tool for DNA typing <italic>Cannabis</italic>, and these polymorphic short tandem repeat (STR) markers have been utilised as a measurement of genetic relationships among cultivars [<xref rid="B360-biomedicines-09-00234" ref-type="bibr">360</xref>,<xref rid="B361-biomedicines-09-00234" ref-type="bibr">361</xref>,<xref rid="B362-biomedicines-09-00234" ref-type="bibr">362</xref>]. More recently, the rapid change in technologies surrounding Next-Generation Sequencing (NGS) platforms has meant that studies can unravel whole genomes in a fraction of the time required via the use of older methods. As a result, the first draft <italic>Cannabis</italic> reference genome, and transcriptome, were constructed in 2011 using the high THCA, low CBDA cultivar, &#x02018;Purple Kush&#x02019;, and the high CBDA, low THCA hemp strains, &#x02018;Finola&#x02019; and &#x02018;USO-31&#x02019; [<xref rid="B363-biomedicines-09-00234" ref-type="bibr">363</xref>]. Using a PacBio long-read sequencing platform, the Purple Kush and Finola genomes were again sequenced in 2019 to generate a physical and genetic map for <italic>Cannabis</italic>, and further distinguish the genes, and importantly the gene products (specifically, the encoded enzymes), underpinning the secondary metabolite profiles responsible for the divergent chemotype between hemp and marijuana cultivars [<xref rid="B364-biomedicines-09-00234" ref-type="bibr">364</xref>,<xref rid="B365-biomedicines-09-00234" ref-type="bibr">365</xref>].</p><p>Earlier work surrounding the chemotypic variance of cannabinoids observed in <italic>Cannabis</italic> unveiled the relationship between THCA and CBDA synthase expression, describing a single locus (<italic>B</italic>), with two codominant alleles, <italic>B<sub>D</sub></italic> and <italic>B<sub>T</sub></italic> [<xref rid="B295-biomedicines-09-00234" ref-type="bibr">295</xref>]. A 1:1:2 segregation ratio results in the production of three chemotypes of the <italic>B</italic> locus, including the (1) pure CBD (<italic>B<sub>D</sub></italic>/<italic>B<sub>D</sub></italic> homozygote), (2) pure THC (<italic>B<sub>T</sub></italic>/<italic>B<sub>T</sub></italic> homozygote), and (3) mixed CBD/THC (<italic>B<sub>D</sub></italic>/<italic>B<sub>T</sub></italic> heterozygote) chemotypes [<xref rid="B295-biomedicines-09-00234" ref-type="bibr">295</xref>]. However, later studies based around NGS platforms indicated an alternate genetic model of synthase gene duplication and rearrangement at multiple linked loci, and that CBDA synthase is more ancient, has a greater affinity for the CBGA substrate, and that the CBDA synthase locus is solely responsible for the cannabinoid chemotypes observed in <italic>Cannabis</italic> [<xref rid="B363-biomedicines-09-00234" ref-type="bibr">363</xref>,<xref rid="B365-biomedicines-09-00234" ref-type="bibr">365</xref>,<xref rid="B366-biomedicines-09-00234" ref-type="bibr">366</xref>,<xref rid="B367-biomedicines-09-00234" ref-type="bibr">367</xref>,<xref rid="B368-biomedicines-09-00234" ref-type="bibr">368</xref>,<xref rid="B369-biomedicines-09-00234" ref-type="bibr">369</xref>]. In an attempt to classify variability in chemotypes, and to associate genotype to chemotype in a diverse germplasm collection, DNA sequence characterised amplified region (SCAR) markers associated with THCA/CBDA synthases were assessed in 22 <italic>Cannabis</italic> varieties representing 2 fibre and 1 drug type plants from East (n = 8), Central (n = 1), and South (n = 2) Asia, as well as from Europe (n = 7) and of mixed (n = 4) domestication status [<xref rid="B370-biomedicines-09-00234" ref-type="bibr">370</xref>]. This approach revealed a variability in cannabinoid profiles (CBD:THC) across &#x02018;chemotype II&#x02019;, or <italic>B<sub>D</sub></italic>/<italic>B<sub>T</sub></italic> equivalent plants, more than three-fold greater than previously observed, supporting the allelic variant and multiple loci prediction, when assuming that a heterozygote plant in a single locus model would have a 1:1 CBD:THC ratio [<xref rid="B370-biomedicines-09-00234" ref-type="bibr">370</xref>].</p><p>Other large-scale genetic diversity studies using NGS, and which compared the evolutionary relationships between 340 <italic>Cannabis</italic> varieties from existing datasets, and from other novel multiplexed libraries, highlighted the murky ancestry of the <italic>Cannabis</italic> plant resulting from generations of repeated rounds of selective breeding, and also provides an extensive data platform for future genotyping efforts [<xref rid="B371-biomedicines-09-00234" ref-type="bibr">371</xref>]. Moreover, Lynch et al. [<xref rid="B371-biomedicines-09-00234" ref-type="bibr">371</xref>] classed their assessed <italic>Cannabis</italic> varieties into three genetic groups, including (1) hemp, (2) narrow leaflet, and (3) broad leaflet drug types, in order to determine the genomic and genetic variation of their population for the potential use of varieties from each group in either agricultural or medicinal applications. The authors indicated unique cannabinoid and terpenoid profiles for each group, structured loosely around geographic origin of each species, and noted the requirement for the inclusion of the putative <italic>Cannabis</italic> species, <italic>C. ruderalis</italic>, in future studies to fully elucidate their genetic distinction and ancestral lineage [<xref rid="B371-biomedicines-09-00234" ref-type="bibr">371</xref>]. The development of expressed sequence tag simple sequence repeat (EST-SSR) markers to assess genetic diversity of 115 <italic>Cannabis</italic> genotypes also revealed geographical-based clustering into 4 groupings, including the Northern China, Southern China, Central China and Europe groupings [<xref rid="B372-biomedicines-09-00234" ref-type="bibr">372</xref>]. Interestingly, a genetic similarity coefficient derived from 45 of 117 randomly selected EST-SSRs markers revealed that despite physical proximity to the other Chinese varieties, Northern Chinese varieties had a greater similarity coefficient to the European grouping, predicted to be related to latitude and day length [<xref rid="B372-biomedicines-09-00234" ref-type="bibr">372</xref>]. The analysis of inter simple sequence repeats (ISSR) of 27 native Chinese hemp varieties identified a similar geographic distribution to genetic distance relationship, while also revealing the hemp varieties were genetically diverse, yet primitive, a finding which adds further weight to the suggestion that the <italic>Cannabis</italic> plant originated in southern China and then spread north [<xref rid="B373-biomedicines-09-00234" ref-type="bibr">373</xref>].</p><p>The recent assembly and annotation of the mitochondrial genome of <italic>Cannabis</italic> using NGS methods will also allow for similar studies to be performed to determine the extent of the genetic diversity among <italic>Cannabis</italic> varieties [<xref rid="B374-biomedicines-09-00234" ref-type="bibr">374</xref>]. In addition, the assembly of two chloroplast genomes from different <italic>Cannabis</italic> varieties will aid in validating the phylogenetic relationship of <italic>Cannabis</italic> among the Rosales order of the Plantae kingdom [<xref rid="B375-biomedicines-09-00234" ref-type="bibr">375</xref>]. However, as with all sequencing, repeated efforts across diverse genotypic populations compared against reference genomes will increase the accuracy and reliability of publicly available repositories. RNA sequencing as a tool for differentiating strains has been used with some success, where the transcriptome isolated from cannabinoid-containing glandular trichomes from different varieties allows for comparative analysis based on the cannabinoid and terpenoid chemical profiles [<xref rid="B376-biomedicines-09-00234" ref-type="bibr">376</xref>,<xref rid="B377-biomedicines-09-00234" ref-type="bibr">377</xref>]. As the regulatory landscape surrounding the use of <italic>Cannabis</italic> evolves, and the value of the unique chemical profile of specific <italic>Cannabis</italic> varieties is realised, breeders are likely to use these sequencing techniques to rapidly characterise and protect their &#x02018;strains&#x02019;. The development of such highly targeted databases provides the platform for precise manipulation of phenotypic or chemotypic traits in <italic>Cannabis</italic> to deliver improved medical efficacy or novel therapeutics.</p><p>A forward and/or reverse genetics approach with the application of chemical mutagenesis agents, such as ethyl methanesulfonate (EMS), a mutagen that introduces point mutations into the plant genome, is an effective approach for functional genomic assessments and effective plant breeding regimes, and has been successfully demonstrated in a variety of plant species, including hemp [<xref rid="B9-biomedicines-09-00234" ref-type="bibr">9</xref>,<xref rid="B378-biomedicines-09-00234" ref-type="bibr">378</xref>,<xref rid="B379-biomedicines-09-00234" ref-type="bibr">379</xref>,<xref rid="B380-biomedicines-09-00234" ref-type="bibr">380</xref>,<xref rid="B381-biomedicines-09-00234" ref-type="bibr">381</xref>,<xref rid="B382-biomedicines-09-00234" ref-type="bibr">382</xref>,<xref rid="B383-biomedicines-09-00234" ref-type="bibr">383</xref>]. The application of alkylating agents such as EMS in a time-dependent manner causes a larger number of point mutations across the genome, compared to an irradiating method such as X-ray, or fast neutron bombardment, both of which produce much larger genome deletions and/or chromosome rearrangements [<xref rid="B384-biomedicines-09-00234" ref-type="bibr">384</xref>,<xref rid="B385-biomedicines-09-00234" ref-type="bibr">385</xref>,<xref rid="B386-biomedicines-09-00234" ref-type="bibr">386</xref>]. Deletions ranging from 0.8 to 12 kilobases (kb) were produced in <italic>Arabidopsis</italic> using fast neutron bombardment, a widely used model plant species with an average gene density of one gene per 4.8 kb. The size of the genome alterations produced by this approach can, however, potentially cause the loss of function, or significantly altered expression of more than one gene. Therefore, a considerable drawback of using such an approach is the time and effort required post-mutagenesis to identify a &#x02018;causative mutation&#x02019;. While the <italic>Arabidopsis</italic> genome is comparatively smaller than that of <italic>Cannabis</italic>, a similar post-mutagenesis investigative strategy would likely be required in other plant species with nuclear genomes either of a similar or significantly larger-size [<xref rid="B385-biomedicines-09-00234" ref-type="bibr">385</xref>,<xref rid="B387-biomedicines-09-00234" ref-type="bibr">387</xref>]. Regardless, these types of methods require rather large numbers of plants to be effective as deletions and point mutations are not site directed, which is a considerable limitation as even rapid standard screening techniques demand intensive laboratory work [<xref rid="B388-biomedicines-09-00234" ref-type="bibr">388</xref>,<xref rid="B389-biomedicines-09-00234" ref-type="bibr">389</xref>,<xref rid="B390-biomedicines-09-00234" ref-type="bibr">390</xref>].</p><p>Since the advent of the CRISPR/Cas9 gene-editing system in late 2012 [<xref rid="B391-biomedicines-09-00234" ref-type="bibr">391</xref>], the ability to manipulate plant genomes has become more cost efficient and less experimentally tedious when compared to the traditional genetic engineering approaches used by plant breeders in other crop species [<xref rid="B392-biomedicines-09-00234" ref-type="bibr">392</xref>]. The CRISPR/Cas9 system effectively directs site-specific genome editing using RNA-guided, microbial-derived nucleases that initiate double-stranded DNA breaks in eukaryotic and bacterial systems [<xref rid="B391-biomedicines-09-00234" ref-type="bibr">391</xref>,<xref rid="B393-biomedicines-09-00234" ref-type="bibr">393</xref>]. The specificity of this system greatly reduces the amount of off-target genome alterations compared to more traditional transformation techniques. However, off-targeting has also been observed with CRISPR/Cas9 use, an inherent challenge when manipulating any biological system [<xref rid="B394-biomedicines-09-00234" ref-type="bibr">394</xref>,<xref rid="B395-biomedicines-09-00234" ref-type="bibr">395</xref>,<xref rid="B396-biomedicines-09-00234" ref-type="bibr">396</xref>,<xref rid="B397-biomedicines-09-00234" ref-type="bibr">397</xref>]. Earlier work was directed towards human applications, but increasingly this system has been utilised in plant systems, with examples in <italic>Arabidopsis</italic>, tobacco (<italic>Nicotiana tabacum</italic>), rice (<italic>Oryza sativa</italic>), lettuce (<italic>Lactuca sativa</italic>), maize (<italic>Zea mays</italic>), soybean (<italic>Glycine max</italic>) and wheat (<italic>Triticum aestivum</italic>) now documented [<xref rid="B398-biomedicines-09-00234" ref-type="bibr">398</xref>,<xref rid="B399-biomedicines-09-00234" ref-type="bibr">399</xref>,<xref rid="B400-biomedicines-09-00234" ref-type="bibr">400</xref>,<xref rid="B401-biomedicines-09-00234" ref-type="bibr">401</xref>,<xref rid="B402-biomedicines-09-00234" ref-type="bibr">402</xref>,<xref rid="B403-biomedicines-09-00234" ref-type="bibr">403</xref>,<xref rid="B404-biomedicines-09-00234" ref-type="bibr">404</xref>,<xref rid="B405-biomedicines-09-00234" ref-type="bibr">405</xref>,<xref rid="B406-biomedicines-09-00234" ref-type="bibr">406</xref>,<xref rid="B407-biomedicines-09-00234" ref-type="bibr">407</xref>,<xref rid="B408-biomedicines-09-00234" ref-type="bibr">408</xref>,<xref rid="B409-biomedicines-09-00234" ref-type="bibr">409</xref>,<xref rid="B410-biomedicines-09-00234" ref-type="bibr">410</xref>]. By no means an exhaustive list of CRISPR/Cas9-facilitated manipulation in plants, the above does, however, highlight the potential applicability of this targeted mutagenesis approach to modulate specific biosynthetic pathways in <italic>Cannabis</italic> to produce superior varieties that display phenotypic and chemotypic traits of interest, and as a tool to discover key genes involved the production of minor cannabinoids. Transformation technologies has thus far been conducted in hemp varieties only, and therefore require further development and considerable refinement for application in other <italic>Cannabis</italic> varieties. The first report of successful hemp transformation emerged in 2001 [<xref rid="B411-biomedicines-09-00234" ref-type="bibr">411</xref>], and two years later, a protocol for successful <italic>Agrobacterium tumefaciens</italic>-mediated transformation of tissue cultured hemp callus was implemented [<xref rid="B412-biomedicines-09-00234" ref-type="bibr">412</xref>]. More recently, Wahby et al. [<xref rid="B413-biomedicines-09-00234" ref-type="bibr">413</xref>,<xref rid="B414-biomedicines-09-00234" ref-type="bibr">414</xref>] successfully transformed hemp using both <italic>A. tumefaciens</italic> and <italic>A</italic>. <italic>rhizogenes</italic>, establishing the initial protocol for hairy root culture in <italic>Cannabis</italic>, a system used for the production of key phytochemicals. Despite these successes, <italic>Cannabis</italic> has proven to be a difficult plant species to transform with such variables as variety, plant age and the explant used for callus production, all demonstrated to be crucial factors underpinning transformant regeneration efficiency [<xref rid="B415-biomedicines-09-00234" ref-type="bibr">415</xref>]. As with any novel plant transformation system, in order to overcome poor transformation efficiency, optimised protocols with respect to culture media, experimental approach, and selected explant material, will be required for routine and robust transformation of <italic>Cannabis</italic>.</p></sec><sec id="sec5dot2-biomedicines-09-00234"><title>5.2. Synthetic Production of Cannabinoids</title><p>Recently, the synthetic biology approach utilising microorganisms to produce high-quality cannabinoid products has removed the requirement for plant material [<xref rid="B287-biomedicines-09-00234" ref-type="bibr">287</xref>,<xref rid="B416-biomedicines-09-00234" ref-type="bibr">416</xref>]. Luo and colleagues [<xref rid="B287-biomedicines-09-00234" ref-type="bibr">287</xref>] were successful in producing CBG, CBD, THC and &#x00394;<sup>9</sup>-THCV from galactose, via manipulation of the native MVA pathway of the yeast <italic>Saccharomyces cerevisiae</italic> post the introduction of <italic>Cannabis</italic> genes encoding cannabinoid synthases, olivetolic acid synthase and geranylpyrophosphate: olivetolate geranyltransferase. Production of THCA from CBGA through functional THCA synthase expression in the two yeast species, <italic>S. cerevisiae</italic> and <italic>Pichia pastoris</italic>, has been demonstrated. However, attempts to introduce the same functionality in <italic>Escherichia coli</italic>, a bacterium, have proved unsuccessful [<xref rid="B293-biomedicines-09-00234" ref-type="bibr">293</xref>,<xref rid="B417-biomedicines-09-00234" ref-type="bibr">417</xref>]. Over-expression of genes encoding enzymes in the MVA and prenyl diphosphate pathways, also in <italic>S. cerevisiae</italic>, produced prenyl alcohol precursors required for terpenoid and cannabinoid synthesis [<xref rid="B418-biomedicines-09-00234" ref-type="bibr">418</xref>], while expression of a functional aromatic prenyltransferase from <italic>Streptomyces</italic> resulted in THCA production from OA and DPP in the yeast, <italic>Komagataella phaffi</italic> [<xref rid="B419-biomedicines-09-00234" ref-type="bibr">419</xref>]. These approaches present an attractive alternative with the ability to conceivably produce large quantities of minor cannabinoids that are only found in trace amounts in planta, while also reducing and/or removing the costs, carbon emissions (associated with indoor growth; [<xref rid="B420-biomedicines-09-00234" ref-type="bibr">420</xref>]) and environmental variables associated with the agricultural crop production. However, it should be noted that due to the criminalisation of <italic>Cannabis</italic> since the early 1930s, there are very few studies analysing water and energy use associated with the cultivation of <italic>Cannabis</italic>, although undoubtedly, as research in this area becomes more prevalent, efficient horticultural practices will reduce the consumption of water and energy for the large-scale cultivation of <italic>Cannabis</italic>.</p></sec><sec id="sec5dot3-biomedicines-09-00234"><title>5.3. Phenotypic Parameters Affecting Cannabis Yield and Potency</title><p>In <italic>Cannabis</italic> plants exhibiting an illicit drug chemotype (high THC), a primary concern, in conjunction with desired cannabinoid content, is overall biomass yield of female floral tissue. Consistent with other agriculturally significant species, <italic>Cannabis</italic> is sensitive to environmental variations which alter physiological characteristics affecting plant growth and yield potential. Early work on <italic>Cannabis</italic> flowering, uncovered the response to photoperiodism [<xref rid="B421-biomedicines-09-00234" ref-type="bibr">421</xref>,<xref rid="B422-biomedicines-09-00234" ref-type="bibr">422</xref>], which has subsequently been exploited, particularly by illicit indoor growers, who can cultivate <italic>Cannabis</italic> year-round by manipulating the response to reduced photoperiod length [<xref rid="B423-biomedicines-09-00234" ref-type="bibr">423</xref>]. Photoperiodism is a well-known biological response critical for development of branching and floral architecture in <italic>Cannabis</italic>, and as a result, has implications for yield potential [<xref rid="B423-biomedicines-09-00234" ref-type="bibr">423</xref>,<xref rid="B424-biomedicines-09-00234" ref-type="bibr">424</xref>]. A reduction in day length from 18 to 12 h induces flowering, and maintenance of this regime for 8 weeks produces an acceptable floral yield [<xref rid="B423-biomedicines-09-00234" ref-type="bibr">423</xref>]. Elevated light intensity from 400 watts per square metre (W m<sup>&#x02212;2</sup>), to 600 W m<sup>&#x02212;2</sup>, produced a higher yield of floral tissue per plant in several chemotypes when grown indoors [<xref rid="B424-biomedicines-09-00234" ref-type="bibr">424</xref>]. In addition, an increase in plant density from 16 to 20 plants m<sup>&#x02212;2</sup> reduced biomass yield of floral tissue in all 600 W m<sup>&#x02212;2</sup> treated plants [<xref rid="B425-biomedicines-09-00234" ref-type="bibr">425</xref>]; a finding that indicates that light interception is compromised at the lower canopy level in crowded growth conditions. The use of different artificial lighting systems in controlled environment greenhouse applications also affects yield, but there are &#x02018;trade offs&#x02019; when using light emitting diode (LED), versus high-intensity discharge (HID) light sources. HID lighting is generally of lower cost and generates greater photon flux density between 400 and 700 nm, while LED lighting has greater configurability for specified needs and emits substantially less heat than HID lighting; with both lighting options having similar electricity to photosynthetic photon conversion efficiencies, expressed as, &#x000b5;mol J<sup>&#x02212;1</sup> [<xref rid="B426-biomedicines-09-00234" ref-type="bibr">426</xref>,<xref rid="B427-biomedicines-09-00234" ref-type="bibr">427</xref>,<xref rid="B428-biomedicines-09-00234" ref-type="bibr">428</xref>]. The importance of light quality has been demonstrated in cucumber (<italic>Cucumis sativus</italic>) where a significant increase in dry weight was measured in plants grown under an &#x02018;artificial solar spectrum&#x02019;, produced by sulfur plasma and quartz-halogen lamps irradiating a light spectrum that emulated standard sunlight, when compared with those plants provided with either fluorescent or HID lighting [<xref rid="B429-biomedicines-09-00234" ref-type="bibr">429</xref>]. Photosynthetic photon flux density significantly affects harvestable floral biomass yield, while elevated UV-B radiation and electrical lighting power density (W m<sup>&#x02212;2</sup>) increased the &#x02018;potency&#x02019; of <italic>Cannabis</italic> through an elevation in THC concentration; all of which highlight the importance of light quantity and quality capture by the photosynthetic apparatus of this species to improve the harvestable output of cultivated <italic>Cannabis</italic> [<xref rid="B423-biomedicines-09-00234" ref-type="bibr">423</xref>,<xref rid="B430-biomedicines-09-00234" ref-type="bibr">430</xref>,<xref rid="B431-biomedicines-09-00234" ref-type="bibr">431</xref>,<xref rid="B432-biomedicines-09-00234" ref-type="bibr">432</xref>,<xref rid="B433-biomedicines-09-00234" ref-type="bibr">433</xref>].</p><p>Manipulating temperature conditions in indoor growth facilities has revealed a relationship with factors affecting plant growth and development. Rate of photosynthesis, water use efficiency, rate of transpiration, and leaf stomatal conductance, all increased in <italic>Cannabis</italic> plants with a temperature increase from 20 to 30 &#x000b0;C, suggesting an optimal temperature range for cultivation [<xref rid="B431-biomedicines-09-00234" ref-type="bibr">431</xref>]. Temperature and photosynthetic rate are tightly linked with the photosynthetic apparatus sensitive to fluctuations in temperature, responding particularly with reduced Ribulose 1,5-bisphosphate (RuBP) regeneration and lowered stomatal aperture, which together decreased CO<sub>2</sub> uptake; both rate reducing outcomes [<xref rid="B434-biomedicines-09-00234" ref-type="bibr">434</xref>,<xref rid="B435-biomedicines-09-00234" ref-type="bibr">435</xref>,<xref rid="B436-biomedicines-09-00234" ref-type="bibr">436</xref>]. It is worthwhile to note that <italic>Cannabis</italic> varieties are similarly sensitive to temperature where photosynthetic rate, water use efficiency, leaf number, and stem elongation, are modulated in response to temperature change [<xref rid="B431-biomedicines-09-00234" ref-type="bibr">431</xref>,<xref rid="B437-biomedicines-09-00234" ref-type="bibr">437</xref>,<xref rid="B438-biomedicines-09-00234" ref-type="bibr">438</xref>]. Mineral supplementation via fertilizer application has produced mixed results in terms of biomass and secondary metabolite concentration and/or profile composition in <italic>Cannabis</italic>. <italic>Cannabis</italic> was shown to be sensitive to nitrogen (N), phosphorus (P) and potassium (K) (NPK) supplementation, as well as the plant biostimulant, humic acid. The application of NPK reduced THC, CBN and CBD content, but increased CBG content in the <italic>Cannabis</italic> inflorescence, while the application of humic acid was found to significantly lower the THC, CBD, CBG, THCV, CBC, CBL and CBT content of the <italic>Cannabis</italic> inflorescence [<xref rid="B439-biomedicines-09-00234" ref-type="bibr">439</xref>]. However, N supplementation alone increased hemp seed yield, plant height, chlorophyll content, while decreasing fibre yield [<xref rid="B440-biomedicines-09-00234" ref-type="bibr">440</xref>]. The application of exogenous hormones during distinct developmental phases of <italic>Cannabis</italic> growth has also produced mixed results in relation to secondary metabolite content and biomass. Gibberellic acid (GA) application to whole flowering plants with developed, resinous trichomes reduced chlorophyll levels, DXS activity, mono- and sesquiterpene levels, and THC content, while increasing HMGR activity, to suggest a degree of interference (either directly or indirectly) by GA to both the MVA and MEP pathways [<xref rid="B441-biomedicines-09-00234" ref-type="bibr">441</xref>,<xref rid="B442-biomedicines-09-00234" ref-type="bibr">442</xref>]. Abscisic acid (ABA) application at the vegetative stage of <italic>Cannabis</italic> development, increased chlorophyll <italic>a</italic> content, but reduced HMGR, THC and CBD content. In contrast, ABA application at the flowering stage of development decreased total chlorophyll and HMGR content, and increased DXS activity and the content of THC in the flowers of female <italic>Cannabis</italic> plants, findings which again indicated either direct or indirect phytohormone-mediated interference of both the MVA and MEP pathways [<xref rid="B441-biomedicines-09-00234" ref-type="bibr">441</xref>,<xref rid="B442-biomedicines-09-00234" ref-type="bibr">442</xref>].</p><p>Alterations of the architecture of the <italic>Cannabis</italic> flower via the application of molecular-assisted breeding, or genetic engineering, are potential strategies to increase the floral yield of <italic>Cannabis</italic>. Alternatively, directed manipulation of the biosynthetic pathways by application of similar approaches leading to increased cannabinoid or terpenoid content would provide greater value via the targeted elevation of the exact concentration of specific secondary metabolites. Currently, research describing the implementation of such strategies in <italic>Cannabis</italic> are scarce. However, investigations of trichome development in <italic>Arabidopsis</italic> and other plant species are not. The extremely well-annotated genome of <italic>Arabidopsis</italic>, combined with the ease that <italic>Arabidopsis</italic> can be genetically manipulated, identifies <italic>Arabidopsis</italic> for use in baseline studies that are potentially applicable to more valuable agricultural species. Indeed, <italic>Arabidopsis</italic>-based studies of trichome development have revealed a cohort of genes of interest. As with the development of any specialised cell type, it is underpinned by a complex gene network, and in <italic>Arabidopsis</italic>, the protein products encoded by the <italic>GLABROUS1</italic> (<italic>GL1</italic>), <italic>GL2, GL3</italic> and <italic>TRANSPARENT TESTA GLABROUS</italic> loci are responsible for various aspects of trichome morphogenesis, maturation, branching and spatial variation [<xref rid="B443-biomedicines-09-00234" ref-type="bibr">443</xref>,<xref rid="B444-biomedicines-09-00234" ref-type="bibr">444</xref>,<xref rid="B445-biomedicines-09-00234" ref-type="bibr">445</xref>,<xref rid="B446-biomedicines-09-00234" ref-type="bibr">446</xref>]. Additional gene products have been identified as essential for correct branching patterns and trichome responses to hormones, with EMS-induced mutation to the MYB encoding gene, <italic>TRIPTYCHON</italic>, resulting in the &#x02018;nesting&#x02019;, or grouping of trichomes with higher local densities [<xref rid="B447-biomedicines-09-00234" ref-type="bibr">447</xref>,<xref rid="B448-biomedicines-09-00234" ref-type="bibr">448</xref>]. A gene encoding a zinc-finger transcription factor from <italic>Arabidopsis</italic>, <italic>GLABROUS INFLORESCENCE STEMS</italic>, increased glandular trichome density on the leaves, sepals, inflorescence and its branches, while also increasing the content of nicotine secretion into the glandular heads when over-expressed in tobacco plants [<xref rid="B449-biomedicines-09-00234" ref-type="bibr">449</xref>]. Similarly, overexpression of a serine proteinase inhibitor, <italic>SaPIN2a</italic>, from American nightshade (<italic>Solanum americanum</italic>) in transformed tobacco, significantly increased the branching and density of glandular trichomes [<xref rid="B450-biomedicines-09-00234" ref-type="bibr">450</xref>]. Regulation of the expression of the gene encoding the DXS synthase 2 (<italic>DXS2</italic>) enzyme, which is active in the MEP pathway in <italic>Cannabis</italic>, and also in tomato (<italic>Solanum lycopersicum</italic>) via a RNA silencing approach, resulted in an increase in trichome density on tomato leaves and reduced the accumulation of the monoterpene, &#x003b2;-phellandrene [<xref rid="B451-biomedicines-09-00234" ref-type="bibr">451</xref>]. In cotton (<italic>Gossypium</italic> spp.), a mutation in the <italic>PIGMENT GLAND FORMATION</italic> locus, resulted in the expression of the glandless phenotype: a strategy adopted to remove toxic gossypol from cotton seeds for human consumption [<xref rid="B452-biomedicines-09-00234" ref-type="bibr">452</xref>]. While the opposite phenotypic outcome of increased trichome density would be the desired result in <italic>Cannabis</italic> experimentation, when taken together, these findings highlight the importance of targeting specific genetic networks for molecular manipulation to initiate the expression of desired and/or designer plant phenotypes.</p><p>Increasing the biomass of agriculturally valuable species is not a novel undertaking, and anthropogenic selection has perhaps inadvertently, been conducted by humans since the dawn of agriculture. Plant height is identified as a target for manipulation in relation to overall biomass yield in maize and sorghum (<italic>Sorghum bicolor</italic>) [<xref rid="B453-biomedicines-09-00234" ref-type="bibr">453</xref>], and in <italic>Cannabis</italic> grown for fibre, stem length is an important parameter for fibre yield which is affected by plant density and soil N content [<xref rid="B454-biomedicines-09-00234" ref-type="bibr">454</xref>,<xref rid="B455-biomedicines-09-00234" ref-type="bibr">455</xref>]. The inverse is true for <italic>Cannabis</italic> varieties grown for their cannabinoid content, where reduced stem lengths produce a shorter overall plant stature and correlates with a greater photoassimilate input into reproductive tissues leading to the development of floral architecture with increased accumulation of cannabinoids and terpenoids [<xref rid="B456-biomedicines-09-00234" ref-type="bibr">456</xref>]. Small [<xref rid="B3-biomedicines-09-00234" ref-type="bibr">3</xref>] suggests that the value of drug chemotype varieties is linked to the development of &#x02018;semi-dwarf <italic>Cannabis</italic> germplasm&#x02019;, characterised by compact, congested flowers on short branches. Such plants ultimately produce more cannabinoids due to greater resource partitioning into floral and trichome development and are of short enough stature that they can be grown at high indoor densities where the artificial environment is readily manipulated to produce greater amounts of secondary metabolites. The combination of key phenotypic traits associated with increased secondary metabolite accumulation, including dense compact floral arrangements, and semi-dwarf stature, and with novel chemotypic traits that confer targeted medical efficacy epitomises the new varieties (chemovars) to be pursued as part of a highly focused research strategy. Similar strategies that use marker assisted breeding and EMS to provide the molecular basis to generate plants that produce elevated levels of desired compounds have been undertaken in other medically significant plant species. Quantitative trait loci mapping of <italic>Artemisia annua</italic> L. (sweet wormwood), a plant species which produces the anti-malarial compound, artemisinin, provided the platform for marker assisted breeding programs to increase artemisinin yield [<xref rid="B457-biomedicines-09-00234" ref-type="bibr">457</xref>], and by extension, revealed both the pathway for similar research that would later be undertaken in opium poppy and the avenues for the future development of similar strategies in <italic>Cannabis</italic>.</p></sec><sec id="sec5dot4-biomedicines-09-00234"><title>5.4. Papaver somniferum: Potential Parallels for Future Cannabis Research</title><p>With significant change surrounding the societal views and scientific inquiry into <italic>Cannabis</italic> on the horizon, it is important to look at past endeavours to envisage future directions. While <italic>Cannabis</italic> is a unique plant for its utility, <italic>Papaver somniferum</italic> (<italic>Papaver</italic>; opium poppy) rivals the versatility seen across <italic>Cannabis</italic> varieties, and given its long history of human use, it is an excellent comparison to investigate. <italic>Papaver</italic>, otherwise known as opium poppy, is responsible for the production of the most medically significant alkaloids, including morphine, codeine, thebaine, oripavine and noscapine. These opioids accumulate in the phloem, particularly the mesocarp capsule of <italic>Papaver</italic> aerial tissues in specialised cells called lactifers, which join to form a latex-containing network of anastomosing vessels [<xref rid="B458-biomedicines-09-00234" ref-type="bibr">458</xref>,<xref rid="B459-biomedicines-09-00234" ref-type="bibr">459</xref>,<xref rid="B460-biomedicines-09-00234" ref-type="bibr">460</xref>]. The therapeutic efficacy of <italic>Papaver</italic>-derived opioids is better understood than the secondary metabolites of <italic>Cannabis</italic>, and the scope of their effects is far reaching. Morphine has been utilised for decades as one of the most widely used analgesics, effective in the post-operative clinical setting [<xref rid="B461-biomedicines-09-00234" ref-type="bibr">461</xref>,<xref rid="B462-biomedicines-09-00234" ref-type="bibr">462</xref>,<xref rid="B463-biomedicines-09-00234" ref-type="bibr">463</xref>]. Codeine has been shown to be a less effective analgesic than morphine [<xref rid="B464-biomedicines-09-00234" ref-type="bibr">464</xref>,<xref rid="B465-biomedicines-09-00234" ref-type="bibr">465</xref>] but has historically been accepted as the prevailing antitussive [<xref rid="B466-biomedicines-09-00234" ref-type="bibr">466</xref>]. More recent evidence suggests however, that there are more effective treatments, especially for chronic coughing disorders [<xref rid="B467-biomedicines-09-00234" ref-type="bibr">467</xref>,<xref rid="B468-biomedicines-09-00234" ref-type="bibr">468</xref>,<xref rid="B469-biomedicines-09-00234" ref-type="bibr">469</xref>]. Additionally, noscapine, another <italic>Papaver</italic> alkaloid, displays antitussive properties, and is also suggested to potentially mitigate stroke mortality and induce apoptosis in a broad set of cancers [<xref rid="B470-biomedicines-09-00234" ref-type="bibr">470</xref>,<xref rid="B471-biomedicines-09-00234" ref-type="bibr">471</xref>,<xref rid="B472-biomedicines-09-00234" ref-type="bibr">472</xref>,<xref rid="B473-biomedicines-09-00234" ref-type="bibr">473</xref>]. Thebaine and oripavine are not themselves used therapeutically. However, they are precursors for a wide range of semi-synthetic opioids including, but not limited to, hydrocodone, oxycodone and hydromorphone, as well as naloxone, which is interestingly employed to treat the acute effects of opioid overdose [<xref rid="B474-biomedicines-09-00234" ref-type="bibr">474</xref>,<xref rid="B475-biomedicines-09-00234" ref-type="bibr">475</xref>,<xref rid="B476-biomedicines-09-00234" ref-type="bibr">476</xref>,<xref rid="B477-biomedicines-09-00234" ref-type="bibr">477</xref>,<xref rid="B478-biomedicines-09-00234" ref-type="bibr">478</xref>,<xref rid="B479-biomedicines-09-00234" ref-type="bibr">479</xref>].</p><p>Given the multitude of efficacious compounds produced by <italic>Papaver</italic>, and the commercial value emanating from such, the desire to generate plant varieties that produce specific chemical profiles is one that is mirrored in <italic>Cannabis</italic>. While the latter is currently reliant on years of predominantly illicit breeding programs to produce plants with increased psychoactive properties, the development of novel <italic>Papaver</italic> varieties has already been established. EMS treatment of poppy seeds preceded the identification of a variety termed <italic>top1</italic> (<italic>thebaine oripavine poppy 1</italic>) which harboured a mutation leading to premature arrest of the morphine and codeine biosynthesis pathway. The resulting <italic>top1</italic> plants displayed a pigmented latex, and the enhanced accumulation of thebaine and oripavine, but failed to produce either codeine or morphine [<xref rid="B480-biomedicines-09-00234" ref-type="bibr">480</xref>]. Similarly, a reduction in codeine 3-O-demethylase (CODM) activity, via either a viral-induced gene silencing (VIGS) strategy, or a fast neutron bombardment mutagenesis approach, yielded <italic>Papaver</italic> plants with enhanced codeine accumulation, but which were unable to synthesise morphine from a codeine substrate [<xref rid="B481-biomedicines-09-00234" ref-type="bibr">481</xref>,<xref rid="B482-biomedicines-09-00234" ref-type="bibr">482</xref>,<xref rid="B483-biomedicines-09-00234" ref-type="bibr">483</xref>]. These high codeine <italic>Papaver</italic> varieties that harbour CODM polymorphisms, provided a basis for a marker-assisted breeding platform, and to produce <italic>Papaver</italic> chemotypes accumulating novel alkaloid profiles [<xref rid="B483-biomedicines-09-00234" ref-type="bibr">483</xref>]. Similar actions utilising <italic>Cannabis</italic> may also mediate alterations to the cannabinoid biosynthesis pathways to produce varieties with elevated minor cannabinoid content. Sequencing of a high noscapine variety of <italic>Papaver</italic>, termed HN1, led to the discovery of a 10 gene cluster responsible for noscapine biosynthesis that was absent in either a high morphine (HM1)- or high thebaine (HT1)-producing variety of <italic>Papaver</italic> [<xref rid="B484-biomedicines-09-00234" ref-type="bibr">484</xref>]. Generation of an F<sub>2</sub> mapping population from HN1 and HM1 parents showed tight linkage of this gene cluster, revealing high noscapine-producing progeny that were homozygous for the HN1 gene cluster, while heterozygosity, or absence of the HN1 gene cluster, was associated with plant lines that produced low or undetectable levels of noscapine, respectively [<xref rid="B484-biomedicines-09-00234" ref-type="bibr">484</xref>]. The identification of the <italic>STORR</italic> (<italic>[S]- to [R]-reticuline</italic>) locus led to the development of high noscapine <italic>Papaver</italic> varieties with a non-functioning cytochrome P450-oxidoreductase fusion protein, inhibiting the [S]-reticuline conversion to [R]-reticuline necessary for completion of the morphinan pathway [<xref rid="B485-biomedicines-09-00234" ref-type="bibr">485</xref>,<xref rid="B486-biomedicines-09-00234" ref-type="bibr">486</xref>,<xref rid="B487-biomedicines-09-00234" ref-type="bibr">487</xref>,<xref rid="B488-biomedicines-09-00234" ref-type="bibr">488</xref>]. A VIGS approach has been successfully utilised to individually regulate the expression of six genes encoding enzymes involved in the final six conversion steps of [R]-reticuline to morphine, each of which were shown to alter the major alkaloid profile [<xref rid="B489-biomedicines-09-00234" ref-type="bibr">489</xref>]. An RNA silencing approach which employed a chimeric hairpin RNA to target all members of the multigene codeinone reductase family produced a non-narcotic, [S]-reticuline-accumulating variety of <italic>Papaver</italic> [<xref rid="B490-biomedicines-09-00234" ref-type="bibr">490</xref>]. In the exploitation of the versatility of <italic>Papaver</italic> beyond narcotics, varieties with high food value have been established through EMS and gamma ray mutagenesis breeding programs to produce increased seed yield (5.66 g/capsule versus the 3.39 g/capsule of control plants) with elevated levels of unsaturated seed oil and no narcotic production [<xref rid="B491-biomedicines-09-00234" ref-type="bibr">491</xref>]. While this is not an exhaustive list of selectively bred, or engineered <italic>Papaver</italic> varieties, the long-standing and successful development of <italic>Papaver</italic> varieties with superior phenotypic and/or chemotypic traits of interest certainly provides a reference for guiding <italic>Cannabis</italic> research strategies, which at present are comparatively in their infancy. Development of varieties producing high levels of alkaloid biosynthetic pathway intermediates is a promising indicator for the potential production of <italic>Cannabis</italic> varieties that reliably produce high levels of minor cannabinoids or intermediates in the cannabinoid biosynthesis pathway.</p></sec></sec><sec sec-type="conclusions" id="sec6-biomedicines-09-00234"><title>6. Conclusions</title><p>In summary, we have reviewed the current literature of several important aspects of cannabinoid research outside of THC and CBD, which dominate discussion in the <italic>Cannabis</italic> research field. Emerging research has begun to reveal the pharmacology and molecular targets of the minor cannabinoids. Due to the wide spectrum of molecular effects involved with cannabinoid consumption, it is clear that there are a range of medical ailments that could be addressed through endocannabinoid augmentation using secondary metabolites of <italic>Cannabis</italic>. Here, we have illustrated that via the utilisation of specific minor cannabinoids, which share some, but not all targets of THC and CBD, the medical reach of cannabinoid-containing pharmaceuticals could potentially be broadened. However, there are many challenges that currently impede this possibility, even outside of the international legal environment. Firstly, there is further room for significant characterisation of minor cannabinoid pharmacology, and currently, disease-orientated preclinical and clinical trials are lacking. Critically, techniques for producing cannabinoid isolates&#x02014;even CBD and THC&#x02014;are still in their infancy, and this remains a clear barrier to large-scale commercialisation of pharmaceutical cannabinoids. Here, we have reviewed the currently available literature which covers the processes involved in the biosynthesis of cannabinoids, as well as the techniques involved in the production of novel <italic>Cannabis</italic> chemotypes, including methods of improving yield that might be adopted from historically similar cases, such as the opioid industry. Based on this historical example, and the existing literature, it is likely that a molecular genetic modification approach will be applied to <italic>Cannabis</italic> to generate new opportunities for the improved yield of specific minor and major cannabinoids in the near future. In conclusion, there are multiple enticing and potentially profitable opportunities for commercial and academic growth in the <italic>Cannabis</italic> market outside of THC and CBD, and here, we highlight some of the most important current perspectives of this growing industry.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization and design, J.M.J.O., J.L.P., T.A.B., A.L.E. and C.P.L.G.; writing, J.M.J.O., J.L.P., T.A.B., A.L.E., L.J.N. and C.P.L.G.; review and editing, J.M.J.O., J.L.P., T.A.B., A.L.E., L.J.N. and C.P.L.G. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>J.M.J.O.&#x02019;s research is supported by CannaPacific Pty Ltd., Australia.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-biomedicines-09-00234"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>R.C.</given-names></name><name><surname>Merlin</surname><given-names>M.D.</given-names></name></person-group><article-title>Letter to the Editor: Small, Ernest. 2015. Evolution and Classification of <italic>Cannabis sativa</italic> (Marijuana, Hemp) in Relation to Human Utilization</article-title><source>Bot. Rev.</source><year>2015</year><volume>81</volume><fpage>295</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1007/s12229-015-9158-2</pub-id></element-citation></ref><ref id="B2-biomedicines-09-00234"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultes</surname><given-names>R.E.</given-names></name><name><surname>Klein</surname><given-names>W.M.</given-names></name><name><surname>Plowman</surname><given-names>T.</given-names></name><name><surname>Lockwood</surname><given-names>T.E.</given-names></name></person-group><article-title>Cannabis: An Example of Taxonomic Neglect</article-title><source>Bot. Museum Leafl. Harvard Univ.</source><year>1974</year><volume>23</volume><fpage>337</fpage><lpage>367</lpage></element-citation></ref><ref id="B3-biomedicines-09-00234"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Small</surname><given-names>E.</given-names></name></person-group><article-title>Evolution and Classification of <italic>Cannabis sativa</italic> (Marijuana, Hemp) in Relation to Human Utilization</article-title><source>Bot. Rev.</source><year>2015</year><volume>81</volume><fpage>189</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1007/s12229-015-9157-3</pub-id></element-citation></ref><ref id="B4-biomedicines-09-00234"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Small</surname><given-names>E.</given-names></name><name><surname>Cronquist</surname><given-names>A.</given-names></name></person-group><article-title>A Practical and Natural Taxonomy for Cannabis</article-title><source>Taxon</source><year>1976</year><volume>25</volume><fpage>405</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.2307/1220524</pub-id></element-citation></ref><ref id="B5-biomedicines-09-00234"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Small</surname><given-names>E.</given-names></name><name><surname>Naraine</surname><given-names>S.G.U.</given-names></name></person-group><article-title>Size Matters: Evolution of Large Drug-Secreting Resin Glands in Elite Pharmaceutical Strains of <italic>Cannabis sativa</italic> (Marijuana)</article-title><source>Genet. Resour. Crop Evol.</source><year>2016</year><volume>254</volume><fpage>349</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1007/s10722-015-0254-2</pub-id></element-citation></ref><ref id="B6-biomedicines-09-00234"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salentijn</surname><given-names>E.M.J.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Amaducci</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Trindade</surname><given-names>L.M.</given-names></name></person-group><article-title>New Developments in Fiber Hemp (<italic>Cannabis sativa</italic> L.) Breeding</article-title><source>Ind. Crops Prod.</source><year>2015</year><volume>68</volume><fpage>32</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.indcrop.2014.08.011</pub-id></element-citation></ref><ref id="B7-biomedicines-09-00234"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mead</surname><given-names>A.</given-names></name></person-group><article-title>The Legal Status of Cannabis (Marijuana) and Cannabidiol (CBD) under U.S. Law</article-title><source>Epilepsy Behav.</source><year>2017</year><volume>70</volume><fpage>288</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2016.11.021</pub-id><pub-id pub-id-type="pmid">28169144</pub-id></element-citation></ref><ref id="B8-biomedicines-09-00234"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaducci</surname><given-names>S.</given-names></name><name><surname>Scordia</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>F.H.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>H.</given-names></name><name><surname>Testa</surname><given-names>G.</given-names></name><name><surname>Cosentino</surname><given-names>S.L.</given-names></name></person-group><article-title>Key Cultivation Techniques for Hemp in Europe and China</article-title><source>Ind. Crop. Prod.</source><year>2015</year><volume>68</volume><fpage>2</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.indcrop.2014.06.041</pub-id></element-citation></ref><ref id="B9-biomedicines-09-00234"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bielecka</surname><given-names>M.</given-names></name><name><surname>Kaminski</surname><given-names>F.</given-names></name><name><surname>Adams</surname><given-names>I.</given-names></name><name><surname>Poulson</surname><given-names>H.</given-names></name><name><surname>Sloan</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Larson</surname><given-names>T.R.</given-names></name><name><surname>Winzer</surname><given-names>T.</given-names></name><name><surname>Graham</surname><given-names>I.A.</given-names></name></person-group><article-title>Targeted Mutation of &#x00394;12 and &#x00394;15 Desaturase Genes in Hemp Produce Major Alterations in Seed Fatty Acid Composition Including a High Oleic Hemp Oil</article-title><source>Plant Biotechnol. J.</source><year>2014</year><volume>12</volume><fpage>613</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1111/pbi.12167</pub-id><?supplied-pmid 24506492?><pub-id pub-id-type="pmid">24506492</pub-id></element-citation></ref><ref id="B10-biomedicines-09-00234"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callaway</surname><given-names>J.C.</given-names></name><name><surname>Tennil&#x000e4;</surname><given-names>T.</given-names></name><name><surname>Pate</surname><given-names>D.W.</given-names></name></person-group><article-title>Occurence of &#x0201c;Omega 3&#x0201d; Stearidonic Acid (Cis-6,9,12,15-Ocadecatetraenoic Acid) in Hemp (<italic>Cannabis sativa</italic> L.) Seed</article-title><source>J. Int. Hemp Assoc.</source><year>1996</year><volume>3</volume><fpage>61</fpage><lpage>63</lpage></element-citation></ref><ref id="B11-biomedicines-09-00234"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimi&#x00107;</surname><given-names>E.</given-names></name><name><surname>Romani&#x00107;</surname><given-names>R.</given-names></name><name><surname>Vujasinovi&#x00107;</surname><given-names>V.</given-names></name></person-group><article-title>Essential Fatty Acids, Nutritive Value and Oxidative Stability of Cold Pressed Hempseed (<italic>Cannabis sativa</italic> L.) Oil from Different Varieties</article-title><source>Acta Aliment.</source><year>2009</year><volume>38</volume><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1556/AAlim.2008.0035</pub-id></element-citation></ref><ref id="B12-biomedicines-09-00234"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deferne</surname><given-names>J.</given-names></name><name><surname>Pate</surname><given-names>D.W.</given-names></name></person-group><article-title>Hemp Seed Oil: A Source of Valuable Essential Fatty Acids</article-title><source>J. Int. Hemp Assoc.</source><year>1996</year><volume>3</volume><fpage>4</fpage><lpage>7</lpage></element-citation></ref><ref id="B13-biomedicines-09-00234"><label>13.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Erasmus</surname><given-names>U.</given-names></name></person-group><source>Fats That Heal, Fats That Kill: The Complete Guide to Fats, Oils, Cholesterol, and Human Health</source><edition>3rd ed.</edition><publisher-name>Alive Books</publisher-name><publisher-loc>Burnaby, BC, Canada</publisher-loc><year>1993</year></element-citation></ref><ref id="B14-biomedicines-09-00234"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stubbs</surname><given-names>C.D.</given-names></name><name><surname>Smith</surname><given-names>A.D.</given-names></name></person-group><article-title>The Modification of Mammalian Membrane Polyunsaturated Fatty Acid Composition in Relation to Membrane Fluidity and Function</article-title><source>Biochim. Biophys. Acta</source><year>1984</year><volume>779</volume><fpage>89</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/0304-4157(84)90005-4</pub-id><pub-id pub-id-type="pmid">6229284</pub-id></element-citation></ref><ref id="B15-biomedicines-09-00234"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callaway</surname><given-names>J.C.</given-names></name></person-group><article-title>Hempseed as a Nutritional Resource: An Overview</article-title><source>Euphytica</source><year>2004</year><volume>140</volume><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1007/s10681-004-4811-6</pub-id></element-citation></ref><ref id="B16-biomedicines-09-00234"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harbige</surname><given-names>L.S.</given-names></name><name><surname>Layward</surname><given-names>L.</given-names></name><name><surname>Morris-Downes</surname><given-names>M.M.</given-names></name><name><surname>Dumonde</surname><given-names>D.C.</given-names></name><name><surname>Amor</surname><given-names>S.</given-names></name></person-group><article-title>The Protective Effects of Omega-6 Fatty Acids in Experimental Autoimmune Encephalomyelitis (EAE) in Relation to Transforming Growth Factor-Beta 1 (TGF-&#x00392;1) up-Regulation and Increased Prostaglandin E2 (PGE2) Production</article-title><source>Clin. Exp. Immunol.</source><year>2000</year><volume>122</volume><fpage>445</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2249.2000.01399.x</pub-id><?supplied-pmid 11122253?><pub-id pub-id-type="pmid">11122253</pub-id></element-citation></ref><ref id="B17-biomedicines-09-00234"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prociuk</surname><given-names>M.A.</given-names></name><name><surname>Edel</surname><given-names>A.L.</given-names></name><name><surname>Richard</surname><given-names>M.N.</given-names></name><name><surname>Gavel</surname><given-names>N.T.</given-names></name><name><surname>Ander</surname><given-names>B.P.</given-names></name><name><surname>Dupasquier</surname><given-names>C.M.C.</given-names></name><name><surname>Pierce</surname><given-names>G.N.</given-names></name></person-group><article-title>Cholesterol-Induced Stimulation of Platelet Aggregation Is Prevented by a Hempseed-Enriched Diet</article-title><source>Can. J. Physiol. Pharmacol.</source><year>2008</year><volume>86</volume><fpage>153</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1139/Y08-011</pub-id><pub-id pub-id-type="pmid">18418423</pub-id></element-citation></ref><ref id="B18-biomedicines-09-00234"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>R.C.</given-names></name><name><surname>Merlin</surname><given-names>M.D.</given-names></name></person-group><article-title>Cannabis Domestication, Breeding History, Present-Day Genetic Diversity, and Future Prospects</article-title><source>CRC Crit. Rev. Plant Sci.</source><year>2016</year><volume>35</volume><fpage>293</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1080/07352689.2016.1267498</pub-id></element-citation></ref><ref id="B19-biomedicines-09-00234"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dayanandan</surname><given-names>P.</given-names></name><name><surname>Kaufman</surname><given-names>P.B.</given-names></name></person-group><article-title>Trichomes of <italic>Cannabis sativa</italic> L. (Cannabaceae)</article-title><source>Am. J. Bot.</source><year>1976</year><volume>63</volume><fpage>578</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1002/j.1537-2197.1976.tb11846.x</pub-id></element-citation></ref><ref id="B20-biomedicines-09-00234"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ElSohly</surname><given-names>M.A.</given-names></name><name><surname>Slade</surname><given-names>D.</given-names></name></person-group><article-title>Chemical Constituents of Marijuana: The Complex Mixture of Natural Cannabinoids</article-title><source>Life Sci.</source><year>2005</year><volume>78</volume><fpage>539</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2005.09.011</pub-id><pub-id pub-id-type="pmid">16199061</pub-id></element-citation></ref><ref id="B21-biomedicines-09-00234"><label>21.</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Pertwee</surname><given-names>R.G.</given-names></name></person-group><source>Handbook of Cannabis</source><publisher-name>Oxford University Press</publisher-name><publisher-loc>Oxford, UK</publisher-loc><year>2015</year><pub-id pub-id-type="doi">10.1093/acprof:oso/9780199662685.001.0001</pub-id></element-citation></ref><ref id="B22-biomedicines-09-00234"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Citti</surname><given-names>C.</given-names></name><name><surname>Linciano</surname><given-names>P.</given-names></name><name><surname>Russo</surname><given-names>F.</given-names></name><name><surname>Luongo</surname><given-names>L.</given-names></name><name><surname>Iannotta</surname><given-names>M.</given-names></name><name><surname>Maione</surname><given-names>S.</given-names></name><name><surname>Lagan&#x000e0;</surname><given-names>A.</given-names></name><name><surname>Capriotti</surname><given-names>A.L.</given-names></name><name><surname>Forni</surname><given-names>F.</given-names></name><name><surname>Vandelli</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>A Novel Phytocannabinoid Isolated from <italic>Cannabis sativa</italic> L. with an in Vivo Cannabimimetic Activity Higher than &#x00394;9-Tetrahydrocannabinol: &#x00394;9-Tetrahydrocannabiphorol</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>20335</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-56785-1</pub-id><?supplied-pmid 31889124?><pub-id pub-id-type="pmid">31889124</pub-id></element-citation></ref><ref id="B23-biomedicines-09-00234"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babaei</surname><given-names>M.</given-names></name><name><surname>Ajdanian</surname><given-names>L.</given-names></name></person-group><article-title>Screening of Different Iranian Ecotypes of Cannabis under Water Deficit Stress</article-title><source>Sci. Hortic.</source><year>2020</year><volume>260</volume><pub-id pub-id-type="doi">10.1016/j.scienta.2019.108904</pub-id></element-citation></ref><ref id="B24-biomedicines-09-00234"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linger</surname><given-names>P.</given-names></name><name><surname>Ostwald</surname><given-names>A.</given-names></name><name><surname>Haensler</surname><given-names>J.</given-names></name></person-group><article-title><italic>Cannabis sativa</italic> L. Growing on Heavy Metal Contaminated Soil: Growth, Cadmium Uptake and Photosynthesis</article-title><source>Biol. Plant.</source><year>2005</year><volume>49</volume><fpage>567</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1007/s10535-005-0051-4</pub-id></element-citation></ref><ref id="B25-biomedicines-09-00234"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouquet</surname><given-names>R.J.</given-names></name></person-group><article-title>Cannabis</article-title><source>Bull. Narc.</source><year>1950</year><volume>2</volume><fpage>14</fpage><lpage>30</lpage></element-citation></ref><ref id="B26-biomedicines-09-00234"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaducci</surname><given-names>S.</given-names></name><name><surname>Zatta</surname><given-names>A.</given-names></name><name><surname>Raffanini</surname><given-names>M.</given-names></name><name><surname>Venturi</surname><given-names>G.</given-names></name></person-group><article-title>Characterisation of Hemp (<italic>Cannabis sativa</italic> L.) Roots under Different Growing Conditions</article-title><source>Plant Soil</source><year>2008</year><volume>313</volume><pub-id pub-id-type="doi">10.1007/s11104-008-9695-0</pub-id></element-citation></ref><ref id="B27-biomedicines-09-00234"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Small</surname><given-names>E.</given-names></name><name><surname>Marcus</surname><given-names>D.</given-names></name><name><surname>Butler</surname><given-names>G.</given-names></name><name><surname>McElroy</surname><given-names>A.R.</given-names></name></person-group><article-title>Apparent Increase in Biomass and Seed Productivity in Hemp (<italic>Cannabis sativa</italic>) Resulting from Branch Proliferation Caused by the European Corn Borer (<italic>Ostrinia nubilalis</italic>)</article-title><source>J. Ind. Hemp</source><year>2007</year><volume>12</volume><fpage>15</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1300/J237v12n01_03</pub-id></element-citation></ref><ref id="B28-biomedicines-09-00234"><label>28.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Government of Canada</collab></person-group><article-title>Department of Justice</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.justice.gc.ca/eng/cj-jp/cannabis/">https://www.justice.gc.ca/eng/cj-jp/cannabis/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-01-15">(accessed on 15 January 2020)</date-in-citation></element-citation></ref><ref id="B29-biomedicines-09-00234"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ney</surname><given-names>L.J.</given-names></name><name><surname>Matthews</surname><given-names>A.</given-names></name><name><surname>Bruno</surname><given-names>R.</given-names></name><name><surname>Felmingham</surname><given-names>K.L.</given-names></name></person-group><article-title>Cannabinoid Interventions for PTSD: Where to Next?</article-title><source>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</source><year>2019</year><volume>93</volume><fpage>124</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2019.03.017</pub-id></element-citation></ref><ref id="B30-biomedicines-09-00234"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lattanzi</surname><given-names>S.</given-names></name><name><surname>Brigo</surname><given-names>F.</given-names></name><name><surname>Trinka</surname><given-names>E.</given-names></name><name><surname>Zaccara</surname><given-names>G.</given-names></name><name><surname>Cagnetti</surname><given-names>C.</given-names></name><name><surname>Del Giovane</surname><given-names>C.</given-names></name><name><surname>Silvestrini</surname><given-names>M.</given-names></name></person-group><article-title>Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis</article-title><source>Drugs</source><year>2018</year><volume>78</volume><fpage>1791</fpage><lpage>1804</lpage><pub-id pub-id-type="doi">10.1007/s40265-018-0992-5</pub-id><?supplied-pmid 30390221?><pub-id pub-id-type="pmid">30390221</pub-id></element-citation></ref><ref id="B31-biomedicines-09-00234"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>S.</given-names></name><name><surname>Hill</surname><given-names>M.N.</given-names></name><name><surname>Cheer</surname><given-names>J.F.</given-names></name><name><surname>Wotjak</surname><given-names>C.T.</given-names></name><name><surname>Holmes</surname><given-names>A.</given-names></name></person-group><article-title>The Endocannabinoid System as a Target for Novel Anxiolytic Drugs</article-title><source>Neurosci. Biobehav. Rev.</source><year>2017</year><volume>76</volume><fpage>56</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2016.12.033</pub-id><?supplied-pmid 28434588?><pub-id pub-id-type="pmid">28434588</pub-id></element-citation></ref><ref id="B32-biomedicines-09-00234"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiting</surname><given-names>P.F.</given-names></name><name><surname>Wolff</surname><given-names>R.F.</given-names></name><name><surname>Deshpande</surname><given-names>S.</given-names></name><name><surname>Di Nisio</surname><given-names>M.</given-names></name><name><surname>Duffy</surname><given-names>S.</given-names></name><name><surname>Hernandez</surname><given-names>A.V.</given-names></name><name><surname>Keurentjes</surname><given-names>J.C.</given-names></name><name><surname>Lang</surname><given-names>S.</given-names></name><name><surname>Misso</surname><given-names>K.</given-names></name><name><surname>Ryder</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Cannabinoids for Medical Use: A Systematic Review and Meta-Analysis</article-title><source>JAMA J. Am. Med. Assoc.</source><year>2015</year><volume>313</volume><fpage>2456</fpage><lpage>2473</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.6358</pub-id><?supplied-pmid 26103030?><pub-id pub-id-type="pmid">26103030</pub-id></element-citation></ref><ref id="B33-biomedicines-09-00234"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wade</surname><given-names>D.T.</given-names></name><name><surname>Collin</surname><given-names>C.</given-names></name><name><surname>Stott</surname><given-names>C.</given-names></name><name><surname>Duncombe</surname><given-names>P.</given-names></name></person-group><article-title>Meta-Analysis of the Efficacy and Safety of Sativex (Nabiximols), on Spasticity in People with Multiple Sclerosis</article-title><source>Mult. Scler.</source><year>2010</year><volume>16</volume><fpage>707</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1177/1352458510367462</pub-id><?supplied-pmid 20558502?><pub-id pub-id-type="pmid">20558502</pub-id></element-citation></ref><ref id="B34-biomedicines-09-00234"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>A.J.</given-names></name><name><surname>Higgins</surname><given-names>M.D.</given-names></name></person-group><article-title>A Systematic Review of the Analgesic Efficacy of Cannabinoid Medications in the Management of Acute Pain</article-title><source>Acta Anaesthesiol. Scand.</source><year>2017</year><volume>61</volume><fpage>268</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1111/aas.12851</pub-id><pub-id pub-id-type="pmid">28090652</pub-id></element-citation></ref><ref id="B35-biomedicines-09-00234"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales</surname><given-names>P.</given-names></name><name><surname>Jagerovic</surname><given-names>N.</given-names></name></person-group><article-title>Novel Approaches and Current Challenges with Targeting the Endocannabinoid System</article-title><source>Expert Opin. Drug Discov.</source><year>2020</year><volume>15</volume><fpage>917</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1080/17460441.2020.1752178</pub-id><pub-id pub-id-type="pmid">32336154</pub-id></element-citation></ref><ref id="B36-biomedicines-09-00234"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales</surname><given-names>P.</given-names></name><name><surname>Hurst</surname><given-names>D.P.</given-names></name><name><surname>Reggio</surname><given-names>P.H.</given-names></name></person-group><article-title>Molecular Targets of the Phytocannabinoids: A Complex Picture</article-title><source>Prog. Chem. Org. Nat. Prod.</source><year>2017</year><volume>103</volume><fpage>103</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-45541-9_4</pub-id><pub-id pub-id-type="pmid">28120232</pub-id></element-citation></ref><ref id="B37-biomedicines-09-00234"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampson</surname><given-names>P.B.</given-names></name></person-group><article-title>Phytocannabinoid Pharmacology: Medicinal Properties of <italic>Cannabis sativa</italic> Constituents Aside from the &#x0201c;Big Two&#x0201d;</article-title><source>J. Nat. Prod.</source><year>2020</year><volume>84</volume><fpage>142</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.0c00965</pub-id><pub-id pub-id-type="pmid">33356248</pub-id></element-citation></ref><ref id="B38-biomedicines-09-00234"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaoni</surname><given-names>Y.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name></person-group><article-title>Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish</article-title><source>J. Am. Chem. Soc.</source><year>1964</year><volume>86</volume><fpage>1646</fpage><lpage>1647</lpage><pub-id pub-id-type="doi">10.1021/ja01062a046</pub-id></element-citation></ref><ref id="B39-biomedicines-09-00234"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mechoulam</surname><given-names>R.</given-names></name><name><surname>Gaoni</surname><given-names>Y.</given-names></name></person-group><article-title>A Total Synthesis of Dl-&#x00394;1-Tetrahydrocannabinol, the Active Constituent of Hashish</article-title><source>J. Am. Chem. Soc.</source><year>1965</year><volume>87</volume><fpage>3273</fpage><lpage>3275</lpage><pub-id pub-id-type="doi">10.1021/ja01092a065</pub-id><?supplied-pmid 14324315?><pub-id pub-id-type="pmid">14324315</pub-id></element-citation></ref><ref id="B40-biomedicines-09-00234"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devane</surname><given-names>W.A.</given-names></name><name><surname>Dysarz</surname><given-names>F.A.</given-names></name><name><surname>Johnson</surname><given-names>M.R.</given-names></name><name><surname>Melvin</surname><given-names>L.S.</given-names></name><name><surname>Howlett</surname><given-names>A.C.</given-names></name></person-group><article-title>Determination and Characterization of a Cannabinoid Receptor in Rat Brain</article-title><source>Mol. Pharmacol.</source><year>1988</year><volume>34</volume><fpage>605</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">2848184</pub-id></element-citation></ref><ref id="B41-biomedicines-09-00234"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munro</surname><given-names>S.</given-names></name><name><surname>Thomas</surname><given-names>K.L.</given-names></name><name><surname>Abu-Shaar</surname><given-names>M.</given-names></name></person-group><article-title>Molecular Characterization of a Peripheral Receptor for Cannabinoids</article-title><source>Nature</source><year>1993</year><volume>365</volume><fpage>61</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/365061a0</pub-id><pub-id pub-id-type="pmid">7689702</pub-id></element-citation></ref><ref id="B42-biomedicines-09-00234"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herkenham</surname><given-names>M.</given-names></name><name><surname>Lynn</surname><given-names>A.B.</given-names></name><name><surname>Little</surname><given-names>M.D.</given-names></name><name><surname>Johnson</surname><given-names>M.R.</given-names></name><name><surname>Melvin</surname><given-names>L.S.</given-names></name><name><surname>De Costa</surname><given-names>B.R.</given-names></name><name><surname>Rice</surname><given-names>K.C.</given-names></name></person-group><article-title>Cannabinoid Receptor Localization in Brain</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1990</year><volume>87</volume><fpage>1932</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1073/pnas.87.5.1932</pub-id><?supplied-pmid 2308954?><pub-id pub-id-type="pmid">2308954</pub-id></element-citation></ref><ref id="B43-biomedicines-09-00234"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devane</surname><given-names>W.A.</given-names></name><name><surname>Hanu&#x00161;</surname><given-names>L.</given-names></name><name><surname>Breuer</surname><given-names>A.</given-names></name><name><surname>Pertwee</surname><given-names>R.G.</given-names></name><name><surname>Stevenson</surname><given-names>L.A.</given-names></name><name><surname>Griffin</surname><given-names>G.</given-names></name><name><surname>Gibson</surname><given-names>D.</given-names></name><name><surname>Mandelbaum</surname><given-names>A.</given-names></name><name><surname>Etinger</surname><given-names>A.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name></person-group><article-title>Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor</article-title><source>Science</source><year>1992</year><volume>258</volume><fpage>1946</fpage><lpage>1949</lpage><pub-id pub-id-type="doi">10.1126/science.1470919</pub-id><pub-id pub-id-type="pmid">1470919</pub-id></element-citation></ref><ref id="B44-biomedicines-09-00234"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mechoulam</surname><given-names>R.</given-names></name><name><surname>Ben-Shabat</surname><given-names>S.</given-names></name><name><surname>Hanus</surname><given-names>L.</given-names></name><name><surname>Ligumsky</surname><given-names>M.</given-names></name><name><surname>Kaminski</surname><given-names>N.E.</given-names></name><name><surname>Schatz</surname><given-names>A.R.</given-names></name><name><surname>Gopher</surname><given-names>A.</given-names></name><name><surname>Almog</surname><given-names>S.</given-names></name><name><surname>Martin</surname><given-names>B.R.</given-names></name><name><surname>Compton</surname><given-names>D.R.</given-names></name><etal/></person-group><article-title>Identification of an Endogenous 2-Monoglyceride, Present in Canine Gut, That Binds to Cannabinoid Receptors</article-title><source>Biochem. Pharmacol.</source><year>1995</year><volume>50</volume><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(95)00109-D</pub-id><pub-id pub-id-type="pmid">7605349</pub-id></element-citation></ref><ref id="B45-biomedicines-09-00234"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugiura</surname><given-names>T.</given-names></name><name><surname>Kondo</surname><given-names>S.</given-names></name><name><surname>Sukagawa</surname><given-names>A.</given-names></name><name><surname>Nakane</surname><given-names>S.</given-names></name><name><surname>Shinoda</surname><given-names>A.</given-names></name><name><surname>Itoh</surname><given-names>K.</given-names></name><name><surname>Yamashita</surname><given-names>A.</given-names></name><name><surname>Waku</surname><given-names>K.</given-names></name></person-group><article-title>2-Arachidonoylglycerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain</article-title><source>Biochem. Biophys. Res. Commun.</source><year>1995</year><volume>215</volume><fpage>89</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1995.2437</pub-id><?supplied-pmid 7575630?><pub-id pub-id-type="pmid">7575630</pub-id></element-citation></ref><ref id="B46-biomedicines-09-00234"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Harvey-White</surname><given-names>J.</given-names></name><name><surname>Osei-Hyiaman</surname><given-names>D.</given-names></name><name><surname>Razdan</surname><given-names>R.</given-names></name><name><surname>Gong</surname><given-names>Q.</given-names></name><name><surname>Chan</surname><given-names>A.C.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Huang</surname><given-names>B.X.</given-names></name><name><surname>Kim</surname><given-names>H.Y.</given-names></name><etal/></person-group><article-title>A Biosynthetic Pathway for Anandamide</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>13345</fpage><lpage>13350</lpage><pub-id pub-id-type="doi">10.1073/pnas.0601832103</pub-id><pub-id pub-id-type="pmid">16938887</pub-id></element-citation></ref><ref id="B47-biomedicines-09-00234"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mechoulam</surname><given-names>R.</given-names></name><name><surname>Parker</surname><given-names>L.A.</given-names></name></person-group><article-title>The Endocannabinoid System and the Brain</article-title><source>Annu. Rev. Psychol.</source><year>2013</year><volume>64</volume><fpage>21</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1146/annurev-psych-113011-143739</pub-id><pub-id pub-id-type="pmid">22804774</pub-id></element-citation></ref><ref id="B48-biomedicines-09-00234"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Marzo</surname><given-names>V.</given-names></name></person-group><article-title>The Endocannabinoid System: Its General Strategy of Action, Tools for Its Pharmacological Manipulation and Potential Therapeutic Exploitation</article-title><source>Pharmacol. Res.</source><year>2009</year><volume>60</volume><fpage>77</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2009.02.010</pub-id><?supplied-pmid 19559360?><pub-id pub-id-type="pmid">19559360</pub-id></element-citation></ref><ref id="B49-biomedicines-09-00234"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kano</surname><given-names>M.</given-names></name><name><surname>Ohno-Shosaku</surname><given-names>T.</given-names></name><name><surname>Hashimotodani</surname><given-names>Y.</given-names></name><name><surname>Uchigashima</surname><given-names>M.</given-names></name><name><surname>Watanabe</surname><given-names>M.</given-names></name></person-group><article-title>Endocannabinoid-Mediated Control of Synaptic Transmission</article-title><source>Physiol. Rev.</source><year>2009</year><volume>89</volume><fpage>309</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1152/physrev.00019.2008</pub-id><?supplied-pmid 19126760?><pub-id pub-id-type="pmid">19126760</pub-id></element-citation></ref><ref id="B50-biomedicines-09-00234"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>R.K.P.</given-names></name></person-group><article-title>A Perspective Review on Fatty Acid Amide Hydrolase (FAAH) Inhibitors as Potential Therapeutic Agents</article-title><source>Eur. J. Med. Chem.</source><year>2020</year><volume>188</volume><fpage>111953</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2019.111953</pub-id><?supplied-pmid 31945644?><pub-id pub-id-type="pmid">31945644</pub-id></element-citation></ref><ref id="B51-biomedicines-09-00234"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ligresti</surname><given-names>A.</given-names></name><name><surname>Cascio</surname><given-names>M.G.</given-names></name><name><surname>Pryce</surname><given-names>G.</given-names></name><name><surname>Kulasegram</surname><given-names>S.</given-names></name><name><surname>Beletskaya</surname><given-names>I.</given-names></name><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Saha</surname><given-names>B.</given-names></name><name><surname>Mahadevan</surname><given-names>A.</given-names></name><name><surname>Visintin</surname><given-names>C.</given-names></name><name><surname>Wiley</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>New Potent and Selective Inhibitors of Anandamide Reuptake with Antispastic Activity in a Mouse Model of Multiple Sclerosis</article-title><source>Br. J. Pharmacol.</source><year>2006</year><volume>147</volume><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0706418</pub-id><?supplied-pmid 16284631?><pub-id pub-id-type="pmid">16284631</pub-id></element-citation></ref><ref id="B52-biomedicines-09-00234"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>M.</given-names></name><name><surname>Dragunow</surname><given-names>M.</given-names></name><name><surname>Faull</surname><given-names>R.L.M.</given-names></name></person-group><article-title>Cannabinoid Receptors in the Human Brain: A Detailed Anatomical and Quantitative Autoradiographic Study in the Fetal, Neonatal and Adult Human Brain</article-title><source>Neuroscience</source><year>1997</year><volume>77</volume><fpage>299</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1016/S0306-4522(96)00428-9</pub-id><pub-id pub-id-type="pmid">9472392</pub-id></element-citation></ref><ref id="B53-biomedicines-09-00234"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>T.</given-names></name><name><surname>Vemuri</surname><given-names>K.</given-names></name><name><surname>Pu</surname><given-names>M.</given-names></name><name><surname>Qu</surname><given-names>L.</given-names></name><name><surname>Han</surname><given-names>G.W.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Shui</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Korde</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Crystal Structure of the Human Cannabinoid Receptor CB1</article-title><source>Cell</source><year>2016</year><volume>167</volume><fpage>750</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.10.004</pub-id><pub-id pub-id-type="pmid">27768894</pub-id></element-citation></ref><ref id="B54-biomedicines-09-00234"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Hua</surname><given-names>T.</given-names></name><name><surname>Vemuri</surname><given-names>K.</given-names></name><name><surname>Ho</surname><given-names>J.H.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Popov</surname><given-names>P.</given-names></name><name><surname>Benchama</surname><given-names>O.</given-names></name><name><surname>Zvonok</surname><given-names>N.</given-names></name><name><surname>Locke</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Crystal Structure of the Human Cannabinoid Receptor CB2</article-title><source>Cell</source><year>2019</year><volume>176</volume><fpage>459</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.12.011</pub-id><pub-id pub-id-type="pmid">30639103</pub-id></element-citation></ref><ref id="B55-biomedicines-09-00234"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katona</surname><given-names>I.</given-names></name><name><surname>Sperl&#x000e1;gh</surname><given-names>B.</given-names></name><name><surname>S&#x000ed;k</surname><given-names>A.</given-names></name><name><surname>K&#x000e4;falvi</surname><given-names>A.</given-names></name><name><surname>Vizi</surname><given-names>E.S.</given-names></name><name><surname>Mackie</surname><given-names>K.</given-names></name><name><surname>Freund</surname><given-names>T.F.</given-names></name></person-group><article-title>Presynaptically Located CB1 Cannabinoid Receptors Regulate GABA Release from Axon Terminals of Specific Hippocampal Interneurons</article-title><source>J. Neurosci.</source><year>1999</year><volume>19</volume><fpage>4544</fpage><lpage>4558</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.19-11-04544.1999</pub-id><pub-id pub-id-type="pmid">10341254</pub-id></element-citation></ref><ref id="B56-biomedicines-09-00234"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derkinderen</surname><given-names>P.</given-names></name><name><surname>Ledent</surname><given-names>C.</given-names></name><name><surname>Parmentier</surname><given-names>M.</given-names></name><name><surname>Girault</surname><given-names>J.A.</given-names></name></person-group><article-title>Cannabinoids Activate P38 Mitogen-Activated Protein Kinases through CB1 Receptors in Hippocampus</article-title><source>J. Neurochem.</source><year>2001</year><volume>77</volume><fpage>957</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2001.00333.x</pub-id><pub-id pub-id-type="pmid">11331425</pub-id></element-citation></ref><ref id="B57-biomedicines-09-00234"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herkenham</surname><given-names>M.</given-names></name><name><surname>Lynn</surname><given-names>A.B.</given-names></name><name><surname>de Costa</surname><given-names>B.R.</given-names></name><name><surname>Richfield</surname><given-names>E.K.</given-names></name></person-group><article-title>Neuronal Localization of Cannabinoid Receptors in the Basal Ganglia of the Rat</article-title><source>Brain Res.</source><year>1991</year><volume>547</volume><fpage>267</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(91)90970-7</pub-id><pub-id pub-id-type="pmid">1909204</pub-id></element-citation></ref><ref id="B58-biomedicines-09-00234"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e1;ty&#x000e1;s</surname><given-names>F.</given-names></name><name><surname>Yanovsky</surname><given-names>Y.</given-names></name><name><surname>Mackie</surname><given-names>K.</given-names></name><name><surname>Kelsch</surname><given-names>W.</given-names></name><name><surname>Misgeld</surname><given-names>U.</given-names></name><name><surname>Freund</surname><given-names>T.F.</given-names></name></person-group><article-title>Subcellular Localization of Type 1 Cannabinoid Receptors in the Rat Basal Ganglia</article-title><source>Neuroscience</source><year>2006</year><volume>137</volume><fpage>337</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2005.09.005</pub-id><pub-id pub-id-type="pmid">16289348</pub-id></element-citation></ref><ref id="B59-biomedicines-09-00234"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bidaut-Russell</surname><given-names>M.</given-names></name><name><surname>Devane</surname><given-names>W.A.</given-names></name><name><surname>Howlett</surname><given-names>A.C.</given-names></name></person-group><article-title>Cannabinoid Receptors and Modulation of Cyclic AMP Accumulation in the Rat Brain</article-title><source>J. Neurochem.</source><year>1990</year><volume>55</volume><fpage>21</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.1990.tb08815.x</pub-id><pub-id pub-id-type="pmid">2162376</pub-id></element-citation></ref><ref id="B60-biomedicines-09-00234"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamura</surname><given-names>Y.</given-names></name><name><surname>Fukaya</surname><given-names>M.</given-names></name><name><surname>Maejima</surname><given-names>T.</given-names></name><name><surname>Yoshida</surname><given-names>T.</given-names></name><name><surname>Miura</surname><given-names>E.</given-names></name><name><surname>Watanabe</surname><given-names>M.</given-names></name><name><surname>Ohno-Shosaku</surname><given-names>T.</given-names></name><name><surname>Kano</surname><given-names>M.</given-names></name></person-group><article-title>The CB1 Cannabinoid Receptor Is the Major Cannabinoid Receptor at Excitatory Presynaptic Sites in the Hippocampus and Cerebellum</article-title><source>J. Neurosci.</source><year>2006</year><volume>26</volume><fpage>2991</fpage><lpage>3001</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4872-05.2006</pub-id><pub-id pub-id-type="pmid">16540577</pub-id></element-citation></ref><ref id="B61-biomedicines-09-00234"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreitzer</surname><given-names>A.C.</given-names></name><name><surname>Regehr</surname><given-names>W.G.</given-names></name></person-group><article-title>Cerebellar Depolarization-Induced Suppression of Inhibition Is Mediated by Endogenous Cannabinoids</article-title><source>J. Neurosci.</source><year>2001</year><volume>21</volume><fpage>RC174</fpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.21-20-j0005.2001</pub-id><?supplied-pmid 11588204?><pub-id pub-id-type="pmid">11588204</pub-id></element-citation></ref><ref id="B62-biomedicines-09-00234"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000e9;v&#x000e9;n&#x000e8;s</surname><given-names>C.</given-names></name><name><surname>Daniel</surname><given-names>H.</given-names></name><name><surname>Soubri&#x000e9;</surname><given-names>P.</given-names></name><name><surname>Cr&#x000e9;pel</surname><given-names>F.</given-names></name></person-group><article-title>Cannabinoids Decrease Excitatory Synaptic Transmission and Impair Long-Term Depression in Rat Cerebellar Purkinje Cells</article-title><source>J. Physiol.</source><year>1998</year><volume>510</volume><fpage>867</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1111/j.1469-7793.1998.867bj.x</pub-id><pub-id pub-id-type="pmid">9660899</pub-id></element-citation></ref><ref id="B63-biomedicines-09-00234"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohno-Shosaku</surname><given-names>T.</given-names></name><name><surname>Maejima</surname><given-names>T.</given-names></name><name><surname>Kano</surname><given-names>M.</given-names></name></person-group><article-title>Endogenous Cannabinoids Mediate Retrograde Signals from Depolarized Postsynaptic Neurons to Presynaptic Terminals</article-title><source>Neuron</source><year>2001</year><volume>29</volume><fpage>729</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(01)00247-1</pub-id><pub-id pub-id-type="pmid">11301031</pub-id></element-citation></ref><ref id="B64-biomedicines-09-00234"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ney</surname><given-names>L.J.</given-names></name><name><surname>Akhurst</surname><given-names>J.</given-names></name><name><surname>Bruno</surname><given-names>R.</given-names></name><name><surname>Laing</surname><given-names>P.A.F.</given-names></name><name><surname>Matthews</surname><given-names>A.</given-names></name><name><surname>Felmingham</surname><given-names>K.L.</given-names></name></person-group><article-title>Dopamine, Endocannabinoids and Their Interaction in Fear Extinction and Negative Affect in PTSD</article-title><source>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</source><year>2021</year><volume>105</volume><fpage>110118</fpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2020.110118</pub-id><?supplied-pmid 32991952?><pub-id pub-id-type="pmid">32991952</pub-id></element-citation></ref><ref id="B65-biomedicines-09-00234"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balsevich</surname><given-names>G.</given-names></name><name><surname>Petrie</surname><given-names>G.N.</given-names></name><name><surname>Hill</surname><given-names>M.N.</given-names></name></person-group><article-title>Endocannabinoids: Effectors of Glucocorticoid Signaling</article-title><source>Front. Neuroendocrinol.</source><year>2017</year><volume>47</volume><fpage>86</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.yfrne.2017.07.005</pub-id><?supplied-pmid 28739508?><pub-id pub-id-type="pmid">28739508</pub-id></element-citation></ref><ref id="B66-biomedicines-09-00234"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez-Mariscal</surname><given-names>I.</given-names></name><name><surname>Krzysik-Walker</surname><given-names>S.M.</given-names></name><name><surname>Doyle</surname><given-names>M.E.</given-names></name><name><surname>Liu</surname><given-names>Q.R.</given-names></name><name><surname>Cimbro</surname><given-names>R.</given-names></name><name><surname>Santa-Cruz Calvo</surname><given-names>S.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Cieala</surname><given-names>A.</given-names></name><name><surname>Moaddel</surname><given-names>R.</given-names></name><name><surname>Carlson</surname><given-names>O.D.</given-names></name><etal/></person-group><article-title>Human CB1 Receptor Isoforms, Present in Hepatocytes and &#x003b2;-Cells, Are Involved in Regulating Metabolism</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>33302</fpage><pub-id pub-id-type="doi">10.1038/srep33302</pub-id><pub-id pub-id-type="pmid">27641999</pub-id></element-citation></ref><ref id="B67-biomedicines-09-00234"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogueiras</surname><given-names>R.</given-names></name><name><surname>Veyrat-Durebex</surname><given-names>C.</given-names></name><name><surname>Suchanek</surname><given-names>P.M.</given-names></name><name><surname>Klein</surname><given-names>M.</given-names></name><name><surname>Tsch&#x000f6;p</surname><given-names>J.</given-names></name><name><surname>Caldwell</surname><given-names>C.</given-names></name><name><surname>Woods</surname><given-names>S.C.</given-names></name><name><surname>Wittmann</surname><given-names>G.</given-names></name><name><surname>Watanabe</surname><given-names>M.</given-names></name><name><surname>Liposits</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Peripheral, but Not Central, CB1 Antagonism Provides Food Intake-Independent Metabolic Benefits in Diet-Induced Obese Rats</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>2977</fpage><lpage>2991</lpage><pub-id pub-id-type="doi">10.2337/db08-0161</pub-id><pub-id pub-id-type="pmid">18716045</pub-id></element-citation></ref><ref id="B68-biomedicines-09-00234"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashton</surname><given-names>J.C.</given-names></name><name><surname>Friberg</surname><given-names>D.</given-names></name><name><surname>Darlington</surname><given-names>C.L.</given-names></name><name><surname>Smith</surname><given-names>P.F.</given-names></name></person-group><article-title>Expression of the Cannabinoid CB2 Receptor in the Rat Cerebellum: An Immunohistochemical Study</article-title><source>Neurosci. Lett.</source><year>2006</year><volume>396</volume><fpage>113</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2005.11.038</pub-id><?supplied-pmid 16356641?><pub-id pub-id-type="pmid">16356641</pub-id></element-citation></ref><ref id="B69-biomedicines-09-00234"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>N&#x000fa;&#x000f1;ez</surname><given-names>E.</given-names></name><name><surname>Benito</surname><given-names>C.</given-names></name><name><surname>Pazos</surname><given-names>M.R.</given-names></name><name><surname>Barbachano</surname><given-names>A.</given-names></name><name><surname>Fajardo</surname><given-names>O.</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>S.</given-names></name><name><surname>Tol&#x000f3;n</surname><given-names>R.M.</given-names></name><name><surname>Romero</surname><given-names>J.</given-names></name></person-group><article-title>Cannabinoid CB2 Receptors Are Expressed by Perivascular Microglial Cells in the Human Brain: An Immunohistochemical Study</article-title><source>Synapse</source><year>2004</year><volume>53</volume><fpage>208</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1002/syn.20050</pub-id><?supplied-pmid 15266552?><pub-id pub-id-type="pmid">15266552</pub-id></element-citation></ref><ref id="B70-biomedicines-09-00234"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>R.A.</given-names></name><name><surname>Coutts</surname><given-names>A.A.</given-names></name><name><surname>McFarlane</surname><given-names>S.M.</given-names></name><name><surname>Anavi-Goffer</surname><given-names>S.</given-names></name><name><surname>Irving</surname><given-names>A.J.</given-names></name><name><surname>Pertwee</surname><given-names>R.G.</given-names></name><name><surname>MacEwan</surname><given-names>D.J.</given-names></name><name><surname>Scott</surname><given-names>R.H.</given-names></name></person-group><article-title>Actions of Cannabinoid Receptor Ligands on Rat Cultured Sensory Neurones: Implications for Antinociception</article-title><source>Neuropharmacology</source><year>2001</year><volume>40</volume><fpage>221</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/S0028-3908(00)00135-0</pub-id><pub-id pub-id-type="pmid">11114401</pub-id></element-citation></ref><ref id="B71-biomedicines-09-00234"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Sickle</surname><given-names>M.D.</given-names></name><name><surname>Duncan</surname><given-names>M.</given-names></name><name><surname>Kingsley</surname><given-names>P.J.</given-names></name><name><surname>Mouihate</surname><given-names>A.</given-names></name><name><surname>Urbani</surname><given-names>P.</given-names></name><name><surname>Mackie</surname><given-names>K.</given-names></name><name><surname>Stella</surname><given-names>N.</given-names></name><name><surname>Makriyannis</surname><given-names>A.</given-names></name><name><surname>Piomelli</surname><given-names>D.</given-names></name><name><surname>Davison</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors</article-title><source>Science</source><year>2005</year><volume>310</volume><fpage>329</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1126/science.1115740</pub-id><pub-id pub-id-type="pmid">16224028</pub-id></element-citation></ref><ref id="B72-biomedicines-09-00234"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wotherspoon</surname><given-names>G.</given-names></name><name><surname>Fox</surname><given-names>A.</given-names></name><name><surname>McIntyre</surname><given-names>P.</given-names></name><name><surname>Colley</surname><given-names>S.</given-names></name><name><surname>Bevan</surname><given-names>S.</given-names></name><name><surname>Winter</surname><given-names>J.</given-names></name></person-group><article-title>Peripheral Nerve Injury Induces Cannabinoid Receptor 2 Protein Expression in Rat Sensory Neurons</article-title><source>Neuroscience</source><year>2005</year><volume>135</volume><fpage>235</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2005.06.009</pub-id><pub-id pub-id-type="pmid">16084654</pub-id></element-citation></ref><ref id="B73-biomedicines-09-00234"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gali&#x000e8;gue</surname><given-names>S.</given-names></name><name><surname>Mary</surname><given-names>S.</given-names></name><name><surname>Marchand</surname><given-names>J.</given-names></name><name><surname>Dussossoy</surname><given-names>D.</given-names></name><name><surname>Carri&#x000e8;re</surname><given-names>D.</given-names></name><name><surname>Carayon</surname><given-names>P.</given-names></name><name><surname>Bouaboula</surname><given-names>M.</given-names></name><name><surname>Shire</surname><given-names>D.</given-names></name><name><surname>LE Fur</surname><given-names>G.</given-names></name><name><surname>Casellas</surname><given-names>P.</given-names></name></person-group><article-title>Expression of Central and Peripheral Cannabinoid Receptors in Human Immune Tissues and Leukocyte Subpopulations</article-title><source>Eur. J. Biochem.</source><year>1995</year><volume>232</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1995.tb20780.x</pub-id><?supplied-pmid 7556170?><pub-id pub-id-type="pmid">7556170</pub-id></element-citation></ref><ref id="B74-biomedicines-09-00234"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynn</surname><given-names>A.B.</given-names></name><name><surname>Herkenham</surname><given-names>M.</given-names></name></person-group><article-title>Localization of Cannabinoid Receptors and Nonsaturable High-Density Cannabinoid Binding Sites in Peripheral Tissues of the Rat: Implications for Receptor-Mediated Immune Modulation by Cannabinoids</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1994</year><volume>268</volume><fpage>1612</fpage><lpage>1623</lpage><pub-id pub-id-type="pmid">8138973</pub-id></element-citation></ref><ref id="B75-biomedicines-09-00234"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Facci</surname><given-names>L.</given-names></name><name><surname>Dal Toso</surname><given-names>R.</given-names></name><name><surname>Romanello</surname><given-names>S.</given-names></name><name><surname>Buriani</surname><given-names>A.</given-names></name><name><surname>Skaper</surname><given-names>S.D.</given-names></name><name><surname>Leon</surname><given-names>A.</given-names></name></person-group><article-title>Mast Cells Express a Peripheral Cannabinoid Receptor with Differential Sensitivity to Anandamide and Palmitoylethanolamide</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1995</year><volume>92</volume><fpage>3376</fpage><lpage>3380</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.8.3376</pub-id><?supplied-pmid 7724569?><pub-id pub-id-type="pmid">7724569</pub-id></element-citation></ref><ref id="B76-biomedicines-09-00234"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>P.M.W.</given-names></name><name><surname>Marczylo</surname><given-names>T.H.</given-names></name><name><surname>El-Talatini</surname><given-names>M.</given-names></name><name><surname>Finney</surname><given-names>M.</given-names></name><name><surname>Nallendran</surname><given-names>V.</given-names></name><name><surname>Taylor</surname><given-names>A.H.</given-names></name><name><surname>Konje</surname><given-names>J.C.</given-names></name></person-group><article-title>Ultra Performance Liquid Chromatography Tandem Mass Spectrometry Method for the Measurement of Anandamide in Human Plasma</article-title><source>Anal. Biochem.</source><year>2008</year><volume>380</volume><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2008.05.033</pub-id><?supplied-pmid 18555789?><pub-id pub-id-type="pmid">18555789</pub-id></element-citation></ref><ref id="B77-biomedicines-09-00234"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fanelli</surname><given-names>F.</given-names></name><name><surname>Di Lallo</surname><given-names>V.D.</given-names></name><name><surname>Belluomo</surname><given-names>I.</given-names></name><name><surname>De Iasio</surname><given-names>R.</given-names></name><name><surname>Baccini</surname><given-names>M.</given-names></name><name><surname>Casadio</surname><given-names>E.</given-names></name><name><surname>Gasparini</surname><given-names>D.I.</given-names></name><name><surname>Colavita</surname><given-names>M.</given-names></name><name><surname>Gambineri</surname><given-names>A.</given-names></name><name><surname>Grossi</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Estimation of Reference Intervals of Five Endocannabinoids and Endocannabinoid Related Compounds in Human Plasma by Two Dimensional-LC/MS/MS</article-title><source>J. Lipid Res.</source><year>2012</year><volume>53</volume><fpage>481</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1194/jlr.M021378</pub-id><?supplied-pmid 22172516?><pub-id pub-id-type="pmid">22172516</pub-id></element-citation></ref><ref id="B78-biomedicines-09-00234"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krumbholz</surname><given-names>A.</given-names></name><name><surname>Anielski</surname><given-names>P.</given-names></name><name><surname>Reisch</surname><given-names>N.</given-names></name><name><surname>Schelling</surname><given-names>G.</given-names></name><name><surname>Thieme</surname><given-names>D.</given-names></name></person-group><article-title>Diagnostic Value of Concentration Profiles of Glucocorticosteroids and Endocannabinoids in Hair</article-title><source>Ther. Drug Monit.</source><year>2013</year><volume>35</volume><fpage>600</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1097/FTD.0b013e3182953e43</pub-id><pub-id pub-id-type="pmid">23942543</pub-id></element-citation></ref><ref id="B79-biomedicines-09-00234"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mwanza</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Deng</surname><given-names>H.</given-names></name></person-group><article-title>Simultaneous HPLC-APCI-MS/MS Quantification of Endogenous Cannabinoids and Glucocorticoids in Hair</article-title><source>J. Chromatogr. B Anal. Technol. Biomed. Life Sci.</source><year>2016</year><volume>1028</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2016.06.002</pub-id></element-citation></ref><ref id="B80-biomedicines-09-00234"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voegel</surname><given-names>C.D.</given-names></name><name><surname>Baumgartner</surname><given-names>M.R.</given-names></name><name><surname>Kraemer</surname><given-names>T.</given-names></name><name><surname>W&#x000fc;st</surname><given-names>S.</given-names></name><name><surname>Binz</surname><given-names>T.M.</given-names></name></person-group><article-title>Simultaneous Quantification of Steroid Hormones and Endocannabinoids (ECs) in Human Hair Using an Automated Supported Liquid Extraction (SLE) and LC-MS/MS&#x02014;Insights into EC Baseline Values and Correlation to Steroid Concentrations</article-title><source>Talanta</source><year>2021</year><volume>222</volume><fpage>121499</fpage><pub-id pub-id-type="doi">10.1016/j.talanta.2020.121499</pub-id><pub-id pub-id-type="pmid">33167212</pub-id></element-citation></ref><ref id="B81-biomedicines-09-00234"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ney</surname><given-names>L.J.</given-names></name><name><surname>Felmingham</surname><given-names>K.L.</given-names></name><name><surname>Bruno</surname><given-names>R.</given-names></name><name><surname>Matthews</surname><given-names>A.</given-names></name><name><surname>Nichols</surname><given-names>D.S.</given-names></name></person-group><article-title>Simultaneous Quantification of Endocannabinoids, Oleoylethanolamide and Steroid Hormones in Human Plasma and Saliva</article-title><source>J. Chromatogr. B Anal. Technol. Biomed. Life Sci.</source><year>2020</year><volume>1152</volume><fpage>122252</fpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2020.122252</pub-id></element-citation></ref><ref id="B82-biomedicines-09-00234"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ney</surname><given-names>L.J.</given-names></name><name><surname>Stone</surname><given-names>C.</given-names></name><name><surname>Nichols</surname><given-names>D.</given-names></name><name><surname>Felmingham</surname><given-names>K.L.</given-names></name><name><surname>Bruno</surname><given-names>R.</given-names></name><name><surname>Matthews</surname><given-names>A.</given-names></name></person-group><article-title>Endocannabinoid Reactivity to Acute Stress: Investigation of the Relationship between Salivary and Plasma Levels</article-title><source>Biol. Psychol.</source><year>2021</year><volume>159</volume><fpage>108022</fpage><pub-id pub-id-type="doi">10.1016/j.biopsycho.2021.108022</pub-id><pub-id pub-id-type="pmid">33460783</pub-id></element-citation></ref><ref id="B83-biomedicines-09-00234"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matias</surname><given-names>I.</given-names></name><name><surname>Gatta-Cherifi</surname><given-names>B.</given-names></name><name><surname>Tabarin</surname><given-names>A.</given-names></name><name><surname>Clark</surname><given-names>S.</given-names></name><name><surname>Leste-Lasserre</surname><given-names>T.</given-names></name><name><surname>Marsicano</surname><given-names>G.</given-names></name><name><surname>Piazza</surname><given-names>P.V.</given-names></name><name><surname>Cota</surname><given-names>D.</given-names></name></person-group><article-title>Endocannabinoids Measurement in Human Saliva as Potential Biomarker of Obesity</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e42399</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0042399</pub-id><?supplied-pmid 22860123?><pub-id pub-id-type="pmid">22860123</pub-id></element-citation></ref><ref id="B84-biomedicines-09-00234"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuel</surname><given-names>H.</given-names></name><name><surname>Burkman</surname><given-names>L.J.</given-names></name><name><surname>Lippes</surname><given-names>J.</given-names></name><name><surname>Crickard</surname><given-names>K.</given-names></name><name><surname>Forester</surname><given-names>E.</given-names></name><name><surname>Piomelli</surname><given-names>D.</given-names></name><name><surname>Giuffrida</surname><given-names>A.</given-names></name></person-group><article-title>N-Acylethanolamines in Human Reproductive Fluids</article-title><source>Chem. Phys. Lipids</source><year>2002</year><volume>121</volume><fpage>211</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/S0009-3084(02)00158-5</pub-id><pub-id pub-id-type="pmid">12505702</pub-id></element-citation></ref><ref id="B85-biomedicines-09-00234"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>M.P.Y.</given-names></name><name><surname>Siu</surname><given-names>S.O.</given-names></name><name><surname>Lau</surname><given-names>E.</given-names></name><name><surname>Mao</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>H.Z.</given-names></name><name><surname>Chiu</surname><given-names>P.C.N.</given-names></name><name><surname>Yeung</surname><given-names>W.S.B.</given-names></name><name><surname>Cox</surname><given-names>D.M.</given-names></name><name><surname>Chu</surname><given-names>I.K.</given-names></name></person-group><article-title>Online Coupling of Reverse-Phase and Hydrophilic Interaction Liquid Chromatography for Protein and Glycoprotein Characterization</article-title><source>Anal. Bioanal. Chem.</source><year>2010</year><volume>398</volume><fpage>791</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1007/s00216-010-3991-2</pub-id><?supplied-pmid 20632160?><pub-id pub-id-type="pmid">20632160</pub-id></element-citation></ref><ref id="B86-biomedicines-09-00234"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>S.E.M.</given-names></name><name><surname>Rapino</surname><given-names>C.</given-names></name><name><surname>Di Tommaso</surname><given-names>M.</given-names></name><name><surname>Pucci</surname><given-names>M.</given-names></name><name><surname>Battista</surname><given-names>N.</given-names></name><name><surname>Paro</surname><given-names>R.</given-names></name><name><surname>Simon</surname><given-names>L.</given-names></name><name><surname>Lutton</surname><given-names>D.</given-names></name><name><surname>Maccarrone</surname><given-names>M.</given-names></name></person-group><article-title>Differences in the Endocannabinoid System of Sperm from Fertile and Infertile Men</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e47704</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0047704</pub-id><pub-id pub-id-type="pmid">23082196</pub-id></element-citation></ref><ref id="B87-biomedicines-09-00234"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malan</surname><given-names>T.P.</given-names></name><name><surname>Ibrahim</surname><given-names>M.M.</given-names></name><name><surname>Deng</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Mata</surname><given-names>H.P.</given-names></name><name><surname>Vanderah</surname><given-names>T.</given-names></name><name><surname>Porreca</surname><given-names>F.</given-names></name><name><surname>Makriyannis</surname><given-names>A.</given-names></name></person-group><article-title>CB2 Cannabinoid Receptor-Mediated Peripheral Antinociception</article-title><source>Pain</source><year>2001</year><volume>93</volume><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(01)00321-9</pub-id><pub-id pub-id-type="pmid">11514083</pub-id></element-citation></ref><ref id="B88-biomedicines-09-00234"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaggar</surname><given-names>S.I.</given-names></name><name><surname>Hasnie</surname><given-names>F.S.</given-names></name><name><surname>Sellaturay</surname><given-names>S.</given-names></name><name><surname>Rice</surname><given-names>A.S.C.</given-names></name></person-group><article-title>The Anti-Hyperalgesic Actions of the Cannabinoid Anandamide and the Putative CB2 Receptor Agonist Palmitoylethanolamide in Visceral and Somatic Inflammatory Pain</article-title><source>Pain</source><year>1998</year><volume>76</volume><fpage>189</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(98)00041-4</pub-id><pub-id pub-id-type="pmid">9696473</pub-id></element-citation></ref><ref id="B89-biomedicines-09-00234"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katona</surname><given-names>I.</given-names></name><name><surname>Freund</surname><given-names>T.F.</given-names></name></person-group><article-title>Multiple Functions of Endocannabinoid Signaling in the Brain</article-title><source>Annu. Rev. Neurosci.</source><year>2012</year><volume>35</volume><fpage>529</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1146/annurev-neuro-062111-150420</pub-id><?supplied-pmid 22524785?><pub-id pub-id-type="pmid">22524785</pub-id></element-citation></ref><ref id="B90-biomedicines-09-00234"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ligresti</surname><given-names>A.</given-names></name><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name></person-group><article-title>From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles through Complex Pharmacology</article-title><source>Physiol. Rev.</source><year>2016</year><volume>96</volume><fpage>1593</fpage><lpage>1659</lpage><pub-id pub-id-type="doi">10.1152/physrev.00002.2016</pub-id><pub-id pub-id-type="pmid">27630175</pub-id></element-citation></ref><ref id="B91-biomedicines-09-00234"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryberg</surname><given-names>E.</given-names></name><name><surname>Larsson</surname><given-names>N.</given-names></name><name><surname>Sj&#x000f6;gren</surname><given-names>S.</given-names></name><name><surname>Hjorth</surname><given-names>S.</given-names></name><name><surname>Hermansson</surname><given-names>N.O.</given-names></name><name><surname>Leonova</surname><given-names>J.</given-names></name><name><surname>Elebring</surname><given-names>T.</given-names></name><name><surname>Nilsson</surname><given-names>K.</given-names></name><name><surname>Drmota</surname><given-names>T.</given-names></name><name><surname>Greasley</surname><given-names>P.J.</given-names></name></person-group><article-title>The Orphan Receptor GPR55 Is a Novel Cannabinoid Receptor</article-title><source>Br. J. Pharmacol.</source><year>2007</year><volume>152</volume><fpage>1092</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0707460</pub-id><?supplied-pmid 17876302?><pub-id pub-id-type="pmid">17876302</pub-id></element-citation></ref><ref id="B92-biomedicines-09-00234"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Fichna</surname><given-names>J.</given-names></name><name><surname>Schicho</surname><given-names>R.</given-names></name><name><surname>Saur</surname><given-names>D.</given-names></name><name><surname>Bashashati</surname><given-names>M.</given-names></name><name><surname>MacKie</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zimmer</surname><given-names>A.</given-names></name><name><surname>G&#x000f6;ke</surname><given-names>B.</given-names></name><name><surname>Sharkey</surname><given-names>K.A.</given-names></name><etal/></person-group><article-title>A Role for O-1602 and G Protein-Coupled Receptor GPR55 in the Control of Colonic Motility in Mice</article-title><source>Neuropharmacology</source><year>2013</year><volume>71</volume><fpage>255</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.03.029</pub-id><pub-id pub-id-type="pmid">23603203</pub-id></element-citation></ref><ref id="B93-biomedicines-09-00234"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>G.R.</given-names></name><name><surname>Lichtman</surname><given-names>A.</given-names></name><name><surname>Dewey</surname><given-names>W.L.</given-names></name><name><surname>Akbarali</surname><given-names>H.I.</given-names></name></person-group><article-title>Evidence for the Putative Cannabinoid Receptor (GPR55)-Mediated Inhibitory Effects on Intestinal Contractility in Mice</article-title><source>Pharmacology</source><year>2012</year><volume>90</volume><fpage>55</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1159/000339076</pub-id><pub-id pub-id-type="pmid">22759743</pub-id></element-citation></ref><ref id="B94-biomedicines-09-00234"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>X.H.</given-names></name><name><surname>Yuece</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>Y.Y.</given-names></name><name><surname>Feng</surname><given-names>Y.J.</given-names></name><name><surname>Feng</surname><given-names>J.Y.</given-names></name><name><surname>Yu</surname><given-names>L.Y.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>Y.N.</given-names></name><name><surname>Storr</surname><given-names>M.</given-names></name></person-group><article-title>A Novel CB Receptor GPR55 and Its Ligands Are Involved in Regulation of Gut Movement in Rodents</article-title><source>Neurogastroenterol. Motil.</source><year>2011</year><volume>23</volume><fpage>862-e342</fpage><pub-id pub-id-type="doi">10.1111/j.1365-2982.2011.01742.x</pub-id><?supplied-pmid 21726355?><pub-id pub-id-type="pmid">21726355</pub-id></element-citation></ref><ref id="B95-biomedicines-09-00234"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galiazzo</surname><given-names>G.</given-names></name><name><surname>Giancola</surname><given-names>F.</given-names></name><name><surname>Stanzani</surname><given-names>A.</given-names></name><name><surname>Fracassi</surname><given-names>F.</given-names></name><name><surname>Bernardini</surname><given-names>C.</given-names></name><name><surname>Forni</surname><given-names>M.</given-names></name><name><surname>Pietra</surname><given-names>M.</given-names></name><name><surname>Chiocchetti</surname><given-names>R.</given-names></name></person-group><article-title>Localization of Cannabinoid Receptors CB1, CB2, GPR55, and PPAR&#x003b1; in the Canine Gastrointestinal Tract</article-title><source>Histochem. Cell Biol.</source><year>2018</year><volume>150</volume><fpage>187</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1007/s00418-018-1684-7</pub-id><?supplied-pmid 29882158?><pub-id pub-id-type="pmid">29882158</pub-id></element-citation></ref><ref id="B96-biomedicines-09-00234"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oka</surname><given-names>S.</given-names></name><name><surname>Nakajima</surname><given-names>K.</given-names></name><name><surname>Yamashita</surname><given-names>A.</given-names></name><name><surname>Kishimoto</surname><given-names>S.</given-names></name><name><surname>Sugiura</surname><given-names>T.</given-names></name></person-group><article-title>Identification of GPR55 as a Lysophosphatidylinositol Receptor</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2007</year><volume>362</volume><fpage>928</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2007.08.078</pub-id><?supplied-pmid 17765871?><pub-id pub-id-type="pmid">17765871</pub-id></element-citation></ref><ref id="B97-biomedicines-09-00234"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauckner</surname><given-names>J.E.</given-names></name><name><surname>Jensen</surname><given-names>J.B.</given-names></name><name><surname>Chen</surname><given-names>H.Y.</given-names></name><name><surname>Lu</surname><given-names>H.C.</given-names></name><name><surname>Hille</surname><given-names>B.</given-names></name><name><surname>Mackie</surname><given-names>K.</given-names></name></person-group><article-title>GPR55 Is a Cannabinoid Receptor That Increases Intracellular Calcium and Inhibits M Current</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>2699</fpage><lpage>2704</lpage><pub-id pub-id-type="doi">10.1073/pnas.0711278105</pub-id><?supplied-pmid 18263732?><pub-id pub-id-type="pmid">18263732</pub-id></element-citation></ref><ref id="B98-biomedicines-09-00234"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waldeck-Welermair</surname><given-names>M.</given-names></name><name><surname>Zoratti</surname><given-names>C.</given-names></name><name><surname>Osibow</surname><given-names>K.</given-names></name><name><surname>Balenga</surname><given-names>N.</given-names></name><name><surname>Goessnitzer</surname><given-names>E.</given-names></name><name><surname>Waldhoer</surname><given-names>M.</given-names></name><name><surname>Malli</surname><given-names>R.</given-names></name><name><surname>Graier</surname><given-names>W.F.</given-names></name></person-group><article-title>Integrin Clustering Enables Anandamide-Induced Ca2+ Signaling in Endothelial Cells via GPR55 by Protection against CB1-Receptor-Triggered Repression</article-title><source>J. Cell Sci.</source><year>2008</year><volume>121</volume><fpage>1704</fpage><lpage>1717</lpage><pub-id pub-id-type="doi">10.1242/jcs.020958</pub-id><pub-id pub-id-type="pmid">18445684</pub-id></element-citation></ref><ref id="B99-biomedicines-09-00234"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Krummey</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>W.</given-names></name><name><surname>Cai</surname><given-names>H.</given-names></name><name><surname>Lenardo</surname><given-names>M.J.</given-names></name></person-group><article-title>The Kinase LRRK2 Is a Regulator of the Transcription Factor NFAT That Modulates the Severity of Inflammatory Bowel Disease</article-title><source>Nat. Immunol.</source><year>2011</year><volume>12</volume><fpage>1063</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1038/ni.2113</pub-id><pub-id pub-id-type="pmid">21983832</pub-id></element-citation></ref><ref id="B100-biomedicines-09-00234"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henstridge</surname><given-names>C.M.</given-names></name><name><surname>Balenga</surname><given-names>N.A.</given-names></name><name><surname>Schr&#x000f6;der</surname><given-names>R.</given-names></name><name><surname>Kargl</surname><given-names>J.K.</given-names></name><name><surname>Platzer</surname><given-names>W.</given-names></name><name><surname>Martini</surname><given-names>L.</given-names></name><name><surname>Arthur</surname><given-names>S.</given-names></name><name><surname>Penman</surname><given-names>J.</given-names></name><name><surname>Whistler</surname><given-names>J.L.</given-names></name><name><surname>Kostenis</surname><given-names>E.</given-names></name><etal/></person-group><article-title>GPR55 Ligands Promote Receptor Coupling to Multiple Signalling Pathways</article-title><source>Br. J. Pharmacol.</source><year>2010</year><volume>160</volume><fpage>604</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00625.x</pub-id><pub-id pub-id-type="pmid">20136841</pub-id></element-citation></ref><ref id="B101-biomedicines-09-00234"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badrichani</surname><given-names>A.Z.</given-names></name><name><surname>Stroka</surname><given-names>D.M.</given-names></name><name><surname>Bilbao</surname><given-names>G.</given-names></name><name><surname>Curiel</surname><given-names>D.T.</given-names></name><name><surname>Bach</surname><given-names>F.H.</given-names></name><name><surname>Ferran</surname><given-names>C.</given-names></name></person-group><article-title>Bcl-2 and Bcl-X(L) Serve an Anti-Inflammatory Function in Endothelial Cells through Inhibition of NF-&#x0039a;B</article-title><source>J. Clin. Investig.</source><year>1999</year><volume>103</volume><fpage>543</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1172/JCI2517</pub-id><pub-id pub-id-type="pmid">10021463</pub-id></element-citation></ref><ref id="B102-biomedicines-09-00234"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.S.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Jew</surname><given-names>C.P.</given-names></name><name><surname>Wager-Miller</surname><given-names>J.</given-names></name><name><surname>Straiker</surname><given-names>A.</given-names></name><name><surname>Spencer</surname><given-names>C.</given-names></name><name><surname>Bradshaw</surname><given-names>H.</given-names></name><name><surname>Mackie</surname><given-names>K.</given-names></name><etal/></person-group><article-title>GPR55, a G-Protein Coupled Receptor for Lysophosphatidylinositol, Plays a Role in Motor Coordination</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e60314</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0060314</pub-id><pub-id pub-id-type="pmid">23565223</pub-id></element-citation></ref><ref id="B103-biomedicines-09-00234"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celorrio</surname><given-names>M.</given-names></name><name><surname>Rojo-Bustamante</surname><given-names>E.</given-names></name><name><surname>Fern&#x000e1;ndez-Su&#x000e1;rez</surname><given-names>D.</given-names></name><name><surname>S&#x000e1;ez</surname><given-names>E.</given-names></name><name><surname>Estella-Hermoso de Mendoza</surname><given-names>A.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>C.E.</given-names></name><name><surname>Ram&#x000ed;rez</surname><given-names>M.J.</given-names></name><name><surname>Oyarz&#x000e1;bal</surname><given-names>J.</given-names></name><name><surname>Franco</surname><given-names>R.</given-names></name><name><surname>Aymerich</surname><given-names>M.S.</given-names></name></person-group><article-title>GPR55: A Therapeutic Target for Parkinson&#x02019;s Disease?</article-title><source>Neuropharmacology</source><year>2017</year><volume>125</volume><fpage>319</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.08.017</pub-id><pub-id pub-id-type="pmid">28807673</pub-id></element-citation></ref><ref id="B104-biomedicines-09-00234"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawzdargo</surname><given-names>M.</given-names></name><name><surname>Nguyen</surname><given-names>T.</given-names></name><name><surname>Lee</surname><given-names>D.K.</given-names></name><name><surname>Lynch</surname><given-names>K.R.</given-names></name><name><surname>Cheng</surname><given-names>R.</given-names></name><name><surname>Heng</surname><given-names>H.H.Q.</given-names></name><name><surname>George</surname><given-names>S.R.</given-names></name><name><surname>O&#x02019;Dowd</surname><given-names>B.F.</given-names></name></person-group><article-title>Identification and Cloning of Three Novel Human G Protein-Coupled Receptor Genes GPR52, &#x003a8;GPR53 and GPR55: GPR55 Is Extensively Expressed in Human Brain</article-title><source>Mol. Brain Res.</source><year>1999</year><volume>64</volume><fpage>193</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/S0169-328X(98)00277-0</pub-id><pub-id pub-id-type="pmid">9931487</pub-id></element-citation></ref><ref id="B105-biomedicines-09-00234"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuelert</surname><given-names>N.</given-names></name><name><surname>McDougall</surname><given-names>J.J.</given-names></name></person-group><article-title>The Abnormal Cannabidiol Analogue O-1602 Reduces Nociception in a Rat Model of Acute Arthritis via the Putative Cannabinoid Receptor GPR55</article-title><source>Neurosci. Lett.</source><year>2011</year><volume>500</volume><fpage>72</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2011.06.004</pub-id><pub-id pub-id-type="pmid">21683763</pub-id></element-citation></ref><ref id="B106-biomedicines-09-00234"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deliu</surname><given-names>E.</given-names></name><name><surname>Sperow</surname><given-names>M.</given-names></name><name><surname>Console-Bram</surname><given-names>L.</given-names></name><name><surname>Carter</surname><given-names>R.L.</given-names></name><name><surname>Tilley</surname><given-names>D.G.</given-names></name><name><surname>Kalamarides</surname><given-names>D.J.</given-names></name><name><surname>Kirby</surname><given-names>L.G.</given-names></name><name><surname>Brailoiu</surname><given-names>G.C.</given-names></name><name><surname>Brailoiu</surname><given-names>E.</given-names></name><name><surname>Benamar</surname><given-names>K.</given-names></name><etal/></person-group><article-title>The Lysophosphatidylinositol Receptor GPR55 Modulates Pain Perception in the Periaqueductal Gray</article-title><source>Mol. Pharmacol.</source><year>2015</year><volume>88</volume><fpage>265</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1124/mol.115.099333</pub-id><pub-id pub-id-type="pmid">25972448</pub-id></element-citation></ref><ref id="B107-biomedicines-09-00234"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carey</surname><given-names>L.M.</given-names></name><name><surname>Gutierrez</surname><given-names>T.</given-names></name><name><surname>Deng</surname><given-names>L.</given-names></name><name><surname>Lee</surname><given-names>W.H.</given-names></name><name><surname>Mackie</surname><given-names>K.</given-names></name><name><surname>Hohmann</surname><given-names>A.G.</given-names></name></person-group><article-title>Inflammatory and Neuropathic Nociception Is Preserved in GPR55 Knockout Mice</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>944</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-01062-2</pub-id><pub-id pub-id-type="pmid">28428628</pub-id></element-citation></ref><ref id="B108-biomedicines-09-00234"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gantz</surname><given-names>I.</given-names></name><name><surname>Muraoka</surname><given-names>A.</given-names></name><name><surname>Yang</surname><given-names>Y.K.</given-names></name><name><surname>Samuelson</surname><given-names>L.C.</given-names></name><name><surname>Zimmerman</surname><given-names>E.M.</given-names></name><name><surname>Cook</surname><given-names>H.</given-names></name><name><surname>Yamada</surname><given-names>T.</given-names></name></person-group><article-title>Cloning and Chromosomal Localization of a Gene (GPR18) Encoding a Novel Seven Transmembrane Receptor Highly Expressed in Spleen and Testis</article-title><source>Genomics</source><year>1997</year><volume>42</volume><fpage>462</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1006/geno.1997.4752</pub-id><?supplied-pmid 9205118?><pub-id pub-id-type="pmid">9205118</pub-id></element-citation></ref><ref id="B109-biomedicines-09-00234"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohno</surname><given-names>M.</given-names></name><name><surname>Hasegawa</surname><given-names>H.</given-names></name><name><surname>Inoue</surname><given-names>A.</given-names></name><name><surname>Muraoka</surname><given-names>M.</given-names></name><name><surname>Miyazaki</surname><given-names>T.</given-names></name><name><surname>Oka</surname><given-names>K.</given-names></name><name><surname>Yasukawa</surname><given-names>M.</given-names></name></person-group><article-title>Identification of N-Arachidonylglycine as the Endogenous Ligand for Orphan G-Protein-Coupled Receptor GPR18</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2006</year><volume>347</volume><fpage>827</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2006.06.175</pub-id><?supplied-pmid 16844083?><pub-id pub-id-type="pmid">16844083</pub-id></element-citation></ref><ref id="B110-biomedicines-09-00234"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>K.</given-names></name><name><surname>Fukuoka</surname><given-names>T.</given-names></name><name><surname>Obata</surname><given-names>K.</given-names></name><name><surname>Yamanaka</surname><given-names>H.</given-names></name><name><surname>Dai</surname><given-names>Y.</given-names></name><name><surname>Tokunaga</surname><given-names>A.</given-names></name><name><surname>Noguchi</surname><given-names>K.</given-names></name></person-group><article-title>Distinct Expression of TRPM8, TRPA1, and TRPV1 MRNAs in Rat Primary Afferent Neurons with A&#x003b4;/C-Fibers and Colocalization with Trk Receptors</article-title><source>J. Comp. Neurol.</source><year>2005</year><volume>493</volume><fpage>596</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1002/cne.20794</pub-id><pub-id pub-id-type="pmid">16304633</pub-id></element-citation></ref><ref id="B111-biomedicines-09-00234"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavanaugh</surname><given-names>D.J.</given-names></name><name><surname>Chesler</surname><given-names>A.T.</given-names></name><name><surname>Jackson</surname><given-names>A.C.</given-names></name><name><surname>Sigal</surname><given-names>Y.M.</given-names></name><name><surname>Yamanaka</surname><given-names>H.</given-names></name><name><surname>Grant</surname><given-names>R.</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>D.</given-names></name><name><surname>Nicoll</surname><given-names>R.A.</given-names></name><name><surname>Shah</surname><given-names>N.M.</given-names></name><name><surname>Julius</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Trpv1 Reporter Mice Reveal Highly Restricted Brain Distribution and Functional Expression in Arteriolar Smooth Muscle Cells</article-title><source>J. Neurosci.</source><year>2011</year><volume>31</volume><fpage>5067</fpage><lpage>5077</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.6451-10.2011</pub-id><?supplied-pmid 21451044?><pub-id pub-id-type="pmid">21451044</pub-id></element-citation></ref><ref id="B112-biomedicines-09-00234"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avelino</surname><given-names>A.</given-names></name><name><surname>Cruz</surname><given-names>F.</given-names></name></person-group><article-title>TRPV1 (Vanilloid Receptor) in the Urinary Tract: Expression, Function and Clinical Applications</article-title><source>Naunyn. Schmiedebergs. Arch. Pharmacol.</source><year>2006</year><volume>373</volume><fpage>287</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1007/s00210-006-0073-2</pub-id><pub-id pub-id-type="pmid">16721555</pub-id></element-citation></ref><ref id="B113-biomedicines-09-00234"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Mergler</surname><given-names>S.</given-names></name><name><surname>Wolosin</surname><given-names>J.M.</given-names></name><name><surname>Reinach</surname><given-names>P.S.</given-names></name></person-group><article-title>Functional TRPV1 Expression in Human Corneal Fibroblasts</article-title><source>Exp. Eye Res.</source><year>2013</year><volume>107</volume><fpage>121</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2012.11.004</pub-id><?supplied-pmid 23232207?><pub-id pub-id-type="pmid">23232207</pub-id></element-citation></ref><ref id="B114-biomedicines-09-00234"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>T&#x000f3;th</surname><given-names>A.</given-names></name><name><surname>Bocz&#x000e1;n</surname><given-names>J.</given-names></name><name><surname>Kedei</surname><given-names>N.</given-names></name><name><surname>Lizanecz</surname><given-names>E.</given-names></name><name><surname>Bagi</surname><given-names>Z.</given-names></name><name><surname>Papp</surname><given-names>Z.</given-names></name><name><surname>&#x000c9;des</surname><given-names>I.</given-names></name><name><surname>Csiba</surname><given-names>L.</given-names></name><name><surname>Blumberg</surname><given-names>P.M.</given-names></name></person-group><article-title>Expression and Distribution of Vanilloid Receptor 1 (TRPV1) in the Adult Rat Brain</article-title><source>Mol. Brain Res.</source><year>2005</year><volume>135</volume><fpage>162</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.molbrainres.2004.12.003</pub-id><pub-id pub-id-type="pmid">15857679</pub-id></element-citation></ref><ref id="B115-biomedicines-09-00234"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caterina</surname><given-names>M.J.</given-names></name><name><surname>Rosen</surname><given-names>T.A.</given-names></name><name><surname>Tominaga</surname><given-names>M.</given-names></name><name><surname>Brake</surname><given-names>A.J.</given-names></name><name><surname>Julius</surname><given-names>D.</given-names></name></person-group><article-title>A Capsaicin-Receptor Homologue with a High Threshold for Noxious Heat</article-title><source>Nature</source><year>1999</year><volume>398</volume><fpage>436</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1038/18906</pub-id><pub-id pub-id-type="pmid">10201375</pub-id></element-citation></ref><ref id="B116-biomedicines-09-00234"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frederick</surname><given-names>J.</given-names></name><name><surname>Buck</surname><given-names>M.E.</given-names></name><name><surname>Matson</surname><given-names>D.J.</given-names></name><name><surname>Cortright</surname><given-names>D.N.</given-names></name></person-group><article-title>Increased TRPA1, TRPM8, and TRPV2 Expression in Dorsal Root Ganglia by Nerve Injury</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2007</year><volume>358</volume><fpage>1058</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2007.05.029</pub-id><?supplied-pmid 17517374?><pub-id pub-id-type="pmid">17517374</pub-id></element-citation></ref><ref id="B117-biomedicines-09-00234"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimosato</surname><given-names>G.</given-names></name><name><surname>Amaya</surname><given-names>F.</given-names></name><name><surname>Ueda</surname><given-names>M.</given-names></name><name><surname>Tanaka</surname><given-names>Y.</given-names></name><name><surname>Decosterd</surname><given-names>I.</given-names></name><name><surname>Tanaka</surname><given-names>M.</given-names></name></person-group><article-title>Peripheral Inflammation Induces Up-Regulation of TRPV2 Expression in Rat DRG</article-title><source>Pain</source><year>2005</year><volume>119</volume><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2005.10.002</pub-id><?supplied-pmid 16298071?><pub-id pub-id-type="pmid">16298071</pub-id></element-citation></ref><ref id="B118-biomedicines-09-00234"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saunders</surname><given-names>C.I.</given-names></name><name><surname>Kunde</surname><given-names>D.A.</given-names></name><name><surname>Crawford</surname><given-names>A.</given-names></name><name><surname>Geraghty</surname><given-names>D.P.</given-names></name></person-group><article-title>Expression of Transient Receptor Potential Vanilloid 1 (TRPV1) and 2 (TRPV2) in Human Peripheral Blood</article-title><source>Mol. Immunol.</source><year>2007</year><volume>44</volume><fpage>1429</fpage><lpage>1435</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2006.04.027</pub-id><pub-id pub-id-type="pmid">16777226</pub-id></element-citation></ref><ref id="B119-biomedicines-09-00234"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoni</surname><given-names>G.</given-names></name><name><surname>Amantini</surname><given-names>C.</given-names></name><name><surname>Maggi</surname><given-names>F.</given-names></name><name><surname>Marinelli</surname><given-names>O.</given-names></name><name><surname>Santoni</surname><given-names>M.</given-names></name><name><surname>Nabissi</surname><given-names>M.</given-names></name><name><surname>Morelli</surname><given-names>M.B.</given-names></name></person-group><article-title>The TRPV2 Cation Channels: From Urothelial Cancer Invasiveness to Glioblastoma Multiforme Interactome Signature</article-title><source>Lab. Investig.</source><year>2020</year><volume>100</volume><fpage>186</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1038/s41374-019-0333-7</pub-id><?supplied-pmid 31653969?><pub-id pub-id-type="pmid">31653969</pub-id></element-citation></ref><ref id="B120-biomedicines-09-00234"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Link</surname><given-names>T.M.</given-names></name><name><surname>Park</surname><given-names>U.</given-names></name><name><surname>Vonakis</surname><given-names>B.M.</given-names></name><name><surname>Raben</surname><given-names>D.M.</given-names></name><name><surname>Soloski</surname><given-names>M.J.</given-names></name><name><surname>Caterina</surname><given-names>M.J.</given-names></name></person-group><article-title>TRPV2 Has a Pivotal Role in Macrophage Particle Binding and Phagocytosis</article-title><source>Nat. Immunol.</source><year>2010</year><volume>11</volume><fpage>232</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1038/ni.1842</pub-id><pub-id pub-id-type="pmid">20118928</pub-id></element-citation></ref><ref id="B121-biomedicines-09-00234"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Spielmann</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Ding</surname><given-names>G.</given-names></name><name><surname>Huang</surname><given-names>F.</given-names></name><name><surname>Gu</surname><given-names>Q.</given-names></name><name><surname>Schwarz</surname><given-names>W.</given-names></name></person-group><article-title>Mast-Cell Degranulation Induced by Physical Stimuli Involves the Activation of Transient-Receptor-Potential Channel TRPV2</article-title><source>Physiol. Res.</source><year>2012</year><volume>61</volume><fpage>113</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.33549/physiolres.932053</pub-id><pub-id pub-id-type="pmid">21574765</pub-id></element-citation></ref><ref id="B122-biomedicines-09-00234"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata</surname><given-names>Y.</given-names></name><name><surname>Ohtake</surname><given-names>H.</given-names></name><name><surname>Suzuki</surname><given-names>O.</given-names></name><name><surname>Matsuda</surname><given-names>J.</given-names></name><name><surname>Komamura</surname><given-names>K.</given-names></name><name><surname>Wakabayashi</surname><given-names>S.</given-names></name></person-group><article-title>Blockade of Sarcolemmal TRPV2 Accumulation Inhibits Progression of Dilated Cardiomyopathy</article-title><source>Cardiovasc. Res.</source><year>2013</year><volume>99</volume><fpage>760</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvt163</pub-id><?supplied-pmid 23786999?><pub-id pub-id-type="pmid">23786999</pub-id></element-citation></ref><ref id="B123-biomedicines-09-00234"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorin</surname><given-names>C.</given-names></name><name><surname>V&#x000f6;geli</surname><given-names>I.</given-names></name><name><surname>Niggli</surname><given-names>E.</given-names></name></person-group><article-title>Dystrophic Cardiomyopathy: Role of TRPV2 Channels in Stretch-Induced Cell Damage</article-title><source>Cardiovasc. Res.</source><year>2015</year><volume>106</volume><fpage>153</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvv021</pub-id><pub-id pub-id-type="pmid">25616416</pub-id></element-citation></ref><ref id="B124-biomedicines-09-00234"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata</surname><given-names>Y.</given-names></name><name><surname>Katanosaka</surname><given-names>Y.</given-names></name><name><surname>Arai</surname><given-names>Y.</given-names></name><name><surname>Shigekawa</surname><given-names>M.</given-names></name><name><surname>Wakabayashi</surname><given-names>S.</given-names></name></person-group><article-title>Dominant-Negative Inhibition of Ca2+ Influx via TRPV2 Ameliorates Muscular Dystrophy in Animal Models</article-title><source>Hum. Mol. Genet.</source><year>2009</year><volume>18</volume><fpage>84</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddn408</pub-id></element-citation></ref><ref id="B125-biomedicines-09-00234"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata</surname><given-names>Y.</given-names></name><name><surname>Wakabayashi</surname><given-names>S.</given-names></name><name><surname>Ito</surname><given-names>S.</given-names></name><name><surname>Kitakaze</surname><given-names>M.</given-names></name></person-group><article-title>Production of TRPV2-Targeting Functional Antibody Ameliorating Dilated Cardiomyopathy and Muscular Dystrophy in Animal Models</article-title><source>Lab. Investig.</source><year>2020</year><volume>100</volume><fpage>324</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1038/s41374-019-0363-1</pub-id><pub-id pub-id-type="pmid">31896817</pub-id></element-citation></ref><ref id="B126-biomedicines-09-00234"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hisanaga</surname><given-names>E.</given-names></name><name><surname>Nagasawa</surname><given-names>M.</given-names></name><name><surname>Ueki</surname><given-names>K.</given-names></name><name><surname>Kulkarni</surname><given-names>R.N.</given-names></name><name><surname>Mori</surname><given-names>M.</given-names></name><name><surname>Kojima</surname><given-names>I.</given-names></name></person-group><article-title>Regulation of Calcium-Permeable TRPV2 Channel by Insulin in Pancreatic &#x003b2;-Cells</article-title><source>Diabetes</source><year>2009</year><volume>58</volume><fpage>174</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.2337/db08-0862</pub-id><?supplied-pmid 18984736?><pub-id pub-id-type="pmid">18984736</pub-id></element-citation></ref><ref id="B127-biomedicines-09-00234"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanzaki</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Y.Q.</given-names></name><name><surname>Mashima</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Shibata</surname><given-names>H.</given-names></name><name><surname>Kojima</surname><given-names>I.</given-names></name></person-group><article-title>Translocation of a Calcium-Permeable Cation Channel Induced by Insulin-like Growth Factor-I</article-title><source>Nat. Cell Biol.</source><year>1999</year><volume>1</volume><fpage>165</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1038/11086</pub-id><?supplied-pmid 10559903?><pub-id pub-id-type="pmid">10559903</pub-id></element-citation></ref><ref id="B128-biomedicines-09-00234"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoyagi</surname><given-names>K.</given-names></name><name><surname>Ohara-Imaizumi</surname><given-names>M.</given-names></name><name><surname>Nishiwaki</surname><given-names>C.</given-names></name><name><surname>Nakamichi</surname><given-names>Y.</given-names></name><name><surname>Nagamatsu</surname><given-names>S.</given-names></name></person-group><article-title>Insulin/Phosphoinositide 3-Kinase Pathway Accelerates the Glucose-Induced First-Phase Insulin Secretion through TrpV2 Recruitment in Pancreatic &#x003b2;-Cells</article-title><source>Biochem. J.</source><year>2010</year><volume>432</volume><fpage>375</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1042/BJ20100864</pub-id><?supplied-pmid 20854263?><pub-id pub-id-type="pmid">20854263</pub-id></element-citation></ref><ref id="B129-biomedicines-09-00234"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caterina</surname><given-names>M.J.</given-names></name><name><surname>Schumacher</surname><given-names>M.A.</given-names></name><name><surname>Tominaga</surname><given-names>M.</given-names></name><name><surname>Rosen</surname><given-names>T.A.</given-names></name><name><surname>Levine</surname><given-names>J.D.</given-names></name><name><surname>Julius</surname><given-names>D.</given-names></name></person-group><article-title>The Capsaicin Receptor: A Heat-Activated Ion Channel in the Pain Pathway</article-title><source>Nature</source><year>1997</year><volume>389</volume><fpage>816</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1038/39807</pub-id><?supplied-pmid 9349813?><pub-id pub-id-type="pmid">9349813</pub-id></element-citation></ref><ref id="B130-biomedicines-09-00234"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>G.D.</given-names></name><name><surname>Gunthorpe</surname><given-names>M.J.</given-names></name><name><surname>Kelsell</surname><given-names>R.E.</given-names></name><name><surname>Hayes</surname><given-names>P.D.</given-names></name><name><surname>Reilly</surname><given-names>P.</given-names></name><name><surname>Facer</surname><given-names>P.</given-names></name><name><surname>Wright</surname><given-names>J.E.</given-names></name><name><surname>Jerman</surname><given-names>J.C.</given-names></name><name><surname>Walhin</surname><given-names>J.P.</given-names></name><name><surname>Ooi</surname><given-names>L.</given-names></name><etal/></person-group><article-title>TRPV3 Is a Temperature-Sensitive Vanilloid Receptor-like Protein</article-title><source>Nature</source><year>2002</year><volume>418</volume><fpage>186</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1038/nature00894</pub-id><pub-id pub-id-type="pmid">12077606</pub-id></element-citation></ref><ref id="B131-biomedicines-09-00234"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000fc;ler</surname><given-names>A.D.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Iida</surname><given-names>T.</given-names></name><name><surname>Shimizu</surname><given-names>I.</given-names></name><name><surname>Tominaga</surname><given-names>M.</given-names></name><name><surname>Caterina</surname><given-names>M.</given-names></name></person-group><article-title>Heat-Evoked Activation of the Ion Channel, TRPV4</article-title><source>J. Neurosci.</source><year>2002</year><volume>22</volume><fpage>6408</fpage><lpage>6414</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-15-06408.2002</pub-id><pub-id pub-id-type="pmid">12151520</pub-id></element-citation></ref><ref id="B132-biomedicines-09-00234"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Ramsey</surname><given-names>I.S.</given-names></name><name><surname>Kotecha</surname><given-names>S.A.</given-names></name><name><surname>Moran</surname><given-names>M.M.</given-names></name><name><surname>Chong</surname><given-names>J.A.</given-names></name><name><surname>Lawson</surname><given-names>D.</given-names></name><name><surname>Ge</surname><given-names>P.</given-names></name><name><surname>Lilly</surname><given-names>J.</given-names></name><name><surname>Silos-Santiago</surname><given-names>I.</given-names></name><name><surname>Xie</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>TRPV3 Is a Calcium-Permeable Temperature-Sensitive Cation Channel</article-title><source>Nature</source><year>2002</year><volume>418</volume><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/nature00882</pub-id><pub-id pub-id-type="pmid">12077604</pub-id></element-citation></ref><ref id="B133-biomedicines-09-00234"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moqrich</surname><given-names>A.</given-names></name><name><surname>Hwang</surname><given-names>S.W.</given-names></name><name><surname>Earley</surname><given-names>T.J.</given-names></name><name><surname>Petrus</surname><given-names>M.J.</given-names></name><name><surname>Murray</surname><given-names>A.N.</given-names></name><name><surname>Spencer</surname><given-names>K.S.R.</given-names></name><name><surname>Andahazy</surname><given-names>M.</given-names></name><name><surname>Story</surname><given-names>G.M.</given-names></name><name><surname>Patapoutian</surname><given-names>A.</given-names></name></person-group><article-title>Impaired Thermosensation in Mice Lacking TRPV3, a Heat and Camphor Sensor in the Skin</article-title><source>Science</source><year>2005</year><volume>307</volume><fpage>1468</fpage><lpage>1472</lpage><pub-id pub-id-type="doi">10.1126/science.1108609</pub-id><?supplied-pmid 15746429?><pub-id pub-id-type="pmid">15746429</pub-id></element-citation></ref><ref id="B134-biomedicines-09-00234"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandadi</surname><given-names>S.</given-names></name><name><surname>Sokabe</surname><given-names>T.</given-names></name><name><surname>Shibasaki</surname><given-names>K.</given-names></name><name><surname>Katanosaka</surname><given-names>K.</given-names></name><name><surname>Mizuno</surname><given-names>A.</given-names></name><name><surname>Moqrich</surname><given-names>A.</given-names></name><name><surname>Patapoutian</surname><given-names>A.</given-names></name><name><surname>Fukumi-Tominaga</surname><given-names>T.</given-names></name><name><surname>Mizumura</surname><given-names>K.</given-names></name><name><surname>Tominaga</surname><given-names>M.</given-names></name></person-group><article-title>TRPV3 in Keratinocytes Transmits Temperature Information to Sensory Neurons via ATP</article-title><source>Pflugers Arch. Eur. J. Physiol.</source><year>2009</year><volume>458</volume><fpage>1093</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1007/s00424-009-0703-x</pub-id><?supplied-pmid 19669158?><pub-id pub-id-type="pmid">19669158</pub-id></element-citation></ref><ref id="B135-biomedicines-09-00234"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>M.K.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Mizuno</surname><given-names>A.</given-names></name><name><surname>Suzuki</surname><given-names>M.</given-names></name><name><surname>Caterina</surname><given-names>M.J.</given-names></name></person-group><article-title>TRPV3 and TRPV4 Mediate Warmth-Evoked Currents in Primary Mouse Keratinocytes</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>21569</fpage><lpage>21575</lpage><pub-id pub-id-type="doi">10.1074/jbc.M401872200</pub-id><pub-id pub-id-type="pmid">15004014</pub-id></element-citation></ref><ref id="B136-biomedicines-09-00234"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todaka</surname><given-names>H.</given-names></name><name><surname>Taniguchi</surname><given-names>J.</given-names></name><name><surname>Satoh</surname><given-names>J.I.</given-names></name><name><surname>Mizuno</surname><given-names>A.</given-names></name><name><surname>Suzuki</surname><given-names>M.</given-names></name></person-group><article-title>Warm Temperature-Sensitive Transient Receptor Potential Vanilloid 4 (TRPV4) Plays an Essential Role in Thermal Hyperalgesia</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>35133</fpage><lpage>35138</lpage><pub-id pub-id-type="doi">10.1074/jbc.M406260200</pub-id><pub-id pub-id-type="pmid">15187078</pub-id></element-citation></ref><ref id="B137-biomedicines-09-00234"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>H.</given-names></name><name><surname>Vriens</surname><given-names>J.</given-names></name><name><surname>Suh</surname><given-names>S.H.</given-names></name><name><surname>Benham</surname><given-names>C.D.</given-names></name><name><surname>Droogmans</surname><given-names>G.</given-names></name><name><surname>Nilius</surname><given-names>B.</given-names></name></person-group><article-title>Heat-Evoked Activation of TRPV4 Channels in a HEK293 Cell Expression System and in Native Mouse Aorta Endothelial Cells</article-title><source>J. Biol. Chem.</source><year>2002</year><volume>277</volume><fpage>47044</fpage><lpage>47051</lpage><pub-id pub-id-type="doi">10.1074/jbc.M208277200</pub-id><?supplied-pmid 12354759?><pub-id pub-id-type="pmid">12354759</pub-id></element-citation></ref><ref id="B138-biomedicines-09-00234"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peier</surname><given-names>A.M.</given-names></name><name><surname>Reeve</surname><given-names>A.J.</given-names></name><name><surname>Andersson</surname><given-names>D.A.</given-names></name><name><surname>Moqrich</surname><given-names>A.</given-names></name><name><surname>Earley</surname><given-names>T.J.</given-names></name><name><surname>Hergarden</surname><given-names>A.C.</given-names></name><name><surname>Story</surname><given-names>G.M.</given-names></name><name><surname>Colley</surname><given-names>S.</given-names></name><name><surname>Hogenesch</surname><given-names>J.B.</given-names></name><name><surname>McIntyre</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A Heat-Sensitive TRP Channel Expressed in Keratinocytes</article-title><source>Science</source><year>2002</year><volume>296</volume><fpage>2046</fpage><lpage>2049</lpage><pub-id pub-id-type="doi">10.1126/science.1073140</pub-id><?supplied-pmid 12016205?><pub-id pub-id-type="pmid">12016205</pub-id></element-citation></ref><ref id="B139-biomedicines-09-00234"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Delling</surname><given-names>M.</given-names></name><name><surname>Jun</surname><given-names>J.C.</given-names></name><name><surname>Clapham</surname><given-names>D.E.</given-names></name></person-group><article-title>Oregano, Thyme and Clove-Derived Flavors and Skin Sensitizers Activate Specific TRP Channels</article-title><source>Nat. Neurosci.</source><year>2006</year><volume>9</volume><fpage>628</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1038/nn1692</pub-id><pub-id pub-id-type="pmid">16617338</pub-id></element-citation></ref><ref id="B140-biomedicines-09-00234"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>S.</given-names></name><name><surname>Yoo</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>T.J.</given-names></name><name><surname>Cho</surname><given-names>H.</given-names></name><name><surname>Hwang</surname><given-names>S.W.</given-names></name></person-group><article-title>Isopentenyl Pyrophosphate Is a Novel Antinociceptive Substance That Inhibits TRPV3 and TRPA1 Ion Channels</article-title><source>Pain</source><year>2011</year><volume>152</volume><fpage>1156</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2011.01.044</pub-id><pub-id pub-id-type="pmid">21353389</pub-id></element-citation></ref><ref id="B141-biomedicines-09-00234"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Bandyopadhyay</surname><given-names>B.</given-names></name><name><surname>Nakamoto</surname><given-names>T.</given-names></name><name><surname>Singh</surname><given-names>B.</given-names></name><name><surname>Liedtke</surname><given-names>W.</given-names></name><name><surname>Melvin</surname><given-names>J.E.</given-names></name><name><surname>Ambudkar</surname><given-names>I.</given-names></name></person-group><article-title>A Role for AQP5 in Activation of TRPV4 by Hypotonicity: Concerted Involvement of AQP5 and TRPV4 in Regulation of Cell Volume Recovery</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>15485</fpage><lpage>15495</lpage><pub-id pub-id-type="doi">10.1074/jbc.M600549200</pub-id><pub-id pub-id-type="pmid">16571723</pub-id></element-citation></ref><ref id="B142-biomedicines-09-00234"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>D.</given-names></name><name><surname>Blase</surname><given-names>C.</given-names></name><name><surname>Bereiter-Hahn</surname><given-names>J.</given-names></name><name><surname>Jendrach</surname><given-names>M.</given-names></name></person-group><article-title>TRPV4 Exhibits a Functional Role in Cell-Volume Regulation</article-title><source>J. Cell Sci.</source><year>2005</year><pub-id pub-id-type="doi">10.1242/jcs.02372</pub-id></element-citation></ref><ref id="B143-biomedicines-09-00234"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vriens</surname><given-names>J.</given-names></name><name><surname>Watanabe</surname><given-names>H.</given-names></name><name><surname>Janssens</surname><given-names>A.</given-names></name><name><surname>Droogmans</surname><given-names>G.</given-names></name><name><surname>Voets</surname><given-names>T.</given-names></name><name><surname>Nilius</surname><given-names>B.</given-names></name></person-group><article-title>Cell Swelling, Heat, and Chemical Agonists Use Distinct Pathways for the Activation of the Cation Channel TRPV4</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>396</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1073/pnas.0303329101</pub-id><?supplied-pmid 14691263?><pub-id pub-id-type="pmid">14691263</pub-id></element-citation></ref><ref id="B144-biomedicines-09-00234"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liedtke</surname><given-names>W.</given-names></name><name><surname>Choe</surname><given-names>Y.</given-names></name><name><surname>Mart&#x000ed;-Renom</surname><given-names>M.A.</given-names></name><name><surname>Bell</surname><given-names>A.M.</given-names></name><name><surname>Denis</surname><given-names>C.S.</given-names></name><name><surname>&#x00160;ali</surname><given-names>A.</given-names></name><name><surname>Hudspeth</surname><given-names>A.J.</given-names></name><name><surname>Friedman</surname><given-names>J.M.</given-names></name><name><surname>Heller</surname><given-names>S.</given-names></name></person-group><article-title>Vanilloid Receptor-Related Osmotically Activated Channel (VR-OAC), a Candidate Vertebrate Osmoreceptor</article-title><source>Cell</source><year>2000</year><volume>103</volume><fpage>525</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)00143-4</pub-id><pub-id pub-id-type="pmid">11081638</pub-id></element-citation></ref><ref id="B145-biomedicines-09-00234"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibasaki</surname><given-names>K.</given-names></name><name><surname>Tominaga</surname><given-names>M.</given-names></name><name><surname>Ishizaki</surname><given-names>Y.</given-names></name></person-group><article-title>Hippocampal Neuronal Maturation Triggers Post-Synaptic Clustering of Brain Temperature-Sensor TRPV4</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2015</year><volume>458</volume><fpage>168</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2015.01.087</pub-id><?supplied-pmid 25637662?><pub-id pub-id-type="pmid">25637662</pub-id></element-citation></ref><ref id="B146-biomedicines-09-00234"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Papadopoulos</surname><given-names>P.</given-names></name><name><surname>Hamel</surname><given-names>E.</given-names></name></person-group><article-title>Endothelial TRPV4 Channels Mediate Dilation of Cerebral Arteries: Impairment and Recovery in Cerebrovascular Pathologies Related to Alzheimer&#x02019;s Disease</article-title><source>Br. J. Pharmacol.</source><year>2013</year><volume>170</volume><fpage>661</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1111/bph.12315</pub-id><pub-id pub-id-type="pmid">23889563</pub-id></element-citation></ref><ref id="B147-biomedicines-09-00234"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wissenbach</surname><given-names>U.</given-names></name><name><surname>B&#x000f6;dding</surname><given-names>M.</given-names></name><name><surname>Freichel</surname><given-names>M.</given-names></name><name><surname>Flockerzi</surname><given-names>V.</given-names></name></person-group><article-title>Trp12, a Novel Trp Related Protein from Kidney</article-title><source>FEBS Lett.</source><year>2000</year><volume>485</volume><fpage>127</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(00)02212-2</pub-id><pub-id pub-id-type="pmid">11094154</pub-id></element-citation></ref><ref id="B148-biomedicines-09-00234"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liedtke</surname><given-names>W.</given-names></name><name><surname>Friedman</surname><given-names>J.M.</given-names></name></person-group><article-title>Abnormal Osmotic Regulation in Trpv4-/- Mice</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2003</year><volume>100</volume><fpage>13698</fpage><lpage>13703</lpage><pub-id pub-id-type="doi">10.1073/pnas.1735416100</pub-id><?supplied-pmid 14581612?><pub-id pub-id-type="pmid">14581612</pub-id></element-citation></ref><ref id="B149-biomedicines-09-00234"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heckel</surname><given-names>E.</given-names></name><name><surname>Boselli</surname><given-names>F.</given-names></name><name><surname>Roth</surname><given-names>S.</given-names></name><name><surname>Krudewig</surname><given-names>A.</given-names></name><name><surname>Belting</surname><given-names>H.G.</given-names></name><name><surname>Charvin</surname><given-names>G.</given-names></name><name><surname>Vermot</surname><given-names>J.</given-names></name></person-group><article-title>Oscillatory Flow Modulates Mechanosensitive Klf2a Expression through Trpv4 and Trpp2 during Heart Valve Development</article-title><source>Curr. Biol.</source><year>2015</year><volume>25</volume><fpage>1354</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2015.03.038</pub-id><?supplied-pmid 25959969?><pub-id pub-id-type="pmid">25959969</pub-id></element-citation></ref><ref id="B150-biomedicines-09-00234"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>H.</given-names></name><name><surname>Davis</surname><given-names>J.B.</given-names></name><name><surname>Smart</surname><given-names>D.</given-names></name><name><surname>Jerman</surname><given-names>J.C.</given-names></name><name><surname>Smith</surname><given-names>G.D.</given-names></name><name><surname>Hayes</surname><given-names>P.</given-names></name><name><surname>Vriens</surname><given-names>J.</given-names></name><name><surname>Cairns</surname><given-names>W.</given-names></name><name><surname>Wissenbach</surname><given-names>U.</given-names></name><name><surname>Prenen</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Activation of TRPV4 Channels (HVRL-2/MTRP12) by Phorbol Derivatives</article-title><source>J. Biol. Chem.</source><year>2002</year><volume>277</volume><fpage>13569</fpage><lpage>13577</lpage><pub-id pub-id-type="doi">10.1074/jbc.M200062200</pub-id><pub-id pub-id-type="pmid">11827975</pub-id></element-citation></ref><ref id="B151-biomedicines-09-00234"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>H.</given-names></name><name><surname>Vriens</surname><given-names>J.</given-names></name><name><surname>Prenen</surname><given-names>J.</given-names></name><name><surname>Droogmans</surname><given-names>G.</given-names></name><name><surname>Voets</surname><given-names>T.</given-names></name><name><surname>Nillus</surname><given-names>B.</given-names></name></person-group><article-title>Anandamide and Arachidonic Acid Use Epoxyeicosatrienoic Acids to Activate TRPV4 Channels</article-title><source>Nature</source><year>2003</year><volume>424</volume><fpage>434</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1038/nature01807</pub-id><?supplied-pmid 12879072?><pub-id pub-id-type="pmid">12879072</pub-id></element-citation></ref><ref id="B152-biomedicines-09-00234"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKemy</surname><given-names>D.D.</given-names></name><name><surname>Neuhausser</surname><given-names>W.M.</given-names></name><name><surname>Julius</surname><given-names>D.</given-names></name></person-group><article-title>Identification of a Cold Receptor Reveals a General Role for TRP Channels in Thermosensation</article-title><source>Nature</source><year>2002</year><volume>416</volume><fpage>52</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1038/nature719</pub-id><pub-id pub-id-type="pmid">11882888</pub-id></element-citation></ref><ref id="B153-biomedicines-09-00234"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peier</surname><given-names>A.M.</given-names></name><name><surname>Moqrich</surname><given-names>A.</given-names></name><name><surname>Hergarden</surname><given-names>A.C.</given-names></name><name><surname>Reeve</surname><given-names>A.J.</given-names></name><name><surname>Andersson</surname><given-names>D.A.</given-names></name><name><surname>Story</surname><given-names>G.M.</given-names></name><name><surname>Earley</surname><given-names>T.J.</given-names></name><name><surname>Dragoni</surname><given-names>I.</given-names></name><name><surname>McIntyre</surname><given-names>P.</given-names></name><name><surname>Bevan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A TRP Channel That Senses Cold Stimuli and Menthol</article-title><source>Cell</source><year>2002</year><volume>108</volume><fpage>705</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)00652-9</pub-id><pub-id pub-id-type="pmid">11893340</pub-id></element-citation></ref><ref id="B154-biomedicines-09-00234"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Camino</surname><given-names>D.</given-names></name><name><surname>Murphy</surname><given-names>S.</given-names></name><name><surname>Heiry</surname><given-names>M.</given-names></name><name><surname>Barrett</surname><given-names>L.B.</given-names></name><name><surname>Earley</surname><given-names>T.J.</given-names></name><name><surname>Cook</surname><given-names>C.A.</given-names></name><name><surname>Petrus</surname><given-names>M.J.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>D&#x02019;Amours</surname><given-names>M.</given-names></name><name><surname>Deering</surname><given-names>N.</given-names></name><etal/></person-group><article-title>TRPA1 Contributes to Cold Hypersensitivity</article-title><source>J. Neurosci.</source><year>2010</year><volume>30</volume><fpage>15165</fpage><lpage>15174</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2580-10.2010</pub-id><?supplied-pmid 21068322?><pub-id pub-id-type="pmid">21068322</pub-id></element-citation></ref><ref id="B155-biomedicines-09-00234"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Story</surname><given-names>G.M.</given-names></name><name><surname>Peier</surname><given-names>A.M.</given-names></name><name><surname>Reeve</surname><given-names>A.J.</given-names></name><name><surname>Eid</surname><given-names>S.R.</given-names></name><name><surname>Mosbacher</surname><given-names>J.</given-names></name><name><surname>Hricik</surname><given-names>T.R.</given-names></name><name><surname>Earley</surname><given-names>T.J.</given-names></name><name><surname>Hergarden</surname><given-names>A.C.</given-names></name><name><surname>Andersson</surname><given-names>D.A.</given-names></name><name><surname>Hwang</surname><given-names>S.W.</given-names></name><etal/></person-group><article-title>ANKTM1, a TRP-like Channel Expressed in Nociceptive Neurons, Is Activated by Cold Temperatures</article-title><source>Cell</source><year>2003</year><volume>112</volume><fpage>819</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(03)00158-2</pub-id><pub-id pub-id-type="pmid">12654248</pub-id></element-citation></ref><ref id="B156-biomedicines-09-00234"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandell</surname><given-names>M.</given-names></name><name><surname>Story</surname><given-names>G.M.</given-names></name><name><surname>Hwang</surname><given-names>S.W.</given-names></name><name><surname>Viswanath</surname><given-names>V.</given-names></name><name><surname>Eid</surname><given-names>S.R.</given-names></name><name><surname>Petrus</surname><given-names>M.J.</given-names></name><name><surname>Earley</surname><given-names>T.J.</given-names></name><name><surname>Patapoutian</surname><given-names>A.</given-names></name></person-group><article-title>Noxious Cold Ion Channel TRPA1 Is Activated by Pungent Compounds and Bradykinin</article-title><source>Neuron</source><year>2004</year><volume>41</volume><fpage>849</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(04)00150-3</pub-id><pub-id pub-id-type="pmid">15046718</pub-id></element-citation></ref><ref id="B157-biomedicines-09-00234"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karashima</surname><given-names>Y.</given-names></name><name><surname>Talavera</surname><given-names>K.</given-names></name><name><surname>Everaerts</surname><given-names>W.</given-names></name><name><surname>Janssens</surname><given-names>A.</given-names></name><name><surname>Kwan</surname><given-names>K.Y.</given-names></name><name><surname>Vennekens</surname><given-names>R.</given-names></name><name><surname>Nilius</surname><given-names>B.</given-names></name><name><surname>Voets</surname><given-names>T.</given-names></name></person-group><article-title>TRPA1 Acts as a Cold Sensor in Vitro and in Vivo</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>1273</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1073/pnas.0808487106</pub-id><pub-id pub-id-type="pmid">19144922</pub-id></element-citation></ref><ref id="B158-biomedicines-09-00234"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNamara</surname><given-names>C.R.</given-names></name><name><surname>Mandel-Brehm</surname><given-names>J.</given-names></name><name><surname>Bautista</surname><given-names>D.M.</given-names></name><name><surname>Siemens</surname><given-names>J.</given-names></name><name><surname>Deranian</surname><given-names>K.L.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Hayward</surname><given-names>N.J.</given-names></name><name><surname>Chong</surname><given-names>J.A.</given-names></name><name><surname>Julius</surname><given-names>D.</given-names></name><name><surname>Moran</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>TRPA1 Mediates Formalin-Induced Pain</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>13525</fpage><lpage>13530</lpage><pub-id pub-id-type="doi">10.1073/pnas.0705924104</pub-id><?supplied-pmid 17686976?><pub-id pub-id-type="pmid">17686976</pub-id></element-citation></ref><ref id="B159-biomedicines-09-00234"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordt</surname><given-names>S.E.</given-names></name><name><surname>Bautista</surname><given-names>D.M.</given-names></name><name><surname>Chuang</surname><given-names>H.H.</given-names></name><name><surname>McKemy</surname><given-names>D.D.</given-names></name><name><surname>Zygmunt</surname><given-names>P.M.</given-names></name><name><surname>H&#x000f6;gest&#x000e4;tt</surname><given-names>E.D.</given-names></name><name><surname>Meng</surname><given-names>I.D.</given-names></name><name><surname>Julius</surname><given-names>D.</given-names></name></person-group><article-title>Mustard Oils and Cannabinoids Excite Sensory Nerve Fibres through the TRP Channel ANKTM1</article-title><source>Nature</source><year>2004</year><volume>427</volume><fpage>260</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1038/nature02282</pub-id><pub-id pub-id-type="pmid">14712238</pub-id></element-citation></ref><ref id="B160-biomedicines-09-00234"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Tominaga</surname><given-names>M.</given-names></name><name><surname>Yamamoto</surname><given-names>S.</given-names></name><name><surname>Fukuoka</surname><given-names>T.</given-names></name><name><surname>Higashi</surname><given-names>T.</given-names></name><name><surname>Kobayashi</surname><given-names>K.</given-names></name><name><surname>Obata</surname><given-names>K.</given-names></name><name><surname>Yamanaka</surname><given-names>H.</given-names></name><name><surname>Noguchi</surname><given-names>K.</given-names></name></person-group><article-title>Sensitization of TRPA1 by PAR2 Contributes to the Sensation of Inflammatory Pain</article-title><source>J. Clin. Investig.</source><year>2007</year><volume>117</volume><fpage>1979</fpage><lpage>1987</lpage><pub-id pub-id-type="doi">10.1172/JCI30951</pub-id><?supplied-pmid 17571167?><pub-id pub-id-type="pmid">17571167</pub-id></element-citation></ref><ref id="B161-biomedicines-09-00234"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagata</surname><given-names>K.</given-names></name><name><surname>Duggan</surname><given-names>A.</given-names></name><name><surname>Kumar</surname><given-names>G.</given-names></name><name><surname>Garc&#x000ed;a-A&#x000f1;overos</surname><given-names>J.</given-names></name></person-group><article-title>Nociceptor and Hair Cell Transducer Properties of TRPA1, a Channel for Pain and Hearing</article-title><source>J. Neurosci.</source><year>2005</year><volume>25</volume><fpage>4052</fpage><lpage>4061</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0013-05.2005</pub-id><pub-id pub-id-type="pmid">15843607</pub-id></element-citation></ref><ref id="B162-biomedicines-09-00234"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bautista</surname><given-names>D.M.</given-names></name><name><surname>Jordt</surname><given-names>S.E.</given-names></name><name><surname>Nikai</surname><given-names>T.</given-names></name><name><surname>Tsuruda</surname><given-names>P.R.</given-names></name><name><surname>Read</surname><given-names>A.J.</given-names></name><name><surname>Poblete</surname><given-names>J.</given-names></name><name><surname>Yamoah</surname><given-names>E.N.</given-names></name><name><surname>Basbaum</surname><given-names>A.I.</given-names></name><name><surname>Julius</surname><given-names>D.</given-names></name></person-group><article-title>TRPA1 Mediates the Inflammatory Actions of Environmental Irritants and Proalgesic Agents</article-title><source>Cell</source><year>2006</year><volume>124</volume><fpage>1269</fpage><lpage>1282</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.02.023</pub-id><pub-id pub-id-type="pmid">16564016</pub-id></element-citation></ref><ref id="B163-biomedicines-09-00234"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kremeyer</surname><given-names>B.</given-names></name><name><surname>Lopera</surname><given-names>F.</given-names></name><name><surname>Cox</surname><given-names>J.J.</given-names></name><name><surname>Momin</surname><given-names>A.</given-names></name><name><surname>Rugiero</surname><given-names>F.</given-names></name><name><surname>Marsh</surname><given-names>S.</given-names></name><name><surname>Woods</surname><given-names>C.G.</given-names></name><name><surname>Jones</surname><given-names>N.G.</given-names></name><name><surname>Paterson</surname><given-names>K.J.</given-names></name><name><surname>Fricker</surname><given-names>F.R.</given-names></name><etal/></person-group><article-title>A Gain-of-Function Mutation in TRPA1 Causes Familial Episodic Pain Syndrome</article-title><source>Neuron</source><year>2010</year><volume>66</volume><fpage>671</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2010.04.030</pub-id><pub-id pub-id-type="pmid">20547126</pub-id></element-citation></ref><ref id="B164-biomedicines-09-00234"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>W.</given-names></name><name><surname>Cui</surname><given-names>T.</given-names></name><name><surname>Cheng</surname><given-names>K.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>S.R.</given-names></name><name><surname>Willenbring</surname><given-names>D.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Pan</surname><given-names>H.L.</given-names></name><name><surname>Ren</surname><given-names>K.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Cannabinoids Suppress Inflammatory and Neuropathic Pain by Targeting &#x00391;3 Glycine Receptors</article-title><source>J. Exp. Med.</source><year>2012</year><volume>209</volume><fpage>1121</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.1084/jem.20120242</pub-id><pub-id pub-id-type="pmid">22585736</pub-id></element-citation></ref><ref id="B165-biomedicines-09-00234"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hejazi</surname><given-names>N.</given-names></name><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>Oz</surname><given-names>M.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Jiang</surname><given-names>H.Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>&#x00394;9-Tetrahydrocannabinol and Endogenous Cannabinoid Anandamide Directly Potentiate the Function of Glycine Receptors</article-title><source>Mol. Pharmacol.</source><year>2006</year><volume>69</volume><fpage>991</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1124/mol.105.019174</pub-id><?supplied-pmid 16332990?><pub-id pub-id-type="pmid">16332990</pub-id></element-citation></ref><ref id="B166-biomedicines-09-00234"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>W.</given-names></name><name><surname>Cheng</surname><given-names>K.</given-names></name><name><surname>Cui</surname><given-names>T.</given-names></name><name><surname>Godlewski</surname><given-names>G.</given-names></name><name><surname>Rice</surname><given-names>K.C.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Cannabinoid Potentiation of Glycine Receptors Contributes to Cannabis-Induced Analgesia</article-title><source>Nat. Chem. Biol.</source><year>2011</year><volume>7</volume><fpage>296</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1038/nchembio.552</pub-id><pub-id pub-id-type="pmid">21460829</pub-id></element-citation></ref><ref id="B167-biomedicines-09-00234"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Sullivan</surname><given-names>S.E.</given-names></name></person-group><article-title>An Update on PPAR Activation by Cannabinoids</article-title><source>Br. J. Pharmacol.</source><year>2016</year><volume>173</volume><fpage>1899</fpage><lpage>1910</lpage><pub-id pub-id-type="doi">10.1111/bph.13497</pub-id><pub-id pub-id-type="pmid">27077495</pub-id></element-citation></ref><ref id="B168-biomedicines-09-00234"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>E.B.</given-names></name><name><surname>Burnett</surname><given-names>A.</given-names></name><name><surname>Hall</surname><given-names>B.</given-names></name><name><surname>Parker</surname><given-names>K.K.</given-names></name></person-group><article-title>Agonistic Properties of Cannabidiol at 5-HT1a Receptors</article-title><source>Neurochem. Res.</source><year>2005</year><volume>30</volume><fpage>1037</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.1007/s11064-005-6978-1</pub-id><?supplied-pmid 16258853?><pub-id pub-id-type="pmid">16258853</pub-id></element-citation></ref><ref id="B169-biomedicines-09-00234"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franklin</surname><given-names>J.M.</given-names></name><name><surname>Carrasco</surname><given-names>G.A.</given-names></name></person-group><article-title>Cannabinoid-Induced Enhanced Interaction and Protein Levels of Serotonin 5-HT2A and Dopamine D2 Receptors in Rat Prefrontal Cortex</article-title><source>J. Psychopharmacol.</source><year>2012</year><volume>26</volume><fpage>1333</fpage><lpage>1347</lpage><pub-id pub-id-type="doi">10.1177/0269881112450786</pub-id><pub-id pub-id-type="pmid">22791651</pub-id></element-citation></ref><ref id="B170-biomedicines-09-00234"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franklin</surname><given-names>J.M.</given-names></name><name><surname>Carrasco</surname><given-names>G.A.</given-names></name></person-group><article-title>Cannabinoid Receptor Agonists Upregulate and Enhance Serotonin 2A (5-HT2A) Receptor Activity via ERK1/2 Signaling</article-title><source>Synapse</source><year>2013</year><volume>67</volume><fpage>145</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1002/syn.21626</pub-id><?supplied-pmid 23151877?><pub-id pub-id-type="pmid">23151877</pub-id></element-citation></ref><ref id="B171-biomedicines-09-00234"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>M.N.</given-names></name><name><surname>Campolongo</surname><given-names>P.</given-names></name><name><surname>Yehuda</surname><given-names>R.</given-names></name><name><surname>Patel</surname><given-names>S.</given-names></name></person-group><article-title>Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder</article-title><source>Neuropsychopharmacology</source><year>2018</year><volume>43</volume><fpage>80</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1038/npp.2017.162</pub-id><pub-id pub-id-type="pmid">28745306</pub-id></element-citation></ref><ref id="B172-biomedicines-09-00234"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blessing</surname><given-names>E.M.</given-names></name><name><surname>Steenkamp</surname><given-names>M.M.</given-names></name><name><surname>Manzanares</surname><given-names>J.</given-names></name><name><surname>Marmar</surname><given-names>C.R.</given-names></name></person-group><article-title>Cannabidiol as a Potential Treatment for Anxiety Disorders</article-title><source>Neurotherapeutics</source><year>2015</year><volume>12</volume><fpage>825</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1007/s13311-015-0387-1</pub-id><?supplied-pmid 26341731?><pub-id pub-id-type="pmid">26341731</pub-id></element-citation></ref><ref id="B173-biomedicines-09-00234"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrold</surname><given-names>J.A.</given-names></name><name><surname>Elliott</surname><given-names>J.C.</given-names></name><name><surname>King</surname><given-names>P.J.</given-names></name><name><surname>Widdowson</surname><given-names>P.S.</given-names></name><name><surname>Williams</surname><given-names>G.</given-names></name></person-group><article-title>Down-Regulation of Cannabinoid-1 (CB-1) Receptors in Specific Extrahypothalamic Regions of Rats with Dietary Obesity: A Role for Endogenous Cannabinoids in Driving Appetite for Palatable Food?</article-title><source>Brain Res.</source><year>2002</year><volume>952</volume><fpage>232</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(02)03245-6</pub-id><pub-id pub-id-type="pmid">12376184</pub-id></element-citation></ref><ref id="B174-biomedicines-09-00234"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamshidi</surname><given-names>N.</given-names></name><name><surname>Taylor</surname><given-names>D.A.</given-names></name></person-group><article-title>Anandamide Administration into the Ventromedial Hypothalamus Stimulates Appetite in Rats</article-title><source>Br. J. Pharmacol.</source><year>2001</year><volume>134</volume><fpage>1151</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0704379</pub-id><pub-id pub-id-type="pmid">11704633</pub-id></element-citation></ref><ref id="B175-biomedicines-09-00234"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portella</surname><given-names>G.</given-names></name><name><surname>Laezza</surname><given-names>C.</given-names></name><name><surname>Laccetti</surname><given-names>P.</given-names></name><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name><name><surname>Bifulco</surname><given-names>M.</given-names></name></person-group><article-title>Inhibitory Effects of Cannabinoid CB1 Receptor Stimulation on Tumor Growth and Metastatic Spreading: Actions on Signals Involved in Angiogenesis and Metastasis</article-title><source>FASEB J.</source><year>2003</year><volume>17</volume><fpage>1771</fpage><lpage>1773</lpage><pub-id pub-id-type="doi">10.1096/fj.02-1129fje</pub-id><pub-id pub-id-type="pmid">12958205</pub-id></element-citation></ref><ref id="B176-biomedicines-09-00234"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linciano</surname><given-names>P.</given-names></name><name><surname>Citti</surname><given-names>C.</given-names></name><name><surname>Luongo</surname><given-names>L.</given-names></name><name><surname>Belardo</surname><given-names>C.</given-names></name><name><surname>Maione</surname><given-names>S.</given-names></name><name><surname>Vandelli</surname><given-names>M.A.</given-names></name><name><surname>Forni</surname><given-names>F.</given-names></name><name><surname>Gigli</surname><given-names>G.</given-names></name><name><surname>Lagan&#x000e0;</surname><given-names>A.</given-names></name><name><surname>Montone</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>Isolation of a High-Affinity Cannabinoid for the Human CB1 Receptor from a Medicinal <italic>Cannabis sativa</italic> Variety: &#x00394;9-Tetrahydrocannabutol, the Butyl Homologue of &#x00394;9-Tetrahydrocannabinol</article-title><source>J. Nat. Prod.</source><year>2020</year><volume>83</volume><fpage>88</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.9b00876</pub-id><pub-id pub-id-type="pmid">31891265</pub-id></element-citation></ref><ref id="B177-biomedicines-09-00234"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>M.J.</given-names></name><name><surname>Blair</surname><given-names>R.E.</given-names></name><name><surname>Falenski</surname><given-names>K.W.</given-names></name><name><surname>Martin</surname><given-names>B.R.</given-names></name><name><surname>DeLorenzo</surname><given-names>R.J.</given-names></name></person-group><article-title>The Endogenous Cannabinoid System Regulates Seizure Frequency and Duration in a Model of Temporal Lobe Epilepsy</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2003</year><volume>307</volume><fpage>129</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1124/jpet.103.051920</pub-id><pub-id pub-id-type="pmid">12954810</pub-id></element-citation></ref><ref id="B178-biomedicines-09-00234"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murillo-Rodr&#x000ed;guez</surname><given-names>E.</given-names></name></person-group><article-title>The Role of the CB1 Receptor in the Regulation of Sleep</article-title><source>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</source><year>2008</year><volume>32</volume><fpage>1420</fpage><lpage>1427</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2008.04.008</pub-id></element-citation></ref><ref id="B179-biomedicines-09-00234"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zagzoog</surname><given-names>A.</given-names></name><name><surname>Mohamed</surname><given-names>K.A.</given-names></name><name><surname>Kim</surname><given-names>H.J.J.</given-names></name><name><surname>Kim</surname><given-names>E.D.</given-names></name><name><surname>Frank</surname><given-names>C.S.</given-names></name><name><surname>Black</surname><given-names>T.</given-names></name><name><surname>Jadhav</surname><given-names>P.D.</given-names></name><name><surname>Holbrook</surname><given-names>L.A.</given-names></name><name><surname>Laprairie</surname><given-names>R.B.</given-names></name></person-group><article-title>In Vitro and in Vivo Pharmacological Activity of Minor Cannabinoids Isolated from <italic>Cannabis sativa</italic></article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>20405</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-77175-y</pub-id><pub-id pub-id-type="pmid">33230154</pub-id></element-citation></ref><ref id="B180-biomedicines-09-00234"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolognini</surname><given-names>D.</given-names></name><name><surname>Costa</surname><given-names>B.</given-names></name><name><surname>Maione</surname><given-names>S.</given-names></name><name><surname>Comelli</surname><given-names>F.</given-names></name><name><surname>Marini</surname><given-names>P.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name><name><surname>Parolaro</surname><given-names>D.</given-names></name><name><surname>Ross</surname><given-names>R.A.</given-names></name><name><surname>Gauson</surname><given-names>L.A.</given-names></name><name><surname>Cascio</surname><given-names>M.G.</given-names></name><etal/></person-group><article-title>The Plant Cannabinoid &#x00394; 9-Tetrahydrocannabivarin Can Decrease Signs of Inflammation and Inflammatory Pain in Mice</article-title><source>Br. J. Pharmacol.</source><year>2010</year><volume>160</volume><fpage>677</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.00756.x</pub-id><?supplied-pmid 20590571?><pub-id pub-id-type="pmid">20590571</pub-id></element-citation></ref><ref id="B181-biomedicines-09-00234"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Espadas</surname><given-names>I.</given-names></name><name><surname>Keifman</surname><given-names>E.</given-names></name><name><surname>Palomo-Garo</surname><given-names>C.</given-names></name><name><surname>Burgaz</surname><given-names>S.</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>C.</given-names></name><name><surname>Fern&#x000e1;ndez-Ruiz</surname><given-names>J.</given-names></name><name><surname>Moratalla</surname><given-names>R.</given-names></name></person-group><article-title>Beneficial Effects of the Phytocannabinoid &#x00394;9-THCV in L-DOPA-Induced Dyskinesia in Parkinson&#x02019;s Disease</article-title><source>Neurobiol. Dis.</source><year>2020</year><volume>141</volume><fpage>104892</fpage><pub-id pub-id-type="doi">10.1016/j.nbd.2020.104892</pub-id><?supplied-pmid 32387338?><pub-id pub-id-type="pmid">32387338</pub-id></element-citation></ref><ref id="B182-biomedicines-09-00234"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wargent</surname><given-names>E.T.</given-names></name><name><surname>Zaibi</surname><given-names>M.S.</given-names></name><name><surname>Silvestri</surname><given-names>C.</given-names></name><name><surname>Hislop</surname><given-names>D.C.</given-names></name><name><surname>Stocker</surname><given-names>C.J.</given-names></name><name><surname>Stott</surname><given-names>C.G.</given-names></name><name><surname>Guy</surname><given-names>G.W.</given-names></name><name><surname>Duncan</surname><given-names>M.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name><name><surname>Cawthorne</surname><given-names>M.A.</given-names></name></person-group><article-title>The Cannabinoid &#x00394;9-Tetrahydrocannabivarin (THCV) Ameliorates Insulin Sensitivity in Two Mouse Models of Obesity</article-title><source>Nutr. Diabetes</source><year>2013</year><volume>3</volume><fpage>e68</fpage><pub-id pub-id-type="doi">10.1038/nutd.2013.9</pub-id><?supplied-pmid 23712280?><pub-id pub-id-type="pmid">23712280</pub-id></element-citation></ref><ref id="B183-biomedicines-09-00234"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>A.J.</given-names></name><name><surname>Weston</surname><given-names>S.E.</given-names></name><name><surname>Jones</surname><given-names>N.A.</given-names></name><name><surname>Smith</surname><given-names>I.</given-names></name><name><surname>Bevan</surname><given-names>S.A.</given-names></name><name><surname>Williamson</surname><given-names>E.M.</given-names></name><name><surname>Stephens</surname><given-names>G.J.</given-names></name><name><surname>Williams</surname><given-names>C.M.</given-names></name><name><surname>Whalley</surname><given-names>B.J.</given-names></name></person-group><article-title>9-Tetrahydrocannabivarin Suppresses in Vitro Epileptiform and in Vivo Seizure Activity in Adult Rats</article-title><source>Epilepsia</source><year>2010</year><volume>51</volume><fpage>1522</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02523.x</pub-id><pub-id pub-id-type="pmid">20196794</pub-id></element-citation></ref><ref id="B184-biomedicines-09-00234"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrahamov</surname><given-names>A.</given-names></name><name><surname>Abrahamov</surname><given-names>A.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name></person-group><article-title>An Efficient New Cannabinoid Antiemetic in Pediatric Oncology</article-title><source>Life Sci.</source><year>1995</year><volume>56</volume><fpage>2097</fpage><lpage>2102</lpage><pub-id pub-id-type="doi">10.1016/0024-3205(95)00194-B</pub-id><pub-id pub-id-type="pmid">7776837</pub-id></element-citation></ref><ref id="B185-biomedicines-09-00234"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darmani</surname><given-names>N.A.</given-names></name></person-group><article-title>&#x00394;9-Tetrahydrocannabinol and Synthetic Cannabinoids Prevent Emesis Produced by the Cannabinoid CB1 Receptor Antagonist/Inverse Agonist SR 141716A</article-title><source>Neuropsychopharmacology</source><year>2001</year><volume>24</volume><fpage>198</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/S0893-133X(00)00197-4</pub-id><pub-id pub-id-type="pmid">11120402</pub-id></element-citation></ref><ref id="B186-biomedicines-09-00234"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darmani</surname><given-names>N.A.</given-names></name></person-group><article-title>The Cannabinoid CB1 Receptor Antagonist SR 141716A Reverses the Antiemetic and Motor Depressant Actions of WIN 55, 212&#x02013;2</article-title><source>Eur. J. Pharmacol.</source><year>2001</year><volume>430</volume><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(01)01355-3</pub-id><pub-id pub-id-type="pmid">11698062</pub-id></element-citation></ref><ref id="B187-biomedicines-09-00234"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darmani</surname><given-names>N.A.</given-names></name><name><surname>Sim-Selley</surname><given-names>L.J.</given-names></name><name><surname>Martin</surname><given-names>B.R.</given-names></name><name><surname>Janoyan</surname><given-names>J.J.</given-names></name><name><surname>Crim</surname><given-names>J.L.</given-names></name><name><surname>Parekh</surname><given-names>B.</given-names></name><name><surname>Breivogel</surname><given-names>C.S.</given-names></name></person-group><article-title>Antiemetic and Motor-Depressive Actions of CP55,940: Cannabinoid CB1 Receptor Characterization, Distribution, and G-Protein Activation</article-title><source>Eur. J. Pharmacol.</source><year>2003</year><volume>459</volume><fpage>83</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(02)02815-7</pub-id><pub-id pub-id-type="pmid">12505537</pub-id></element-citation></ref><ref id="B188-biomedicines-09-00234"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darmani</surname><given-names>N.A.</given-names></name><name><surname>Janoyan</surname><given-names>J.J.</given-names></name><name><surname>Crim</surname><given-names>J.</given-names></name><name><surname>Ramirez</surname><given-names>J.</given-names></name></person-group><article-title>Receptor Mechanism and Antiemetic Activity of Structurally-Diverse Cannabinoids against Radiation-Induced Emesis in the Least Shrew</article-title><source>Eur. J. Pharmacol.</source><year>2007</year><volume>563</volume><fpage>187</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2007.01.093</pub-id><pub-id pub-id-type="pmid">17362921</pub-id></element-citation></ref><ref id="B189-biomedicines-09-00234"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lastres-Becker</surname><given-names>I.</given-names></name><name><surname>Cebeira</surname><given-names>M.</given-names></name><name><surname>De Ceballos</surname><given-names>M.L.</given-names></name><name><surname>Zeng</surname><given-names>B.Y.</given-names></name><name><surname>Jenner</surname><given-names>P.</given-names></name><name><surname>Ramos</surname><given-names>J.A.</given-names></name><name><surname>Fern&#x000e1;ndez-Ruiz</surname><given-names>J.J.</given-names></name></person-group><article-title>Increased Cannabinoid CB1 Receptor Binding and Activation of GTP-Binding Proteins in the Basal Ganglia of Patients with Parkinson&#x02019;s Syndrome and of MPTP-Treated Marmosets</article-title><source>Eur. J. Neurosci.</source><year>2001</year><volume>14</volume><fpage>1827</fpage><lpage>1832</lpage><pub-id pub-id-type="doi">10.1046/j.0953-816x.2001.01812.x</pub-id><?supplied-pmid 11860478?><pub-id pub-id-type="pmid">11860478</pub-id></element-citation></ref><ref id="B190-biomedicines-09-00234"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarfaraz</surname><given-names>S.</given-names></name><name><surname>Afaq</surname><given-names>F.</given-names></name><name><surname>Adhami</surname><given-names>V.M.</given-names></name><name><surname>Mukhtar</surname><given-names>H.</given-names></name></person-group><article-title>Cannabinoid Receptor as a Novel Target for the Treatment of Prostate Cancer</article-title><source>Cancer Res.</source><year>2005</year><volume>65</volume><fpage>1635</fpage><lpage>1641</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-3410</pub-id><pub-id pub-id-type="pmid">15753356</pub-id></element-citation></ref><ref id="B191-biomedicines-09-00234"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qamri</surname><given-names>Z.</given-names></name><name><surname>Preet</surname><given-names>A.</given-names></name><name><surname>Nasser</surname><given-names>M.W.</given-names></name><name><surname>Bass</surname><given-names>C.E.</given-names></name><name><surname>Leone</surname><given-names>G.</given-names></name><name><surname>Barsky</surname><given-names>S.H.</given-names></name><name><surname>Ganju</surname><given-names>R.K.</given-names></name></person-group><article-title>Synthetic Cannabinoid Receptor Agonists Inhibit Tumor Growth and Metastasis of Breast Cancer</article-title><source>Mol. Cancer Ther.</source><year>2009</year><volume>8</volume><fpage>3117</fpage><lpage>3129</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-09-0448</pub-id><pub-id pub-id-type="pmid">19887554</pub-id></element-citation></ref><ref id="B192-biomedicines-09-00234"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preet</surname><given-names>A.</given-names></name><name><surname>Qamri</surname><given-names>Z.</given-names></name><name><surname>Nasser</surname><given-names>M.W.</given-names></name><name><surname>Prasad</surname><given-names>A.</given-names></name><name><surname>Shilo</surname><given-names>K.</given-names></name><name><surname>Zou</surname><given-names>X.</given-names></name><name><surname>Groopman</surname><given-names>J.E.</given-names></name><name><surname>Ganju</surname><given-names>R.K.</given-names></name></person-group><article-title>Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non-Small Cell Lung Cancer Growth and Metastasis</article-title><source>Cancer Prev. Res.</source><year>2011</year><volume>4</volume><fpage>65</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-10-0181</pub-id></element-citation></ref><ref id="B193-biomedicines-09-00234"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izzo</surname><given-names>A.A.</given-names></name><name><surname>Capasso</surname><given-names>R.</given-names></name><name><surname>Aviello</surname><given-names>G.</given-names></name><name><surname>Borrelli</surname><given-names>F.</given-names></name><name><surname>Romano</surname><given-names>B.</given-names></name><name><surname>Piscitelli</surname><given-names>F.</given-names></name><name><surname>Gallo</surname><given-names>L.</given-names></name><name><surname>Capasso</surname><given-names>F.</given-names></name><name><surname>Orlando</surname><given-names>P.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name></person-group><article-title>Inhibitory Effect of Cannabichromene, a Major Non-Psychotropic Cannabinoid Extracted from <italic>Cannabis sativa</italic>, on Inflammation-Induced Hypermotility in Mice</article-title><source>Br. J. Pharmacol.</source><year>2012</year><volume>166</volume><fpage>1444</fpage><lpage>1460</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2012.01879.x</pub-id><pub-id pub-id-type="pmid">22300105</pub-id></element-citation></ref><ref id="B194-biomedicines-09-00234"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrelli</surname><given-names>F.</given-names></name><name><surname>Fasolino</surname><given-names>I.</given-names></name><name><surname>Romano</surname><given-names>B.</given-names></name><name><surname>Capasso</surname><given-names>R.</given-names></name><name><surname>Maiello</surname><given-names>F.</given-names></name><name><surname>Coppola</surname><given-names>D.</given-names></name><name><surname>Orlando</surname><given-names>P.</given-names></name><name><surname>Battista</surname><given-names>G.</given-names></name><name><surname>Pagano</surname><given-names>E.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Beneficial Effect of the Non-Psychotropic Plant Cannabinoid Cannabigerol on Experimental Inflammatory Bowel Disease</article-title><source>Biochem. Pharmacol.</source><year>2013</year><volume>85</volume><fpage>1306</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2013.01.017</pub-id><pub-id pub-id-type="pmid">23415610</pub-id></element-citation></ref><ref id="B195-biomedicines-09-00234"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez-G&#x000e1;lvez</surname><given-names>Y.</given-names></name><name><surname>Palomo-Garo</surname><given-names>C.</given-names></name><name><surname>Fern&#x000e1;ndez-Ruiz</surname><given-names>J.</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>C.</given-names></name></person-group><article-title>Potential of the Cannabinoid CB2 Receptor as a Pharmacological Target against Inflammation in Parkinson&#x02019;s Disease</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><year>2016</year><volume>64</volume><fpage>200</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2015.03.017</pub-id><?supplied-pmid 25863279?><pub-id pub-id-type="pmid">25863279</pub-id></element-citation></ref><ref id="B196-biomedicines-09-00234"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javed</surname><given-names>H.</given-names></name><name><surname>Azimullah</surname><given-names>S.</given-names></name><name><surname>Haque</surname><given-names>M.E.</given-names></name><name><surname>Ojha</surname><given-names>S.K.</given-names></name></person-group><article-title>Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson&#x02019;s Disease</article-title><source>Front. Neurosci.</source><year>2016</year><volume>10</volume><fpage>321</fpage><pub-id pub-id-type="doi">10.3389/fnins.2016.00321</pub-id><pub-id pub-id-type="pmid">27531971</pub-id></element-citation></ref><ref id="B197-biomedicines-09-00234"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vigli</surname><given-names>D.</given-names></name><name><surname>Cosentino</surname><given-names>L.</given-names></name><name><surname>Raggi</surname><given-names>C.</given-names></name><name><surname>Laviola</surname><given-names>G.</given-names></name><name><surname>Woolley-Roberts</surname><given-names>M.</given-names></name><name><surname>De Filippis</surname><given-names>B.</given-names></name></person-group><article-title>Chronic Treatment with the Phytocannabinoid Cannabidivarin (CBDV) Rescues Behavioural Alterations and Brain Atrophy in a Mouse Model of Rett Syndrome</article-title><source>Neuropharmacology</source><year>2018</year><volume>140</volume><fpage>121</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2018.07.029</pub-id><?supplied-pmid 30056123?><pub-id pub-id-type="pmid">30056123</pub-id></element-citation></ref><ref id="B198-biomedicines-09-00234"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anavi-Goffer</surname><given-names>S.</given-names></name><name><surname>Baillie</surname><given-names>G.</given-names></name><name><surname>Irving</surname><given-names>A.J.</given-names></name><name><surname>Gertsch</surname><given-names>J.</given-names></name><name><surname>Greig</surname><given-names>I.R.</given-names></name><name><surname>Pertwee</surname><given-names>R.G.</given-names></name><name><surname>Ross</surname><given-names>R.A.</given-names></name></person-group><article-title>Modulation of L-&#x003b1;-Lysophosphatidylinositol/GPR55 Mitogen-Activated Protein Kinase (MAPK) Signaling by Cannabinoids</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>91</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.296020</pub-id><pub-id pub-id-type="pmid">22027819</pub-id></element-citation></ref><ref id="B199-biomedicines-09-00234"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iannotti</surname><given-names>F.A.</given-names></name><name><surname>Hill</surname><given-names>C.L.</given-names></name><name><surname>Leo</surname><given-names>A.</given-names></name><name><surname>Alhusaini</surname><given-names>A.</given-names></name><name><surname>Soubrane</surname><given-names>C.</given-names></name><name><surname>Mazzarella</surname><given-names>E.</given-names></name><name><surname>Russo</surname><given-names>E.</given-names></name><name><surname>Whalley</surname><given-names>B.J.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name><name><surname>Stephens</surname><given-names>G.J.</given-names></name></person-group><article-title>Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability</article-title><source>ACS Chem. Neurosci.</source><year>2014</year><volume>5</volume><fpage>1131</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1021/cn5000524</pub-id><pub-id pub-id-type="pmid">25029033</pub-id></element-citation></ref><ref id="B200-biomedicines-09-00234"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Ligresti</surname><given-names>A.</given-names></name><name><surname>Moriello</surname><given-names>A.S.</given-names></name><name><surname>Allar&#x000e0;</surname><given-names>M.</given-names></name><name><surname>Bisogno</surname><given-names>T.</given-names></name><name><surname>Petrosino</surname><given-names>S.</given-names></name><name><surname>Stott</surname><given-names>C.G.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name></person-group><article-title>Effects of Cannabinoids and Cannabinoid-Enriched Cannabis Extracts on TRP Channels and Endocannabinoid Metabolic Enzymes</article-title><source>Br. J. Pharmacol.</source><year>2011</year><volume>163</volume><fpage>1479</fpage><lpage>1494</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.01166.x</pub-id><pub-id pub-id-type="pmid">21175579</pub-id></element-citation></ref><ref id="B201-biomedicines-09-00234"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Orlando</surname><given-names>P.</given-names></name><name><surname>Moriello</surname><given-names>A.S.</given-names></name><name><surname>Aviello</surname><given-names>G.</given-names></name><name><surname>Stott</surname><given-names>C.</given-names></name><name><surname>Izzo</surname><given-names>A.A.</given-names></name><name><surname>di Marzo</surname><given-names>V.</given-names></name></person-group><article-title>Cannabinoid Actions at TRPV Channels: Effects on TRPV3 and TRPV4 and Their Potential Relevance to Gastrointestinal Inflammation</article-title><source>Acta Physiol.</source><year>2012</year><volume>204</volume><fpage>255</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1111/j.1748-1716.2011.02338.x</pub-id></element-citation></ref><ref id="B202-biomedicines-09-00234"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Vellani</surname><given-names>V.</given-names></name><name><surname>Schiano-Moriello</surname><given-names>A.</given-names></name><name><surname>Marini</surname><given-names>P.</given-names></name><name><surname>Magherini</surname><given-names>P.C.</given-names></name><name><surname>Orlando</surname><given-names>P.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name></person-group><article-title>Plant-Derived Cannabinoids Modulate the Activity of Transient Receptor Potential Channels of Ankyrin Type-1 and Melastatin Type-8</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2008</year><volume>325</volume><fpage>1007</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1124/jpet.107.134809</pub-id><pub-id pub-id-type="pmid">18354058</pub-id></element-citation></ref><ref id="B203-biomedicines-09-00234"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrelli</surname><given-names>F.</given-names></name><name><surname>Pagano</surname><given-names>E.</given-names></name><name><surname>Romano</surname><given-names>B.</given-names></name><name><surname>Panzera</surname><given-names>S.</given-names></name><name><surname>Maiello</surname><given-names>F.</given-names></name><name><surname>Coppola</surname><given-names>D.</given-names></name><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Buono</surname><given-names>L.</given-names></name><name><surname>Orlando</surname><given-names>P.</given-names></name><name><surname>Izzo</surname><given-names>A.A.</given-names></name></person-group><article-title>Colon Carcinogenesis Is Inhibited by the TRPM8 Antagonist Cannabigerol, a Cannabis-Derived Non-Psychotropic Cannabinoid</article-title><source>Carcinogenesis</source><year>2014</year><volume>35</volume><fpage>2787</fpage><lpage>2797</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgu205</pub-id><?supplied-pmid 25269802?><pub-id pub-id-type="pmid">25269802</pub-id></element-citation></ref><ref id="B204-biomedicines-09-00234"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagano</surname><given-names>E.</given-names></name><name><surname>Romano</surname><given-names>B.</given-names></name><name><surname>Iannotti</surname><given-names>F.A.</given-names></name><name><surname>Parisi</surname><given-names>O.A.</given-names></name><name><surname>D&#x02019;Armiento</surname><given-names>M.</given-names></name><name><surname>Pignatiello</surname><given-names>S.</given-names></name><name><surname>Coretti</surname><given-names>L.</given-names></name><name><surname>Lucaf&#x000f2;</surname><given-names>M.</given-names></name><name><surname>Venneri</surname><given-names>T.</given-names></name><name><surname>Stocco</surname><given-names>G.</given-names></name><etal/></person-group><article-title>The Non-Euphoric Phytocannabinoid Cannabidivarin Counteracts Intestinal Inflammation in Mice and Cytokine Expression in Biopsies from UC Pediatric Patients</article-title><source>Pharmacol. Res.</source><year>2019</year><volume>149</volume><fpage>104464</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2019.104464</pub-id><pub-id pub-id-type="pmid">31553934</pub-id></element-citation></ref><ref id="B205-biomedicines-09-00234"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iannotti</surname><given-names>F.A.</given-names></name><name><surname>Pagano</surname><given-names>E.</given-names></name><name><surname>Moriello</surname><given-names>A.S.</given-names></name><name><surname>Alvino</surname><given-names>F.G.</given-names></name><name><surname>Sorrentino</surname><given-names>N.C.</given-names></name><name><surname>D&#x02019;Orsi</surname><given-names>L.</given-names></name><name><surname>Gazzerro</surname><given-names>E.</given-names></name><name><surname>Capasso</surname><given-names>R.</given-names></name><name><surname>De Leonibus</surname><given-names>E.</given-names></name><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Effects of Non-Euphoric Plant Cannabinoids on Muscle Quality and Performance of Dystrophic Mdx Mice</article-title><source>Br. J. Pharmacol.</source><year>2019</year><volume>176</volume><fpage>1568</fpage><lpage>1584</lpage><pub-id pub-id-type="doi">10.1111/bph.14460</pub-id><pub-id pub-id-type="pmid">30074247</pub-id></element-citation></ref><ref id="B206-biomedicines-09-00234"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a-Arencibia</surname><given-names>M.</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>S.</given-names></name><name><surname>de Lago</surname><given-names>E.</given-names></name><name><surname>Ramos</surname><given-names>J.A.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name><name><surname>Fern&#x000e1;ndez-Ruiz</surname><given-names>J.</given-names></name></person-group><article-title>Evaluation of the Neuroprotective Effect of Cannabinoids in a Rat Model of Parkinson&#x02019;s Disease: Importance of Antioxidant and Cannabinoid Receptor-Independent Properties</article-title><source>Brain Res.</source><year>2007</year><volume>1134</volume><fpage>162</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2006.11.063</pub-id><pub-id pub-id-type="pmid">17196181</pub-id></element-citation></ref><ref id="B207-biomedicines-09-00234"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Marzo</surname><given-names>V.</given-names></name></person-group><article-title>Enhanced Levels of Endogenous Cannabinoids in the Globus Pallidus Are Associated with a Reduction in Movement in an Animal Model of Parkinson&#x02019;s Disease</article-title><source>FASEB J.</source><year>2000</year><volume>14</volume><fpage>1432</fpage><lpage>1438</lpage><pub-id pub-id-type="doi">10.1096/fasebj.14.10.1432</pub-id><?supplied-pmid 10877836?><pub-id pub-id-type="pmid">10877836</pub-id></element-citation></ref><ref id="B208-biomedicines-09-00234"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>S.H.</given-names></name><name><surname>Henry</surname><given-names>B.</given-names></name><name><surname>Hill</surname><given-names>M.</given-names></name><name><surname>Crossman</surname><given-names>A.</given-names></name><name><surname>Brotchie</surname><given-names>J.</given-names></name></person-group><article-title>Stimulation of Cannabinoid Receptors Reduces Levodopa-Induced Dyskinesia in the MPTP-Lesioned Nonhuman Primate Model of Parkinson&#x02019;s Disease</article-title><source>Mov. Disord.</source><year>2002</year><volume>17</volume><fpage>1180</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1002/mds.10289</pub-id><pub-id pub-id-type="pmid">12465055</pub-id></element-citation></ref><ref id="B209-biomedicines-09-00234"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgese</surname><given-names>M.G.</given-names></name><name><surname>Cassano</surname><given-names>T.</given-names></name><name><surname>Cuomo</surname><given-names>V.</given-names></name><name><surname>Giuffrida</surname><given-names>A.</given-names></name></person-group><article-title>Anti-Dyskinetic Effects of Cannabinoids in a Rat Model of Parkinson&#x02019;s Disease: Role of CB1 and TRPV1 Receptors</article-title><source>Exp. Neurol.</source><year>2007</year><volume>208</volume><fpage>110</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2007.07.021</pub-id><pub-id pub-id-type="pmid">17900568</pub-id></element-citation></ref><ref id="B210-biomedicines-09-00234"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sa&#x000f1;udo-Pe&#x000f1;a</surname><given-names>M.C.</given-names></name><name><surname>Patrick</surname><given-names>S.L.</given-names></name><name><surname>Khen</surname><given-names>S.</given-names></name><name><surname>Patrick</surname><given-names>R.L.</given-names></name><name><surname>Tsou</surname><given-names>K.</given-names></name><name><surname>Walker</surname><given-names>J.M.</given-names></name></person-group><article-title>Cannabinoid Effects in Basal Ganglia in a Rat Model of Parkinson&#x02019;s Disease</article-title><source>Neurosci. Lett.</source><year>1998</year><volume>248</volume><fpage>171</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(98)00368-1</pub-id><pub-id pub-id-type="pmid">9654336</pub-id></element-citation></ref><ref id="B211-biomedicines-09-00234"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donadelli</surname><given-names>M.</given-names></name><name><surname>Dando</surname><given-names>I.</given-names></name><name><surname>Zaniboni</surname><given-names>T.</given-names></name><name><surname>Costanzo</surname><given-names>C.</given-names></name><name><surname>Dalla Pozza</surname><given-names>E.</given-names></name><name><surname>Scupoli</surname><given-names>M.T.</given-names></name><name><surname>Scarpa</surname><given-names>A.</given-names></name><name><surname>Zappavigna</surname><given-names>S.</given-names></name><name><surname>Marra</surname><given-names>M.</given-names></name><name><surname>Abbruzzese</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Gemcitabine/Cannabinoid Combination Triggers Autophagy in Pancreatic Cancer Cells through a ROS-Mediated Mechanism</article-title><source>Cell Death Dis.</source><year>2011</year><volume>2</volume><fpage>E152</fpage><pub-id pub-id-type="doi">10.1038/cddis.2011.36</pub-id><pub-id pub-id-type="pmid">21525939</pub-id></element-citation></ref><ref id="B212-biomedicines-09-00234"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afrin</surname><given-names>F.</given-names></name><name><surname>Chi</surname><given-names>M.</given-names></name><name><surname>Eamens</surname><given-names>A.L.</given-names></name><name><surname>Duchatel</surname><given-names>R.J.</given-names></name><name><surname>Douglas</surname><given-names>A.M.</given-names></name><name><surname>Schneider</surname><given-names>J.</given-names></name><name><surname>Gedye</surname><given-names>C.</given-names></name><name><surname>Woldu</surname><given-names>A.S.</given-names></name><name><surname>Dun</surname><given-names>M.D.</given-names></name></person-group><article-title>Can Hemp Help? Low-THC Cannabis and Non-THC Cannabinoids for the Treatment of Cancer</article-title><source>Cancers</source><year>2020</year><volume>12</volume><pub-id pub-id-type="doi">10.3390/cancers12041033</pub-id><?supplied-pmid 32340151?><pub-id pub-id-type="pmid">32340151</pub-id></element-citation></ref><ref id="B213-biomedicines-09-00234"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Melck</surname><given-names>D.</given-names></name><name><surname>Palmisano</surname><given-names>A.</given-names></name><name><surname>Bisogno</surname><given-names>T.</given-names></name><name><surname>Laezza</surname><given-names>C.</given-names></name><name><surname>Bifulco</surname><given-names>M.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name></person-group><article-title>The Endogenous Cannabinoid Anandamide Inhibits Human Breast Cancer Cell Proliferation</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1998</year><volume>95</volume><fpage>8375</fpage><lpage>8380</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.14.8375</pub-id><pub-id pub-id-type="pmid">9653194</pub-id></element-citation></ref><ref id="B214-biomedicines-09-00234"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cianchi</surname><given-names>F.</given-names></name><name><surname>Papucci</surname><given-names>L.</given-names></name><name><surname>Schiavone</surname><given-names>N.</given-names></name><name><surname>Lulli</surname><given-names>M.</given-names></name><name><surname>Magnelli</surname><given-names>L.</given-names></name><name><surname>Vinci</surname><given-names>M.C.</given-names></name><name><surname>Messerini</surname><given-names>L.</given-names></name><name><surname>Manera</surname><given-names>C.</given-names></name><name><surname>Ronconi</surname><given-names>E.</given-names></name><name><surname>Romagnani</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Cannabinoid Receptor Activation Induces Apoptosis through Tumor Necrosis Factor &#x003b1;-Mediated Ceramide de Novo Synthesis in Colon Cancer Cells</article-title><source>Clin. Cancer Res.</source><year>2008</year><volume>14</volume><fpage>7691</fpage><lpage>7700</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0799</pub-id><pub-id pub-id-type="pmid">19047095</pub-id></element-citation></ref><ref id="B215-biomedicines-09-00234"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bl&#x000e1;zquez</surname><given-names>C.</given-names></name><name><surname>Casanova</surname><given-names>M.L.</given-names></name><name><surname>Planas</surname><given-names>A.</given-names></name><name><surname>Del Pulgar</surname><given-names>T.G.</given-names></name><name><surname>Villanueva</surname><given-names>C.</given-names></name><name><surname>Fern&#x000e1;ndez-Ace&#x000f1;ero</surname><given-names>M.J.</given-names></name><name><surname>Aragon&#x000e9;s</surname><given-names>J.</given-names></name><name><surname>Huffman</surname><given-names>J.W.</given-names></name><name><surname>Jorcano</surname><given-names>J.L.</given-names></name><name><surname>Guzm&#x000e1;n</surname><given-names>M.</given-names></name></person-group><article-title>Inhibition of Tumor Angiogenesis by Cannabinoids</article-title><source>FASEB J.</source><year>2003</year><volume>17</volume><fpage>529</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1096/fj.02-0795fje</pub-id><?supplied-pmid 12514108?><pub-id pub-id-type="pmid">12514108</pub-id></element-citation></ref><ref id="B216-biomedicines-09-00234"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha</surname><given-names>J.M.</given-names></name><name><surname>Carlini</surname><given-names>E.A.</given-names></name><name><surname>Pereira</surname><given-names>A.E.</given-names></name><name><surname>Ramos</surname><given-names>O.L.</given-names></name><name><surname>Pimentel</surname><given-names>C.</given-names></name><name><surname>Gagliardi</surname><given-names>R.</given-names></name><name><surname>Sanvito</surname><given-names>W.L.</given-names></name><name><surname>Lander</surname><given-names>N.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name></person-group><article-title>Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients</article-title><source>Pharmacology</source><year>1980</year><volume>21</volume><fpage>175</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1159/000137430</pub-id><?supplied-pmid 7413719?><pub-id pub-id-type="pmid">7413719</pub-id></element-citation></ref><ref id="B217-biomedicines-09-00234"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>E.C.</given-names></name><name><surname>Tsien</surname><given-names>R.W.</given-names></name><name><surname>Whalley</surname><given-names>B.J.</given-names></name><name><surname>Devinsky</surname><given-names>O.</given-names></name></person-group><article-title>Cannabinoids and Epilepsy</article-title><source>Neurotherapeutics</source><year>2015</year><volume>12</volume><fpage>747</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1007/s13311-015-0375-5</pub-id><?supplied-pmid 26282273?><pub-id pub-id-type="pmid">26282273</pub-id></element-citation></ref><ref id="B218-biomedicines-09-00234"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stockings</surname><given-names>E.</given-names></name><name><surname>Zagic</surname><given-names>D.</given-names></name><name><surname>Campbell</surname><given-names>G.</given-names></name><name><surname>Weier</surname><given-names>M.</given-names></name><name><surname>Hall</surname><given-names>W.D.</given-names></name><name><surname>Nielsen</surname><given-names>S.</given-names></name><name><surname>Herkes</surname><given-names>G.K.</given-names></name><name><surname>Farrell</surname><given-names>M.</given-names></name><name><surname>Degenhardt</surname><given-names>L.</given-names></name></person-group><article-title>Evidence for Cannabis and Cannabinoids for Epilepsy: A Systematic Review of Controlled and Observational Evidence</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><year>2018</year><volume>89</volume><fpage>741</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2017-317168</pub-id><pub-id pub-id-type="pmid">29511052</pub-id></element-citation></ref><ref id="B219-biomedicines-09-00234"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karanian</surname><given-names>D.A.</given-names></name><name><surname>Karim</surname><given-names>S.L.</given-names></name><name><surname>Wood</surname><given-names>J.A.T.</given-names></name><name><surname>Williams</surname><given-names>J.S.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Makriyannis</surname><given-names>A.</given-names></name><name><surname>Bahr</surname><given-names>B.A.</given-names></name></person-group><article-title>Endocannabinoid Enhancement Protects against Kainic Acid-Induced Seizures and Associated Brain Damage</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2007</year><volume>322</volume><fpage>1059</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1124/jpet.107.120147</pub-id><pub-id pub-id-type="pmid">17545313</pub-id></element-citation></ref><ref id="B220-biomedicines-09-00234"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naidoo</surname><given-names>V.</given-names></name><name><surname>Karanian</surname><given-names>D.A.</given-names></name><name><surname>Vadivel</surname><given-names>S.K.</given-names></name><name><surname>Locklear</surname><given-names>J.R.</given-names></name><name><surname>Wood</surname><given-names>J.A.T.</given-names></name><name><surname>Nasr</surname><given-names>M.</given-names></name><name><surname>Quizon</surname><given-names>P.M.P.</given-names></name><name><surname>Graves</surname><given-names>E.E.</given-names></name><name><surname>Shukla</surname><given-names>V.</given-names></name><name><surname>Makriyannis</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Equipotent Inhibition of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase&#x02014;Dual Targets of the Endocannabinoid System to Protect against Seizure Pathology</article-title><source>Neurotherapeutics</source><year>2012</year><volume>9</volume><fpage>801</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1007/s13311-011-0100-y</pub-id><pub-id pub-id-type="pmid">22270809</pub-id></element-citation></ref><ref id="B221-biomedicines-09-00234"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devinsky</surname><given-names>O.</given-names></name><name><surname>Patel</surname><given-names>A.D.</given-names></name><name><surname>Cross</surname><given-names>J.H.</given-names></name><name><surname>Villanueva</surname><given-names>V.</given-names></name><name><surname>Wirrell</surname><given-names>E.C.</given-names></name><name><surname>Privitera</surname><given-names>M.</given-names></name><name><surname>Greenwood</surname><given-names>S.M.</given-names></name><name><surname>Roberts</surname><given-names>C.</given-names></name><name><surname>Checketts</surname><given-names>D.</given-names></name><name><surname>VanLandingham</surname><given-names>K.E.</given-names></name><etal/></person-group><article-title>Effect of Cannabidiol on Drop Seizures in the Lennox&#x02013;Gastaut Syndrome</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>378</volume><fpage>1888</fpage><lpage>1897</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1714631</pub-id><pub-id pub-id-type="pmid">29768152</pub-id></element-citation></ref><ref id="B222-biomedicines-09-00234"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devinsky</surname><given-names>O.</given-names></name><name><surname>Cross</surname><given-names>J.H.</given-names></name><name><surname>Laux</surname><given-names>L.</given-names></name><name><surname>Marsh</surname><given-names>E.</given-names></name><name><surname>Miller</surname><given-names>I.</given-names></name><name><surname>Nabbout</surname><given-names>R.</given-names></name><name><surname>Scheffer</surname><given-names>I.E.</given-names></name><name><surname>Thiele</surname><given-names>E.A.</given-names></name><name><surname>Wright</surname><given-names>S.</given-names></name></person-group><article-title>Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>376</volume><fpage>2011</fpage><lpage>2020</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1611618</pub-id><?supplied-pmid 28538134?><pub-id pub-id-type="pmid">28538134</pub-id></element-citation></ref><ref id="B223-biomedicines-09-00234"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Press</surname><given-names>C.A.</given-names></name><name><surname>Knupp</surname><given-names>K.G.</given-names></name><name><surname>Chapman</surname><given-names>K.E.</given-names></name></person-group><article-title>Parental Reporting of Response to Oral Cannabis Extracts for Treatment of Refractory Epilepsy</article-title><source>Epilepsy Behav.</source><year>2015</year><volume>45</volume><fpage>49</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2015.02.043</pub-id><?supplied-pmid 25845492?><pub-id pub-id-type="pmid">25845492</pub-id></element-citation></ref><ref id="B224-biomedicines-09-00234"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guggenhuber</surname><given-names>S.</given-names></name><name><surname>Monory</surname><given-names>K.</given-names></name><name><surname>Lutz</surname><given-names>B.</given-names></name><name><surname>Klugmann</surname><given-names>M.</given-names></name></person-group><article-title>AAV Vector-Mediated Overexpression of CB1 Cannabinoid Receptor in Pyramidal Neurons of the Hippocampus Protects against Seizure-Induced Excitoxicity</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>e15707</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0015707</pub-id><?supplied-pmid 21203567?><pub-id pub-id-type="pmid">21203567</pub-id></element-citation></ref><ref id="B225-biomedicines-09-00234"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riva</surname><given-names>N.</given-names></name><name><surname>Mora</surname><given-names>G.</given-names></name><name><surname>Sorar&#x000f9;</surname><given-names>G.</given-names></name><name><surname>Lunetta</surname><given-names>C.</given-names></name><name><surname>Ferraro</surname><given-names>O.E.</given-names></name><name><surname>Falzone</surname><given-names>Y.</given-names></name><name><surname>Leocani</surname><given-names>L.</given-names></name><name><surname>Fazio</surname><given-names>R.</given-names></name><name><surname>Comola</surname><given-names>M.</given-names></name><name><surname>Comi</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Safety and Efficacy of Nabiximols on Spasticity Symptoms in Patients with Motor Neuron Disease (CANALS): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial</article-title><source>Lancet Neurol.</source><year>2019</year><volume>18</volume><fpage>155</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(18)30406-X</pub-id><pub-id pub-id-type="pmid">30554828</pub-id></element-citation></ref><ref id="B226-biomedicines-09-00234"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beal</surname><given-names>J.E.</given-names></name><name><surname>Olson</surname><given-names>R.</given-names></name><name><surname>Laubenstein</surname><given-names>L.</given-names></name><name><surname>Morales</surname><given-names>J.O.</given-names></name><name><surname>Bellman</surname><given-names>P.</given-names></name><name><surname>Yangco</surname><given-names>B.</given-names></name><name><surname>Lefkowitz</surname><given-names>L.</given-names></name><name><surname>Plasse</surname><given-names>T.F.</given-names></name><name><surname>Shepard</surname><given-names>K.V.</given-names></name></person-group><article-title>Dronabinol as a Treatment for Anorexia Associated with Weight Loss in Patients with AIDS</article-title><source>J. Pain Symptom Manag.</source><year>1995</year><volume>10</volume><fpage>89</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/0885-3924(94)00117-4</pub-id></element-citation></ref><ref id="B227-biomedicines-09-00234"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foltin</surname><given-names>R.W.</given-names></name><name><surname>Fischman</surname><given-names>M.W.</given-names></name><name><surname>Byrne</surname><given-names>M.F.</given-names></name></person-group><article-title>Effects of Smoked Marijuana on Food Intake and Body Weight of Humans Living in a Residential Laboratory</article-title><source>Appetite</source><year>1988</year><volume>11</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/S0195-6663(88)80017-5</pub-id></element-citation></ref><ref id="B228-biomedicines-09-00234"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattes</surname><given-names>R.D.</given-names></name><name><surname>Engelman</surname><given-names>K.</given-names></name><name><surname>Shaw</surname><given-names>L.M.</given-names></name><name><surname>Elsohly</surname><given-names>M.A.</given-names></name></person-group><article-title>Cannabinoids and Appetite Stimulation</article-title><source>Pharmacol. Biochem. Behav.</source><year>1994</year><volume>49</volume><fpage>187</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/0091-3057(94)90475-8</pub-id><pub-id pub-id-type="pmid">7816872</pub-id></element-citation></ref><ref id="B229-biomedicines-09-00234"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>C.M.</given-names></name><name><surname>Rogers</surname><given-names>P.J.</given-names></name><name><surname>Kirkham</surname><given-names>T.C.</given-names></name></person-group><article-title>Hyperphagia in Pre-Fed Rats Following Oral &#x00394;9-THC</article-title><source>Physiol. Behav.</source><year>1998</year><volume>65</volume><fpage>343</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/S0031-9384(98)00170-X</pub-id><pub-id pub-id-type="pmid">9855485</pub-id></element-citation></ref><ref id="B230-biomedicines-09-00234"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feinberg</surname><given-names>I.</given-names></name><name><surname>Jones</surname><given-names>R.</given-names></name><name><surname>Walker</surname><given-names>J.M.</given-names></name><name><surname>Cavness</surname><given-names>C.</given-names></name><name><surname>March</surname><given-names>J.</given-names></name></person-group><article-title>Effects of High Dosage Delta-9-Tetrahydrocannabinol on Sleep Patterns in Man</article-title><source>Clin. Pharmacol. Ther.</source><year>1975</year><volume>14</volume><fpage>458</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1002/cpt1975174458</pub-id></element-citation></ref><ref id="B231-biomedicines-09-00234"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freemon</surname><given-names>F.R.</given-names></name></person-group><article-title>The Effect of Chronically Administered Delta-9-Tetrahydrocannabinol upon the Polygraphically Monitored Sleep of Normal Volunteers</article-title><source>Drug Alcohol Depend.</source><year>1982</year><volume>10</volume><fpage>345</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1016/0376-8716(82)90036-9</pub-id><pub-id pub-id-type="pmid">6299682</pub-id></element-citation></ref><ref id="B232-biomedicines-09-00234"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pivik</surname><given-names>R.T.</given-names></name><name><surname>Zarcone</surname><given-names>V.</given-names></name><name><surname>Dement</surname><given-names>W.C.</given-names></name><name><surname>Hollister</surname><given-names>L.E.</given-names></name></person-group><article-title>Delta-9-Tetrahydrocannabinol and Synhexl: Effects on Human Sleep Patterns</article-title><source>Clin. Pharmacol. Ther.</source><year>1972</year><volume>13</volume><fpage>426</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1002/cpt1972133426</pub-id><pub-id pub-id-type="pmid">4337346</pub-id></element-citation></ref><ref id="B233-biomedicines-09-00234"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>N.</given-names></name><name><surname>Pacher</surname><given-names>P.</given-names></name><name><surname>Tegeder</surname><given-names>I.</given-names></name><name><surname>Amaya</surname><given-names>F.</given-names></name><name><surname>Constantin</surname><given-names>C.E.</given-names></name><name><surname>Brenner</surname><given-names>G.J.</given-names></name><name><surname>Rubino</surname><given-names>T.</given-names></name><name><surname>Michalski</surname><given-names>C.W.</given-names></name><name><surname>Marsicano</surname><given-names>G.</given-names></name><name><surname>Monory</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Cannabinoids Mediate Analgesia Largely via Peripheral Type 1 Cannabinoid Receptors in Nociceptors</article-title><source>Nat. Neurosci.</source><year>2007</year><volume>10</volume><fpage>870</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1038/nn1916</pub-id><?supplied-pmid 17558404?><pub-id pub-id-type="pmid">17558404</pub-id></element-citation></ref><ref id="B234-biomedicines-09-00234"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>I.D.</given-names></name><name><surname>Manning</surname><given-names>B.H.</given-names></name><name><surname>Martin</surname><given-names>W.J.</given-names></name><name><surname>Fields</surname><given-names>H.L.</given-names></name></person-group><article-title>An Analgesia Circuit Activated by Cannabinoids</article-title><source>Nature</source><year>1998</year><volume>395</volume><fpage>381</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1038/26481</pub-id><?supplied-pmid 9759727?><pub-id pub-id-type="pmid">9759727</pub-id></element-citation></ref><ref id="B235-biomedicines-09-00234"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottani</surname><given-names>A.</given-names></name><name><surname>Leone</surname><given-names>S.</given-names></name><name><surname>Sandrini</surname><given-names>M.</given-names></name><name><surname>Ferrari</surname><given-names>A.</given-names></name><name><surname>Bertolini</surname><given-names>A.</given-names></name></person-group><article-title>The Analgesic Activity of Paracetamol Is Prevented by the Blockade of Cannabinoid CB1 Receptors</article-title><source>Eur. J. Pharmacol.</source><year>2006</year><volume>531</volume><fpage>280</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2005.12.015</pub-id><pub-id pub-id-type="pmid">16438952</pub-id></element-citation></ref><ref id="B236-biomedicines-09-00234"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>J.M.</given-names></name><name><surname>Hohmann</surname><given-names>A.G.</given-names></name><name><surname>Martin</surname><given-names>W.J.</given-names></name><name><surname>Strangman</surname><given-names>N.M.</given-names></name><name><surname>Huang</surname><given-names>S.M.</given-names></name><name><surname>Tsou</surname><given-names>K.</given-names></name></person-group><article-title>The Neurobiology of Cannabinoid Analgesia</article-title><source>Life Sci.</source><year>1999</year><volume>65</volume><fpage>665</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1016/S0024-3205(99)00289-1</pub-id><pub-id pub-id-type="pmid">10462067</pub-id></element-citation></ref><ref id="B237-biomedicines-09-00234"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leweke</surname><given-names>F.M.</given-names></name><name><surname>Piomelli</surname><given-names>D.</given-names></name><name><surname>Pahlisch</surname><given-names>F.</given-names></name><name><surname>Muhl</surname><given-names>D.</given-names></name><name><surname>Gerth</surname><given-names>C.W.</given-names></name><name><surname>Hoyer</surname><given-names>C.</given-names></name><name><surname>Klosterk&#x000f6;tter</surname><given-names>J.</given-names></name><name><surname>Hellmich</surname><given-names>M.</given-names></name><name><surname>Koethe</surname><given-names>D.</given-names></name></person-group><article-title>Cannabidiol Enhances Anandamide Signaling and Alleviates Psychotic Symptoms of Schizophrenia</article-title><source>Transl. Psychiatry</source><year>2012</year><volume>2</volume><fpage>e94</fpage><pub-id pub-id-type="doi">10.1038/tp.2012.15</pub-id><pub-id pub-id-type="pmid">22832859</pub-id></element-citation></ref><ref id="B238-biomedicines-09-00234"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutz</surname><given-names>B.</given-names></name><name><surname>Marsicano</surname><given-names>G.</given-names></name><name><surname>Maldonado</surname><given-names>R.</given-names></name><name><surname>Hillard</surname><given-names>C.J.</given-names></name></person-group><article-title>The Endocannabinoid System in Guarding against Fear, Anxiety and Stress</article-title><source>Nat. Rev. Neurosci.</source><year>2015</year><volume>16</volume><fpage>705</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1038/nrn4036</pub-id><?supplied-pmid 26585799?><pub-id pub-id-type="pmid">26585799</pub-id></element-citation></ref><ref id="B239-biomedicines-09-00234"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>M.</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>E.</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>R.M.</given-names></name><name><surname>Del Arco</surname><given-names>I.</given-names></name><name><surname>Villan&#x000fa;a</surname><given-names>M.A.</given-names></name><name><surname>Carrera</surname><given-names>M.R.A.</given-names></name><name><surname>Rodr&#x000ed;guez De Fonseca</surname><given-names>F.</given-names></name></person-group><article-title>Acute Administration of the CB1 Cannabinoid Receptor Antagonist SR 141716A Induces Anxiety-like Responses in the Rat</article-title><source>Neuroreport</source><year>1997</year><volume>8</volume><fpage>491</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1097/00001756-199701200-00023</pub-id><pub-id pub-id-type="pmid">9080435</pub-id></element-citation></ref><ref id="B240-biomedicines-09-00234"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreira</surname><given-names>F.A.</given-names></name><name><surname>Aguiar</surname><given-names>D.C.</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>F.S.</given-names></name></person-group><article-title>Anxiolytic-like Effect of Cannabinoids Injected into the Rat Dorsolateral Periaqueductal Gray</article-title><source>Neuropharmacology</source><year>2007</year><volume>52</volume><fpage>958</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2006.10.013</pub-id><pub-id pub-id-type="pmid">17156799</pub-id></element-citation></ref><ref id="B241-biomedicines-09-00234"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rey</surname><given-names>A.A.</given-names></name><name><surname>Purrio</surname><given-names>M.</given-names></name><name><surname>Viveros</surname><given-names>M.P.</given-names></name><name><surname>Lutz</surname><given-names>B.</given-names></name></person-group><article-title>Biphasic Effects of Cannabinoids in Anxiety Responses: CB1 and GABA B Receptors in the Balance of Gabaergic and Glutamatergic Neurotransmission</article-title><source>Neuropsychopharmacology</source><year>2012</year><volume>37</volume><fpage>2624</fpage><lpage>2634</lpage><pub-id pub-id-type="doi">10.1038/npp.2012.123</pub-id><pub-id pub-id-type="pmid">22850737</pub-id></element-citation></ref><ref id="B242-biomedicines-09-00234"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ney</surname><given-names>L.J.</given-names></name><name><surname>Matthews</surname><given-names>A.</given-names></name><name><surname>Bruno</surname><given-names>R.</given-names></name><name><surname>Felmingham</surname><given-names>K.L.</given-names></name></person-group><article-title>Modulation of the Endocannabinoid System by Sex Hormones: Implications for Posttraumatic Stress Disorder</article-title><source>Neurosci. Biobehav. Rev.</source><year>2018</year><volume>94</volume><fpage>302</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2018.07.006</pub-id><pub-id pub-id-type="pmid">30017748</pub-id></element-citation></ref><ref id="B243-biomedicines-09-00234"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>G.T.</given-names></name><name><surname>Flanagan</surname><given-names>A.M.</given-names></name><name><surname>Earleywine</surname><given-names>M.</given-names></name><name><surname>Abrams</surname><given-names>D.I.</given-names></name><name><surname>Aggarwal</surname><given-names>S.K.</given-names></name><name><surname>Grinspoon</surname><given-names>L.</given-names></name></person-group><article-title>Cannabis in Palliative Medicine: Improving Care and Reducing Opioid-Related Morbidity</article-title><source>Am. J. Hosp. Palliat. Med.</source><year>2011</year><volume>28</volume><fpage>297</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1177/1049909111402318</pub-id></element-citation></ref><ref id="B244-biomedicines-09-00234"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bar-Sela</surname><given-names>G.</given-names></name><name><surname>Vorobeichik</surname><given-names>M.</given-names></name><name><surname>Drawsheh</surname><given-names>S.</given-names></name><name><surname>Omer</surname><given-names>A.</given-names></name><name><surname>Goldberg</surname><given-names>V.</given-names></name><name><surname>Muller</surname><given-names>E.</given-names></name></person-group><article-title>The Medical Necessity for Medicinal Cannabis: Prospective, Observational Study Evaluating the Treatment in Cancer Patients on Supportive or Palliative Care</article-title><source>Evid.-Based Complement. Altern. Med.</source><year>2013</year><volume>2013</volume><fpage>510392</fpage><pub-id pub-id-type="doi">10.1155/2013/510392</pub-id><?supplied-pmid 23956774?><pub-id pub-id-type="pmid">23956774</pub-id></element-citation></ref><ref id="B245-biomedicines-09-00234"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motwani</surname><given-names>M.P.</given-names></name><name><surname>Bennett</surname><given-names>F.</given-names></name><name><surname>Norris</surname><given-names>P.C.</given-names></name><name><surname>Maini</surname><given-names>A.A.</given-names></name><name><surname>George</surname><given-names>M.J.</given-names></name><name><surname>Newson</surname><given-names>J.</given-names></name><name><surname>Henderson</surname><given-names>A.</given-names></name><name><surname>Hobbs</surname><given-names>A.J.</given-names></name><name><surname>Tepper</surname><given-names>M.</given-names></name><name><surname>White</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Potent Anti-Inflammatory and Pro-Resolving Effects of Anabasum in a Human Model of Self-Resolving Acute Inflammation</article-title><source>Clin. Pharmacol. Ther.</source><year>2018</year><volume>104</volume><fpage>675</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1002/cpt.980</pub-id><pub-id pub-id-type="pmid">29238967</pub-id></element-citation></ref><ref id="B246-biomedicines-09-00234"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>P.</given-names></name></person-group><article-title>Rationale for Cannabis-Based Interventions in the Opioid Overdose Crisis</article-title><source>Harm Reduct. J.</source><year>2017</year><volume>14</volume><fpage>58</fpage><pub-id pub-id-type="doi">10.1186/s12954-017-0183-9</pub-id><pub-id pub-id-type="pmid">28821296</pub-id></element-citation></ref><ref id="B247-biomedicines-09-00234"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boehnke</surname><given-names>K.F.</given-names></name><name><surname>Litinas</surname><given-names>E.</given-names></name><name><surname>Clauw</surname><given-names>D.J.</given-names></name></person-group><article-title>Medical Cannabis Use Is Associated with Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients with Chronic Pain</article-title><source>J. Pain</source><year>2016</year><volume>17</volume><fpage>739</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1016/j.jpain.2016.03.002</pub-id><pub-id pub-id-type="pmid">27001005</pub-id></element-citation></ref><ref id="B248-biomedicines-09-00234"><label>248.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Groce</surname><given-names>E.</given-names></name></person-group><source>The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research</source><publisher-name>National Academies Press</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2017</year><pub-id pub-id-type="doi">10.17226/24625</pub-id></element-citation></ref><ref id="B249-biomedicines-09-00234"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dos Santos</surname><given-names>R.G.</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>F.S.</given-names></name><name><surname>Crippa</surname><given-names>J.A.S.</given-names></name><name><surname>Hallak</surname><given-names>J.E.C.</given-names></name><name><surname>Rossi</surname><given-names>G.N.</given-names></name><name><surname>Rocha</surname><given-names>J.M.</given-names></name><name><surname>Zuardi</surname><given-names>A.W.</given-names></name></person-group><article-title>Serious Adverse Effects of Cannabidiol (CBD): A Review of Randomized Controlled Trials</article-title><source>Expert Opin. Drug Metab. Toxicol.</source><year>2020</year><volume>16</volume><fpage>517</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1080/17425255.2020.1754793</pub-id><?supplied-pmid 32271618?><pub-id pub-id-type="pmid">32271618</pub-id></element-citation></ref><ref id="B250-biomedicines-09-00234"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>C.M.</given-names></name></person-group><article-title>A Review of Human Studies Assessing Cannabidiol&#x02019;s (CBD) Therapeutic Actions and Potential</article-title><source>J. Clin. Pharmacol.</source><year>2019</year><volume>59</volume><fpage>923</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1002/jcph.1387</pub-id><?supplied-pmid 30730563?><pub-id pub-id-type="pmid">30730563</pub-id></element-citation></ref><ref id="B251-biomedicines-09-00234"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pauli</surname><given-names>C.S.</given-names></name><name><surname>Conroy</surname><given-names>M.</given-names></name><name><surname>Vanden Heuvel</surname><given-names>B.D.</given-names></name><name><surname>Park</surname><given-names>S.H.</given-names></name></person-group><article-title>Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects</article-title><source>Front. Pharmacol.</source><year>2020</year><volume>11</volume><fpage>63</fpage><pub-id pub-id-type="doi">10.3389/fphar.2020.00063</pub-id><pub-id pub-id-type="pmid">32161538</pub-id></element-citation></ref><ref id="B252-biomedicines-09-00234"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhathasan</surname><given-names>N.</given-names></name><name><surname>Dufort</surname><given-names>A.</given-names></name><name><surname>MacKillop</surname><given-names>J.</given-names></name><name><surname>Gottschalk</surname><given-names>R.</given-names></name><name><surname>Minuzzi</surname><given-names>L.</given-names></name><name><surname>Frey</surname><given-names>B.N.</given-names></name></person-group><article-title>The Use of Cannabinoids for Sleep: A Critical Review on Clinical Trials</article-title><source>Exp. Clin. Psychopharmacol.</source><year>2019</year><volume>27</volume><fpage>383</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1037/pha0000285</pub-id><?supplied-pmid 31120284?><pub-id pub-id-type="pmid">31120284</pub-id></element-citation></ref><ref id="B253-biomedicines-09-00234"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>N.</given-names></name><name><surname>Stockings</surname><given-names>E.</given-names></name><name><surname>Campbell</surname><given-names>G.</given-names></name><name><surname>Tran</surname><given-names>L.T.</given-names></name><name><surname>Zagic</surname><given-names>D.</given-names></name><name><surname>Hall</surname><given-names>W.D.</given-names></name><name><surname>Farrell</surname><given-names>M.</given-names></name><name><surname>Degenhardt</surname><given-names>L.</given-names></name></person-group><article-title>Cannabinoids for the Treatment of Mental Disorders and Symptoms of Mental Disorders: A Systematic Review and Meta-Analysis</article-title><source>Lancet Psychiatry</source><year>2019</year><volume>6</volume><fpage>995</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(19)30401-8</pub-id><pub-id pub-id-type="pmid">31672337</pub-id></element-citation></ref><ref id="B254-biomedicines-09-00234"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>M.D.</given-names></name><name><surname>Tian</surname><given-names>L.</given-names></name><name><surname>Wenger</surname><given-names>J.P.</given-names></name><name><surname>Omburo</surname><given-names>S.N.</given-names></name><name><surname>Soto-Fuentes</surname><given-names>W.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Gang</surname><given-names>D.R.</given-names></name><name><surname>Weiblen</surname><given-names>G.D.</given-names></name><name><surname>Dixon</surname><given-names>R.A.</given-names></name></person-group><article-title>Identification of Candidate Genes Affecting &#x00394;9-Tetrahydrocannabinol Biosynthesis in <italic>Cannabis sativa</italic></article-title><source>J. Exp. Bot.</source><year>2009</year><volume>60</volume><fpage>3715</fpage><lpage>3726</lpage><pub-id pub-id-type="doi">10.1093/jxb/erp210</pub-id><pub-id pub-id-type="pmid">19581347</pub-id></element-citation></ref><ref id="B255-biomedicines-09-00234"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stout</surname><given-names>J.M.</given-names></name><name><surname>Boubakir</surname><given-names>Z.</given-names></name><name><surname>Ambrose</surname><given-names>S.J.</given-names></name><name><surname>Purves</surname><given-names>R.W.</given-names></name><name><surname>Page</surname><given-names>J.E.</given-names></name></person-group><article-title>The Hexanoyl-CoA Precursor for Cannabinoid Biosynthesis Is Formed by an Acyl-Activating Enzyme in <italic>Cannabis sativa</italic> Trichomes</article-title><source>Plant J.</source><year>2012</year><volume>71</volume><fpage>353</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1111/j.1365-313X.2012.04949.x</pub-id><pub-id pub-id-type="pmid">22353623</pub-id></element-citation></ref><ref id="B256-biomedicines-09-00234"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E.-S.</given-names></name><name><surname>Mahlberg</surname><given-names>P.G.</given-names></name></person-group><article-title>Secretory Cavity Development in Glandular Trichomes of <italic>Cannabis sativa</italic> L. (Cannabaceae)</article-title><source>Am. J. Bot.</source><year>1991</year><volume>78</volume><fpage>220</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1002/j.1537-2197.1991.tb15749.x</pub-id></element-citation></ref><ref id="B257-biomedicines-09-00234"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E.S.</given-names></name><name><surname>Mahlberg</surname><given-names>P.G.</given-names></name></person-group><article-title>Secretory Vesicle Formation in the Secretory Cavity of Glandular Trichomes of <italic>Cannabis sativa</italic> L. (Cannabaceae)</article-title><source>Mol. Cells</source><year>2003</year><volume>15</volume><fpage>387</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1142/S0578563403000816</pub-id><pub-id pub-id-type="pmid">12872998</pub-id></element-citation></ref><ref id="B258-biomedicines-09-00234"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahlberg</surname><given-names>P.G.</given-names></name><name><surname>Eun</surname><given-names>S.K.</given-names></name></person-group><article-title>Accumulation of Cannabinoids in Glandular Trichomes of Cannabis (Cannabaceae)</article-title><source>J. Ind. Hemp</source><year>2004</year><volume>9</volume><fpage>15</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1300/J237v09n01_04</pub-id></element-citation></ref><ref id="B259-biomedicines-09-00234"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahlberg</surname><given-names>P.G.</given-names></name><name><surname>Kim</surname><given-names>E.-S.</given-names></name></person-group><article-title>Cuticle Development on Glandular Trichomes of <italic>Cannabis sativa</italic> (Cannabaceae)</article-title><source>Am. J. Bot.</source><year>1991</year><volume>78</volume><fpage>1113</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.1002/j.1537-2197.1991.tb14518.x</pub-id></element-citation></ref><ref id="B260-biomedicines-09-00234"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arigoni</surname><given-names>D.</given-names></name><name><surname>Sagner</surname><given-names>S.</given-names></name><name><surname>Latzel</surname><given-names>C.</given-names></name><name><surname>Eisenreich</surname><given-names>W.</given-names></name><name><surname>Bacher</surname><given-names>A.</given-names></name><name><surname>Zenk</surname><given-names>M.H.</given-names></name></person-group><article-title>Terpenoid Biosynthesis from 1-Deoxy-D-Xylulose in Higher Plants by Intramolecular Skeletal Rearrangement</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1997</year><volume>94</volume><fpage>10600</fpage><lpage>10605</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.20.10600</pub-id><?supplied-pmid 9380681?><pub-id pub-id-type="pmid">9380681</pub-id></element-citation></ref><ref id="B261-biomedicines-09-00234"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fellermeier</surname><given-names>M.</given-names></name><name><surname>Eisenreich</surname><given-names>W.</given-names></name><name><surname>Bacher</surname><given-names>A.</given-names></name><name><surname>Zenk</surname><given-names>M.H.</given-names></name></person-group><article-title>Biosynthesis of Cannabinoids: Incorporation Experiments with 13C-Labeled Glucoses</article-title><source>Eur. J. Biochem.</source><year>2001</year><volume>268</volume><fpage>1596</fpage><lpage>1604</lpage><pub-id pub-id-type="doi">10.1046/j.1432-1327.2001.02030.x</pub-id><pub-id pub-id-type="pmid">11248677</pub-id></element-citation></ref><ref id="B262-biomedicines-09-00234"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwender</surname><given-names>J.</given-names></name><name><surname>Zeidler</surname><given-names>J.</given-names></name><name><surname>Gr&#x000f6;ner</surname><given-names>R.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>C.</given-names></name><name><surname>Focke</surname><given-names>M.</given-names></name><name><surname>Braun</surname><given-names>S.</given-names></name><name><surname>Lichtenthaler</surname><given-names>F.W.</given-names></name><name><surname>Lichtenthaler</surname><given-names>H.K.</given-names></name></person-group><article-title>Incorporation of 1-Deoxy-D-Xylulose into Isoprene and Phytol by Higher Plants and Algae</article-title><source>FEBS Lett.</source><year>1997</year><pub-id pub-id-type="doi">10.1016/S0014-5793(97)01002-8</pub-id></element-citation></ref><ref id="B263-biomedicines-09-00234"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botella-Pav&#x000ed;a</surname><given-names>P.</given-names></name><name><surname>Besumbes</surname><given-names>&#x000d3;.</given-names></name><name><surname>Phillips</surname><given-names>M.A.</given-names></name><name><surname>Carretero-Paulet</surname><given-names>L.</given-names></name><name><surname>Boronat</surname><given-names>A.</given-names></name><name><surname>Rodr&#x000ed;guez-Concepci&#x000f3;n</surname><given-names>M.</given-names></name></person-group><article-title>Regulation of Carotenoid Biosynthesis in Plants: Evidence for a Key Role of Hydroxymethylbutenyl Diphosphate Reductase in Controlling the Supply of Plastidial Isoprenoid Precursors</article-title><source>Plant J.</source><year>2004</year><volume>40</volume><fpage>188</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1111/j.1365-313X.2004.02198.x</pub-id><pub-id pub-id-type="pmid">15447646</pub-id></element-citation></ref><ref id="B264-biomedicines-09-00234"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>M.A.</given-names></name><name><surname>Le&#x000f3;n</surname><given-names>P.</given-names></name><name><surname>Boronat</surname><given-names>A.</given-names></name><name><surname>Rodr&#x000ed;guez-Concepci&#x000f3;n</surname><given-names>M.</given-names></name></person-group><article-title>The Plastidial MEP Pathway: Unified Nomenclature and Resources</article-title><source>Trends Plant Sci.</source><year>2008</year><volume>13</volume><fpage>619</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/j.tplants.2008.09.003</pub-id><?supplied-pmid 18948055?><pub-id pub-id-type="pmid">18948055</pub-id></element-citation></ref><ref id="B265-biomedicines-09-00234"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>M.H.</given-names></name><name><surname>Chang</surname><given-names>C.Y.</given-names></name><name><surname>Hsu</surname><given-names>S.J.</given-names></name><name><surname>Chen</surname><given-names>J.J.</given-names></name></person-group><article-title>Chloroplast Localization of Methylerythritol 4-Phosphate Pathway Enzymes and Regulation of Mitochondrial Genes in IspD and IspE Albino Mutants in Arabidopsis</article-title><source>Plant Mol. Biol.</source><year>2008</year><volume>66</volume><fpage>663</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1007/s11103-008-9297-5</pub-id><pub-id pub-id-type="pmid">18236010</pub-id></element-citation></ref><ref id="B266-biomedicines-09-00234"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bick</surname><given-names>J.A.</given-names></name><name><surname>Lange</surname><given-names>B.M.</given-names></name></person-group><article-title>Metabolic Cross Talk between Cytosolic and Plastidial Pathways of Isoprenoid Biosynthesis: Unidirectional Transport of Intermediates across the Chloroplast Envelope Membrane</article-title><source>Arch. Biochem. Biophys.</source><year>2003</year><volume>415</volume><fpage>146</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/S0003-9861(03)00233-9</pub-id><pub-id pub-id-type="pmid">12831836</pub-id></element-citation></ref><ref id="B267-biomedicines-09-00234"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buhaescu</surname><given-names>I.</given-names></name><name><surname>Izzedine</surname><given-names>H.</given-names></name></person-group><article-title>Mevalonate Pathway: A Review of Clinical and Therapeutical Implications</article-title><source>Clin. Biochem.</source><year>2007</year><volume>40</volume><fpage>575</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2007.03.016</pub-id><pub-id pub-id-type="pmid">17467679</pub-id></element-citation></ref><ref id="B268-biomedicines-09-00234"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>J.L.</given-names></name><name><surname>Brown</surname><given-names>M.S.</given-names></name></person-group><article-title>Regulation of the Mevalonate Pathway</article-title><source>Nature</source><year>1990</year><volume>343</volume><fpage>425</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/343425a0</pub-id><pub-id pub-id-type="pmid">1967820</pub-id></element-citation></ref><ref id="B269-biomedicines-09-00234"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miziorko</surname><given-names>H.M.</given-names></name></person-group><article-title>Enzymes of the Mevalonate Pathway of Isoprenoid Biosynthesis</article-title><source>Arch. Biochem. Biophys.</source><year>2011</year><volume>505</volume><fpage>131</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2010.09.028</pub-id><?supplied-pmid 20932952?><pub-id pub-id-type="pmid">20932952</pub-id></element-citation></ref><ref id="B270-biomedicines-09-00234"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guirimand</surname><given-names>G.</given-names></name><name><surname>Simkin</surname><given-names>A.J.</given-names></name><name><surname>Papon</surname><given-names>N.</given-names></name><name><surname>Besseau</surname><given-names>S.</given-names></name><name><surname>Burlat</surname><given-names>V.</given-names></name><name><surname>St-Pierre</surname><given-names>B.</given-names></name><name><surname>Giglioli-Guivarc&#x02019;h</surname><given-names>N.</given-names></name><name><surname>Clastre</surname><given-names>M.</given-names></name><name><surname>Courdavault</surname><given-names>V.</given-names></name></person-group><article-title>Cycloheximide as a Tool to Investigate Protein Import in Peroxisomes: A Case Study of the Subcellular Localization of Isoprenoid Biosynthetic Enzymes</article-title><source>J. Plant Physiol.</source><year>2012</year><volume>169</volume><fpage>825</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1016/j.jplph.2012.01.020</pub-id><pub-id pub-id-type="pmid">22459325</pub-id></element-citation></ref><ref id="B271-biomedicines-09-00234"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simkin</surname><given-names>A.J.</given-names></name><name><surname>Guirimand</surname><given-names>G.</given-names></name><name><surname>Papon</surname><given-names>N.</given-names></name><name><surname>Courdavault</surname><given-names>V.</given-names></name><name><surname>Thabet</surname><given-names>I.</given-names></name><name><surname>Ginis</surname><given-names>O.</given-names></name><name><surname>Bouzid</surname><given-names>S.</given-names></name><name><surname>Giglioli-Guivarc&#x02019;h</surname><given-names>N.</given-names></name><name><surname>Clastre</surname><given-names>M.</given-names></name></person-group><article-title>Peroxisomal Localisation of the Final Steps of the Mevalonic Acid Pathway in Planta</article-title><source>Planta</source><year>2011</year><volume>234</volume><fpage>903</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.1007/s00425-011-1444-6</pub-id><?supplied-pmid 21655959?><pub-id pub-id-type="pmid">21655959</pub-id></element-citation></ref><ref id="B272-biomedicines-09-00234"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vranov&#x000e1;</surname><given-names>E.</given-names></name><name><surname>Coman</surname><given-names>D.</given-names></name><name><surname>Gruissem</surname><given-names>W.</given-names></name></person-group><article-title>Network Analysis of the MVA and MEP Pathways for Isoprenoid Synthesis</article-title><source>Annu. Rev. Plant Biol.</source><year>2013</year><volume>64</volume><fpage>665</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1146/annurev-arplant-050312-120116</pub-id><pub-id pub-id-type="pmid">23451776</pub-id></element-citation></ref><ref id="B273-biomedicines-09-00234"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thabet</surname><given-names>I.</given-names></name><name><surname>Guirimand</surname><given-names>G.</given-names></name><name><surname>Courdavault</surname><given-names>V.</given-names></name><name><surname>Papon</surname><given-names>N.</given-names></name><name><surname>Godet</surname><given-names>S.</given-names></name><name><surname>Dutilleul</surname><given-names>C.</given-names></name><name><surname>Bouzid</surname><given-names>S.</given-names></name><name><surname>Giglioli-Guivarc&#x02019;h</surname><given-names>N.</given-names></name><name><surname>Clastre</surname><given-names>M.</given-names></name><name><surname>Simkin</surname><given-names>A.J.</given-names></name></person-group><article-title>The Subcellular Localization of Periwinkle Farnesyl Diphosphate Synthase Provides Insight into the Role of Peroxisome in Isoprenoid Biosynthesis</article-title><source>J. Plant Physiol.</source><year>2011</year><volume>168</volume><fpage>2110</fpage><lpage>2116</lpage><pub-id pub-id-type="doi">10.1016/j.jplph.2011.06.017</pub-id><?supplied-pmid 21872968?><pub-id pub-id-type="pmid">21872968</pub-id></element-citation></ref><ref id="B274-biomedicines-09-00234"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>M.</given-names></name><name><surname>Hahn</surname><given-names>F.M.</given-names></name><name><surname>Poulter</surname><given-names>C.D.</given-names></name><name><surname>Leustek</surname><given-names>T.</given-names></name></person-group><article-title>Analysis of the Isopentenyl Disphosphate Isomerase Gene from <italic>Arabidopsis thaliana</italic></article-title><source>Plant Mol. Biol.</source><year>1998</year><volume>36</volume><fpage>323</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1023/A:1005935516274</pub-id><?supplied-pmid 9484444?><pub-id pub-id-type="pmid">9484444</pub-id></element-citation></ref><ref id="B275-biomedicines-09-00234"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>K.</given-names></name><name><surname>Kasahara</surname><given-names>H.</given-names></name><name><surname>Yamaguchi</surname><given-names>S.</given-names></name><name><surname>Kawaide</surname><given-names>H.</given-names></name><name><surname>Kamiya</surname><given-names>Y.</given-names></name><name><surname>Nojiri</surname><given-names>H.</given-names></name><name><surname>Yamane</surname><given-names>H.</given-names></name></person-group><article-title>Genetic Evidence for the Role of Isopentenyl Diphosphate Isomerases in the Mevalonate Pathway and Plant Development in Arabidopsis</article-title><source>Plant Cell Physiol.</source><year>2008</year><volume>49</volume><fpage>604</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1093/pcp/pcn032</pub-id><pub-id pub-id-type="pmid">18303110</pub-id></element-citation></ref><ref id="B276-biomedicines-09-00234"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sapir-Mir</surname><given-names>M.</given-names></name><name><surname>Mett</surname><given-names>A.</given-names></name><name><surname>Belausov</surname><given-names>E.</given-names></name><name><surname>Tal-Meshulam</surname><given-names>S.</given-names></name><name><surname>Frydman</surname><given-names>A.</given-names></name><name><surname>Gidoni</surname><given-names>D.</given-names></name><name><surname>Eya</surname><given-names>Y.</given-names></name></person-group><article-title>Peroxisomal Localization of Arabidopsis Isopentenyl Diphosphate Isomerases Suggests That Part of the Plant Isoprenoid Mevalonic Acid Pathway Is Compartmentalized to Peroxisomes</article-title><source>Plant Physiol.</source><year>2008</year><volume>148</volume><fpage>1219</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1104/pp.108.127951</pub-id><pub-id pub-id-type="pmid">18988695</pub-id></element-citation></ref><ref id="B277-biomedicines-09-00234"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>C.C.</given-names></name><name><surname>Wildung</surname><given-names>M.R.</given-names></name><name><surname>Croteau</surname><given-names>R.</given-names></name></person-group><article-title>Geranyl Diphosphate Synthase: Cloning, Expression, and Characterization of This Prenyltransferase as a Heterodimer</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1999</year><volume>96</volume><fpage>13062</fpage><lpage>13067</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.23.13062</pub-id><pub-id pub-id-type="pmid">10557273</pub-id></element-citation></ref><ref id="B278-biomedicines-09-00234"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouvier</surname><given-names>F.</given-names></name><name><surname>Suire</surname><given-names>C.</given-names></name><name><surname>D&#x02019;Harlingue</surname><given-names>A.</given-names></name><name><surname>Backhaus</surname><given-names>R.A.</given-names></name><name><surname>Camara</surname><given-names>B.</given-names></name></person-group><article-title>Molecular Cloning of Geranyl Diphosphate Synthase and Compartmentation of Monoterpene Synthesis in Plant Cells</article-title><source>Plant J.</source><year>2000</year><volume>24</volume><fpage>241</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1046/j.1365-313x.2000.00875.x</pub-id><?supplied-pmid 11069698?><pub-id pub-id-type="pmid">11069698</pub-id></element-citation></ref><ref id="B279-biomedicines-09-00234"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogura</surname><given-names>K.</given-names></name><name><surname>Koyama</surname><given-names>T.</given-names></name></person-group><article-title>Enzymatic Aspects of Isoprenoid Chain Elongation</article-title><source>Chem. Rev.</source><year>1998</year><volume>98</volume><fpage>1263</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1021/cr9600464</pub-id><?supplied-pmid 11848932?><pub-id pub-id-type="pmid">11848932</pub-id></element-citation></ref><ref id="B280-biomedicines-09-00234"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohnuma</surname><given-names>S.I.</given-names></name><name><surname>Hirooka</surname><given-names>K.</given-names></name><name><surname>Tsuruoka</surname><given-names>N.</given-names></name><name><surname>Yano</surname><given-names>M.</given-names></name><name><surname>Ohto</surname><given-names>C.</given-names></name><name><surname>Nakane</surname><given-names>H.</given-names></name><name><surname>Nishino</surname><given-names>T.</given-names></name></person-group><article-title>A Pathway Where Polyprenyl Diphosphate Elongates in Prenyltransferase: Insight into a Common Mechanism of Chain Length Determination of Prenyltransferases</article-title><source>J. Biol. Chem.</source><year>1998</year><volume>273</volume><fpage>26705</fpage><lpage>26713</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.41.26705</pub-id><?supplied-pmid 9756913?><pub-id pub-id-type="pmid">9756913</pub-id></element-citation></ref><ref id="B281-biomedicines-09-00234"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Ohnuma</surname><given-names>S.I.</given-names></name></person-group><article-title>Chain-Length Determination Mechanism of Isoprenyl Diphosphate Synthases and Implications for Molecular Evolution</article-title><source>Trends Biochem. Sci.</source><year>1999</year><volume>24</volume><fpage>445</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/S0968-0004(99)01464-4</pub-id><pub-id pub-id-type="pmid">10542413</pub-id></element-citation></ref><ref id="B282-biomedicines-09-00234"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>J.K.</given-names></name><name><surname>Bohlmann</surname><given-names>J.</given-names></name></person-group><article-title>Terpenes in <italic>Cannabis sativa</italic>&#x02014;From Plant Genome to Humans</article-title><source>Plant Sci.</source><year>2019</year><volume>284</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.plantsci.2019.03.022</pub-id><pub-id pub-id-type="pmid">31084880</pub-id></element-citation></ref><ref id="B283-biomedicines-09-00234"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldfield</surname><given-names>E.</given-names></name><name><surname>Lin</surname><given-names>F.Y.</given-names></name></person-group><article-title>Terpene Biosynthesis: Modularity Rules</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2012</year><volume>51</volume><fpage>1124</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1002/anie.201103110</pub-id><pub-id pub-id-type="pmid">22105807</pub-id></element-citation></ref><ref id="B284-biomedicines-09-00234"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagne</surname><given-names>S.J.</given-names></name><name><surname>Stout</surname><given-names>J.M.</given-names></name><name><surname>Liu</surname><given-names>E.</given-names></name><name><surname>Boubakir</surname><given-names>Z.</given-names></name><name><surname>Clark</surname><given-names>S.M.</given-names></name><name><surname>Page</surname><given-names>J.E.</given-names></name></person-group><article-title>Identification of Olivetolic Acid Cyclase from <italic>Cannabis sativa</italic> Reveals a Unique Catalytic Route to Plant Polyketides</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>12811</fpage><lpage>12816</lpage><pub-id pub-id-type="doi">10.1073/pnas.1200330109</pub-id><pub-id pub-id-type="pmid">22802619</pub-id></element-citation></ref><ref id="B285-biomedicines-09-00234"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taura</surname><given-names>F.</given-names></name><name><surname>Tanaka</surname><given-names>S.</given-names></name><name><surname>Taguchi</surname><given-names>C.</given-names></name><name><surname>Fukamizu</surname><given-names>T.</given-names></name><name><surname>Tanaka</surname><given-names>H.</given-names></name><name><surname>Shoyama</surname><given-names>Y.</given-names></name><name><surname>Morimoto</surname><given-names>S.</given-names></name></person-group><article-title>Characterization of Olivetol Synthase, a Polyketide Synthase Putatively Involved in Cannabinoid Biosynthetic Pathway</article-title><source>FEBS Lett.</source><year>2009</year><volume>583</volume><fpage>2061</fpage><lpage>2066</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2009.05.024</pub-id><pub-id pub-id-type="pmid">19454282</pub-id></element-citation></ref><ref id="B286-biomedicines-09-00234"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fellermeier</surname><given-names>M.</given-names></name><name><surname>Zenk</surname><given-names>M.H.</given-names></name></person-group><article-title>Prenylation of Olivetolate by a Hemp Transferase Yields Cannabigerolic Acid, the Precursor of Tetrahydrocannabinol</article-title><source>FEBS Lett.</source><year>1998</year><volume>427</volume><fpage>283</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(98)00450-5</pub-id><pub-id pub-id-type="pmid">9607329</pub-id></element-citation></ref><ref id="B287-biomedicines-09-00234"><label>287.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Reiter</surname><given-names>M.A.</given-names></name><name><surname>D&#x02019;Espaux</surname><given-names>L.</given-names></name><name><surname>Wong</surname><given-names>J.</given-names></name><name><surname>Denby</surname><given-names>C.M.</given-names></name><name><surname>Lechner</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Grzybowski</surname><given-names>A.T.</given-names></name><name><surname>Harth</surname><given-names>S.</given-names></name><name><surname>Lin</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Complete Biosynthesis of Cannabinoids and Their Unnatural Analogues in Yeast</article-title><source>Nature</source><year>2019</year><volume>567</volume><fpage>123</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-0978-9</pub-id><pub-id pub-id-type="pmid">30814733</pub-id></element-citation></ref><ref id="B288-biomedicines-09-00234"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valliere</surname><given-names>M.A.</given-names></name><name><surname>Korman</surname><given-names>T.P.</given-names></name><name><surname>Woodall</surname><given-names>N.B.</given-names></name><name><surname>Khitrov</surname><given-names>G.A.</given-names></name><name><surname>Taylor</surname><given-names>R.E.</given-names></name><name><surname>Baker</surname><given-names>D.</given-names></name><name><surname>Bowie</surname><given-names>J.U.</given-names></name></person-group><article-title>A Cell-Free Platform for the Prenylation of Natural Products and Application to Cannabinoid Production</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>565</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-08448-y</pub-id><pub-id pub-id-type="pmid">30718485</pub-id></element-citation></ref><ref id="B289-biomedicines-09-00234"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taura</surname><given-names>F.</given-names></name><name><surname>Morimoto</surname><given-names>S.</given-names></name><name><surname>Shoyama</surname><given-names>Y.</given-names></name></person-group><article-title>Purification and Characterization of Cannabidiolic-Acid Synthase from <italic>Cannabis sativa</italic> L. Biochemical Analysis of a Novel Enzyme That Catalyzes the Oxidocyclization of Cannabigerolic Acid to Cannabidiolic Acid</article-title><source>J. Biol. Chem.</source><year>1996</year><volume>271</volume><fpage>17411</fpage><lpage>17416</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.29.17411</pub-id><pub-id pub-id-type="pmid">8663284</pub-id></element-citation></ref><ref id="B290-biomedicines-09-00234"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morimoto</surname><given-names>S.</given-names></name><name><surname>Komatsu</surname><given-names>K.</given-names></name><name><surname>Taura</surname><given-names>F.</given-names></name><name><surname>Shoyama</surname><given-names>Y.</given-names></name></person-group><article-title>Purification and Characterization of Cannabichromenic Acid Synthase from <italic>Cannabis sativa</italic></article-title><source>Phytochemistry</source><year>1998</year><volume>49</volume><fpage>1525</fpage><lpage>1529</lpage><pub-id pub-id-type="doi">10.1016/S0031-9422(98)00278-7</pub-id><pub-id pub-id-type="pmid">9862135</pub-id></element-citation></ref><ref id="B291-biomedicines-09-00234"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoyama</surname><given-names>Y.</given-names></name><name><surname>Tamada</surname><given-names>T.</given-names></name><name><surname>Kurihara</surname><given-names>K.</given-names></name><name><surname>Takeuchi</surname><given-names>A.</given-names></name><name><surname>Taura</surname><given-names>F.</given-names></name><name><surname>Arai</surname><given-names>S.</given-names></name><name><surname>Blaber</surname><given-names>M.</given-names></name><name><surname>Shoyama</surname><given-names>Y.</given-names></name><name><surname>Morimoto</surname><given-names>S.</given-names></name><name><surname>Kuroki</surname><given-names>R.</given-names></name></person-group><article-title>Structure and Function of &#x00394;1-Tetrahydrocannabinolic Acid (THCA) Synthase, the Enzyme Controlling the Psychoactivity of <italic>Cannabis sativa</italic></article-title><source>J. Mol. Biol.</source><year>2012</year><volume>423</volume><fpage>96</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2012.06.030</pub-id><pub-id pub-id-type="pmid">22766313</pub-id></element-citation></ref><ref id="B292-biomedicines-09-00234"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taura</surname><given-names>F.</given-names></name><name><surname>Morimoto</surname><given-names>S.</given-names></name><name><surname>Shoyama</surname><given-names>Y.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name></person-group><article-title>First Direct Evidence for the Mechanism of &#x00394;1-Tetrahydrocannabinolie Acid Biosynthesis</article-title><source>J. Am. Chem. Soc.</source><year>1995</year><volume>117</volume><fpage>9766</fpage><lpage>9767</lpage><pub-id pub-id-type="doi">10.1021/ja00143a024</pub-id></element-citation></ref><ref id="B293-biomedicines-09-00234"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taura</surname><given-names>F.</given-names></name><name><surname>Dono</surname><given-names>E.</given-names></name><name><surname>Sirikantaramas</surname><given-names>S.</given-names></name><name><surname>Yoshimura</surname><given-names>K.</given-names></name><name><surname>Shoyama</surname><given-names>Y.</given-names></name><name><surname>Morimoto</surname><given-names>S.</given-names></name></person-group><article-title>Production of &#x00394;1-Tetrahydrocannabinolic Acid by the Biosynthetic Enzyme Secreted from Transgenic Pichia Pastoris</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2007</year><volume>361</volume><fpage>675</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2007.07.079</pub-id><?supplied-pmid 17669365?><pub-id pub-id-type="pmid">17669365</pub-id></element-citation></ref><ref id="B294-biomedicines-09-00234"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Zeeuw</surname><given-names>R.A.</given-names></name><name><surname>Wijsbeek</surname><given-names>J.</given-names></name><name><surname>Brejmer</surname><given-names>D.D.</given-names></name><name><surname>Vree</surname><given-names>T.B.</given-names></name><name><surname>Van Ginneken</surname><given-names>C.A.M.</given-names></name><name><surname>Van Rossum</surname><given-names>J.M.</given-names></name></person-group><article-title>Cannabinoids with a Propyl Side Chain in Cannabis: Occurrence and Chromatographic Behavior</article-title><source>Science</source><year>1972</year><volume>175</volume><fpage>778</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1126/science.175.4023.778</pub-id><?supplied-pmid 5057817?><pub-id pub-id-type="pmid">5057817</pub-id></element-citation></ref><ref id="B295-biomedicines-09-00234"><label>295.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Meijer</surname><given-names>E.P.M.</given-names></name><name><surname>Bagatta</surname><given-names>M.</given-names></name><name><surname>Carboni</surname><given-names>A.</given-names></name><name><surname>Crucitti</surname><given-names>P.</given-names></name><name><surname>Moliterni</surname><given-names>V.M.C.</given-names></name><name><surname>Ranalli</surname><given-names>P.</given-names></name><name><surname>Mandolino</surname><given-names>G.</given-names></name></person-group><article-title>The Inheritance of Chemical Phenotype in <italic>Cannabis sativa</italic> L.</article-title><source>Genetics</source><year>2003</year><volume>163</volume><fpage>335</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">12586720</pub-id></element-citation></ref><ref id="B296-biomedicines-09-00234"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoyama</surname><given-names>Y.</given-names></name><name><surname>Hirano</surname><given-names>H.</given-names></name><name><surname>Nishioka</surname><given-names>I.</given-names></name></person-group><article-title>Biosynthesis of Propyl Cannabinoid Acid and Its Biosynthetic Relationship with Pentyl and Methyl Cannabinoid Acids</article-title><source>Phytochemistry</source><year>1984</year><volume>23</volume><fpage>1909</fpage><lpage>1984</lpage><pub-id pub-id-type="doi">10.1016/S0031-9422(00)84939-0</pub-id></element-citation></ref><ref id="B297-biomedicines-09-00234"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanter</surname><given-names>S.L.</given-names></name><name><surname>Musumeci</surname><given-names>M.R.</given-names></name><name><surname>Hollister</surname><given-names>L.E.</given-names></name></person-group><article-title>Quantitative Determination of &#x00394;9-Tetrahydrocannabinol and &#x00394;9-Tetrahydrocannabinolic Acid in Marihuana by High-Pressure Liquid Chromatography</article-title><source>J. Chromatogr. A</source><year>1979</year><volume>171</volume><fpage>504</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1016/S0021-9673(01)95346-4</pub-id></element-citation></ref><ref id="B298-biomedicines-09-00234"><label>298.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrotin-Brunel</surname><given-names>H.</given-names></name><name><surname>Buijs</surname><given-names>W.</given-names></name><name><surname>Van Spronsen</surname><given-names>J.</given-names></name><name><surname>Roosmalen</surname><given-names>M.J.E.V.</given-names></name><name><surname>Peters</surname><given-names>C.J.</given-names></name><name><surname>Verpoorte</surname><given-names>R.</given-names></name><name><surname>Witkamp</surname><given-names>G.J.</given-names></name></person-group><article-title>Decarboxylation of &#x00394;9-Tetrahydrocannabinol: Kinetics and Molecular Modeling</article-title><source>J. Mol. Struct.</source><year>2011</year><volume>987</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2010.11.061</pub-id></element-citation></ref><ref id="B299-biomedicines-09-00234"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoyama</surname><given-names>Y.</given-names></name><name><surname>Yagi</surname><given-names>M.</given-names></name><name><surname>Nishioka</surname><given-names>I.</given-names></name><name><surname>Yamauchi</surname><given-names>T.</given-names></name></person-group><article-title>Biosynthesis of Cannabinoid Acids</article-title><source>Phytochemistry</source><year>1975</year><volume>14</volume><fpage>2189</fpage><lpage>2192</lpage><pub-id pub-id-type="doi">10.1016/S0031-9422(00)91096-3</pub-id></element-citation></ref><ref id="B300-biomedicines-09-00234"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veress</surname><given-names>T.</given-names></name><name><surname>Szanto</surname><given-names>J.I.</given-names></name><name><surname>Leisztner</surname><given-names>L.</given-names></name></person-group><article-title>Determination of Cannabinoid Acids by High-Performance Liquid Chromatography of Their Neutral Derivatives Formed by Thermal Decarboxylation. I. Study of the Decarboxylation Process in Open Reactors</article-title><source>J. Chromatogr. A</source><year>1990</year><pub-id pub-id-type="doi">10.1016/0021-9673(90)85118-F</pub-id></element-citation></ref><ref id="B301-biomedicines-09-00234"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanu&#x00161;</surname><given-names>L.O.</given-names></name><name><surname>Meyer</surname><given-names>S.M.</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>E.</given-names></name><name><surname>Taglialatela-Scafati</surname><given-names>O.</given-names></name><name><surname>Appendino</surname><given-names>G.</given-names></name></person-group><article-title>Phytocannabinoids: A Unified Critical Inventory</article-title><source>Nat. Prod. Rep.</source><year>2016</year><volume>33</volume><fpage>1357</fpage><lpage>1392</lpage><pub-id pub-id-type="doi">10.1039/C6NP00074F</pub-id><?supplied-pmid 27722705?><pub-id pub-id-type="pmid">27722705</pub-id></element-citation></ref><ref id="B302-biomedicines-09-00234"><label>302.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>S.A.</given-names></name><name><surname>Ross</surname><given-names>S.A.</given-names></name><name><surname>Slade</surname><given-names>D.</given-names></name><name><surname>Radwan</surname><given-names>M.M.</given-names></name><name><surname>Khan</surname><given-names>I.A.</given-names></name><name><surname>ElSohly</surname><given-names>M.A.</given-names></name></person-group><article-title>Structure Determination and Absolute Configuration of Cannabichromanone Derivatives from High Potency <italic>Cannabis sativa</italic></article-title><source>Tetrahedron Lett.</source><year>2008</year><volume>49</volume><fpage>6050</fpage><lpage>6053</lpage><pub-id pub-id-type="doi">10.1016/j.tetlet.2008.07.178</pub-id><?supplied-pmid 19844597?><pub-id pub-id-type="pmid">19844597</pub-id></element-citation></ref><ref id="B303-biomedicines-09-00234"><label>303.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>S.A.</given-names></name><name><surname>Ross</surname><given-names>S.A.</given-names></name><name><surname>Slade</surname><given-names>D.</given-names></name><name><surname>Radwan</surname><given-names>M.M.</given-names></name><name><surname>Zulfiqar</surname><given-names>F.</given-names></name><name><surname>ElSohly</surname><given-names>M.A.</given-names></name></person-group><article-title>Cannabinoid Ester Constituents from High-Potency <italic>Cannabis sativa</italic></article-title><source>J. Nat. Prod.</source><year>2008</year><volume>71</volume><fpage>536</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1021/np070454a</pub-id><pub-id pub-id-type="pmid">18303850</pub-id></element-citation></ref><ref id="B304-biomedicines-09-00234"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radwan</surname><given-names>M.M.</given-names></name><name><surname>Ross</surname><given-names>S.A.</given-names></name><name><surname>Slade</surname><given-names>D.</given-names></name><name><surname>Ahmed</surname><given-names>S.A.</given-names></name><name><surname>Zulfiqar</surname><given-names>F.</given-names></name><name><surname>Elsohly</surname><given-names>M.A.</given-names></name></person-group><article-title>Isolation and Characterization of New Cannabis Constituents from a High Potency Variety</article-title><source>Planta Med.</source><year>2008</year><volume>74</volume><fpage>267</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1055/s-2008-1034311</pub-id><pub-id pub-id-type="pmid">18283614</pub-id></element-citation></ref><ref id="B305-biomedicines-09-00234"><label>305.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagani</surname><given-names>A.</given-names></name><name><surname>Scala</surname><given-names>F.</given-names></name><name><surname>Chianese</surname><given-names>G.</given-names></name><name><surname>Grassi</surname><given-names>G.</given-names></name><name><surname>Appendino</surname><given-names>G.</given-names></name><name><surname>Taglialatela-Scafati</surname><given-names>O.</given-names></name></person-group><article-title>Cannabioxepane, a Novel Tetracyclic Cannabinoid from Hemp, <italic>Cannabis sativa</italic> L.</article-title><source>Tetrahedron</source><year>2011</year><volume>67</volume><fpage>3369</fpage><lpage>3373</lpage><pub-id pub-id-type="doi">10.1016/j.tet.2011.03.062</pub-id></element-citation></ref><ref id="B306-biomedicines-09-00234"><label>306.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zulfiqar</surname><given-names>F.</given-names></name><name><surname>Ross</surname><given-names>S.A.</given-names></name><name><surname>Slade</surname><given-names>D.</given-names></name><name><surname>Ahmed</surname><given-names>S.A.</given-names></name><name><surname>Radwan</surname><given-names>M.M.</given-names></name><name><surname>Ali</surname><given-names>Z.</given-names></name><name><surname>Khan</surname><given-names>I.A.</given-names></name><name><surname>Elsohly</surname><given-names>M.A.</given-names></name></person-group><article-title>Cannabisol, a Novel &#x00394; 9-THC Dimer Possessing a Unique Methylene Bridge, Isolated from <italic>Cannabis sativa</italic></article-title><source>Tetrahedron Lett.</source><year>2012</year><volume>53</volume><fpage>3560</fpage><lpage>3562</lpage><pub-id pub-id-type="doi">10.1016/j.tetlet.2012.04.139</pub-id><?supplied-pmid 27695140?><pub-id pub-id-type="pmid">27695140</pub-id></element-citation></ref><ref id="B307-biomedicines-09-00234"><label>307.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollastro</surname><given-names>F.</given-names></name><name><surname>Taglialatela-Scafati</surname><given-names>O.</given-names></name><name><surname>Allar&#x000e0;</surname><given-names>M.</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>E.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Appendino</surname><given-names>G.</given-names></name></person-group><article-title>Bioactive Prenylogous Cannabinoid from Fiber Hemp (<italic>Cannabis sativa</italic>)</article-title><source>J. Nat. Prod.</source><year>2011</year><volume>74</volume><fpage>2019</fpage><lpage>2022</lpage><pub-id pub-id-type="doi">10.1021/np200500p</pub-id><pub-id pub-id-type="pmid">21902175</pub-id></element-citation></ref><ref id="B308-biomedicines-09-00234"><label>308.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taglialatela-Scafati</surname><given-names>O.</given-names></name><name><surname>Pagani</surname><given-names>A.</given-names></name><name><surname>Scala</surname><given-names>F.</given-names></name><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name><name><surname>Grassi</surname><given-names>G.</given-names></name><name><surname>Appendino</surname><given-names>G.</given-names></name></person-group><article-title>Cannabimovone, a Cannabinoid with a Rearranged Terpenoid Skeleton from Hemp (Eur. J. Org. Chem. 11/2010)</article-title><source>Eur. J. Org. Chem.</source><year>2010</year><volume>2010</volume><fpage>2023</fpage><pub-id pub-id-type="doi">10.1002/ejoc.201090025</pub-id></element-citation></ref><ref id="B309-biomedicines-09-00234"><label>309.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>A.</given-names></name><name><surname>Stevenson</surname><given-names>L.A.</given-names></name><name><surname>Wease</surname><given-names>K.N.</given-names></name><name><surname>Price</surname><given-names>M.R.</given-names></name><name><surname>Baillie</surname><given-names>G.</given-names></name><name><surname>Ross</surname><given-names>R.A.</given-names></name><name><surname>Pertwee</surname><given-names>R.G.</given-names></name></person-group><article-title>Evidence That the Plant Cannabinoid &#x00394; 9-Tetrahydrocannabivarin Is a Cannabinoid CB 1 and CB 2 Receptor Antagonist</article-title><source>Br. J. Pharmacol.</source><year>2005</year><volume>146</volume><fpage>917</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0706414</pub-id><?supplied-pmid 16205722?><pub-id pub-id-type="pmid">16205722</pub-id></element-citation></ref><ref id="B310-biomedicines-09-00234"><label>310.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pertwee</surname><given-names>R.G.</given-names></name><name><surname>Thomas</surname><given-names>A.</given-names></name><name><surname>Stevenson</surname><given-names>L.A.</given-names></name><name><surname>Ross</surname><given-names>R.A.</given-names></name><name><surname>Varvel</surname><given-names>S.A.</given-names></name><name><surname>Lichtman</surname><given-names>A.H.</given-names></name><name><surname>Martin</surname><given-names>B.R.</given-names></name><name><surname>Razdan</surname><given-names>R.K.</given-names></name></person-group><article-title>The Psychoactive Plant Cannabinoid, &#x00394; 9-Tetrahydrocannabinol, Is Antagonized by &#x00394; 8- and &#x00394; 9-Tetrahydrocannabivarin in Mice in Vivo</article-title><source>Br. J. Pharmacol.</source><year>2007</year><volume>150</volume><fpage>586</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0707124</pub-id><pub-id pub-id-type="pmid">17245367</pub-id></element-citation></ref><ref id="B311-biomedicines-09-00234"><label>311.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a</surname><given-names>C.</given-names></name><name><surname>Palomo-Garo</surname><given-names>C.</given-names></name><name><surname>Garc&#x000ed;a-Arencibia</surname><given-names>M.</given-names></name><name><surname>Ramos</surname><given-names>J.A.</given-names></name><name><surname>Pertwee</surname><given-names>R.G.</given-names></name><name><surname>Fern&#x000e1;ndez-Ruiz</surname><given-names>J.</given-names></name></person-group><article-title>Symptom-Relieving and Neuroprotective Effects of the Phytocannabinoid &#x00394; 9-THCV in Animal Models of Parkinson&#x02019;s Disease</article-title><source>Br. J. Pharmacol.</source><year>2011</year><volume>163</volume><fpage>1495</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01278.x</pub-id><pub-id pub-id-type="pmid">21323909</pub-id></element-citation></ref><ref id="B312-biomedicines-09-00234"><label>312.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y.L.</given-names></name><name><surname>Weston</surname><given-names>S.E.</given-names></name><name><surname>Whalley</surname><given-names>B.J.</given-names></name><name><surname>Stephens</surname><given-names>G.J.</given-names></name></person-group><article-title>The Phytocannabinoid &#x00394; 9-Tetrahydrocannabivarin Modulates Inhibitory Neurotransmission in the Cerebellum</article-title><source>Br. J. Pharmacol.</source><year>2008</year><volume>154</volume><fpage>204</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1038/bjp.2008.57</pub-id><pub-id pub-id-type="pmid">18311186</pub-id></element-citation></ref><ref id="B313-biomedicines-09-00234"><label>313.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>I.</given-names></name><name><surname>Whalley</surname><given-names>B.J.</given-names></name><name><surname>Stephens</surname><given-names>G.J.</given-names></name></person-group><article-title>Effects of &#x00394; 9-Tetrahydrocannabivarin on [35S]GTP&#x003b3;S Binding in Mouse Brain Cerebellum and Piriform Cortex Membranes</article-title><source>Br. J. Pharmacol.</source><year>2008</year><pub-id pub-id-type="doi">10.1038/bjp.2008.190</pub-id><?supplied-pmid 18493244?><pub-id pub-id-type="pmid">18493244</pub-id></element-citation></ref><ref id="B314-biomedicines-09-00234"><label>314.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cascio</surname><given-names>M.G.</given-names></name><name><surname>Zamberletti</surname><given-names>E.</given-names></name><name><surname>Marini</surname><given-names>P.</given-names></name><name><surname>Parolaro</surname><given-names>D.</given-names></name><name><surname>Pertwee</surname><given-names>R.G.</given-names></name></person-group><article-title>The Phytocannabinoid, &#x00394;9-Tetrahydrocannabivarin, Can Act through 5-HT1A Receptors to Produce Antipsychotic Effects</article-title><source>Br. J. Pharmacol.</source><year>2015</year><volume>172</volume><fpage>1305</fpage><lpage>1318</lpage><pub-id pub-id-type="doi">10.1111/bph.13000</pub-id><pub-id pub-id-type="pmid">25363799</pub-id></element-citation></ref><ref id="B315-biomedicines-09-00234"><label>315.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>O&#x02019;Sullivan</surname><given-names>S.E.</given-names></name><name><surname>Bennett</surname><given-names>A.J.</given-names></name><name><surname>Kendall</surname><given-names>D.A.</given-names></name><name><surname>Randall</surname><given-names>M.D.</given-names></name></person-group><article-title>Cannabinoids and Peroxisome Proliferator-Activated Receptor &#x003b3; (PPARg)</article-title><source>Proceedings of the 16th Annual Symposium on the Cannabinoids</source><conf-loc>Tihany, Hungary</conf-loc><conf-date>24&#x02013;28 June 2006</conf-date><volume>Volume 59</volume></element-citation></ref><ref id="B316-biomedicines-09-00234"><label>316.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Englund</surname><given-names>A.</given-names></name><name><surname>Atakan</surname><given-names>Z.</given-names></name><name><surname>Kralj</surname><given-names>A.</given-names></name><name><surname>Tunstall</surname><given-names>N.</given-names></name><name><surname>Murray</surname><given-names>R.</given-names></name><name><surname>Morrison</surname><given-names>P.</given-names></name></person-group><article-title>The Effect of Five Day Dosing with THCV on THC-Induced Cognitive, Psychological and Physiological Effects in Healthy Male Human Volunteers: A Placebo-Controlled, Double-Blind, Crossover Pilot Trial</article-title><source>J. Psychopharmacol.</source><year>2016</year><volume>30</volume><fpage>140</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1177/0269881115615104</pub-id><?supplied-pmid 26577065?><pub-id pub-id-type="pmid">26577065</pub-id></element-citation></ref><ref id="B317-biomedicines-09-00234"><label>317.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tudge</surname><given-names>L.</given-names></name><name><surname>Williams</surname><given-names>C.</given-names></name><name><surname>Cowen</surname><given-names>P.J.</given-names></name><name><surname>McCabe</surname><given-names>C.</given-names></name></person-group><article-title>Neural Effects of Cannabinoid CB1 Neutral Antagonist Tetrahydrocannabivarin on Food Reward and Aversion in Healthy Volunteers</article-title><source>Int. J. Neuropsychopharmacol.</source><year>2015</year><volume>18</volume><fpage>Pyu094</fpage><pub-id pub-id-type="doi">10.1093/ijnp/pyu094</pub-id></element-citation></ref><ref id="B318-biomedicines-09-00234"><label>318.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rzepa</surname><given-names>E.</given-names></name><name><surname>Tudge</surname><given-names>L.</given-names></name><name><surname>McCabe</surname><given-names>C.</given-names></name></person-group><article-title>The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers</article-title><source>Int. J. Neuropsychopharmacol.</source><year>2016</year><volume>19</volume><fpage>Pyv092</fpage><pub-id pub-id-type="doi">10.1093/ijnp/pyv092</pub-id><?supplied-pmid 26362774?><pub-id pub-id-type="pmid">26362774</pub-id></element-citation></ref><ref id="B319-biomedicines-09-00234"><label>319.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moldzio</surname><given-names>R.</given-names></name><name><surname>Pacher</surname><given-names>T.</given-names></name><name><surname>Krewenka</surname><given-names>C.</given-names></name><name><surname>Kranner</surname><given-names>B.</given-names></name><name><surname>Novak</surname><given-names>J.</given-names></name><name><surname>Duvigneau</surname><given-names>J.C.</given-names></name><name><surname>Rausch</surname><given-names>W.D.</given-names></name></person-group><article-title>Effects of Cannabinoids &#x00394;(9)-Tetrahydrocannabinol, &#x00394;(9)-Tetrahydrocannabinolic Acid and Cannabidiol in MPP+ Affected Murine Mesencephalic Cultures</article-title><source>Phytomedicine</source><year>2012</year><volume>19</volume><fpage>819</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2012.04.002</pub-id><pub-id pub-id-type="pmid">22571976</pub-id></element-citation></ref><ref id="B320-biomedicines-09-00234"><label>320.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verhoeckx</surname><given-names>K.C.M.</given-names></name><name><surname>Korthout</surname><given-names>H.A.A.J.</given-names></name><name><surname>Van Meeteren-Kreikamp</surname><given-names>A.P.</given-names></name><name><surname>Ehlert</surname><given-names>K.A.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Van Der Greef</surname><given-names>J.</given-names></name><name><surname>Rodenburg</surname><given-names>R.J.T.</given-names></name><name><surname>Witkamp</surname><given-names>R.F.</given-names></name></person-group><article-title>Unheated <italic>Cannabis sativa</italic> Extracts and Its Major Compound THC-Acid Have Potential Immuno-Modulating Properties Not Mediated by CB1 and CB2 Receptor Coupled Pathways</article-title><source>Int. Immunopharmacol.</source><year>2006</year><volume>6</volume><fpage>656</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2005.10.002</pub-id><pub-id pub-id-type="pmid">16504929</pub-id></element-citation></ref><ref id="B321-biomedicines-09-00234"><label>321.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollister</surname><given-names>L.E.</given-names></name><name><surname>Gillespie</surname><given-names>H.K.</given-names></name></person-group><article-title>Delta-8- and Delta-9-Tetrahydrocannabinol Comparison in Man by Oral and Intravenous Administration</article-title><source>Clin. Pharmacol. Ther.</source><year>1973</year><volume>14</volume><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1002/cpt1973143353</pub-id><?supplied-pmid 4698563?><pub-id pub-id-type="pmid">4698563</pub-id></element-citation></ref><ref id="B322-biomedicines-09-00234"><label>322.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rock</surname><given-names>E.M.</given-names></name><name><surname>Limebeer</surname><given-names>C.L.</given-names></name><name><surname>Navaratnam</surname><given-names>R.</given-names></name><name><surname>Sticht</surname><given-names>M.A.</given-names></name><name><surname>Bonner</surname><given-names>N.</given-names></name><name><surname>Engeland</surname><given-names>K.</given-names></name><name><surname>Downey</surname><given-names>R.</given-names></name><name><surname>Morris</surname><given-names>H.</given-names></name><name><surname>Jackson</surname><given-names>M.</given-names></name><name><surname>Parker</surname><given-names>L.A.</given-names></name></person-group><article-title>A Comparison of Cannabidiolic Acid with Other Treatments for Anticipatory Nausea Using a Rat Model of Contextually Elicited Conditioned Gaping</article-title><source>Psychopharmacology</source><year>2014</year><volume>231</volume><fpage>3207</fpage><lpage>3215</lpage><pub-id pub-id-type="doi">10.1007/s00213-014-3498-1</pub-id><?supplied-pmid 24595502?><pub-id pub-id-type="pmid">24595502</pub-id></element-citation></ref><ref id="B323-biomedicines-09-00234"><label>323.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadal</surname><given-names>X.</given-names></name><name><surname>del R&#x000ed;o</surname><given-names>C.</given-names></name><name><surname>Casano</surname><given-names>S.</given-names></name><name><surname>Palomares</surname><given-names>B.</given-names></name><name><surname>Ferreiro-Vera</surname><given-names>C.</given-names></name><name><surname>Navarrete</surname><given-names>C.</given-names></name><name><surname>S&#x000e1;nchez-Carnerero</surname><given-names>C.</given-names></name><name><surname>Cantarero</surname><given-names>I.</given-names></name><name><surname>Bellido</surname><given-names>M.L.</given-names></name><name><surname>Meyer</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Tetrahydrocannabinolic Acid Is a Potent PPAR&#x003b3; Agonist with Neuroprotective Activity</article-title><source>Br. J. Pharmacol.</source><year>2017</year><volume>174</volume><fpage>4263</fpage><lpage>4276</lpage><pub-id pub-id-type="doi">10.1111/bph.14019</pub-id><?supplied-pmid 28853159?><pub-id pub-id-type="pmid">28853159</pub-id></element-citation></ref><ref id="B324-biomedicines-09-00234"><label>324.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morano</surname><given-names>A.</given-names></name><name><surname>Cifelli</surname><given-names>P.</given-names></name><name><surname>Nencini</surname><given-names>P.</given-names></name><name><surname>Antonilli</surname><given-names>L.</given-names></name><name><surname>Fattouch</surname><given-names>J.</given-names></name><name><surname>Ruffolo</surname><given-names>G.</given-names></name><name><surname>Roseti</surname><given-names>C.</given-names></name><name><surname>Aronica</surname><given-names>E.</given-names></name><name><surname>Limatola</surname><given-names>C.</given-names></name><name><surname>Di Bonaventura</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Cannabis in Epilepsy: From Clinical Practice to Basic Research Focusing on the Possible Role of Cannabidivarin</article-title><source>Epilepsia Open</source><year>2016</year><volume>1</volume><fpage>145</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1002/epi4.12015</pub-id><pub-id pub-id-type="pmid">29588939</pub-id></element-citation></ref><ref id="B325-biomedicines-09-00234"><label>325.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>T.D.M.</given-names></name><name><surname>Cascio</surname><given-names>M.G.</given-names></name><name><surname>Romano</surname><given-names>B.</given-names></name><name><surname>Duncan</surname><given-names>M.</given-names></name><name><surname>Pertwee</surname><given-names>R.G.</given-names></name><name><surname>Williams</surname><given-names>C.M.</given-names></name><name><surname>Whalley</surname><given-names>B.J.</given-names></name><name><surname>Hill</surname><given-names>A.J.</given-names></name></person-group><article-title>Cannabidivarin-Rich Cannabis Extracts Are Anticonvulsant in Mouse and Rat via a CB1 Receptor-Independent Mechanism</article-title><source>Br. J. Pharmacol.</source><year>2013</year><volume>170</volume><fpage>679</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1111/bph.12321</pub-id><?supplied-pmid 23902406?><pub-id pub-id-type="pmid">23902406</pub-id></element-citation></ref><ref id="B326-biomedicines-09-00234"><label>326.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>A.J.</given-names></name><name><surname>Mercier</surname><given-names>M.S.</given-names></name><name><surname>Hill</surname><given-names>T.D.M.</given-names></name><name><surname>Glyn</surname><given-names>S.E.</given-names></name><name><surname>Jones</surname><given-names>N.A.</given-names></name><name><surname>Yamasaki</surname><given-names>Y.</given-names></name><name><surname>Futamura</surname><given-names>T.</given-names></name><name><surname>Duncan</surname><given-names>M.</given-names></name><name><surname>Stott</surname><given-names>C.G.</given-names></name><name><surname>Stephens</surname><given-names>G.J.</given-names></name><etal/></person-group><article-title>Cannabidivarin Is Anticonvulsant in Mouse and Rat</article-title><source>Br. J. Pharmacol.</source><year>2012</year><volume>167</volume><fpage>1629</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2012.02207.x</pub-id><?supplied-pmid 22970845?><pub-id pub-id-type="pmid">22970845</pub-id></element-citation></ref><ref id="B327-biomedicines-09-00234"><label>327.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amada</surname><given-names>N.</given-names></name><name><surname>Yamasaki</surname><given-names>Y.</given-names></name><name><surname>Williams</surname><given-names>C.M.</given-names></name><name><surname>Whalley</surname><given-names>B.J.</given-names></name></person-group><article-title>Cannabidivarin (CBDV) Suppresses Pentylenetetrazole (PTZ)-Induced Increases in Epilepsy-Related Gene Expression</article-title><source>PeerJ</source><year>2013</year><volume>1</volume><fpage>E214</fpage><pub-id pub-id-type="doi">10.7717/peerj.214</pub-id><?supplied-pmid 24282673?><pub-id pub-id-type="pmid">24282673</pub-id></element-citation></ref><ref id="B328-biomedicines-09-00234"><label>328.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huizenga</surname><given-names>M.N.</given-names></name><name><surname>Sepulveda-Rodriguez</surname><given-names>A.</given-names></name><name><surname>Forcelli</surname><given-names>P.A.</given-names></name></person-group><article-title>Preclinical Safety and Efficacy of Cannabidivarin for Early Life Seizures</article-title><source>Neuropharmacology</source><year>2019</year><volume>148</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2019.01.002</pub-id><pub-id pub-id-type="pmid">30633929</pub-id></element-citation></ref><ref id="B329-biomedicines-09-00234"><label>329.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>N.</given-names></name><name><surname>Neeper</surname><given-names>M.P.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Hutchinson</surname><given-names>T.L.</given-names></name><name><surname>Lubin</surname><given-names>M.L.</given-names></name><name><surname>Flores</surname><given-names>C.M.</given-names></name></person-group><article-title>TRPV2 Is Activated by Cannabidiol and Mediates CGRP Release in Cultured Rat Dorsal Root Ganglion Neurons</article-title><source>J. Neurosci.</source><year>2008</year><volume>28</volume><fpage>6231</fpage><lpage>6238</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0504-08.2008</pub-id><?supplied-pmid 18550765?><pub-id pub-id-type="pmid">18550765</pub-id></element-citation></ref><ref id="B330-biomedicines-09-00234"><label>330.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pretzsch</surname><given-names>C.M.</given-names></name><name><surname>Voinescu</surname><given-names>B.</given-names></name><name><surname>Lythgoe</surname><given-names>D.</given-names></name><name><surname>Horder</surname><given-names>J.</given-names></name><name><surname>Mendez</surname><given-names>M.A.</given-names></name><name><surname>Wichers</surname><given-names>R.</given-names></name><name><surname>Ajram</surname><given-names>L.</given-names></name><name><surname>Ivin</surname><given-names>G.</given-names></name><name><surname>Heasman</surname><given-names>M.</given-names></name><name><surname>Edden</surname><given-names>R.A.E.</given-names></name><etal/></person-group><article-title>Effects of Cannabidivarin (CBDV) on Brain Excitation and Inhibition Systems in Adults with and without Autism Spectrum Disorder (ASD): A Single Dose Trial during Magnetic Resonance Spectroscopy</article-title><source>Transl. Psychiatry</source><year>2019</year><volume>9</volume><fpage>313</fpage><pub-id pub-id-type="doi">10.1038/s41398-019-0654-8</pub-id><pub-id pub-id-type="pmid">31748505</pub-id></element-citation></ref><ref id="B331-biomedicines-09-00234"><label>331.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eibach</surname><given-names>L.</given-names></name><name><surname>Scheffel</surname><given-names>S.</given-names></name><name><surname>Cardebring</surname><given-names>M.</given-names></name><name><surname>Lettau</surname><given-names>M.</given-names></name><name><surname>&#x000d6;zg&#x000fc;r Celik</surname><given-names>M.</given-names></name><name><surname>Morguet</surname><given-names>A.</given-names></name><name><surname>Roehle</surname><given-names>R.</given-names></name><name><surname>Stein</surname><given-names>C.</given-names></name></person-group><article-title>Cannabidivarin for HIV-Associated Neuropathic Pain: A Randomized, Blinded, Controlled Clinical Trial</article-title><source>Clin. Pharmacol. Ther.</source><year>2020</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/cpt.2016</pub-id></element-citation></ref><ref id="B332-biomedicines-09-00234"><label>332.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>C.</given-names></name><name><surname>Ferk</surname><given-names>F.</given-names></name><name><surname>Mi&#x00161;&#x000ed;k</surname><given-names>M.</given-names></name><name><surname>Ropek</surname><given-names>N.</given-names></name><name><surname>Nersesyan</surname><given-names>A.</given-names></name><name><surname>Mejri</surname><given-names>D.</given-names></name><name><surname>Holzmann</surname><given-names>K.</given-names></name><name><surname>Lavorgna</surname><given-names>M.</given-names></name><name><surname>Isidori</surname><given-names>M.</given-names></name><name><surname>Knasm&#x000fc;ller</surname><given-names>S.</given-names></name></person-group><article-title>Low Doses of Widely Consumed Cannabinoids (Cannabidiol and Cannabidivarin) Cause DNA Damage and Chromosomal Aberrations in Human-Derived Cells</article-title><source>Arch. Toxicol.</source><year>2019</year><volume>93</volume><fpage>179</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1007/s00204-018-2322-9</pub-id><pub-id pub-id-type="pmid">30341733</pub-id></element-citation></ref><ref id="B333-biomedicines-09-00234"><label>333.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cascio</surname><given-names>M.G.</given-names></name><name><surname>Gauson</surname><given-names>L.A.</given-names></name><name><surname>Stevenson</surname><given-names>L.A.</given-names></name><name><surname>Ross</surname><given-names>R.A.</given-names></name><name><surname>Pertwee</surname><given-names>R.G.</given-names></name></person-group><article-title>Evidence That the Plant Cannabinoid Cannabigerol Is a Highly Potent &#x003b1; 2-Adrenoceptor Agonist and Moderately Potent 5HT 1A Receptor Antagonist</article-title><source>Br. J. Pharmacol.</source><year>2010</year><volume>159</volume><fpage>129</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00515.x</pub-id><pub-id pub-id-type="pmid">20002104</pub-id></element-citation></ref><ref id="B334-biomedicines-09-00234"><label>334.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valdeolivas</surname><given-names>S.</given-names></name><name><surname>Navarrete</surname><given-names>C.</given-names></name><name><surname>Cantarero</surname><given-names>I.</given-names></name><name><surname>Bellido</surname><given-names>M.L.</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>E.</given-names></name><name><surname>Sagredo</surname><given-names>O.</given-names></name></person-group><article-title>Neuroprotective Properties of Cannabigerol in Huntington&#x02019;s Disease: Studies in R6/2 Mice and 3-Nitropropionate-Lesioned Mice</article-title><source>Neurotherapeutics</source><year>2015</year><volume>12</volume><fpage>185</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1007/s13311-014-0304-z</pub-id><pub-id pub-id-type="pmid">25252936</pub-id></element-citation></ref><ref id="B335-biomedicines-09-00234"><label>335.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gugliandolo</surname><given-names>A.</given-names></name><name><surname>Pollastro</surname><given-names>F.</given-names></name><name><surname>Grassi</surname><given-names>G.</given-names></name><name><surname>Bramanti</surname><given-names>P.</given-names></name><name><surname>Mazzon</surname><given-names>E.</given-names></name></person-group><article-title>In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>1992</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19071992</pub-id><?supplied-pmid 29986533?><pub-id pub-id-type="pmid">29986533</pub-id></element-citation></ref><ref id="B336-biomedicines-09-00234"><label>336.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kathmann</surname><given-names>M.</given-names></name><name><surname>Flau</surname><given-names>K.</given-names></name><name><surname>Redmer</surname><given-names>A.</given-names></name><name><surname>Tr&#x000e4;nkle</surname><given-names>C.</given-names></name><name><surname>Schlicker</surname><given-names>E.</given-names></name></person-group><article-title>Cannabidiol Is an Allosteric Modulator at Mu- and Delta-Opioid Receptors</article-title><source>Naunyn. Schmiedebergs. Arch. Pharmacol.</source><year>2006</year><volume>372</volume><fpage>354</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1007/s00210-006-0033-x</pub-id><?supplied-pmid 16489449?><pub-id pub-id-type="pmid">16489449</pub-id></element-citation></ref><ref id="B337-biomedicines-09-00234"><label>337.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ligresti</surname><given-names>A.</given-names></name><name><surname>Moriello</surname><given-names>A.S.</given-names></name><name><surname>Starowicz</surname><given-names>K.</given-names></name><name><surname>Matias</surname><given-names>I.</given-names></name><name><surname>Pisanti</surname><given-names>S.</given-names></name><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Laezza</surname><given-names>C.</given-names></name><name><surname>Portella</surname><given-names>G.</given-names></name><name><surname>Bifulco</surname><given-names>M.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name></person-group><article-title>Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2006</year><volume>318</volume><fpage>1375</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1124/jpet.106.105247</pub-id><pub-id pub-id-type="pmid">16728591</pub-id></element-citation></ref><ref id="B338-biomedicines-09-00234"><label>338.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booker</surname><given-names>L.</given-names></name><name><surname>Naidu</surname><given-names>P.S.</given-names></name><name><surname>Razdan</surname><given-names>R.K.</given-names></name><name><surname>Mahadevan</surname><given-names>A.</given-names></name><name><surname>Lichtman</surname><given-names>A.H.</given-names></name></person-group><article-title>Evaluation of Prevalent Phytocannabinoids in the Acetic Acid Model of Visceral Nociception</article-title><source>Drug Alcohol Depend.</source><year>2009</year><volume>105</volume><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2009.06.009</pub-id><?supplied-pmid 19679411?><pub-id pub-id-type="pmid">19679411</pub-id></element-citation></ref><ref id="B339-biomedicines-09-00234"><label>339.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esposito</surname><given-names>G.</given-names></name><name><surname>Scuderi</surname><given-names>C.</given-names></name><name><surname>Valenza</surname><given-names>M.</given-names></name><name><surname>Togna</surname><given-names>G.I.</given-names></name><name><surname>Latina</surname><given-names>V.</given-names></name><name><surname>de Filippis</surname><given-names>D.</given-names></name><name><surname>Cipriano</surname><given-names>M.</given-names></name><name><surname>Carrat&#x000f9;</surname><given-names>M.R.</given-names></name><name><surname>Iuvone</surname><given-names>T.</given-names></name><name><surname>Steardo</surname><given-names>L.</given-names></name></person-group><article-title>Cannabidiol Reduces A&#x003b2;-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPAR&#x003b3; Involvement</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e28668</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0028668</pub-id><pub-id pub-id-type="pmid">22163051</pub-id></element-citation></ref><ref id="B340-biomedicines-09-00234"><label>340.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenthaler</surname><given-names>S.</given-names></name><name><surname>P&#x000f6;hn</surname><given-names>B.</given-names></name><name><surname>Kolmanz</surname><given-names>C.</given-names></name><name><surname>Nguyen Huu</surname><given-names>C.</given-names></name><name><surname>Krewenka</surname><given-names>C.</given-names></name><name><surname>Huber</surname><given-names>A.</given-names></name><name><surname>Kranner</surname><given-names>B.</given-names></name><name><surname>Rausch</surname><given-names>W.D.</given-names></name><name><surname>Moldzio</surname><given-names>R.</given-names></name></person-group><article-title>Differences in Receptor Binding Affinity of Several Phytocannabinoids Do Not Explain Their Effects on Neural Cell Cultures</article-title><source>Neurotoxicol. Teratol.</source><year>2014</year><volume>46</volume><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.ntt.2014.09.003</pub-id><pub-id pub-id-type="pmid">25311884</pub-id></element-citation></ref><ref id="B341-biomedicines-09-00234"><label>341.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>C.E.</given-names></name><name><surname>Elsohly</surname><given-names>M.A.</given-names></name></person-group><article-title>Biological Activity of Cannabichromene, Its Homologs and Isomers</article-title><source>J. Clin. Pharmacol.</source><year>1981</year><volume>21</volume><fpage>283S</fpage><lpage>291S</lpage><pub-id pub-id-type="doi">10.1002/j.1552-4604.1981.tb02606.x</pub-id><?supplied-pmid 7298870?><pub-id pub-id-type="pmid">7298870</pub-id></element-citation></ref><ref id="B342-biomedicines-09-00234"><label>342.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeLong</surname><given-names>G.T.</given-names></name><name><surname>Wolf</surname><given-names>C.E.</given-names></name><name><surname>Poklis</surname><given-names>A.</given-names></name><name><surname>Lichtman</surname><given-names>A.H.</given-names></name></person-group><article-title>Pharmacological Evaluation of the Natural Constituent of <italic>Cannabis sativa</italic>, Cannabichromene and Its Modulation by &#x00394;9-Tetrahydrocannabinol</article-title><source>Drug Alcohol Depend.</source><year>2010</year><volume>112</volume><fpage>126</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2010.05.019</pub-id><pub-id pub-id-type="pmid">20619971</pub-id></element-citation></ref><ref id="B343-biomedicines-09-00234"><label>343.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>W.M.</given-names></name><name><surname>Hatoum</surname><given-names>N.S.</given-names></name></person-group><article-title>Neurobehavioral Actions of Cannabichromene and Interactions with &#x00394;9-Tetrahydrocannabinol</article-title><source>Gen. Pharmacol.</source><year>1983</year><volume>14</volume><fpage>247</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/0306-3623(83)90004-6</pub-id><pub-id pub-id-type="pmid">6301931</pub-id></element-citation></ref><ref id="B344-biomedicines-09-00234"><label>344.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udoh</surname><given-names>M.</given-names></name><name><surname>Santiago</surname><given-names>M.</given-names></name><name><surname>Devenish</surname><given-names>S.</given-names></name><name><surname>McGregor</surname><given-names>I.S.</given-names></name><name><surname>Connor</surname><given-names>M.</given-names></name></person-group><article-title>Cannabichromene Is a Cannabinoid CB2 Receptor Agonist</article-title><source>Br. J. Pharmacol.</source><year>2019</year><volume>176</volume><fpage>4537</fpage><lpage>4547</lpage><pub-id pub-id-type="doi">10.1111/bph.14815</pub-id><pub-id pub-id-type="pmid">31368508</pub-id></element-citation></ref><ref id="B345-biomedicines-09-00234"><label>345.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>B.</given-names></name><name><surname>Borrelli</surname><given-names>F.</given-names></name><name><surname>Fasolino</surname><given-names>I.</given-names></name><name><surname>Capasso</surname><given-names>R.</given-names></name><name><surname>Piscitelli</surname><given-names>F.</given-names></name><name><surname>Cascio</surname><given-names>M.G.</given-names></name><name><surname>Pertwee</surname><given-names>R.G.</given-names></name><name><surname>Coppola</surname><given-names>D.</given-names></name><name><surname>Vassallo</surname><given-names>L.</given-names></name><name><surname>Orlando</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The Cannabinoid TRPA1 Agonist Cannabichromene Inhibits Nitric Oxide Production in Macrophages and Ameliorates Murine Colitis</article-title><source>Br. J. Pharmacol.</source><year>2013</year><volume>169</volume><fpage>213</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1111/bph.12120</pub-id><?supplied-pmid 23373571?><pub-id pub-id-type="pmid">23373571</pub-id></element-citation></ref><ref id="B346-biomedicines-09-00234"><label>346.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinjyo</surname><given-names>N.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name></person-group><article-title>The Effect of Cannabichromene on Adult Neural Stem/Progenitor Cells</article-title><source>Neurochem. Int.</source><year>2013</year><volume>63</volume><fpage>432</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2013.08.002</pub-id><?supplied-pmid 23941747?><pub-id pub-id-type="pmid">23941747</pub-id></element-citation></ref><ref id="B347-biomedicines-09-00234"><label>347.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahadevan</surname><given-names>A.</given-names></name><name><surname>Siegel</surname><given-names>C.</given-names></name><name><surname>Martin</surname><given-names>B.R.</given-names></name><name><surname>Abood</surname><given-names>M.E.</given-names></name><name><surname>Beletskaya</surname><given-names>I.</given-names></name><name><surname>Razdan</surname><given-names>R.K.</given-names></name></person-group><article-title>Novel Cannabinol Probes for CB1 and CB2 Cannabinoid Receptors</article-title><source>J. Med. Chem.</source><year>2000</year><volume>43</volume><fpage>3778</fpage><lpage>3785</lpage><pub-id pub-id-type="doi">10.1021/jm0001572</pub-id><?supplied-pmid 11020293?><pub-id pub-id-type="pmid">11020293</pub-id></element-citation></ref><ref id="B348-biomedicines-09-00234"><label>348.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>I.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Kuzuoka</surname><given-names>K.</given-names></name><name><surname>Narimatsu</surname><given-names>S.</given-names></name><name><surname>Yoshimura</surname><given-names>H.</given-names></name></person-group><article-title>The Pharmacological Activity of Cannabinol and Its Major Metabolite, 11-Hydroxycannabinol</article-title><source>Chem. Pharm. Bull.</source><year>1987</year><volume>35</volume><fpage>2144</fpage><lpage>2147</lpage><pub-id pub-id-type="doi">10.1248/cpb.35.2144</pub-id></element-citation></ref><ref id="B349-biomedicines-09-00234"><label>349.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Yamaori</surname><given-names>S.</given-names></name><name><surname>Funahashi</surname><given-names>T.</given-names></name><name><surname>Kimura</surname><given-names>T.</given-names></name><name><surname>Yamamoto</surname><given-names>I.</given-names></name></person-group><article-title>Cytochrome P450 Enzymes Involved in the Metabolism of Tetrahydrocannabinols and Cannabinol by Human Hepatic Microsomes</article-title><source>Life Sci.</source><year>2007</year><volume>80</volume><fpage>1415</fpage><lpage>1419</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2006.12.032</pub-id><pub-id pub-id-type="pmid">17303175</pub-id></element-citation></ref><ref id="B350-biomedicines-09-00234"><label>350.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaori</surname><given-names>S.</given-names></name><name><surname>Kushihara</surname><given-names>M.</given-names></name><name><surname>Yamamoto</surname><given-names>I.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name></person-group><article-title>Characterization of Major Phytocannabinoids, Cannabidiol and Cannabinol, as Isoform-Selective and Potent Inhibitors of Human CYP1 Enzymes</article-title><source>Biochem. Pharmacol.</source><year>2010</year><volume>79</volume><fpage>1691</fpage><lpage>1698</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2010.01.028</pub-id><pub-id pub-id-type="pmid">20117100</pub-id></element-citation></ref><ref id="B351-biomedicines-09-00234"><label>351.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aiken</surname><given-names>C.T.</given-names></name><name><surname>Tobin</surname><given-names>A.J.</given-names></name><name><surname>Schweitzer</surname><given-names>E.S.</given-names></name></person-group><article-title>A Cell-Based Screen for Drugs to Treat Huntington&#x02019;s Disease</article-title><source>Neurobiol. Dis.</source><year>2004</year><volume>16</volume><fpage>546</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2004.04.001</pub-id><pub-id pub-id-type="pmid">15262266</pub-id></element-citation></ref><ref id="B352-biomedicines-09-00234"><label>352.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>M.</given-names></name><name><surname>Faull</surname><given-names>R.L.M.</given-names></name><name><surname>Dragunow</surname><given-names>M.</given-names></name></person-group><article-title>Loss of Cannabinoid Receptors in the Substantia Nigra in Huntington&#x02019;s Disease</article-title><source>Neuroscience</source><year>1993</year><volume>56</volume><fpage>523</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1016/0306-4522(93)90352-G</pub-id><pub-id pub-id-type="pmid">8255419</pub-id></element-citation></ref><ref id="B353-biomedicines-09-00234"><label>353.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bl&#x000e1;zquez</surname><given-names>C.</given-names></name><name><surname>Chiarlone</surname><given-names>A.</given-names></name><name><surname>Sagredo</surname><given-names>O.</given-names></name><name><surname>Aguado</surname><given-names>T.</given-names></name><name><surname>Pazos</surname><given-names>M.R.</given-names></name><name><surname>Resel</surname><given-names>E.</given-names></name><name><surname>Palazuelos</surname><given-names>J.</given-names></name><name><surname>Julien</surname><given-names>B.</given-names></name><name><surname>Salazar</surname><given-names>M.</given-names></name><name><surname>B&#x000f6;rner</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Loss of Striatal Type 1 Cannabinoid Receptors Is a Key Pathogenic Factor in Huntington&#x02019;s Disease</article-title><source>Brain</source><year>2011</year><volume>134</volume><fpage>119</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1093/brain/awq278</pub-id><?supplied-pmid 20929960?><pub-id pub-id-type="pmid">20929960</pub-id></element-citation></ref><ref id="B354-biomedicines-09-00234"><label>354.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weydt</surname><given-names>P.</given-names></name><name><surname>Hong</surname><given-names>S.</given-names></name><name><surname>Witting</surname><given-names>A.</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>T.</given-names></name><name><surname>Stella</surname><given-names>N.</given-names></name><name><surname>Kliot</surname><given-names>M.</given-names></name></person-group><article-title>Cannabinol Delays Symptom Onset in SOD1 (G93A) Transgenic Mice without Affecting Survival</article-title><source>Amyotroph. Lateral Scler. Other Mot. Neuron Disord.</source><year>2005</year><volume>6</volume><fpage>182</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1080/14660820510030149</pub-id><?supplied-pmid 16183560?><pub-id pub-id-type="pmid">16183560</pub-id></element-citation></ref><ref id="B355-biomedicines-09-00234"><label>355.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>H.</given-names></name><name><surname>Cairns</surname><given-names>B.E.</given-names></name></person-group><article-title>Cannabidiol, Cannabinol and Their Combinations Act as Peripheral Analgesics in a Rat Model of Myofascial Pain</article-title><source>Arch. Oral Biol.</source><year>2019</year><volume>104</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.archoralbio.2019.05.028</pub-id><pub-id pub-id-type="pmid">31158702</pub-id></element-citation></ref><ref id="B356-biomedicines-09-00234"><label>356.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baroi</surname><given-names>S.</given-names></name><name><surname>Saha</surname><given-names>A.</given-names></name><name><surname>Bachar</surname><given-names>R.</given-names></name><name><surname>Bachar</surname><given-names>S.C.</given-names></name></person-group><article-title>Cannabinoid as Potential Aromatase Inhibitor through Molecular Modeling and Screening for Anti-Cancer Activity</article-title><source>Dhaka Univ. J. Pharm. Sci.</source><year>2020</year><volume>19</volume><fpage>47</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.3329/dujps.v19i1.47818</pub-id></element-citation></ref><ref id="B357-biomedicines-09-00234"><label>357.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furqan</surname><given-names>T.</given-names></name><name><surname>Batool</surname><given-names>S.</given-names></name><name><surname>Habib</surname><given-names>R.</given-names></name><name><surname>Shah</surname><given-names>M.</given-names></name><name><surname>Kalasz</surname><given-names>H.</given-names></name><name><surname>Darvas</surname><given-names>F.</given-names></name><name><surname>Kuca</surname><given-names>K.</given-names></name><name><surname>Nepovimova</surname><given-names>E.</given-names></name><name><surname>Batool</surname><given-names>S.</given-names></name><name><surname>Nurulain</surname><given-names>S.M.</given-names></name></person-group><article-title>Cannabis Constituents and Acetylcholinesterase Interaction: Molecular Docking, in Vitro Studies and Association with CNR1 RS806368 and ACHE RS17228602</article-title><source>Biomolecules</source><year>2020</year><volume>10</volume><elocation-id>758</elocation-id><pub-id pub-id-type="doi">10.3390/biom10050758</pub-id><?supplied-pmid 32414087?><pub-id pub-id-type="pmid">32414087</pub-id></element-citation></ref><ref id="B358-biomedicines-09-00234"><label>358.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>K.</given-names></name><name><surname>Akiyama</surname><given-names>Y.</given-names></name><name><surname>Fukui</surname><given-names>K.</given-names></name><name><surname>Kamada</surname><given-names>H.</given-names></name><name><surname>Satoh</surname><given-names>S.</given-names></name></person-group><article-title>Characterization; Genome Sizes and Morphology of Sex Chromosomes in Hemp (<italic>Cannabis sativa</italic> L.)</article-title><source>Cytologia</source><year>1998</year><volume>635</volume><fpage>459</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1508/cytologia.63.459</pub-id></element-citation></ref><ref id="B359-biomedicines-09-00234"><label>359.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>K.</given-names></name><name><surname>Shimomura</surname><given-names>K.</given-names></name><name><surname>Komeda</surname><given-names>Y.</given-names></name><name><surname>Kamada</surname><given-names>H.</given-names></name><name><surname>Satoh</surname><given-names>S.</given-names></name></person-group><article-title>A Male-Associated DNA Sequence in a Dioecious Plant, <italic>Cannabis sativa</italic> L.</article-title><source>Plant Cell Physiol.</source><year>1995</year><volume>36</volume><fpage>1549</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.pcp.a078920</pub-id><?supplied-pmid 8589931?><pub-id pub-id-type="pmid">8589931</pub-id></element-citation></ref><ref id="B360-biomedicines-09-00234"><label>360.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alghanim</surname><given-names>H.J.</given-names></name><name><surname>Almirall</surname><given-names>J.R.</given-names></name></person-group><article-title>Development of Microsatellite Markers in <italic>Cannabis sativa</italic> for DNA Typing and Genetic Relatedness Analyses</article-title><source>Anal. Bioanal. Chem.</source><year>2003</year><volume>376</volume><fpage>1225</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1007/s00216-003-1984-0</pub-id><pub-id pub-id-type="pmid">12811461</pub-id></element-citation></ref><ref id="B361-biomedicines-09-00234"><label>361.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilmore</surname><given-names>S.</given-names></name><name><surname>Peakall</surname><given-names>R.</given-names></name><name><surname>Robertson</surname><given-names>J.</given-names></name></person-group><article-title>Short Tandem Repeat (STR) DNA Markers Are Hypervariable and Informative in <italic>Cannabis sativa</italic>: Implications for Forensic Investigations</article-title><source>Forensic Sci. Int.</source><year>2003</year><volume>131</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/S0379-0738(02)00397-3</pub-id><pub-id pub-id-type="pmid">12505473</pub-id></element-citation></ref><ref id="B362-biomedicines-09-00234"><label>362.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>H.M.</given-names></name><name><surname>Hou</surname><given-names>R.J.</given-names></name><name><surname>Tsai</surname><given-names>L.C.</given-names></name><name><surname>Wei</surname><given-names>C.S.</given-names></name><name><surname>Liu</surname><given-names>S.W.</given-names></name><name><surname>Huang</surname><given-names>L.H.</given-names></name><name><surname>Kuo</surname><given-names>Y.C.</given-names></name><name><surname>Linacre</surname><given-names>A.</given-names></name><name><surname>Lee</surname><given-names>J.C.I.</given-names></name></person-group><article-title>A Highly Polymorphic STR Locus in <italic>Cannabis sativa</italic></article-title><source>Forensic Sci. Int.</source><year>2003</year><volume>131</volume><fpage>53</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/S0379-0738(02)00395-X</pub-id><pub-id pub-id-type="pmid">12505471</pub-id></element-citation></ref><ref id="B363-biomedicines-09-00234"><label>363.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Bakel</surname><given-names>H.</given-names></name><name><surname>Stout</surname><given-names>J.M.</given-names></name><name><surname>Cote</surname><given-names>A.G.</given-names></name><name><surname>Tallon</surname><given-names>C.M.</given-names></name><name><surname>Sharpe</surname><given-names>A.G.</given-names></name><name><surname>Hughes</surname><given-names>T.R.</given-names></name><name><surname>Page</surname><given-names>J.E.</given-names></name></person-group><article-title>The Draft Genome and Transcriptome of <italic>Cannabis sativa</italic></article-title><source>Genome Biol.</source><year>2011</year><volume>12</volume><fpage>R102</fpage><pub-id pub-id-type="doi">10.1186/gb-2011-12-10-r102</pub-id><?supplied-pmid 22014239?><pub-id pub-id-type="pmid">22014239</pub-id></element-citation></ref><ref id="B364-biomedicines-09-00234"><label>364.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Xie</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Pei</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>A High-Quality Reference Genome of Wild <italic>Cannabis sativa</italic></article-title><source>Hortic. Res.</source><year>2020</year><volume>7</volume><fpage>73</fpage><pub-id pub-id-type="doi">10.1038/s41438-020-0295-3</pub-id><pub-id pub-id-type="pmid">32377363</pub-id></element-citation></ref><ref id="B365-biomedicines-09-00234"><label>365.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laverty</surname><given-names>K.U.</given-names></name><name><surname>Stout</surname><given-names>J.M.</given-names></name><name><surname>Sullivan</surname><given-names>M.J.</given-names></name><name><surname>Shah</surname><given-names>H.</given-names></name><name><surname>Gill</surname><given-names>N.</given-names></name><name><surname>Holbrook</surname><given-names>L.</given-names></name><name><surname>Deikus</surname><given-names>G.</given-names></name><name><surname>Sebra</surname><given-names>R.</given-names></name><name><surname>Hughes</surname><given-names>T.R.</given-names></name><name><surname>Page</surname><given-names>J.E.</given-names></name><etal/></person-group><article-title>A Physical and Genetic Map of <italic>Cannabis sativa</italic> Identifies Extensive Rearrangements at the THC/CBD Acid Synthase Loci</article-title><source>Genome Res.</source><year>2019</year><volume>29</volume><fpage>146</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1101/gr.242594.118</pub-id><pub-id pub-id-type="pmid">30409771</pub-id></element-citation></ref><ref id="B366-biomedicines-09-00234"><label>366.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojoma</surname><given-names>M.</given-names></name><name><surname>Seki</surname><given-names>H.</given-names></name><name><surname>Yoshida</surname><given-names>S.</given-names></name><name><surname>Muranaka</surname><given-names>T.</given-names></name></person-group><article-title>DNA Polymorphisms in the Tetrahydrocannabinolic Acid (THCA) Synthase Gene in &#x0201c;Drug-Type&#x0201d; and &#x0201c;Fiber-Type&#x0201d; <italic>Cannabis sativa</italic> L.</article-title><source>Forensic Sci. Int.</source><year>2006</year><volume>159</volume><fpage>132</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.forsciint.2005.07.005</pub-id><?supplied-pmid 16143478?><pub-id pub-id-type="pmid">16143478</pub-id></element-citation></ref><ref id="B367-biomedicines-09-00234"><label>367.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKernan</surname><given-names>K.</given-names></name><name><surname>Helbert</surname><given-names>Y.</given-names></name><name><surname>Tadigotla</surname><given-names>V.</given-names></name><name><surname>McLaughlin</surname><given-names>S.</given-names></name><name><surname>Spangler</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Smith</surname><given-names>D.</given-names></name></person-group><article-title>Single Molecule Sequencing of THCA Synthase Reveals Copy Number Variation in Modern Drug-Type <italic>Cannabis sativa</italic> L.</article-title><source>bioRxiv</source><year>2015</year><fpage>28654</fpage><pub-id pub-id-type="doi">10.1101/028654</pub-id></element-citation></ref><ref id="B368-biomedicines-09-00234"><label>368.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onofri</surname><given-names>C.</given-names></name><name><surname>De Meijer</surname><given-names>E.P.M.</given-names></name><name><surname>Mandolino</surname><given-names>G.</given-names></name></person-group><article-title>Sequence Heterogeneity of Cannabidiolic- and Tetrahydrocannabinolic Acid-Synthase in <italic>Cannabis sativa</italic> L. and Its Relationship with Chemical Phenotype</article-title><source>Phytochemistry</source><year>2015</year><volume>116</volume><fpage>57</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.phytochem.2015.03.006</pub-id><?supplied-pmid 25865737?><pub-id pub-id-type="pmid">25865737</pub-id></element-citation></ref><ref id="B369-biomedicines-09-00234"><label>369.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiblen</surname><given-names>G.D.</given-names></name><name><surname>Wenger</surname><given-names>J.P.</given-names></name><name><surname>Craft</surname><given-names>K.J.</given-names></name><name><surname>ElSohly</surname><given-names>M.A.</given-names></name><name><surname>Mehmedic</surname><given-names>Z.</given-names></name><name><surname>Treiber</surname><given-names>E.L.</given-names></name><name><surname>Marks</surname><given-names>M.D.</given-names></name></person-group><article-title>Gene Duplication and Divergence Affecting Drug Content in <italic>Cannabis sativa</italic></article-title><source>New Phytol.</source><year>2015</year><volume>208</volume><fpage>1241</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1111/nph.13562</pub-id><?supplied-pmid 26189495?><pub-id pub-id-type="pmid">26189495</pub-id></element-citation></ref><ref id="B370-biomedicines-09-00234"><label>370.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welling</surname><given-names>M.T.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Shapter</surname><given-names>T.</given-names></name><name><surname>Raymond</surname><given-names>C.A.</given-names></name><name><surname>King</surname><given-names>G.J.</given-names></name></person-group><article-title>Characterisation of Cannabinoid Composition in a Diverse <italic>Cannabis sativa</italic> L. Germplasm Collection</article-title><source>Euphytica</source><year>2016</year><volume>208</volume><fpage>463</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1007/s10681-015-1585-y</pub-id></element-citation></ref><ref id="B371-biomedicines-09-00234"><label>371.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>R.C.</given-names></name><name><surname>Vergara</surname><given-names>D.</given-names></name><name><surname>Tittes</surname><given-names>S.</given-names></name><name><surname>White</surname><given-names>K.</given-names></name><name><surname>Schwartz</surname><given-names>C.J.</given-names></name><name><surname>Gibbs</surname><given-names>M.J.</given-names></name><name><surname>Ruthenburg</surname><given-names>T.C.</given-names></name><name><surname>DeCesare</surname><given-names>K.</given-names></name><name><surname>Land</surname><given-names>D.P.</given-names></name><name><surname>Kane</surname><given-names>N.C.</given-names></name></person-group><article-title>Genomic and Chemical Diversity in Cannabis</article-title><source>CRC. Crit. Rev. Plant Sci.</source><year>2016</year><volume>35</volume><fpage>349</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1080/07352689.2016.1265363</pub-id></element-citation></ref><ref id="B372-biomedicines-09-00234"><label>372.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>C.</given-names></name><name><surname>Xin</surname><given-names>P.</given-names></name><name><surname>Cheng</surname><given-names>C.</given-names></name><name><surname>Tang</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Zang</surname><given-names>G.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name></person-group><article-title>Diversity Analysis in <italic>Cannabis sativa</italic> based on Large-Scale Development of Expressed Sequence Tag-Derived Simple Sequence Repeat Markers</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e110638</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0110638</pub-id><pub-id pub-id-type="pmid">25329551</pub-id></element-citation></ref><ref id="B373-biomedicines-09-00234"><label>373.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.G.</given-names></name><name><surname>Chang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.F.</given-names></name><name><surname>Guan</surname><given-names>F.Z.</given-names></name><name><surname>Yuan</surname><given-names>H.M.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>L.J.</given-names></name></person-group><article-title>Analysis of the Genetic Diversity of Chinese Native <italic>Cannabis sativa</italic> Cultivars by Using ISSR and Chromosome Markers</article-title><source>Genet. Mol. Res.</source><year>2014</year><volume>13</volume><fpage>10490</fpage><lpage>10500</lpage><pub-id pub-id-type="doi">10.4238/2014.December.12.10</pub-id><pub-id pub-id-type="pmid">25511032</pub-id></element-citation></ref><ref id="B374-biomedicines-09-00234"><label>374.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>K.H.</given-names></name><name><surname>Vergara</surname><given-names>D.</given-names></name><name><surname>Keepers</surname><given-names>K.G.</given-names></name><name><surname>Kane</surname><given-names>N.C.</given-names></name></person-group><article-title>The Complete Mitochondrial Genome for <italic>Cannabis sativa</italic></article-title><source>Mitochondrial DNA Part B Resour.</source><year>2016</year><volume>1</volume><fpage>715</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1080/23802359.2016.1155083</pub-id></element-citation></ref><ref id="B375-biomedicines-09-00234"><label>375.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>H.</given-names></name><name><surname>Seo</surname><given-names>B.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Ahn</surname><given-names>D.H.</given-names></name><name><surname>Jo</surname><given-names>E.</given-names></name><name><surname>Park</surname><given-names>J.K.</given-names></name><name><surname>Min</surname><given-names>G.S.</given-names></name></person-group><article-title>Two Complete Chloroplast Genome Sequences of <italic>Cannabis sativa</italic> Varieties</article-title><source>Mitochondrial DNA</source><year>2015</year><volume>27</volume><fpage>2835</fpage><lpage>2837</lpage><pub-id pub-id-type="doi">10.3109/19401736.2015.1053117</pub-id><pub-id pub-id-type="pmid">26104156</pub-id></element-citation></ref><ref id="B376-biomedicines-09-00234"><label>376.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>J.K.</given-names></name><name><surname>Page</surname><given-names>J.E.</given-names></name><name><surname>Bohlmann</surname><given-names>J.</given-names></name></person-group><article-title>Terpene Synthases from <italic>Cannabis sativa</italic></article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0173911</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0173911</pub-id><pub-id pub-id-type="pmid">28355238</pub-id></element-citation></ref><ref id="B377-biomedicines-09-00234"><label>377.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zager</surname><given-names>J.J.</given-names></name><name><surname>Lange</surname><given-names>I.</given-names></name><name><surname>Srividya</surname><given-names>N.</given-names></name><name><surname>Smith</surname><given-names>A.</given-names></name><name><surname>Markus Lange</surname><given-names>B.</given-names></name></person-group><article-title>Gene Networks Underlying Cannabinoid and Terpenoid Accumulation in Cannabis</article-title><source>Plant Physiol.</source><year>2019</year><volume>180</volume><fpage>1877</fpage><lpage>1897</lpage><pub-id pub-id-type="doi">10.1104/pp.18.01506</pub-id><?supplied-pmid 31138625?><pub-id pub-id-type="pmid">31138625</pub-id></element-citation></ref><ref id="B378-biomedicines-09-00234"><label>378.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amano</surname><given-names>E.</given-names></name><name><surname>Smith</surname><given-names>H.H.</given-names></name></person-group><article-title>Mutations Induced by Ethyl Methanesulfonate in Maize</article-title><source>Mutat. Res. Fundam. Mol. Mech. Mutagen.</source><year>1965</year><volume>2</volume><fpage>344</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/0027-5107(65)90070-9</pub-id></element-citation></ref><ref id="B379-biomedicines-09-00234"><label>379.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Froese-Gertzen</surname><given-names>E.E.</given-names></name><name><surname>Konzak</surname><given-names>C.F.</given-names></name><name><surname>Nilan</surname><given-names>R.A.</given-names></name><name><surname>Heiner</surname><given-names>R.E.</given-names></name></person-group><article-title>The Effect of Ethyl Methanesulfonate on the Growth Response, Chromosome Structure and Mutation Rate in Barley</article-title><source>Radiat. Bot.</source><year>1964</year><volume>4</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/S0033-7560(64)80050-8</pub-id></element-citation></ref><ref id="B380-biomedicines-09-00234"><label>380.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jander</surname><given-names>G.</given-names></name><name><surname>Baerson</surname><given-names>S.R.</given-names></name><name><surname>Hudak</surname><given-names>J.A.</given-names></name><name><surname>Gonzalez</surname><given-names>K.A.</given-names></name><name><surname>Gruys</surname><given-names>K.J.</given-names></name><name><surname>Last</surname><given-names>R.L.</given-names></name></person-group><article-title>Ethylmethanesulfonate Saturation Mutagenesis in Arabidopsis to Determine Frequency of Herbicide Resistance</article-title><source>Plant Physiol.</source><year>2003</year><volume>131</volume><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1104/pp.102.010397</pub-id><?supplied-pmid 12529522?><pub-id pub-id-type="pmid">12529522</pub-id></element-citation></ref><ref id="B381-biomedicines-09-00234"><label>381.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luan</surname><given-names>Y.S.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>X.R.</given-names></name><name><surname>An</surname><given-names>L.J.</given-names></name></person-group><article-title>Mutation Induced by Ethylmethanesulphonate (EMS), in Vitro Screening for Salt Tolerance and Plant Regeneration of Sweet Potato (<italic>Ipomoea batatas</italic> L.)</article-title><source>Plant Cell. Tissue Organ Cult.</source><year>2007</year><volume>88</volume><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1007/s11240-006-9183-2</pub-id></element-citation></ref><ref id="B382-biomedicines-09-00234"><label>382.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stavreva</surname><given-names>D.A.</given-names></name><name><surname>Pt&#x000e1;&#x0010d;ek</surname><given-names>O.</given-names></name><name><surname>Plewa</surname><given-names>M.J.</given-names></name><name><surname>Gichner</surname><given-names>T.</given-names></name></person-group><article-title>Single Cell Gel Electrophoresis Analysis of Genomic Damage Induced by Ethyl Methanesulfonate in Cultured Tobacco Cells</article-title><source>Mutat Res.</source><year>1998</year><volume>422</volume><fpage>323</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1016/S0027-5107(98)00213-9</pub-id><pub-id pub-id-type="pmid">9838179</pub-id></element-citation></ref><ref id="B383-biomedicines-09-00234"><label>383.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>S.</given-names></name><name><surname>Mizoguchi</surname><given-names>T.</given-names></name><name><surname>Aoki</surname><given-names>K.</given-names></name><name><surname>Kubo</surname><given-names>Y.</given-names></name><name><surname>Mori</surname><given-names>H.</given-names></name><name><surname>Imanishi</surname><given-names>S.</given-names></name><name><surname>Yamazaki</surname><given-names>Y.</given-names></name><name><surname>Shibata</surname><given-names>D.</given-names></name><name><surname>Ezura</surname><given-names>H.</given-names></name></person-group><article-title>Ethylmethanesulfonate (EMS) Mutagenesis of Solanum Lycopersicum Cv. Micro-Tom for Large-Scale Mutant Screens</article-title><source>Plant Biotechnol.</source><year>2007</year><volume>24</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.5511/plantbiotechnology.24.33</pub-id></element-citation></ref><ref id="B384-biomedicines-09-00234"><label>384.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koornneeff</surname><given-names>M.</given-names></name><name><surname>Dellaert</surname><given-names>L.W.M.</given-names></name><name><surname>van der Veen</surname><given-names>J.H.</given-names></name></person-group><article-title>EMS- and Relation-Induced Mutation Frequencies at Individual Loci in <italic>Arabidopsis thaliana</italic> (L.) Heynh</article-title><source>Mutat. Res. Fundam. Mol. Mech. Mutagen.</source><year>1982</year><volume>93</volume><fpage>109</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/0027-5107(82)90129-4</pub-id></element-citation></ref><ref id="B385-biomedicines-09-00234"><label>385.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Century</surname><given-names>K.</given-names></name><name><surname>Straight</surname><given-names>S.</given-names></name><name><surname>Ronald</surname><given-names>P.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Lassner</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>A Fast Neutron Deletion Mutagenesis-Based Reverse Genetics System for Plants</article-title><source>Plant J.</source><year>2001</year><volume>27</volume><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1046/j.1365-313x.2001.01084.x</pub-id><pub-id pub-id-type="pmid">11532169</pub-id></element-citation></ref><ref id="B386-biomedicines-09-00234"><label>386.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirley</surname><given-names>B.W.</given-names></name><name><surname>Hanley</surname><given-names>S.</given-names></name><name><surname>Goodman</surname><given-names>H.M.</given-names></name></person-group><article-title>Effects of Ionizing Radiation on a Plant Genome: Analysis of Two Arabidopsis Transparent Testa Mutations</article-title><source>Plant Cell</source><year>1992</year><volume>4</volume><fpage>333</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1105/tpc.4.3.333</pub-id><?supplied-pmid 1354004?><pub-id pub-id-type="pmid">1354004</pub-id></element-citation></ref><ref id="B387-biomedicines-09-00234"><label>387.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bevan</surname><given-names>M.</given-names></name><name><surname>Bancroft</surname><given-names>I.</given-names></name><name><surname>Bent</surname><given-names>E.</given-names></name><name><surname>Love</surname><given-names>K.</given-names></name><name><surname>Goodman</surname><given-names>H.</given-names></name><name><surname>Dean</surname><given-names>C.</given-names></name><name><surname>Bergkamp</surname><given-names>R.</given-names></name><name><surname>Dirkse</surname><given-names>W.</given-names></name><name><surname>Van Staveren</surname><given-names>M.</given-names></name><name><surname>Stiekema</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Analysis of 1.9 Mb of Contiguous Sequence from Chromosome 4 of <italic>Arabidopsis thaliana</italic></article-title><source>Nature</source><year>1998</year><volume>391</volume><fpage>485</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1038/35140</pub-id><pub-id pub-id-type="pmid">9461215</pub-id></element-citation></ref><ref id="B388-biomedicines-09-00234"><label>388.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolon</surname><given-names>Y.T.</given-names></name><name><surname>Haun</surname><given-names>W.J.</given-names></name><name><surname>Xu</surname><given-names>W.W.</given-names></name><name><surname>Grant</surname><given-names>D.</given-names></name><name><surname>Stacey</surname><given-names>M.G.</given-names></name><name><surname>Nelson</surname><given-names>R.T.</given-names></name><name><surname>Gerhardt</surname><given-names>D.J.</given-names></name><name><surname>Jeddeloh</surname><given-names>J.A.</given-names></name><name><surname>Stacey</surname><given-names>G.</given-names></name><name><surname>Muehlbauer</surname><given-names>G.J.</given-names></name><etal/></person-group><article-title>Phenotypic and Genomic Analyses of a Fast Neutron Mutant Population Resource in Soybean</article-title><source>Plant Physiol.</source><year>2011</year><volume>156</volume><fpage>240</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1104/pp.110.170811</pub-id><?supplied-pmid 21321255?><pub-id pub-id-type="pmid">21321255</pub-id></element-citation></ref><ref id="B389-biomedicines-09-00234"><label>389.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colbert</surname><given-names>T.</given-names></name><name><surname>Till</surname><given-names>B.J.</given-names></name><name><surname>Tompa</surname><given-names>R.</given-names></name><name><surname>Reynolds</surname><given-names>S.</given-names></name><name><surname>Steine</surname><given-names>M.N.</given-names></name><name><surname>Yeung</surname><given-names>A.T.</given-names></name><name><surname>McCallum</surname><given-names>C.M.</given-names></name><name><surname>Comai</surname><given-names>L.</given-names></name><name><surname>Henikoff</surname><given-names>S.</given-names></name></person-group><article-title>High-Throughput Screening for Induced Point Mutations</article-title><source>Plant Physiol.</source><year>2001</year><volume>126</volume><fpage>480</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1104/pp.126.2.480</pub-id><?supplied-pmid 11402178?><pub-id pub-id-type="pmid">11402178</pub-id></element-citation></ref><ref id="B390-biomedicines-09-00234"><label>390.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jander</surname><given-names>G.</given-names></name><name><surname>Norris</surname><given-names>S.R.</given-names></name><name><surname>Joshi</surname><given-names>V.</given-names></name><name><surname>Fraga</surname><given-names>M.</given-names></name><name><surname>Rugg</surname><given-names>A.</given-names></name><name><surname>Yu</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Last</surname><given-names>R.L.</given-names></name></person-group><article-title>Application of a High-Throughput HPLC-MS/MS Assay to Arabidopsis Mutant Screening; Evidence That Threonine Aldolase Plays a Role in Seed Nutritional Quality</article-title><source>Plant J.</source><year>2004</year><volume>39</volume><fpage>465</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1111/j.1365-313X.2004.02140.x</pub-id><?supplied-pmid 15255874?><pub-id pub-id-type="pmid">15255874</pub-id></element-citation></ref><ref id="B391-biomedicines-09-00234"><label>391.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jinek</surname><given-names>M.</given-names></name><name><surname>Chylinski</surname><given-names>K.</given-names></name><name><surname>Fonfara</surname><given-names>I.</given-names></name><name><surname>Hauer</surname><given-names>M.</given-names></name><name><surname>Doudna</surname><given-names>J.A.</given-names></name><name><surname>Charpentier</surname><given-names>E.</given-names></name></person-group><article-title>A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity</article-title><source>Science</source><year>2012</year><volume>337</volume><fpage>816</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1126/science.1225829</pub-id><?supplied-pmid 22745249?><pub-id pub-id-type="pmid">22745249</pub-id></element-citation></ref><ref id="B392-biomedicines-09-00234"><label>392.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaganathan</surname><given-names>D.</given-names></name><name><surname>Ramasamy</surname><given-names>K.</given-names></name><name><surname>Sellamuthu</surname><given-names>G.</given-names></name><name><surname>Jayabalan</surname><given-names>S.</given-names></name><name><surname>Venkataraman</surname><given-names>G.</given-names></name></person-group><article-title>CRISPR for Crop Improvement: An Update Review</article-title><source>Front. Plant Sci.</source><year>2018</year><volume>9</volume><fpage>985</fpage><pub-id pub-id-type="doi">10.3389/fpls.2018.00985</pub-id><pub-id pub-id-type="pmid">30065734</pub-id></element-citation></ref><ref id="B393-biomedicines-09-00234"><label>393.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mali</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Esvelt</surname><given-names>K.M.</given-names></name><name><surname>Aach</surname><given-names>J.</given-names></name><name><surname>Guell</surname><given-names>M.</given-names></name><name><surname>DiCarlo</surname><given-names>J.E.</given-names></name><name><surname>Norville</surname><given-names>J.E.</given-names></name><name><surname>Church</surname><given-names>G.M.</given-names></name></person-group><article-title>RNA-Guided Human Genome Engineering via Cas9</article-title><source>Science</source><year>2013</year><volume>339</volume><fpage>823</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1126/science.1232033</pub-id><pub-id pub-id-type="pmid">23287722</pub-id></element-citation></ref><ref id="B394-biomedicines-09-00234"><label>394.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Foden</surname><given-names>J.A.</given-names></name><name><surname>Khayter</surname><given-names>C.</given-names></name><name><surname>Maeder</surname><given-names>M.L.</given-names></name><name><surname>Reyon</surname><given-names>D.</given-names></name><name><surname>Joung</surname><given-names>J.K.</given-names></name><name><surname>Sander</surname><given-names>J.D.</given-names></name></person-group><article-title>High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells</article-title><source>Nat. Biotechnol.</source><year>2013</year><volume>31</volume><fpage>822</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1038/nbt.2623</pub-id><pub-id pub-id-type="pmid">23792628</pub-id></element-citation></ref><ref id="B395-biomedicines-09-00234"><label>395.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>P.D.</given-names></name><name><surname>Scott</surname><given-names>D.A.</given-names></name><name><surname>Weinstein</surname><given-names>J.A.</given-names></name><name><surname>Ran</surname><given-names>F.A.</given-names></name><name><surname>Konermann</surname><given-names>S.</given-names></name><name><surname>Agarwala</surname><given-names>V.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Fine</surname><given-names>E.J.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Shalem</surname><given-names>O.</given-names></name><etal/></person-group><article-title>DNA Targeting Specificity of RNA-Guided Cas9 Nucleases</article-title><source>Nat. Biotechnol.</source><year>2013</year><volume>31</volume><fpage>827</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1038/nbt.2647</pub-id><?supplied-pmid 23873081?><pub-id pub-id-type="pmid">23873081</pub-id></element-citation></ref><ref id="B396-biomedicines-09-00234"><label>396.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ran</surname><given-names>F.A.</given-names></name><name><surname>Hsu</surname><given-names>P.D.</given-names></name><name><surname>Wright</surname><given-names>J.</given-names></name><name><surname>Agarwala</surname><given-names>V.</given-names></name><name><surname>Scott</surname><given-names>D.A.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name></person-group><article-title>Genome Engineering Using the CRISPR-Cas9 System</article-title><source>Nat. Protoc.</source><year>2013</year><volume>8</volume><fpage>2281</fpage><lpage>2308</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.143</pub-id><pub-id pub-id-type="pmid">24157548</pub-id></element-citation></ref><ref id="B397-biomedicines-09-00234"><label>397.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>S.Q.</given-names></name><name><surname>Nguyen</surname><given-names>N.T.</given-names></name><name><surname>Malagon-Lopez</surname><given-names>J.</given-names></name><name><surname>Topkar</surname><given-names>V.V.</given-names></name><name><surname>Aryee</surname><given-names>M.J.</given-names></name><name><surname>Joung</surname><given-names>J.K.</given-names></name></person-group><article-title>CIRCLE-Seq: A Highly Sensitive in Vitro Screen for Genome-Wide CRISPR-Cas9 Nuclease off-Targets</article-title><source>Nat. Methods</source><year>2017</year><volume>14</volume><fpage>607</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4278</pub-id><?supplied-pmid 28459458?><pub-id pub-id-type="pmid">28459458</pub-id></element-citation></ref><ref id="B398-biomedicines-09-00234"><label>398.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>J.W.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Kwon</surname><given-names>S.I.</given-names></name><name><surname>Corval&#x000e1;n</surname><given-names>C.</given-names></name><name><surname>Cho</surname><given-names>S.W.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>S.G.</given-names></name><name><surname>Kim</surname><given-names>S.T.</given-names></name><name><surname>Choe</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>J.S.</given-names></name></person-group><article-title>DNA-Free Genome Editing in Plants with Preassembled CRISPR-Cas9 Ribonucleoproteins</article-title><source>Nat. Biotechnol.</source><year>2015</year><volume>33</volume><fpage>1162</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1038/nbt.3389</pub-id><?supplied-pmid 26479191?><pub-id pub-id-type="pmid">26479191</pub-id></element-citation></ref><ref id="B399-biomedicines-09-00234"><label>399.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowder</surname><given-names>L.G.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Baltes</surname><given-names>N.J.</given-names></name><name><surname>Paul</surname><given-names>J.W.</given-names></name><name><surname>Tang</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Voytas</surname><given-names>D.F.</given-names></name><name><surname>Hsieh</surname><given-names>T.F.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Qi</surname><given-names>Y.</given-names></name></person-group><article-title>A CRISPR/Cas9 Toolbox for Multiplexed Plant Genome Editing and Transcriptional Regulation</article-title><source>Plant Physiol.</source><year>2015</year><volume>169</volume><fpage>971</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1104/pp.15.00636</pub-id><?supplied-pmid 26297141?><pub-id pub-id-type="pmid">26297141</pub-id></element-citation></ref><ref id="B400-biomedicines-09-00234"><label>400.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>W.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Bi</surname><given-names>H.</given-names></name><name><surname>Fromm</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Weeks</surname><given-names>D.P.</given-names></name></person-group><article-title>Demonstration of CRISPR/Cas9/SgRNA-Mediated Targeted Gene Modification in Arabidopsis, Tobacco, Sorghum and Rice</article-title><source>Nucleic Acids Res.</source><year>2013</year><volume>41</volume><fpage>e188</fpage><pub-id pub-id-type="doi">10.1093/nar/gkt780</pub-id><pub-id pub-id-type="pmid">23999092</pub-id></element-citation></ref><ref id="B401-biomedicines-09-00234"><label>401.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Ding</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>D.L.</given-names></name><name><surname>Wei</surname><given-names>P.</given-names></name><name><surname>Cao</surname><given-names>F.</given-names></name><name><surname>Zhu</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Mao</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Efficient Genome Editing in Plants Using a CRISPR/Cas System</article-title><source>Cell Res.</source><year>2013</year><volume>23</volume><fpage>1229</fpage><lpage>1232</lpage><pub-id pub-id-type="doi">10.1038/cr.2013.114</pub-id><pub-id pub-id-type="pmid">23958582</pub-id></element-citation></ref><ref id="B402-biomedicines-09-00234"><label>402.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bortesi</surname><given-names>L.</given-names></name><name><surname>Fischer</surname><given-names>R.</given-names></name></person-group><article-title>The CRISPR/Cas9 System for Plant Genome Editing and Beyond</article-title><source>Biotechnol. Adv.</source><year>2015</year><volume>33</volume><fpage>41</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2014.12.006</pub-id><pub-id pub-id-type="pmid">25536441</pub-id></element-citation></ref><ref id="B403-biomedicines-09-00234"><label>403.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Podevin</surname><given-names>N.</given-names></name><name><surname>Davies</surname><given-names>H.V.</given-names></name><name><surname>Hartung</surname><given-names>F.</given-names></name><name><surname>Nogu&#x000e9;</surname><given-names>F.</given-names></name><name><surname>Casacuberta</surname><given-names>J.M.</given-names></name></person-group><article-title>Site-Directed Nucleases: A Paradigm Shift in Predictable, Knowledge-Based Plant Breeding</article-title><source>Trends Biotechnol.</source><year>2013</year><volume>31</volume><fpage>375</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2013.03.004</pub-id><pub-id pub-id-type="pmid">23601269</pub-id></element-citation></ref><ref id="B404-biomedicines-09-00234"><label>404.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Zhu</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Qiu</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A Robust CRISPR/Cas9 System for Convenient, High-Efficiency Multiplex Genome Editing in Monocot and Dicot Plants</article-title><source>Mol. Plant</source><year>2015</year><volume>8</volume><fpage>1274</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1016/j.molp.2015.04.007</pub-id><pub-id pub-id-type="pmid">25917172</pub-id></element-citation></ref><ref id="B405-biomedicines-09-00234"><label>405.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>Z.</given-names></name><name><surname>Abulfaraj</surname><given-names>A.</given-names></name><name><surname>Idris</surname><given-names>A.</given-names></name><name><surname>Ali</surname><given-names>S.</given-names></name><name><surname>Tashkandi</surname><given-names>M.</given-names></name><name><surname>Mahfouz</surname><given-names>M.M.</given-names></name></person-group><article-title>CRISPR/Cas9-Mediated Viral Interference in Plants</article-title><source>Genome Biol.</source><year>2015</year><volume>16</volume><pub-id pub-id-type="doi">10.1186/s13059-015-0799-6</pub-id></element-citation></ref><ref id="B406-biomedicines-09-00234"><label>406.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>H.L.</given-names></name><name><surname>Dong</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Z.P.</given-names></name><name><surname>Zhang</surname><given-names>H.Y.</given-names></name><name><surname>Han</surname><given-names>C.Y.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>X.C.</given-names></name><name><surname>Chen</surname><given-names>Q.J.</given-names></name></person-group><article-title>A CRISPR/Cas9 Toolkit for Multiplex Genome Editing in Plants</article-title><source>BMC Plant Biol.</source><year>2014</year><volume>14</volume><elocation-id>327</elocation-id><pub-id pub-id-type="doi">10.1186/s12870-014-0327-y</pub-id><?supplied-pmid 25432517?><pub-id pub-id-type="pmid">25432517</pub-id></element-citation></ref><ref id="B407-biomedicines-09-00234"><label>407.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Cheng</surname><given-names>X.</given-names></name><name><surname>Shan</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>C.</given-names></name><name><surname>Qiu</surname><given-names>J.L.</given-names></name></person-group><article-title>Simultaneous Editing of Three Homoeoalleles in Hexaploid Bread Wheat Confers Heritable Resistance to Powdery Mildew</article-title><source>Nat. Biotechnol.</source><year>2014</year><volume>32</volume><fpage>947</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1038/nbt.2969</pub-id><?supplied-pmid 25038773?><pub-id pub-id-type="pmid">25038773</pub-id></element-citation></ref><ref id="B408-biomedicines-09-00234"><label>408.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.F.</given-names></name><name><surname>Norville</surname><given-names>J.E.</given-names></name><name><surname>Aach</surname><given-names>J.</given-names></name><name><surname>McCormack</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Bush</surname><given-names>J.</given-names></name><name><surname>Church</surname><given-names>G.M.</given-names></name><name><surname>Sheen</surname><given-names>J.</given-names></name></person-group><article-title>Multiplex and Homologous Recombination-Mediated Genome Editing in Arabidopsis and Nicotiana Benthamiana Using Guide RNA and Cas9</article-title><source>Nat. Biotechnol.</source><year>2013</year><volume>31</volume><fpage>688</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1038/nbt.2654</pub-id><?supplied-pmid 23929339?><pub-id pub-id-type="pmid">23929339</pub-id></element-citation></ref><ref id="B409-biomedicines-09-00234"><label>409.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belhaj</surname><given-names>K.</given-names></name><name><surname>Chaparro-Garcia</surname><given-names>A.</given-names></name><name><surname>Kamoun</surname><given-names>S.</given-names></name><name><surname>Patron</surname><given-names>N.J.</given-names></name><name><surname>Nekrasov</surname><given-names>V.</given-names></name></person-group><article-title>Editing Plant Genomes with CRISPR/Cas9</article-title><source>Curr. Opin. Biotechnol.</source><year>2015</year><volume>32</volume><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2014.11.007</pub-id><pub-id pub-id-type="pmid">25437637</pub-id></element-citation></ref><ref id="B410-biomedicines-09-00234"><label>410.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>Z.B.</given-names></name><name><surname>Xing</surname><given-names>A.</given-names></name><name><surname>Moon</surname><given-names>B.P.</given-names></name><name><surname>Koellhoffer</surname><given-names>J.P.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Ward</surname><given-names>R.T.</given-names></name><name><surname>Clifton</surname><given-names>E.</given-names></name><name><surname>Falco</surname><given-names>S.C.</given-names></name><name><surname>Cigan</surname><given-names>A.M.</given-names></name></person-group><article-title>Cas9-Guide RNA Directed Genome Editing in Soybean</article-title><source>Plant Physiol.</source><year>2015</year><volume>169</volume><fpage>960</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1104/pp.15.00783</pub-id><pub-id pub-id-type="pmid">26294043</pub-id></element-citation></ref><ref id="B411-biomedicines-09-00234"><label>411.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mackinnon</surname><given-names>L.</given-names></name><name><surname>McDougall</surname><given-names>G.</given-names></name><name><surname>Aziz</surname><given-names>N.</given-names></name><name><surname>Millam</surname><given-names>S.</given-names></name></person-group><source>Progress Towards Transformation of Fibre Hemp</source><comment>Scottish Crop Research Institute Annual Report 2000/2001</comment><publisher-name>Scottish Crop Research Institute</publisher-name><publisher-loc>Dundee, UK</publisher-loc><year>2000</year><fpage>84</fpage><lpage>86</lpage></element-citation></ref><ref id="B412-biomedicines-09-00234"><label>412.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feeney</surname><given-names>M.</given-names></name><name><surname>Punja</surname><given-names>Z.K.</given-names></name></person-group><article-title>Tissue Culture and Agrobacterium-Mediated Transformation of Hemp (<italic>Cannabis sativa</italic> L.)</article-title><source>Vitr. Cell. Dev. Biol. Plant</source><year>2003</year><volume>39</volume><fpage>578</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1079/IVP2003454</pub-id></element-citation></ref><ref id="B413-biomedicines-09-00234"><label>413.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahby</surname><given-names>I.</given-names></name><name><surname>Caba</surname><given-names>J.M.</given-names></name><name><surname>Ligero</surname><given-names>F.</given-names></name></person-group><article-title>Agrobacterium Infection of Hemp (<italic>Cannabis sativa</italic> L.): Establishment of Hairy Root Cultures</article-title><source>J. Plant Interact.</source><year>2013</year><volume>8</volume><fpage>312</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1080/17429145.2012.746399</pub-id></element-citation></ref><ref id="B414-biomedicines-09-00234"><label>414.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>S.</given-names></name><name><surname>Srivastava</surname><given-names>A.K.</given-names></name></person-group><article-title>Hairy Root Culture for Mass-Production of High-Value Secondary Metabolites</article-title><source>Crit. Rev. Biotechnol.</source><year>2007</year><volume>27</volume><fpage>29</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1080/07388550601173918</pub-id><pub-id pub-id-type="pmid">17364688</pub-id></element-citation></ref><ref id="B415-biomedicines-09-00234"><label>415.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0015a;lusarkiewicz-Jarzina</surname><given-names>A.</given-names></name><name><surname>Ponitka</surname><given-names>A.</given-names></name><name><surname>Kaczmarek</surname><given-names>Z.</given-names></name></person-group><article-title>Influence of Cultivar, Explant Source and Plant Growth Regulator on Callus Induction and Plant Regeneration of <italic>Cannabis sativa</italic> L.</article-title><source>Acta Biol. Cracoviensia Ser. Bot.</source><year>2005</year><volume>47</volume><fpage>145</fpage><lpage>151</lpage></element-citation></ref><ref id="B416-biomedicines-09-00234"><label>416.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>&#x000c2;.</given-names></name><name><surname>Hansen</surname><given-names>E.H.</given-names></name><name><surname>Kayser</surname><given-names>O.</given-names></name><name><surname>Carlsen</surname><given-names>S.</given-names></name><name><surname>Stehle</surname><given-names>F.</given-names></name></person-group><article-title>Designing Microorganisms for Heterologous Biosynthesis of Cannabinoids</article-title><source>FEMS Yeast Res.</source><year>2017</year><volume>17</volume><fpage>Fox037</fpage><pub-id pub-id-type="doi">10.1093/femsyr/fox037</pub-id><?supplied-pmid 28582498?><pub-id pub-id-type="pmid">28582498</pub-id></element-citation></ref><ref id="B417-biomedicines-09-00234"><label>417.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zirpel</surname><given-names>B.</given-names></name><name><surname>Stehle</surname><given-names>F.</given-names></name><name><surname>Kayser</surname><given-names>O.</given-names></name></person-group><article-title>Production of &#x00394;9-Tetrahydrocannabinolic Acid from Cannabigerolic Acid by Whole Cells of Pichia (Komagataella) Pastoris Expressing &#x00394;9-Tetrahydrocannabinolic Acid Synthase from <italic>Cannabis sativa</italic> L.</article-title><source>Biotechnol. Lett.</source><year>2015</year><volume>37</volume><fpage>1869</fpage><lpage>1875</lpage><pub-id pub-id-type="doi">10.1007/s10529-015-1853-x</pub-id><?supplied-pmid 25994576?><pub-id pub-id-type="pmid">25994576</pub-id></element-citation></ref><ref id="B418-biomedicines-09-00234"><label>418.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohto</surname><given-names>C.</given-names></name><name><surname>Muramatsu</surname><given-names>M.</given-names></name><name><surname>Obata</surname><given-names>S.</given-names></name><name><surname>Sakuradani</surname><given-names>E.</given-names></name><name><surname>Shimizu</surname><given-names>S.</given-names></name></person-group><article-title>Overexpression of the Gene Encoding HMG-CoA Reductase in Saccharomyces Cerevisiae for Production of Prenyl Alcohols</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2009</year><volume>82</volume><fpage>837</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1007/s00253-008-1807-5</pub-id><?supplied-pmid 19083230?><pub-id pub-id-type="pmid">19083230</pub-id></element-citation></ref><ref id="B419-biomedicines-09-00234"><label>419.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zirpel</surname><given-names>B.</given-names></name><name><surname>Degenhardt</surname><given-names>F.</given-names></name><name><surname>Martin</surname><given-names>C.</given-names></name><name><surname>Kayser</surname><given-names>O.</given-names></name><name><surname>Stehle</surname><given-names>F.</given-names></name></person-group><article-title>Engineering Yeasts as Platform Organisms for Cannabinoid Biosynthesis</article-title><source>J. Biotechnol.</source><year>2017</year><volume>259</volume><fpage>204</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2017.07.008</pub-id><pub-id pub-id-type="pmid">28694184</pub-id></element-citation></ref><ref id="B420-biomedicines-09-00234"><label>420.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>E.</given-names></name></person-group><article-title>The Carbon Footprint of Indoor Cannabis Production</article-title><source>Energy Policy</source><year>2012</year><volume>46</volume><fpage>58</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.enpol.2012.03.023</pub-id></element-citation></ref><ref id="B421-biomedicines-09-00234"><label>421.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borthwick</surname><given-names>H.A.</given-names></name><name><surname>Scully</surname><given-names>N.J.</given-names></name></person-group><article-title>Photoperiodic Responses of Hemp</article-title><source>Bot. Gaz.</source><year>1954</year><volume>116</volume><fpage>14</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1086/335843</pub-id></element-citation></ref><ref id="B422-biomedicines-09-00234"><label>422.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaffner</surname><given-names>J.H.</given-names></name></person-group><article-title>The Influence of Relative Length of Daylight on the Reversal of Sex in Hemp</article-title><source>Ecology</source><year>1923</year><volume>4</volume><fpage>323</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.2307/1929179</pub-id></element-citation></ref><ref id="B423-biomedicines-09-00234"><label>423.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potter</surname><given-names>D.J.</given-names></name><name><surname>Duncombe</surname><given-names>P.</given-names></name></person-group><article-title>The Effect of Electrical Lighting Power and Irradiance on Indoor-Grown Cannabis Potency and Yield</article-title><source>J. Forensic Sci.</source><year>2012</year><volume>57</volume><fpage>618</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1111/j.1556-4029.2011.02024.x</pub-id><pub-id pub-id-type="pmid">22211717</pub-id></element-citation></ref><ref id="B424-biomedicines-09-00234"><label>424.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spitzer-Rimon</surname><given-names>B.</given-names></name><name><surname>Duchin</surname><given-names>S.</given-names></name><name><surname>Bernstein</surname><given-names>N.</given-names></name><name><surname>Kamenetsky</surname><given-names>R.</given-names></name></person-group><article-title>Architecture and Florogenesis in Female <italic>Cannabis sativa</italic> Plants</article-title><source>Front. Plant Sci.</source><year>2019</year><volume>10</volume><fpage>350</fpage><pub-id pub-id-type="doi">10.3389/fpls.2019.00350</pub-id><pub-id pub-id-type="pmid">31001293</pub-id></element-citation></ref><ref id="B425-biomedicines-09-00234"><label>425.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanhove</surname><given-names>W.</given-names></name><name><surname>Van Damme</surname><given-names>P.</given-names></name><name><surname>Meert</surname><given-names>N.</given-names></name></person-group><article-title>Factors Determining Yield and Quality of Illicit Indoor Cannabis (Cannabis Spp.) Production</article-title><source>Forensic Sci. Int.</source><year>2011</year><volume>212</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1016/j.forsciint.2011.06.006</pub-id><?supplied-pmid 21737218?><pub-id pub-id-type="pmid">21802229</pub-id></element-citation></ref><ref id="B426-biomedicines-09-00234"><label>426.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Vir&#x00161;ile</surname><given-names>A.</given-names></name><name><surname>Olle</surname><given-names>M.</given-names></name><name><surname>Duchovskis</surname><given-names>P.</given-names></name></person-group><article-title>LED Lighting in Horticulture</article-title><source>Light Emitting Diodes for Agriculture: Smart Lighting</source><publisher-name>Springer</publisher-name><publisher-loc>Singapore</publisher-loc><year>2017</year><fpage>113</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1007/978-981-10-5807-3_7</pub-id></element-citation></ref><ref id="B427-biomedicines-09-00234"><label>427.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>J.A.</given-names></name><name><surname>Bugbee</surname><given-names>B.</given-names></name></person-group><article-title>Economic Analysis of Greenhouse Lighting: Light Emitting Diodes vs. High Intensity Discharge Fixtures</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e99010</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0099010</pub-id><pub-id pub-id-type="pmid">24905835</pub-id></element-citation></ref><ref id="B428-biomedicines-09-00234"><label>428.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamulaitis</surname><given-names>G.</given-names></name><name><surname>Duchovskis</surname><given-names>P.</given-names></name><name><surname>Bliznikas</surname><given-names>Z.</given-names></name><name><surname>Breive</surname><given-names>K.</given-names></name><name><surname>Ulinskaite</surname><given-names>R.</given-names></name><name><surname>Brazaityte</surname><given-names>A.</given-names></name><name><surname>Novi&#x0010d;kovas</surname><given-names>A.</given-names></name><name><surname>&#x0017d;ukauskas</surname><given-names>A.</given-names></name></person-group><article-title>High-Power Light-Emitting Diode Based Facility for Plant Cultivation</article-title><source>J. Phys. D. Appl. Phys.</source><year>2005</year><volume>38</volume><fpage>3182</fpage><lpage>3187</lpage><pub-id pub-id-type="doi">10.1088/0022-3727/38/17/S20</pub-id></element-citation></ref><ref id="B429-biomedicines-09-00234"><label>429.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogewoning</surname><given-names>S.W.</given-names></name><name><surname>Douwstra</surname><given-names>P.</given-names></name><name><surname>Trouwborst</surname><given-names>G.</given-names></name><name><surname>Van Ieperen</surname><given-names>W.</given-names></name><name><surname>Harbinson</surname><given-names>J.</given-names></name></person-group><article-title>An Artificial Solar Spectrum Substantially Alters Plant Development Compared with Usual Climate Room Irradiance Spectra</article-title><source>J. Exp. Bot.</source><year>2010</year><volume>61</volume><fpage>1267</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1093/jxb/erq005</pub-id><pub-id pub-id-type="pmid">20202994</pub-id></element-citation></ref><ref id="B430-biomedicines-09-00234"><label>430.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backer</surname><given-names>R.</given-names></name><name><surname>Schwinghamer</surname><given-names>T.</given-names></name><name><surname>Rosenbaum</surname><given-names>P.</given-names></name><name><surname>McCarty</surname><given-names>V.</given-names></name><name><surname>Eichhorn Bilodeau</surname><given-names>S.</given-names></name><name><surname>Lyu</surname><given-names>D.</given-names></name><name><surname>Ahmed</surname><given-names>M.B.</given-names></name><name><surname>Robinson</surname><given-names>G.</given-names></name><name><surname>Lefsrud</surname><given-names>M.</given-names></name><name><surname>Wilkins</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Closing the Yield Gap for Cannabis: A Meta-Analysis of Factors Determining Cannabis Yield</article-title><source>Front. Plant Sci.</source><year>2019</year><volume>10</volume><pub-id pub-id-type="doi">10.3389/fpls.2019.00495</pub-id></element-citation></ref><ref id="B431-biomedicines-09-00234"><label>431.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>S.</given-names></name><name><surname>Lata</surname><given-names>H.</given-names></name><name><surname>Khan</surname><given-names>I.A.</given-names></name><name><surname>Elsohly</surname><given-names>M.A.</given-names></name></person-group><article-title>Photosynthetic Response of <italic>Cannabis sativa</italic> L. to Variations in Photosynthetic Photon Flux Densities, Temperature and CO2 Conditions</article-title><source>Physiol. Mol. Biol. Plants</source><year>2008</year><volume>14</volume><fpage>299</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1007/s12298-008-0027-x</pub-id><?supplied-pmid 23572895?><pub-id pub-id-type="pmid">23572895</pub-id></element-citation></ref><ref id="B432-biomedicines-09-00234"><label>432.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>S.</given-names></name><name><surname>Lata</surname><given-names>H.</given-names></name><name><surname>Mehmedic</surname><given-names>Z.</given-names></name><name><surname>Khan</surname><given-names>I.A.</given-names></name><name><surname>ElSohly</surname><given-names>M.A.</given-names></name></person-group><article-title>Light Dependence of Photosynthesis and Water Vapor Exchange Characteristics in Different High &#x00394;9-THC Yielding Varieties of <italic>Cannabis sativa</italic> L.</article-title><source>J. Appl. Res. Med. Aromat. Plants</source><year>2015</year><volume>2</volume><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.jarmap.2015.03.002</pub-id></element-citation></ref><ref id="B433-biomedicines-09-00234"><label>433.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lydon</surname><given-names>J.</given-names></name><name><surname>Teramura</surname><given-names>A.H.</given-names></name><name><surname>Coffman</surname><given-names>C.B.</given-names></name></person-group><article-title>UV-B Radiation Effects on Photosynthesis, Growth and Cannabinoid Production of Two <italic>Cannabis sativa</italic> Chemotypes</article-title><source>Photochem. Photobiol.</source><year>1987</year><volume>46</volume><fpage>201</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1111/j.1751-1097.1987.tb04757.x</pub-id><pub-id pub-id-type="pmid">3628508</pub-id></element-citation></ref><ref id="B434-biomedicines-09-00234"><label>434.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>J.</given-names></name><name><surname>Bjorkman</surname><given-names>O.</given-names></name></person-group><article-title>Photosynthetic Response and Adaptation to Temperature in Higher Plants</article-title><source>Annu. Rev. Plant Physiol.</source><year>1980</year><volume>31</volume><fpage>491</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1146/annurev.pp.31.060180.002423</pub-id></element-citation></ref><ref id="B435-biomedicines-09-00234"><label>435.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Larcher</surname><given-names>W.</given-names></name></person-group><article-title>Photosynthesis as a Tool for Indicating Temperature Stress Events</article-title><source>Ecophysiology of Photosynthesis</source><person-group person-group-type="editor"><name><surname>Schulze</surname><given-names>E.</given-names></name><name><surname>Caldwell</surname><given-names>M.M.</given-names></name></person-group><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>1995</year><fpage>261</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1007/978-3-642-79354-7_13</pub-id></element-citation></ref><ref id="B436-biomedicines-09-00234"><label>436.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hikosaka</surname><given-names>K.</given-names></name><name><surname>Ishikawa</surname><given-names>K.</given-names></name><name><surname>Borjigidai</surname><given-names>A.</given-names></name><name><surname>Muller</surname><given-names>O.</given-names></name><name><surname>Onoda</surname><given-names>Y.</given-names></name></person-group><article-title>Temperature Acclimation of Photosynthesis: Mechanisms Involved in the Changes in Temperature Dependence of Photosynthetic Rate</article-title><source>J. Exp. Bot.</source><year>2006</year><volume>57</volume><fpage>291</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1093/jxb/erj049</pub-id><pub-id pub-id-type="pmid">16364948</pub-id></element-citation></ref><ref id="B437-biomedicines-09-00234"><label>437.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>S.</given-names></name><name><surname>Lata</surname><given-names>H.</given-names></name><name><surname>Khan</surname><given-names>I.A.</given-names></name><name><surname>ElSohly</surname><given-names>M.A.</given-names></name></person-group><article-title>Temperature Response of Photosynthesis in Different Drug and Fiber Varieties of <italic>Cannabis sativa</italic> L.</article-title><source>Physiol. Mol. Biol. Plants</source><year>2011</year><volume>17</volume><fpage>297</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1007/s12298-011-0068-4</pub-id><pub-id pub-id-type="pmid">23573022</pub-id></element-citation></ref><ref id="B438-biomedicines-09-00234"><label>438.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Werf</surname><given-names>H.M.G.</given-names></name><name><surname>Brouwer</surname><given-names>K.</given-names></name><name><surname>Wijlhuizen</surname><given-names>M.</given-names></name><name><surname>Withagen</surname><given-names>J.C.M.</given-names></name></person-group><article-title>The Effect of Temperature on Leaf Appearance and Canopy Establishment in Fibre Hemp (<italic>Cannabis sativa</italic> L.)</article-title><source>Ann. Appl. Biol.</source><year>1995</year><volume>126</volume><fpage>551</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1111/j.1744-7348.1995.tb05389.x</pub-id></element-citation></ref><ref id="B439-biomedicines-09-00234"><label>439.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>N.</given-names></name><name><surname>Gorelick</surname><given-names>J.</given-names></name><name><surname>Zerahia</surname><given-names>R.</given-names></name><name><surname>Koch</surname><given-names>S.</given-names></name></person-group><article-title>Impact of N, P, K, and Humic Acid Supplementation on the Chemical Profile of Medical Cannabis (<italic>Cannabis sativa</italic> L)</article-title><source>Front. Plant Sci.</source><year>2019</year><volume>10</volume><pub-id pub-id-type="doi">10.3389/fpls.2019.00736</pub-id><?supplied-pmid 31263470?><pub-id pub-id-type="pmid">31263470</pub-id></element-citation></ref><ref id="B440-biomedicines-09-00234"><label>440.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma&#x0013c;ceva</surname><given-names>M.</given-names></name><name><surname>Vikmane</surname><given-names>M.</given-names></name><name><surname>Stramkale</surname><given-names>V.</given-names></name></person-group><article-title>Changes of Photosynthesis-Related Parameters and Productivity of <italic>Cannabis sativa</italic> under Different Nitrogen Supply</article-title><source>Environ. Exp. Biol.</source><year>2011</year><volume>9</volume><fpage>61</fpage><lpage>69</lpage></element-citation></ref><ref id="B441-biomedicines-09-00234"><label>441.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansouri</surname><given-names>H.</given-names></name><name><surname>Asrar</surname><given-names>Z.</given-names></name></person-group><article-title>Effects of Abscisic Acid on Content and Biosynthesis of Terpenoids in <italic>Cannabis sativa</italic> at Vegetative Stage</article-title><source>Biol. Plant.</source><year>2012</year><volume>56</volume><fpage>153</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1007/s10535-012-0033-2</pub-id></element-citation></ref><ref id="B442-biomedicines-09-00234"><label>442.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansouri</surname><given-names>H.</given-names></name><name><surname>Asrar</surname><given-names>Z.</given-names></name><name><surname>Mehrabani</surname><given-names>M.</given-names></name></person-group><article-title>Effects of Gibberellic Acid on Primary Terpenoids and &#x00394;9-Tetrahydrocannabinol in <italic>Cannabis sativa</italic> at Flowering Stage</article-title><source>J. Integr. Plant Biol.</source><year>2009</year><volume>51</volume><fpage>553</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1111/j.1744-7909.2009.00833.x</pub-id><pub-id pub-id-type="pmid">19522814</pub-id></element-citation></ref><ref id="B443-biomedicines-09-00234"><label>443.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larkin</surname><given-names>J.C.</given-names></name><name><surname>Oppenheimer</surname><given-names>D.G.</given-names></name><name><surname>Lloyd</surname><given-names>A.M.</given-names></name><name><surname>Paparozzi</surname><given-names>E.T.</given-names></name><name><surname>Marks</surname><given-names>M.D.</given-names></name></person-group><article-title>Roles of the GLABROUS1 and TRANSPARENT TESTA GLABRA Genes in Arabidopsis Trichome Development</article-title><source>Plant Cell</source><year>1994</year><volume>6</volume><fpage>1065</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.2307/3869885</pub-id><?supplied-pmid 12244266?><pub-id pub-id-type="pmid">12244266</pub-id></element-citation></ref><ref id="B444-biomedicines-09-00234"><label>444.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Payne</surname><given-names>C.T.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Lloyd</surname><given-names>A.M.</given-names></name></person-group><article-title>GL3 Encodes a BHLH Protein That Regulates Trichome Development in Arabidopsis through Interaction with GL1 and TTG1</article-title><source>Genetics</source><year>2000</year><volume>156</volume><fpage>1349</fpage><lpage>1362</lpage><pub-id pub-id-type="pmid">11063707</pub-id></element-citation></ref><ref id="B445-biomedicines-09-00234"><label>445.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rerie</surname><given-names>W.G.</given-names></name><name><surname>Feldmann</surname><given-names>K.A.</given-names></name><name><surname>Marks</surname><given-names>M.D.</given-names></name></person-group><article-title>The GLABRA2 Gene Encodes a Homeo Domain Protein Required for Normal Trichome Development in Arabidopsis</article-title><source>Genes Dev.</source><year>1994</year><volume>8</volume><fpage>1388</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1101/gad.8.12.1388</pub-id><pub-id pub-id-type="pmid">7926739</pub-id></element-citation></ref><ref id="B446-biomedicines-09-00234"><label>446.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szymanski</surname><given-names>D.B.</given-names></name><name><surname>Jilk</surname><given-names>R.A.</given-names></name><name><surname>Pollock</surname><given-names>S.M.</given-names></name><name><surname>Marks</surname><given-names>M.D.</given-names></name></person-group><article-title>Control of GL2 Expression in Arabidopsis Leaves and Trichomes</article-title><source>Development</source><year>1998</year><volume>125</volume><fpage>1161</fpage><lpage>1171</lpage><pub-id pub-id-type="pmid">9477315</pub-id></element-citation></ref><ref id="B447-biomedicines-09-00234"><label>447.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000fc;lskamp</surname><given-names>M.</given-names></name><name><surname>Mis&#x000e9;ra</surname><given-names>S.</given-names></name><name><surname>J&#x000fc;rgens</surname><given-names>G.</given-names></name></person-group><article-title>Genetic Dissection of Trichome Cell Development in Arabidopsis</article-title><source>Cell</source><year>1994</year><volume>76</volume><fpage>555</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(94)90118-X</pub-id><pub-id pub-id-type="pmid">8313475</pub-id></element-citation></ref><ref id="B448-biomedicines-09-00234"><label>448.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perazza</surname><given-names>D.</given-names></name><name><surname>Herzog</surname><given-names>M.</given-names></name><name><surname>H&#x000fc;lskamp</surname><given-names>M.</given-names></name><name><surname>Brown</surname><given-names>S.</given-names></name><name><surname>Dorne</surname><given-names>A.M.</given-names></name><name><surname>Bonneville</surname><given-names>J.M.</given-names></name></person-group><article-title>Trichome Cell Growth in <italic>Arabidopsis thaliana</italic> Can Be Derepressed by Mutations in at Least Five Genes</article-title><source>Genetics</source><year>1999</year><volume>152</volume><fpage>461</fpage><lpage>476</lpage><pub-id pub-id-type="pmid">10224275</pub-id></element-citation></ref><ref id="B449-biomedicines-09-00234"><label>449.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>R.</given-names></name><name><surname>Hua</surname><given-names>C.</given-names></name><name><surname>Ali</surname><given-names>I.</given-names></name><name><surname>Zhang</surname><given-names>A.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Gan</surname><given-names>Y.</given-names></name></person-group><article-title>AtGIS, a C2H2 Zinc-Finger Transcription Factor from Arabidopsis Regulates Glandular Trichome Development through GA Signaling in Tobacco</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2017</year><volume>483</volume><fpage>209</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2016.12.164</pub-id><pub-id pub-id-type="pmid">28034756</pub-id></element-citation></ref><ref id="B450-biomedicines-09-00234"><label>450.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Xia</surname><given-names>K.F.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>Z.F.</given-names></name></person-group><article-title>Overexpression of a Weed (Solanum Americanum) Proteinase Inhibitor in Transgenic Tobacco Results in Increased Glandular Trichome Density and Enhanced Resistance to Helicoverpa Armigera and Spodoptera Litura</article-title><source>Int. J. Mol. Sci.</source><year>2009</year><volume>10</volume><fpage>1896</fpage><lpage>1910</lpage><pub-id pub-id-type="doi">10.3390/ijms10041896</pub-id><?supplied-pmid 19468345?><pub-id pub-id-type="pmid">19468345</pub-id></element-citation></ref><ref id="B451-biomedicines-09-00234"><label>451.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paetzold</surname><given-names>H.</given-names></name><name><surname>Garms</surname><given-names>S.</given-names></name><name><surname>Bartram</surname><given-names>S.</given-names></name><name><surname>Wieczorek</surname><given-names>J.</given-names></name><name><surname>Ur&#x000f3;s-Gracia</surname><given-names>E.M.</given-names></name><name><surname>Rodr&#x000ed;guez-Concepci&#x000f3;n</surname><given-names>M.</given-names></name><name><surname>Boland</surname><given-names>W.</given-names></name><name><surname>Strack</surname><given-names>D.</given-names></name><name><surname>Hause</surname><given-names>B.</given-names></name><name><surname>Walter</surname><given-names>M.H.</given-names></name></person-group><article-title>The Isogene 1-Deoxy-D-Xylulose 5-Phosphate Synthase 2 Controls Isoprenoid Profiles, Precursor Pathway Allocation, and Density of Tomato Trichomes</article-title><source>Mol. Plant</source><year>2010</year><volume>3</volume><fpage>904</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1093/mp/ssq032</pub-id><pub-id pub-id-type="pmid">20591838</pub-id></element-citation></ref><ref id="B452-biomedicines-09-00234"><label>452.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Fang</surname><given-names>L.</given-names></name><name><surname>Wan</surname><given-names>Q.</given-names></name><name><surname>Liang</surname><given-names>W.</given-names></name><name><surname>Mei</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Genetic Basis for Glandular Trichome Formation in Cotton</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>10456</fpage><pub-id pub-id-type="doi">10.1038/ncomms10456</pub-id><?supplied-pmid 26795254?><pub-id pub-id-type="pmid">26795254</pub-id></element-citation></ref><ref id="B453-biomedicines-09-00234"><label>453.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salas Fernandez</surname><given-names>M.G.</given-names></name><name><surname>Becraft</surname><given-names>P.W.</given-names></name><name><surname>Yin</surname><given-names>Y.</given-names></name><name><surname>L&#x000fc;bberstedt</surname><given-names>T.</given-names></name></person-group><article-title>From Dwarves to Giants? Plant Height Manipulation for Biomass Yield</article-title><source>Trends Plant Sci.</source><year>2009</year><volume>14</volume><fpage>454</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1016/j.tplants.2009.06.005</pub-id><pub-id pub-id-type="pmid">19616467</pub-id></element-citation></ref><ref id="B454-biomedicines-09-00234"><label>454.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campiglia</surname><given-names>E.</given-names></name><name><surname>Radicetti</surname><given-names>E.</given-names></name><name><surname>Mancinelli</surname><given-names>R.</given-names></name></person-group><article-title>Plant Density and Nitrogen Fertilization Affect Agronomic Performance of Industrial Hemp (<italic>Cannabis sativa</italic> L.) in Mediterranean Environment</article-title><source>Ind. Crop. Prod</source><year>2017</year><volume>100</volume><fpage>246</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/j.indcrop.2017.02.022</pub-id></element-citation></ref><ref id="B455-biomedicines-09-00234"><label>455.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Werf</surname><given-names>H.M.G.</given-names></name><name><surname>Wijlhuizen</surname><given-names>M.</given-names></name><name><surname>de Schutter</surname><given-names>J.A.A.</given-names></name></person-group><article-title>Plant Density and Self-Thinning Affect Yield and Quality of Fibre Hemp (<italic>Cannabis sativa</italic> L.)</article-title><source>Field Crop. Res.</source><year>1995</year><volume>40</volume><fpage>153</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/0378-4290(94)00103-J</pub-id></element-citation></ref><ref id="B456-biomedicines-09-00234"><label>456.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Small</surname><given-names>E.</given-names></name></person-group><article-title>Dwarf Germplasm: The Key to Giant Cannabis Hempseed and Cannabinoid Crops</article-title><source>Genet. Resour. Crop Evol.</source><year>2018</year><volume>65</volume><fpage>1071</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.1007/s10722-017-0597-y</pub-id></element-citation></ref><ref id="B457-biomedicines-09-00234"><label>457.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>L.A.</given-names></name><name><surname>Besser</surname><given-names>K.</given-names></name><name><surname>Blumer</surname><given-names>S.</given-names></name><name><surname>Branigan</surname><given-names>C.A.</given-names></name><name><surname>Czechowski</surname><given-names>T.</given-names></name><name><surname>Elias</surname><given-names>L.</given-names></name><name><surname>Guterman</surname><given-names>I.</given-names></name><name><surname>Harvey</surname><given-names>D.</given-names></name><name><surname>Isaac</surname><given-names>P.G.</given-names></name><name><surname>Khan</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>The Genetic Map of Artemisia Annua L Identifies Loci Affecting Yield of the Antimalarial Drug Artemisinin</article-title><source>Science</source><year>2010</year><volume>327</volume><fpage>328</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1126/science.1182612</pub-id><?supplied-pmid 20075252?><pub-id pub-id-type="pmid">20075252</pub-id></element-citation></ref><ref id="B458-biomedicines-09-00234"><label>458.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fairbairn</surname><given-names>J.</given-names></name><name><surname>Kapoor</surname><given-names>L.</given-names></name></person-group><article-title>The Lactiferous Vessels of Papaver Somniferum L.</article-title><source>Planta Med.</source><year>1960</year><volume>8</volume><fpage>49</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1055/s-0028-1101536</pub-id></element-citation></ref><ref id="B459-biomedicines-09-00234"><label>459.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nessler</surname><given-names>C.L.</given-names></name><name><surname>Mahlberg</surname><given-names>P.G.</given-names></name></person-group><article-title>Laticifers in Stamens of Papaver Somniferum L.</article-title><source>Planta</source><year>1976</year><volume>129</volume><fpage>83</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1007/BF00390918</pub-id><pub-id pub-id-type="pmid">24430820</pub-id></element-citation></ref><ref id="B460-biomedicines-09-00234"><label>460.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weid</surname><given-names>M.</given-names></name><name><surname>Ziegler</surname><given-names>J.</given-names></name><name><surname>Kutchan</surname><given-names>T.M.</given-names></name></person-group><article-title>The Roles of Latex and the Vascular Bundle in Morphine Biosynthesis in the Opium Poppy, Papaver Somniferum</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>13957</fpage><lpage>13962</lpage><pub-id pub-id-type="doi">10.1073/pnas.0405704101</pub-id><?supplied-pmid 15353584?><pub-id pub-id-type="pmid">15353584</pub-id></element-citation></ref><ref id="B461-biomedicines-09-00234"><label>461.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuller</surname><given-names>J.G.</given-names></name><name><surname>McMorland</surname><given-names>G.H.</given-names></name><name><surname>Douglas</surname><given-names>M.J.</given-names></name><name><surname>Palmer</surname><given-names>L.</given-names></name></person-group><article-title>Epidural Morphine for Analgesia after Caesarean Section: A Report of 4880 Patients</article-title><source>Can. J. Anaesth.</source><year>1990</year><volume>37</volume><fpage>636</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1007/BF03006481</pub-id><?supplied-pmid 2208533?><pub-id pub-id-type="pmid">2208533</pub-id></element-citation></ref><ref id="B462-biomedicines-09-00234"><label>462.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stenseth</surname><given-names>K.</given-names></name><name><surname>Sellevold</surname><given-names>O.</given-names></name><name><surname>Breivik</surname><given-names>H.</given-names></name></person-group><article-title>Epidural Morphine for Postoperative Pain: Experience with 1085 Patients</article-title><source>Acta Anaesthesiol. Scand.</source><year>1985</year><volume>29</volume><fpage>148</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1111/j.1399-6576.1985.tb02176.x</pub-id><?supplied-pmid 3976321?><pub-id pub-id-type="pmid">3976321</pub-id></element-citation></ref><ref id="B463-biomedicines-09-00234"><label>463.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walder</surname><given-names>B.</given-names></name><name><surname>Schafer</surname><given-names>M.</given-names></name><name><surname>Henzi</surname><given-names>I.</given-names></name><name><surname>Tram&#x000e8;r</surname><given-names>M.R.</given-names></name></person-group><article-title>Efficacy and Safety of Patient-Controlled Opioid Analgesia for Acute Postoperative Pain</article-title><source>Acta Anaesthesiol. Scand.</source><year>2001</year><volume>45</volume><fpage>795</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1034/j.1399-6576.2001.045007795.x</pub-id><pub-id pub-id-type="pmid">11472277</pub-id></element-citation></ref><ref id="B464-biomedicines-09-00234"><label>464.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldsack</surname><given-names>C.</given-names></name><name><surname>Scuplak</surname><given-names>S.M.</given-names></name><name><surname>Smith</surname><given-names>M.</given-names></name></person-group><article-title>A Double-Blind Comparison of Codeine and Morphine for Postoperative Analgesia Following Intracranial Surgery</article-title><source>Anaesthesia</source><year>1996</year><volume>51</volume><fpage>1029</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2044.1996.tb14997.x</pub-id><pub-id pub-id-type="pmid">8943593</pub-id></element-citation></ref><ref id="B465-biomedicines-09-00234"><label>465.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>D.J.</given-names></name><name><surname>Zacny</surname><given-names>J.P.</given-names></name></person-group><article-title>Subjective, Psychomotor, and Analgesic Effects of Oral Codeine and Morphine in Healthy Volunteers</article-title><source>Psychopharmacology</source><year>1998</year><volume>140</volume><fpage>191</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1007/s002130050757</pub-id><pub-id pub-id-type="pmid">9860110</pub-id></element-citation></ref><ref id="B466-biomedicines-09-00234"><label>466.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sevelius</surname><given-names>H.</given-names></name><name><surname>McCoy</surname><given-names>J.F.</given-names></name><name><surname>Colmore</surname><given-names>J.P.</given-names></name></person-group><article-title>Dose Response to Codeine in Patients with Chronic Cough</article-title><source>Clin. Pharmacol. Ther.</source><year>1971</year><volume>12</volume><fpage>449</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1002/cpt1971123449</pub-id><pub-id pub-id-type="pmid">4936034</pub-id></element-citation></ref><ref id="B467-biomedicines-09-00234"><label>467.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolser</surname><given-names>D.C.</given-names></name><name><surname>Davenport</surname><given-names>P.W.</given-names></name></person-group><article-title>Codeine and Cough: An Ineffective Gold Standard</article-title><source>Curr. Opin. Allergy Clin. Immunol.</source><year>2007</year><volume>7</volume><fpage>32</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1097/ACI.0b013e3280115145</pub-id><pub-id pub-id-type="pmid">17218808</pub-id></element-citation></ref><ref id="B468-biomedicines-09-00234"><label>468.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freestone</surname><given-names>C.</given-names></name><name><surname>Eccles</surname><given-names>R.</given-names></name></person-group><article-title>Assessment of the Antitussive Efficacy of Codeine in Cough Associated with Common Cold</article-title><source>J. Pharm. Pharmacol.</source><year>1997</year><volume>49</volume><fpage>1045</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.1997.tb06039.x</pub-id><pub-id pub-id-type="pmid">9364418</pub-id></element-citation></ref><ref id="B469-biomedicines-09-00234"><label>469.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahama</surname><given-names>K.</given-names></name><name><surname>Shirasaki</surname><given-names>T.</given-names></name></person-group><article-title>Central and Peripheral Mechanisms of Narcotic Antitussives: Codeine-Sensitive and -Resistant Coughs</article-title><source>Cough</source><year>2007</year><volume>152</volume><fpage>349</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1186/1745-9974-3-8</pub-id></element-citation></ref><ref id="B470-biomedicines-09-00234"><label>470.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>T.</given-names></name><name><surname>Chougule</surname><given-names>M.B.</given-names></name><name><surname>Ichite</surname><given-names>N.</given-names></name><name><surname>Patlolla</surname><given-names>R.R.</given-names></name><name><surname>Singh</surname><given-names>M.</given-names></name></person-group><article-title>Antitumor Activity of Noscapine in Human Non-Small Cell Lung Cancer Xenograft Model</article-title><source>Cancer Chemother. Pharmacol.</source><year>2008</year><volume>63</volume><fpage>117</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1007/s00280-008-0720-z</pub-id><?supplied-pmid 18338172?><pub-id pub-id-type="pmid">18338172</pub-id></element-citation></ref><ref id="B471-biomedicines-09-00234"><label>471.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>H.C.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name></person-group><article-title>Noscapine and Analogues as Potential Chemotherapeutic Agents</article-title><source>Drug News Perspect.</source><year>2000</year><volume>13</volume><fpage>543</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1358/dnp.2000.13.9.858482</pub-id><?supplied-pmid 12879125?><pub-id pub-id-type="pmid">12879125</pub-id></element-citation></ref><ref id="B472-biomedicines-09-00234"><label>472.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rida</surname><given-names>P.C.G.</given-names></name><name><surname>Livecche</surname><given-names>D.</given-names></name><name><surname>Ogden</surname><given-names>A.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Aneja</surname><given-names>R.</given-names></name></person-group><article-title>The Noscapine Chronicle: A Pharmaco-Historic Biography of the Opiate Alkaloid Family and Its Clinical Applications</article-title><source>Med. Res. Rev.</source><year>2015</year><volume>35</volume><fpage>1072</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1002/med.21357</pub-id><pub-id pub-id-type="pmid">26179481</pub-id></element-citation></ref><ref id="B473-biomedicines-09-00234"><label>473.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>K.</given-names></name><name><surname>Ke</surname><given-names>Y.</given-names></name><name><surname>Keshava</surname><given-names>N.</given-names></name><name><surname>Shanks</surname><given-names>J.</given-names></name><name><surname>Kapp</surname><given-names>J.A.</given-names></name><name><surname>Tekmal</surname><given-names>R.R.</given-names></name><name><surname>Petros</surname><given-names>J.</given-names></name><name><surname>Joshi</surname><given-names>H.C.</given-names></name></person-group><article-title>Opium Alkaloid Noscapine Is an Antitumor Agent That Arrests Metaphase and Induces Apoptosis in Dividing Cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1998</year><volume>95</volume><fpage>1601</fpage><lpage>1606</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.4.1601</pub-id><?supplied-pmid 9465062?><pub-id pub-id-type="pmid">9465062</pub-id></element-citation></ref><ref id="B474-biomedicines-09-00234"><label>474.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>R.J.</given-names></name><name><surname>Leisch</surname><given-names>H.</given-names></name><name><surname>Rochon</surname><given-names>L.</given-names></name><name><surname>Hudlicky</surname><given-names>T.</given-names></name><name><surname>Cox</surname><given-names>D.P.</given-names></name></person-group><article-title>One-Pot Conversion of Thebaine to Hydrocodone and Synthesis of Neopinone Ketal</article-title><source>J. Org. Chem.</source><year>2009</year><volume>74</volume><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1021/jo802454v</pub-id><pub-id pub-id-type="pmid">19072148</pub-id></element-citation></ref><ref id="B475-biomedicines-09-00234"><label>475.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endoma-Arias</surname><given-names>M.A.A.</given-names></name><name><surname>Cox</surname><given-names>D.P.</given-names></name><name><surname>Hudlicky</surname><given-names>T.</given-names></name></person-group><article-title>General Method of Synthesis for Naloxone, Naltrexone, Nalbuphone, and Nalbuphine by the Reaction of Grignard Reagents with an Oxazolidine Derived from Oxymorphone</article-title><source>Adv. Synth. Catal.</source><year>2013</year><volume>355</volume><fpage>1869</fpage><lpage>1873</lpage><pub-id pub-id-type="doi">10.1002/adsc.201300284</pub-id></element-citation></ref><ref id="B476-biomedicines-09-00234"><label>476.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacHara</surname><given-names>A.</given-names></name><name><surname>Werner</surname><given-names>L.</given-names></name><name><surname>Endoma-Arias</surname><given-names>M.A.</given-names></name><name><surname>Cox</surname><given-names>D.P.</given-names></name><name><surname>Hudlicky</surname><given-names>T.</given-names></name></person-group><article-title>Improved Synthesis of Buprenorphine from Thebaine and/or Oripavine via Palladium-Catalyzed N-Demethylation/Acylation and/or Concomitant O-Demethylation</article-title><source>Adv. Synth. Catal.</source><year>2012</year><volume>354</volume><fpage>613</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1002/adsc.201100807</pub-id></element-citation></ref><ref id="B477-biomedicines-09-00234"><label>477.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>B.</given-names></name><name><surname>&#x00160;najdr</surname><given-names>I.</given-names></name><name><surname>Machara</surname><given-names>A.</given-names></name><name><surname>Endoma-Arias</surname><given-names>M.A.A.</given-names></name><name><surname>Stamatatos</surname><given-names>T.C.</given-names></name><name><surname>Cox</surname><given-names>D.P.</given-names></name><name><surname>Hudlick&#x000fd;</surname><given-names>T.</given-names></name></person-group><article-title>Conversion of Thebaine to Oripavine and Other Useful Intermediates for the Semisynthesis of Opiate-Derived Agents: Synthesis of Hydromorphone</article-title><source>Adv. Synth. Catal.</source><year>2014</year><volume>356</volume><fpage>2679</fpage><lpage>2687</lpage><pub-id pub-id-type="doi">10.1002/adsc.201400445</pub-id></element-citation></ref><ref id="B478-biomedicines-09-00234"><label>478.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orman</surname><given-names>J.S.</given-names></name><name><surname>Keating</surname><given-names>G.M.</given-names></name></person-group><article-title>Buprenorphine/Naloxone: A Review of Its Use in the Treatment of Opioid Dependence</article-title><source>Drugs</source><year>2009</year><volume>69</volume><fpage>577</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.2165/00003495-200969050-00006</pub-id><?supplied-pmid 19368419?><pub-id pub-id-type="pmid">19368419</pub-id></element-citation></ref><ref id="B479-biomedicines-09-00234"><label>479.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Werner</surname><given-names>L.</given-names></name><name><surname>Wernerova</surname><given-names>M.</given-names></name><name><surname>MacHara</surname><given-names>A.</given-names></name><name><surname>Endoma-Arias</surname><given-names>M.A.</given-names></name><name><surname>Duchek</surname><given-names>J.</given-names></name><name><surname>Adams</surname><given-names>D.R.</given-names></name><name><surname>Cox</surname><given-names>D.P.</given-names></name><name><surname>Hudlicky</surname><given-names>T.</given-names></name></person-group><article-title>Unexpected N-Demethylation of Oxymorphone and Oxycodone N-Oxides Mediated by the Burgess Reagent: Direct Synthesis of Naltrexone, Naloxone, and Other Antagonists from Oxymorphone</article-title><source>Adv. Synth. Catal.</source><year>2012</year><volume>354</volume><fpage>2706</fpage><lpage>2712</lpage><pub-id pub-id-type="doi">10.1002/adsc.201200676</pub-id></element-citation></ref><ref id="B480-biomedicines-09-00234"><label>480.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millgate</surname><given-names>A.G.</given-names></name><name><surname>Pogson</surname><given-names>B.J.</given-names></name><name><surname>Wilson</surname><given-names>I.W.</given-names></name><name><surname>Kutchan</surname><given-names>T.M.</given-names></name><name><surname>Zenk</surname><given-names>M.H.</given-names></name><name><surname>Gerlach</surname><given-names>W.L.</given-names></name><name><surname>Fist</surname><given-names>A.J.</given-names></name><name><surname>Larkin</surname><given-names>P.J.</given-names></name></person-group><article-title>Morphine-Pathway Block in Top1 Poppies</article-title><source>Nature</source><year>2004</year><volume>431</volume><fpage>413</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1038/431413a</pub-id><pub-id pub-id-type="pmid">15386001</pub-id></element-citation></ref><ref id="B481-biomedicines-09-00234"><label>481.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagel</surname><given-names>J.M.</given-names></name><name><surname>Facchini</surname><given-names>P.J.</given-names></name></person-group><article-title>Dioxygenases Catalyze the O-Demethylation Steps of Morphine Biosynthesis in Opium Poppy</article-title><source>Nat. Chem. Biol.</source><year>2010</year><volume>6</volume><fpage>273</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1038/nchembio.317</pub-id><?supplied-pmid 20228795?><pub-id pub-id-type="pmid">20228795</pub-id></element-citation></ref><ref id="B482-biomedicines-09-00234"><label>482.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Fist</surname><given-names>A.J.</given-names></name><name><surname>Miller</surname><given-names>J.A.C.</given-names></name><name><surname>Gregory</surname><given-names>D.</given-names></name></person-group><article-title>Papaver Somniferum with High Concentration of Codeine</article-title><patent>WO2009143574</patent><day>3</day><month>12</month><year>2009</year></element-citation></ref><ref id="B483-biomedicines-09-00234"><label>483.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Winzer</surname><given-names>T.</given-names></name><name><surname>Walker</surname><given-names>T.C.</given-names></name><name><surname>Meade</surname><given-names>F.</given-names></name><name><surname>Larson</surname><given-names>T.R.</given-names></name><name><surname>Graham</surname><given-names>I.A.</given-names></name></person-group><article-title>Modified Plant</article-title><patent>WO2017122011</patent><day>20</day><month>7</month><year>2017</year></element-citation></ref><ref id="B484-biomedicines-09-00234"><label>484.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winzer</surname><given-names>T.</given-names></name><name><surname>Gazda</surname><given-names>V.</given-names></name><name><surname>He</surname><given-names>Z.</given-names></name><name><surname>Kaminski</surname><given-names>F.</given-names></name><name><surname>Kern</surname><given-names>M.</given-names></name><name><surname>Larson</surname><given-names>T.R.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Meade</surname><given-names>F.</given-names></name><name><surname>Teodor</surname><given-names>R.</given-names></name><name><surname>Vaistij</surname><given-names>F.E.</given-names></name><etal/></person-group><article-title>A Papaver Somniferum 10-Gene Cluster for Synthesis of the Anticancer Alkaloid Noscapine</article-title><source>Science</source><year>2012</year><volume>336</volume><fpage>1704</fpage><lpage>1708</lpage><pub-id pub-id-type="doi">10.1126/science.1220757</pub-id><pub-id pub-id-type="pmid">22653730</pub-id></element-citation></ref><ref id="B485-biomedicines-09-00234"><label>485.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Winzer</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Ning</surname><given-names>Z.</given-names></name><name><surname>He</surname><given-names>Z.</given-names></name><name><surname>Teodor</surname><given-names>R.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Bowser</surname><given-names>T.A.</given-names></name><name><surname>Graham</surname><given-names>I.A.</given-names></name><etal/></person-group><article-title>The Opium Poppy Genome and Morphinan Production</article-title><source>Science</source><year>2018</year><volume>362</volume><fpage>343</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1126/science.aat4096</pub-id><?supplied-pmid 30166436?><pub-id pub-id-type="pmid">30166436</pub-id></element-citation></ref><ref id="B486-biomedicines-09-00234"><label>486.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Winzer</surname><given-names>T.</given-names></name><name><surname>Graham</surname><given-names>I.A.</given-names></name><name><surname>Walker</surname><given-names>T.C.</given-names></name></person-group><article-title>Genes Involved in Noscapine Production</article-title><patent>WO2013136057</patent><day>19</day><month>9</month><year>2013</year></element-citation></ref><ref id="B487-biomedicines-09-00234"><label>487.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winzer</surname><given-names>T.</given-names></name><name><surname>Kern</surname><given-names>M.</given-names></name><name><surname>King</surname><given-names>A.J.</given-names></name><name><surname>Larson</surname><given-names>T.R.</given-names></name><name><surname>Teodor</surname><given-names>R.I.</given-names></name><name><surname>Donninger</surname><given-names>S.L.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Dowle</surname><given-names>A.A.</given-names></name><name><surname>Cartwright</surname><given-names>J.</given-names></name><name><surname>Bates</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Morphinan Biosynthesis in Opium Poppy Requires a P450-Oxidoreductase Fusion Protein</article-title><source>Science</source><year>2015</year><volume>349</volume><fpage>309</fpage><lpage>3012</lpage><pub-id pub-id-type="doi">10.1126/science.aab1852</pub-id><?supplied-pmid 26113639?><pub-id pub-id-type="pmid">26113639</pub-id></element-citation></ref><ref id="B488-biomedicines-09-00234"><label>488.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Winzer</surname><given-names>T.</given-names></name><name><surname>Graham</surname><given-names>I.A.</given-names></name><name><surname>Walker</surname><given-names>T.C.</given-names></name></person-group><article-title>Production of Noscapine</article-title><patent>WO2016207643</patent><day>29</day><month>12</month><year>2016</year></element-citation></ref><ref id="B489-biomedicines-09-00234"><label>489.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wijekoon</surname><given-names>C.P.</given-names></name><name><surname>Facchini</surname><given-names>P.J.</given-names></name></person-group><article-title>Systematic Knockdown of Morphine Pathway Enzymes in Opium Poppy Using Virus-Induced Gene Silencing</article-title><source>Plant J.</source><year>2012</year><volume>69</volume><fpage>1052</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1111/j.1365-313X.2011.04855.x</pub-id><?supplied-pmid 22098111?><pub-id pub-id-type="pmid">22098111</pub-id></element-citation></ref><ref id="B490-biomedicines-09-00234"><label>490.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>R.S.</given-names></name><name><surname>Millgate</surname><given-names>A.G.</given-names></name><name><surname>Chitty</surname><given-names>J.A.</given-names></name><name><surname>Thisleton</surname><given-names>J.</given-names></name><name><surname>Miller</surname><given-names>J.A.C.</given-names></name><name><surname>Fist</surname><given-names>A.J.</given-names></name><name><surname>Gerlach</surname><given-names>W.L.</given-names></name><name><surname>Larkin</surname><given-names>P.J.</given-names></name></person-group><article-title>RNAi-Mediated Replacement of Morphine with the Nonnarcotic Alkaloid Reticuline in Opium Poppy</article-title><source>Nat. Biotechnol.</source><year>2004</year><volume>22</volume><fpage>1559</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1038/nbt1033</pub-id><?supplied-pmid 15543134?><pub-id pub-id-type="pmid">15543134</pub-id></element-citation></ref><ref id="B491-biomedicines-09-00234"><label>491.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>J.R.</given-names></name><name><surname>Lal</surname><given-names>R.K.</given-names></name><name><surname>Gupta</surname><given-names>A.P.</given-names></name><name><surname>Misra</surname><given-names>H.O.</given-names></name><name><surname>Pant</surname><given-names>V.</given-names></name><name><surname>Singh</surname><given-names>N.K.</given-names></name><name><surname>Pandey</surname><given-names>V.</given-names></name></person-group><article-title>Development of Non-Narcotic (Opiumless and Alkaloid-Free) Opium Poppy, Papaver Somniferum</article-title><source>Plant Breed.</source><year>1999</year><volume>118</volume><fpage>449</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1046/j.1439-0523.1999.00419.x</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="biomedicines-09-00234-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>A close up of the female floral architecture of mature <italic>Cannabis sativa</italic> plants. The cannabinoid-containing glandular trichomes are visible in the magnified image, and are characterised by a globular head which is connected to the plant via a stalk. Colouration of the heads ranges from translucent, to a creamy white, to brown.</p></caption><graphic xlink:href="biomedicines-09-00234-g001"/></fig><fig id="biomedicines-09-00234-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>An overview of the mevalonate and methylerythritol 4-phosphate pathways in <italic>Cannabis sativa</italic>. The MEP (<bold>A</bold>) and MVA (<bold>B</bold>) pathways both produce terpenoid precursors, as well as the substrate for cannabinoid production, GPP. (<bold>A</bold>) The MEP pathway begins in the plastid with the condensation of pyruvate and glyceraldehyde 3-phosphate by DXS to produce DXP, prior to a series of enzymatic reactions to produce HDMPP. HDR then converts HDMPP to IPP and DMAPP, serving as the precursor to GPP, GGPP, and subsequently monoterpene and diterpene production. (<bold>B</bold>) The cytosolic MVA pathway is initiated by the conversion of acetyl-CoA to HMG-CoA and then to MVA, catalysed by the regulated, and rate-limiting enzyme, HMGR. MVA undergoes phosphorylation and then is decarboxylated to produce IPP, which is then converted to FPP as the basis for sesquiterpene and triterpene synthesis, or for GPP production for use in the cannabinoid biosynthesis pathway.</p></caption><graphic xlink:href="biomedicines-09-00234-g002"/></fig><fig id="biomedicines-09-00234-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>An overview of the cannabinoid biosynthesis pathway in <italic>Cannabis sativa</italic>. Malonyl-CoA, formed from acetyl-CoA, is used downstream with hexanoyl-CoA to produce olivetolic acid (OA). Next, OA is used as substrate along with other biomolecules by the GOT enzyme to produce the major cannabinoid precursor, CBGA. When GOT uses substrates additional to OA, such as divarinic acid or nerylpyrophosphate, a range of other minor cannabinoids are produced.</p></caption><graphic xlink:href="biomedicines-09-00234-g003"/></fig></floats-group></article>